<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e907868-0c62-40e2-8cc4-c207983567cd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/620e3367-dba3-4fac-b102-595775b08d43">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
        <rdfs:label>TTPA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb14be4d-073a-4ba3-99ec-575f678cc6dc">
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f88ebe1-1504-460b-9b76-8dcb97a0ab77">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
        <rdfs:label>ACAD8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/837d3404-f23b-4854-88fb-6e79ca2d38d3">
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad687c14-f9fa-40d4-babc-517dba08d937">
        <rdfs:label>HJV</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34c58f66-6058-4da8-9075-587966a0b97f">
        <rdfs:label>HAMP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b2e17ee4-5f89-4e1c-9503-e44bc76de471">
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/76d672d9-81d9-4701-b8c4-0f1df5f87f29">
        <rdfs:label>ATP7A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5b1639af-eb36-4af0-89cd-4c6a97b679d1">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7092a982-37b2-42bb-bf72-92662f7f44e0">
        <rdfs:label>ECM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0cbe747f-8c8a-4eb6-a925-e75525246dc6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6ed9c23-11b7-4d1a-9a6c-99f69f4dd0f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2494a167-c888-4de8-b99d-a53584a59387"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36b94086-c064-47cf-aaea-2106dccc8299">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d21cbfd-63c0-42d1-a63d-9889c696912a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <dc:identifier>ECO:0000352</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5bc1ca5b-298e-478d-8fe9-d2aa0e2884be">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/429f9201-d87d-4e05-b5b2-eaac5e3ee60d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/925a9e63-2664-4dbc-aece-be054fc8e447"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d625eb18-ed0e-4201-a786-f7980de21234">
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:label>Nephropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85bddb2a-815e-4497-9ee5-62d081837935">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7971d15b-9fa9-4d18-8a79-3d6d446701ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a0e90cd8-cd50-4364-81c0-2d898496e31c"/>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/34d7abca-27fb-4bb7-b8e9-21235c764b48">
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c8c5806-6758-4e78-a286-18fc6ffa52b2">
        <rdfs:label>PLA2G6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7462670e-c404-4181-a847-9c4fe707c697">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e57bf7d-fa2f-4c88-9140-ace01fd6c284">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e9dbece-395e-44a7-ba77-a3f793c1cd8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa8393a0-7553-4ddb-9d2b-e21c66c4e298"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/394505c8-cd49-4ecc-b3af-26a494474341">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33ff6f47-82be-4ce7-94f4-e4cc121de3a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66e2cba1-24a4-4238-b2a9-80d181c92ccb">
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5d7252f-9400-42ca-aa54-7c4b3c67d3d5">
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fbe32904-df11-411a-b5ff-385aad98ab82">
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d2ccf3c7-f37a-4ecd-b60c-d535c991fabd">
        <rdfs:label>QDPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9355ae6e-ea1b-4e0b-b387-388cdf2da3f0">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9465bf0b-37c3-4386-9bcf-90c57981837d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19ae7b48-98fa-4e37-a39b-38b1949153e3">
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d0dc1775-bb90-4125-acdf-712a4af01557"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39e650cf-156e-432f-9e30-dcd5825b2484"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76c33719-d1b8-41dc-ba8c-932b798b3e46">
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a03db97a-4b92-4383-89e2-c0701d7cfa98">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3fc9c84-fca3-46ea-88af-71777249c667">
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <dc:identifier>HP:0003288</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee4550c0-d01a-45b7-974f-9afb27d2be2c">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/438e274d-63a9-422f-a179-ec65c4a77572">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98867ddb-85b8-4648-89cd-f2d96e1f1b3e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa80c7d3-ac14-4758-84b4-ce1489eadcd8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce30a751-6a0d-451b-9436-535142215b40">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/861118d3-adcf-4066-b6cb-b5c29ae8018e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e8ed6b6-113f-4f19-b661-f816232e2d7c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1ab75f3-3032-4c83-9d06-2baf2ad896a2">
        <rdfs:label>Hyperglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f21e3c81-d695-4882-b179-50bc71a6c9df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cfb74776-ae3a-4858-8463-b164e6bebabf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb736a80-51a7-4485-80ef-2b875f870cfd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba6e3b93-d864-4353-ac73-b679bbc868f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/37f6efbe-5147-47cc-854e-c9145d972135">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4bb3204-8bdf-4dfd-aa32-85194331938f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
        <rdfs:label>ANO5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>anoctamin 5</rdfs:label>
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8199735f-54b3-414b-a150-b76e28ac4e2e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8868f8b-5665-4cce-8bab-de55c7a26603">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
        <rdfs:label>HPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84008013-1a64-41b6-9d01-9efe6a118a59">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bff43c7c-e77d-437c-b719-9184b79c427f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8b64518-1b8d-4c2d-979a-98683c70479f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a69b3d6-714e-44d8-a0ab-e2112c0ce2bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e24fef9-b1d5-4d44-9f56-94d4bb7123cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b2df967-b2f7-4b13-98b6-5f3560f9380a">
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32063036-c2f2-42a9-8b32-0c75198cdb82">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/940ea4b4-1e9b-4a47-8800-bf05ad0db202">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6796b752-c08e-4f42-8f2e-27378cda9cf6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d41b042-b674-4c43-a6fa-8cf7d111d818">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/912d3b00-631e-4f48-b6f6-b31231bfa80c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec016261-7a37-4639-83a9-1ef60ce0c95c">
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:label>Splenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bcfecda2-1918-4713-9949-11319fe092c1"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
        <dc:identifier>ECO:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a4fedf6-1fce-4f11-8ba0-c4f27d41bd2e">
        <rdfs:label>Motor function impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26d3dd94-df32-4b57-933f-0ff3c2c1ad43">
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6e01f8db-924c-47bf-a7e4-2e69e23a7f09">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0788894b-b1bf-4b4c-abec-ee3a6fd251b9">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0defed4a-587f-4d4a-9a72-3dab1aa6124a">
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/55b41b08-14ef-4b64-b120-29405222fddf">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2bf38274-2fbc-493b-802a-21a76d5381cb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b3d7f45-d213-49a4-96e1-f939b563ef46">
        <rdfs:label>MT-TS2</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e174d087-fadb-4752-84b3-99bc94fc26a1">
        <rdfs:label>MTTC</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/667a36f8-81a9-4a84-b5e7-8c41393ee0cc">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
        <rdfs:label>MT-TL1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75964069-903e-47a4-bad0-6d89a621961e">
        <rdfs:label>MT-ND5</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49da481e-1230-45f0-a836-b6c4cb77f02b">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
        <rdfs:label>MT-TS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-TK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b6539e0a-5b36-4970-85d7-fa53f1bd7a22">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
        <rdfs:label>MT-TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec1368f6-8e1a-4f8f-a943-4efb603a1047">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ce979ebb-26c0-46a5-92b6-9e940d0820f6">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
        <rdfs:label>MT-ND6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/03c5b866-ae2d-47e6-a923-ba7fa2f6c8cc">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
        <rdfs:label>MT-TQ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c11a2d1-4c6c-4fb3-b742-27bee65c6e99">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
        <rdfs:label>MT-TE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf6e5c79-6984-4b8e-87a8-9fec6dd93ddf">
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff2d451f-ed0a-41ce-b75d-b3d7e439709f">
        <rdfs:label>SLC1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf9aa3e3-4b84-4a99-9a40-639fecbbae9c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5384b484-55bd-46b2-82ef-2894bcf96d31">
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b82de10a-3b01-4d1d-b6c0-0090e595d749">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>Mental impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3440f582-51e2-4eaf-9313-2fc1c7950f9e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f1ae00b-14c1-4abd-9b49-4d20911cfa22">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
        <dc:identifier>HP:0002355</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Difficulty walking</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79674e00-2507-4717-841a-8bade75c65ff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Emotional lability</rdfs:label>
        <dc:identifier>HP:0000712</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1183b60-fd49-410b-bdf0-050166ab9283"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33a3024b-8b28-45cf-ba9a-7ee8c2377802"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fe52612-7507-4721-b782-7d1a40b017a3"/>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28d5343b-877f-4a3a-a8dc-f7b49f6ca6ee">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <dc:identifier>HP:0000649</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c9ef449-36b8-4c1d-9d3c-648ba800db35">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006958</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71fd3ae3-c522-42dd-af1b-4069b2e80d49">
        <rdfs:label>Dementia</rdfs:label>
        <dc:identifier>HP:0000726</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2f42cf9-9ce2-4517-a675-21cab64ebf19">
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b95717a-864e-4d86-a8f3-429b1000b9f9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6de003c1-dc0c-4917-ad72-2831b17e2bf8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low Hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a4f0687-20f5-4ac3-b475-b211368aedcc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c58cacd0-8d54-4747-a6a6-2a848390094e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/984e0684-69e1-4a0a-a367-3bfaf202f2dc"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/372525f8-13b4-41c3-8d7c-f16d10ea8bd9"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/94f16e7a-c919-4496-9da1-670769891f8c"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31060ba6-dd11-4d95-8841-451904f9fe81"/>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/158bbbb7-0d8a-4b8d-8e58-a5c4eedb9b67"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e4aaf4f1-2ec5-48f4-840a-a7c249c71420"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/80b3142b-44f1-4c1e-b91a-4c3d3398ee00"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4970f186-2d15-45ec-8579-3fd50e2d0c56"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0927270c-5aa1-41df-adb3-a69d0172843e"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/779a890d-6f7e-469a-9993-cb093da9504d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d836007d-66fb-4357-874f-e61c3800c453"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cc54cf1-e391-4f89-869a-3a7871e7f829">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed7c6a5d-67d7-43da-be7b-579341095136"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd124a4f-13dc-4ccd-8ecf-d20ebc8e80dc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
        <dc:identifier>HP:0001896</dc:identifier>
        <rdfs:label>Reticulocytopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/919c035d-9b10-4772-8056-a1a4d4bec9cc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa8393a0-7553-4ddb-9d2b-e21c66c4e298">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
        <rdfs:label>AKR1D1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84717bd3-7ddb-431b-ab27-cc4b1cb3bb71">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ddbb668-324d-4342-bcb4-1bad0a9d52c6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kinetic tremor</rdfs:label>
        <dc:identifier>HP:0030186</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21937b62-deca-4607-96e9-1f88d5b4b1e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2ccf3c7-f37a-4ecd-b60c-d535c991fabd"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afb2ecf8-b706-4109-bc9a-6a3c28ee4ed0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <dc:identifier>HP:0002174</dc:identifier>
        <rdfs:label>Postural tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/628b31a0-0d08-4d7b-815d-072bf37e4d54">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad4b5a4f-f14a-4797-81b1-8918f1f4dbfa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02be67ec-3776-4c6b-bbc0-4c0fbe19aea2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf2dd1ed-fb52-448e-8617-bf202e6ca761"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4eb3d841-3975-4d4a-ae50-59b8f76f1270"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0662f242-5be5-4b81-9728-66952d6c2c16">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bradykinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
        <dc:identifier>HP:0002067</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa5e4f16-d470-4052-a93b-1f815fd43a87">
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57825045-9451-4e03-94b2-7804230761a9">
        <rdfs:label>PHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dc001e51-2718-4e63-ab6b-e4dbf1463a2f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b13894b3-0ce5-49f7-a6a2-d58afd6566f1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6154c3f0-88db-4f74-8711-6de7d76119de"/>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31cc53bc-6304-4a12-b470-d78047e0c927"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91cbc48a-0450-441c-99dd-bcd5a30156da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b90ad4f5-1b95-4233-88d2-49ea46f48250">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <dc:identifier>HP:0008315</dc:identifier>
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee1fefc8-9b3e-4214-94bf-5dcf1a0eae3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ea7c0ef-4f68-4e5d-9e61-eb41b2679184">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce8a3bf5-a39f-4cdd-a55b-df837549bba3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>Hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ca7538d-6a17-421d-aaf9-75a34a6b5590">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a39a196-bb48-4587-a43b-2bd7b73176db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9dcfd31-ba5e-47d0-99b5-24b00ff4ee25">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd85097e-cce6-4f0b-8f7b-ba92d3437219"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aee6c7a5-190c-4253-b5a6-5041bcc07ad1"/>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c75d830f-b86b-45b6-b51a-5de6a13869cd">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c6986064-f6a6-443a-9c62-b4db41143056">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d666a57-0f7a-4a04-a773-ede5340e42f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54b0dc2b-dfd9-4555-8b2f-26895e7455e1">
        <dc:identifier>HP:0003162</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59ca518e-1eb9-40e5-9218-064a9367fab3">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e5bada56-fd8f-4906-a344-7f71e5cec49e"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87faf5fb-38bc-4b11-89cb-b4c781a8745f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/841e9b55-1db7-47f3-8eff-c7aadaaeb5ad">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a3235dad-8013-4863-a1e9-b650e5f1f188"/>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50e3c8b3-a0a8-4c91-97da-61b6ab87a48a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f242ef35-7397-4db8-87fd-726c7d6109ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/154acf91-91cb-4cff-9080-4b254b63c357">
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d56e745-87a8-4d04-9d20-f46af71006df">
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7484af1d-0b15-471b-83db-64eecfcfab96">
        <rdfs:label>GNPTAB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd45ade6-a8ca-4da6-a21b-f283b261ad73">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aebe5e41-b2b2-42ec-9761-85feba3b5347">
        <rdfs:label>GIF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff6412ed-abeb-4f8d-ad91-69bd4604762b">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/624ad472-30d7-49fe-a309-9f323ddf4863"/>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51386873-76b8-437c-ae83-0b32a5dfbbf0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/919f4dce-012c-464c-99b0-9e10421919b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/156e9d1d-812d-4d2a-882f-793eb6de650a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85214e62-7f10-469e-8fa3-df5b3a122d59"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55cb08ae-c060-4c0a-92e8-1150d5459421">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/14e62da4-5cfd-4b50-b0b6-d1c51b026376">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d66dc1da-9c6d-40ec-a376-700fc953c10e">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffbc7dcd-43dd-4464-80f3-6ed18bd86a13">
        <rdfs:label>SLC6A19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8f113bb-b986-4537-8f15-e07860c3fb5e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3d33dc1a-ec30-40dd-b780-2163a99e3be9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c81aa8b1-02d0-4beb-8677-0dfbafdc2563">
        <rdfs:label>APOB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0788894b-b1bf-4b4c-abec-ee3a6fd251b9"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14d609cb-89a6-4a2f-b73a-097cbb15678c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69e47751-062f-4a06-867f-db551190ba96">
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:label>Growth abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7dc98c48-4151-4dab-ae81-dcdd6d03a24b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f88ebe1-1504-460b-9b76-8dcb97a0ab77"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5d39cf39-15a6-463b-8bdd-fd0508d8bbbc">
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <rdfs:label>transferrin</rdfs:label>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30d1ed83-ea7a-4be0-a97e-f470879d347c">
        <rdfs:label>TF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3db549b0-1793-44ac-b438-2098309be1d4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfa980ba-7c55-4626-b485-3e1503538f6f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ec45e91-d32d-454e-92f7-76c69af32e11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc833139-c914-4448-9090-9f5e2a019579">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c39f832-d72d-400c-9175-7cbad01fff76"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9aafac6c-fee7-4253-9672-aecd27cf112e">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81385546-e9b7-4551-b88e-24c03a389886">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c6fc9d36-00d2-42f1-8643-935489a40d68"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4564627b-5493-47e9-913e-dfb06e3bf852">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e174d087-fadb-4752-84b3-99bc94fc26a1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/49da481e-1230-45f0-a836-b6c4cb77f02b"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b6539e0a-5b36-4970-85d7-fa53f1bd7a22"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec1368f6-8e1a-4f8f-a943-4efb603a1047"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ce979ebb-26c0-46a5-92b6-9e940d0820f6"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/667a36f8-81a9-4a84-b5e7-8c41393ee0cc"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75964069-903e-47a4-bad0-6d89a621961e"/>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/03c5b866-ae2d-47e6-a923-ba7fa2f6c8cc"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b3d7f45-d213-49a4-96e1-f939b563ef46"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cffecfa5-31d0-4ab9-8bb6-5fa55eefee54">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a114e330-ec9e-4682-bbb2-2641a1c1578a">
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d5d34fd-5d96-4c15-bd9a-b21697d7911a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33005eb9-34c9-41f7-a78e-334a0ecb6492"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/55300f55-e435-4876-bc81-c5a7c9cb46a7"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03ab9a80-d0cb-48c4-9263-a622733931e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c728e15c-f22d-48a0-b9d1-cde59f6b5443"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c1ded9bb-3b34-4527-a704-ed03bdb81f23">
    <rdfs:label>Dystroglycan</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ad09d41-6b6e-4499-b011-f512d9625eeb">
        <rdfs:label>DAG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d82e9e49-efd9-491e-ad04-edafae660455">
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c3a0567a-9d1a-47a9-821b-0fe122b0ae44">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
        <rdfs:label>MTHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efe4bece-dbc4-48fd-b954-e5fc6c6c5ebc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be8f16db-ab86-4321-a6fa-76366bb97b79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6df6dec2-4887-47c5-a2d2-e226ce2219d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c220de08-6c31-4124-a016-97def314a896">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/921a66c6-df9f-4440-85bd-0617f3c5317f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240">
        <rdfs:label>Disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b232d36b-a921-466e-8e4f-3846260a2e5a"/>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8">
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5ae1805-09d7-457d-a426-56882ef03914">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da166e6e-cb69-4336-ab21-68449bb5d833">
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
    <rdfs:label>uromodulin</rdfs:label>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1818203a-0c22-40d6-b3c0-bcb6603ce4e7">
        <rdfs:label>UMOD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42b0015b-f93d-43e6-a073-0eeb0084a191">
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f9cdd87-b69b-460c-881d-1fb73fc4f40c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
        <rdfs:label>GATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2aaf8443-0b11-4d2d-abc6-ba970ec863f7">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ddf9c8d-46e1-4542-a6e6-0f103db64b8b">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49da76b2-ca89-4b20-a746-adbfd2e9901a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9eedf5e0-552a-4b97-bf92-16b78497768c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cb79704-147c-4c9c-b289-10ec8bc29e86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5b83bdf-8d7d-4a16-8097-876cbd7c4f4a">
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2237bbd9-b0e8-4e9b-b2b3-4d2f5ccbf5f8"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa7eb84c-b6ef-4adc-b322-335b551f25d2">
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/292798b9-a42e-4db7-8882-7c84a7aa4c59"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/229eaba7-60cc-4749-9d62-04fcadff94b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f03a8c5-b4f9-4f35-a1bf-2162e67b547b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0cae948-9cbc-440e-9ed8-b1ab587a90b9">
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fa8393a0-7553-4ddb-9d2b-e21c66c4e298"/>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa12e177-b4e6-4373-9596-0dfcd5e47c8a">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8cbec8c4-a3b9-4c40-b127-55658f3e8ceb"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb9143c7-27fc-4472-95f6-c7cf255f3182">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffd000e4-811d-4448-bc96-00166c626fe3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/785cd945-00d3-4703-9ab5-8396d0ddbcf2">
        <dc:identifier>HP:0002664</dc:identifier>
        <rdfs:label>neoplastic growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a53429e2-7e0b-40c1-be5a-f3d8b22800f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/198172ee-f0b7-457f-91ab-877316d8c758"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/72fb9dd7-617b-427d-a0b7-af434d86911f">
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e8ed6b6-113f-4f19-b661-f816232e2d7c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/628edfe1-c360-4f4f-8db2-31145bfc80c3">
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f69358cf-db8f-4ff7-803b-26c899096763">
        <rdfs:label>ANKH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8501b114-648f-4a6b-ad96-11c23e4a1ad0">
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3ad2fdcf-496a-4e4b-a4c1-b45e926b20d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
        <rdfs:label>HSD17B4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/611a4a9f-727d-4097-b74e-6d90b8337f3d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5401d66a-8b47-4798-98fd-c7b39171aa3a">
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cff0915-4706-4d2e-a059-5bc03d15aa5c">
        <dc:identifier>HP:0002401</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Stroke-like attacks</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3147694-c072-4510-acd5-2fc2c09d1153">
        <dc:identifier>HP:0030890</dc:identifier>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6295b1a8-209a-42e4-bc8e-a97ca1ca18af">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f11c89e6-1f1d-45b8-aafd-f65b28c48ccf">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e55c910-68e4-4fdc-9e39-44d502b5425f"/>
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d3b0d95-85ad-4258-9968-613be1320241">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ab46386-dbb2-4358-9dff-eb45429b7e46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/337460b9-11df-4a3c-9498-18e34c18a092">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3125b5c-5deb-424c-a605-6cebb16cc9e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/89d001f0-5271-46d8-b04d-ae07de9d6aa7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8881984d-4f87-4869-887e-8effc49f9e7d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
        <rdfs:label>POMT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2e3216ff-a9f3-482e-884a-d3c3f0fd6c59">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dffd29a1-39b4-4d49-813a-519a15de459f">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/830ec962-39ff-4c78-b5c5-b8f3aa566774">
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4049ab3d-cf81-442f-802e-496342c7e588"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7535338-87bb-4d82-a0ca-7422fed383fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9dffca04-b813-418b-a4e5-c867980db299"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/628b31a0-0d08-4d7b-815d-072bf37e4d54"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/209c4c19-c913-433d-8f8e-8852e05f4a87">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3a0567a-9d1a-47a9-821b-0fe122b0ae44"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b83e41a-e1a3-4f24-b0d9-0fca7b5f5eea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a320027-799b-44ab-bb7c-dd5ab5e50862">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f5863107-b6f2-4795-bb78-fe766f1e8172">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf0dae62-4a83-428b-a93a-d8ce9f51525f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d55b1f5-2f69-4e71-8844-18903e553f0a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3440f582-51e2-4eaf-9313-2fc1c7950f9e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5384b484-55bd-46b2-82ef-2894bcf96d31"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8762937e-3cd7-42be-a595-477eb3155b91"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55345d3a-ff71-46fb-a27a-09ee81000d2e">
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <rdfs:label>ferrochelatase</rdfs:label>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ee995afe-6de1-4889-b965-64ebd83ab101">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68d1d7d1-0742-4074-9f88-d81f8d441fb9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/830ec962-39ff-4c78-b5c5-b8f3aa566774"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30472bcd-d169-42d1-a754-1fff6f29457e">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb2a2c81-c160-4436-8518-9e7da8d13fc9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum  prolactin</rdfs:label>
        <dc:identifier>HP:0040086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c19f5da-951b-40e2-82c8-51e7ba78b9ff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <dc:identifier>HP:0010893</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f8d84c9-d104-40b8-9f95-bf9b64490c13">
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1509c050-93c5-4fac-b9f4-367072ff0790">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
        <rdfs:label>DPM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36248301-393b-4067-a40c-acc99f755f76">
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52ae6c5d-6693-464c-83df-627af25e278a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
        <rdfs:label>UGT1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/31ff4534-0791-47f2-940f-38957647e9d1">
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ebc9c285-245a-4fb7-8f5d-9e94b546b540">
        <rdfs:label>SLC5A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ca6b8ef-4906-4815-9a19-eb2b278306e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2deea33c-c721-4000-a960-7cb705cec68d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc9f4f86-8d47-4198-ba4d-de418dce9c89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77f6a055-07be-4e08-9979-847f5c70e113">
        <rdfs:label>Osteoporosis</rdfs:label>
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba34e0be-9f38-4531-a786-4a1df60575f3"/>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a98819bd-548b-41d7-8afb-63026382aadb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1bdce05b-974c-47cf-a2a4-02f583b86c3d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a52dc1b-35b8-4843-b5ab-ed0c2c64bdea">
        <rdfs:label>ISPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/303fbb57-5476-43b3-bbf7-41bf45b86475">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3dacd70-b9e7-46e4-a67c-322aaaa55445"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33c6e6b9-bde3-4b21-9ef3-b9050dfec70e">
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>Short stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab1bea66-b5a9-40fd-829c-28bf95e181f7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ffd20b7-b6ee-481d-bfdf-6acdbe114351"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b63dbae-b9cc-4060-97cb-a255110247f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50dcd9ee-89bc-4c64-8073-3de3bfd630db">
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a08f8841-780e-4247-8487-6217ca99054f">
        <rdfs:label>POMK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca1ec1bb-656d-4678-8665-3cb95aa02458">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9de18fb-8547-4330-b953-53da35b05468">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Epilepsy</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b20dbc0c-a450-4950-b35e-46ae1d15e65e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6945fffa-d5e8-4126-a816-08c89f847b2f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <dc:identifier>HP:0001285</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f244888-d485-41dc-9ebf-d3fd39d67ec7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
        <rdfs:label>GALK1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fda7c95f-cabb-4bb8-ae18-0923b2a910c6">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d2ccf3c7-f37a-4ecd-b60c-d535c991fabd"/>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9eaf9638-fddd-4e9d-8729-d9d358c2212b">
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/febced14-8874-421a-9d41-9e39a2738e3f"/>
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36b94086-c064-47cf-aaea-2106dccc8299"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dffd5a41-d48d-45ce-a95b-78358a2c58f7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010818</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d906c75-a083-47ef-9ee9-b11f0d842765">
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e8c7abf-ff68-4dad-883e-9745bd3503ee">
        <rdfs:label>CPT1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1cc176e-3cf2-45a3-9e51-4263b076453a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25433df1-99a0-4cef-a6f4-8e53cc7edd87">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06b88440-c43f-4dfb-8fbc-ec937754be12"/>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7acf5a3-d37c-477a-a036-b5618246da0f">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>Polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36b94086-c064-47cf-aaea-2106dccc8299"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/482d223c-bced-49b9-b5d7-31d983e41290">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fa3ecd6-6252-4174-8b71-c921ebc454d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8ed527f-143f-4960-a743-079243b129fb">
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d39a54fb-b9b2-42e5-9f10-a488a43df2e5">
        <rdfs:label>SLC39A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d9e7c8b-0e51-44c6-a3f5-41144da0ada4">
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c3a0567a-9d1a-47a9-821b-0fe122b0ae44"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6319e3b8-f32a-41de-b1dd-531178bd3e26">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46f47c8d-89ad-4351-88e6-3f7e672f54f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/22bf67fe-676a-4663-ae9d-2b5bc2ab8d73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52ae6c5d-6693-464c-83df-627af25e278a"/>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4875d89f-e94e-40e5-94da-090bcf47e7c3">
        <rdfs:label>Study is still recruiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0762029-a4eb-4c51-9c6e-f2b5f712eef2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/27806587-f009-42e4-b896-098b59f70e24">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/46d77015-011b-47f8-b6db-6dafcf1883e8">
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c99c820e-b9b5-45c9-99d4-e4eb2966aed0">
        <rdfs:label>MLYCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/885e771c-d821-47c3-bef2-e9579d223b6a">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ef863d37-ee8b-40b0-9464-865fc9734992"/>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/354dfd40-7b02-4072-bc6c-136ff11e04c1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <dc:identifier>HP:0012638</dc:identifier>
        <rdfs:label>Muscular abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0b6d209-a841-42a7-b1bc-d1ed6f2ec6ae">
        <dc:identifier>HP:0000505</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1a52a6a-60e3-4754-bd9a-f50d26c5afae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6fd8515-d9af-4627-8742-3996305b94a2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/18585770-8482-4107-ae08-c9ac9fae7c7c">
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f05eb646-b57a-4f01-be7f-23064db520fa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
        <rdfs:label>HADH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/617cd8d8-c9a0-4421-8606-f4ea463e45c7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51b88939-7787-4da1-9191-7688656bdceb"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42cad462-8af4-4a76-b96b-fdafe64ef68e">
        <dc:identifier>HP:0006785</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:label>Muscle dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/93dd31ae-aebe-435e-b71e-6946194556bb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0d971cd-fd58-4553-a520-cf7bbddb5fab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b44b8dc6-b3b3-46fb-9e66-7b08275ba9e0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70a8c7cc-4b34-4fe4-89bc-50629ad68845">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed6d9788-f97d-448f-9b32-c0462eb38f16"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3203df0d-7d0b-4dc5-b732-a8379cc10fc0">
        <dc:identifier>HP:0001250*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3577538a-dcbf-4923-b1b8-d71698d15e78"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c11391e-4225-4bc3-a3df-832d57427a33">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8c53661-72b2-4617-8ac8-a41a24b1af51"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7fc84159-ad31-4452-8004-4869bef54c6f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33005eb9-34c9-41f7-a78e-334a0ecb6492">
        <rdfs:label>MCCC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/55300f55-e435-4876-bc81-c5a7c9cb46a7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
        <rdfs:label>MCCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de3389ae-150e-4ad3-84c2-7518efcb8450">
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ca7538d-6a17-421d-aaf9-75a34a6b5590"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60d5c2ff-febc-465b-ab87-b04a8cf27785">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c486945a-43ff-40cc-94fa-0fe5fadd7d6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36c6d0b4-8c73-4512-bc62-7a3a21f1eded">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03afbbf0-72a5-4323-8b36-06c62dfcfefe">
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <dc:identifier>HP:0004337*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cd028f94-c3c6-4f18-bc38-50e51caac95f"/>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97276c96-7a1d-4c78-b9c0-9cd7e6e4b4cc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cc7bac6-7f94-4348-92ce-79ee0e8162cc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>fatigue</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76ed025f-c30c-43a3-bf17-af0e40d93d99">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b262573-18f6-4800-a0b2-eca3a4c05a11">
        <rdfs:label>lethargy</rdfs:label>
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29108093-ecd0-4813-95bb-67f5febc8adb">
        <rdfs:label>anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4282f233-a6a5-4e9d-8adc-69250357c3c2">
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9d1a5d1-d181-4f93-9873-c87fb90c4c06">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
        <rdfs:label>MMADHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f62518fc-e144-4758-94f5-d31b28eb0a2d">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5948958c-c2c0-48ed-a702-a536f3e243d3"/>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42cad462-8af4-4a76-b96b-fdafe64ef68e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93dd31ae-aebe-435e-b71e-6946194556bb"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9d0ad85-842a-41fd-95be-3308940893a6">
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b83bdf-8d7d-4a16-8097-876cbd7c4f4a"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9128140-c15e-4277-a2d0-7b6b9a7dc91a">
        <rdfs:label>low brain creatine phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9de18fb-8547-4330-b953-53da35b05468"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9eedf5e0-552a-4b97-bf92-16b78497768c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e27b0ebd-b585-44bf-9655-e87a872ae8dd">
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48f84418-5bb8-44cb-a32f-fde4b1835a97">
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <dc:identifier>HP:0011443</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c8eb361-4e11-4cec-8908-c9735474a8ab">
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <dc:identifier>HP:0012113</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ab74a9e-0a13-4217-9729-74248892df97">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <rdfs:label>low cerebral creatine</rdfs:label>
        <dc:identifier>HP:0025051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68cf9f5a-e19a-499f-aefc-452827a1a332">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e4428a2-32c5-4329-bdfa-c1d2032bff1e">
        <dc:identifier>HP:0012823*</dc:identifier>
        <rdfs:label>Slow recovery</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a74b31bf-994a-41fb-9957-d7d63eaf2486"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aba6df31-4591-47f1-8329-04617ffc0105">
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/47a1527b-dc2c-4b06-b49d-c6c80609f6e5">
        <rdfs:label>AUH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b49cec5-3f98-46a2-ae85-ca4f68a82ae0">
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/701852fc-54b1-4290-8ee7-fd59814c1b82">
        <rdfs:label>ASAH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b5d576c-7f17-424d-abce-48665d7c71e7">
        <rdfs:label>MT-CO3</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a8dab726-613b-475c-afe4-d7ae908d0555">
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3cb33523-8779-42b8-a033-f410309220ac">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
        <rdfs:label>CTNS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf093379-6d03-4c7d-8cf8-1db20de811e5">
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ccf4c27f-7f64-490f-b0e8-738cbcb1e40a">
        <rdfs:label>OPA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/573497eb-0277-4d03-b743-1e0937748b34">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/158bbbb7-0d8a-4b8d-8e58-a5c4eedb9b67">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0927270c-5aa1-41df-adb3-a69d0172843e">
        <rdfs:label>RPS7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/984e0684-69e1-4a0a-a367-3bfaf202f2dc">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94f16e7a-c919-4496-9da1-670769891f8c">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/372525f8-13b4-41c3-8d7c-f16d10ea8bd9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
        <rdfs:label>RPL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4970f186-2d15-45ec-8579-3fd50e2d0c56">
        <rdfs:label>RPS26</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d836007d-66fb-4357-874f-e61c3800c453">
        <rdfs:label>RPS17</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31060ba6-dd11-4d95-8841-451904f9fe81">
        <rdfs:label>and</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e4aaf4f1-2ec5-48f4-840a-a7c249c71420">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/779a890d-6f7e-469a-9993-cb093da9504d">
        <rdfs:label>GATA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/80b3142b-44f1-4c1e-b91a-4c3d3398ee00">
        <rdfs:label>RPS19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9f877cb5-263b-4255-a96d-8d31963724ee">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12c8c60a-587e-43b9-9dc7-b51fc2c1ccb6">
        <rdfs:label>ADA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Adenosine deaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a353c49-ae56-4bc9-81c2-1f3de6ccde4a">
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/61586b79-ca66-467b-97ea-5b02e5dce4e8">
        <rdfs:label>APRT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7bc9a331-7db3-4407-9152-0814d4f54a7f">
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06ee9bae-e66b-4d84-a7c9-435a932bbfa4">
        <rdfs:label>HEF</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4793bb54-7d0d-420c-a195-cd45990708e7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
        <rdfs:label>UROD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa4ebb51-52eb-4989-8535-13d47f0baa29">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6794bb6-ef3e-4108-b6a4-7b0166f619a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36438749-6c4a-4cc5-8d52-ff3942cebb6a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7d7142b-b5cd-4a19-895e-6929e53bf1f2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <dc:identifier>done</dc:identifier>
        <rdfs:label>Hyperurecemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/446fb2da-5eb8-4475-850e-1ad7ac5e3b92">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bcf0e02b-3551-4429-98a6-629db620d0c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1818203a-0c22-40d6-b3c0-bcb6603ce4e7"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c0f36a0e-271b-4b02-b067-662e2fd4d6b7">
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a8b6dc3e-d445-49a2-86ef-cc32cd9b254a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5490bd3e-2398-49de-850f-5e5db91008db">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0ba3c87-aab6-4568-a3b6-29fa388cc8ce">
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:label>Itchy skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c25a444-4f78-4bb8-805a-a89996abd9b3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec41786d-48df-410d-a252-c5dc2e92d915">
        <rdfs:label>Scaling Skin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17bda352-ff59-4c09-894e-8645ee6ee038">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e85a63a2-d460-4306-b6b4-a69c29703eb9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/506e60fa-327a-434e-a310-0024a2908105">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>VX‐like lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e4b483d-1456-4cda-b4b0-7f2c147d6631">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007431</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d37d99c-0eed-406a-b730-839550a78a8f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythema</rdfs:label>
        <dc:identifier>HP:0010783</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06f50bd2-76e7-4da6-9eb1-156d53095c69">
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <dc:identifier>HP:0031517*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/164600a7-f4af-4fa4-aff0-ce84f44a6e0a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fca1c716-7690-4a17-a3e6-3558dd0bf756">
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc456c7e-1143-41a4-a17a-1b600897613a">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7aa38a87-1c14-4ed9-b22c-b63827673626">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5007d7e-c78b-457a-9690-7041691be841">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cbda4d7f-9be7-426d-ad0d-d3e18f49c670"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4e0e6147-20fb-43d9-8b57-59969590614b"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e86ad0d1-28dc-4b1b-9b60-cdaef1f455d5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8e5e43d8-e441-4e71-831e-04b962f9f20d">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
        <rdfs:label>MT-ND4L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ec1368f6-8e1a-4f8f-a943-4efb603a1047"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ce979ebb-26c0-46a5-92b6-9e940d0820f6"/>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/214bc455-dd28-4c66-bad3-6e7256328741">
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba134cde-3d29-4651-bd75-1aa1afb65d7e">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/efc2b774-19c5-48bf-815b-e092cda75c0e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e71aac6-efd7-4034-b7b1-c7bc996dfb2e">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
        <rdfs:label>MT-CYB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57532074-b222-4f1a-9424-0c4f8ac1216f">
        <rdfs:label>MT-CO1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9b5d576c-7f17-424d-abce-48665d7c71e7"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e94d73d9-834c-456d-846d-667b3ed24384">
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <rdfs:label>biotinidase</rdfs:label>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff18f1ad-4184-42e0-9c49-5de01d733984">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e55ae40-e18f-4fb3-bbe3-a63061dbc27a">
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/092202c6-0221-44eb-bd13-eb06b50986e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
        <rdfs:label>PIGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d28d875a-16e5-4b1c-9eb8-258f337594b8">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba134cde-3d29-4651-bd75-1aa1afb65d7e"/>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ad2243f-5bf3-4c3a-9345-0daca9605e87">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7548d017-0519-4ef2-be66-fc99c0068bad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb742638-8b5d-4c4f-9c01-5b2ef6a1ee72">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>developmental delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3dd15c67-e598-43c2-a62f-767398652d9a"/>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/592b443b-7bee-44a2-8d97-4c99083f8839">
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e46a3a4-d680-4a19-825a-da28fdaf717f">
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65e802a6-199d-4dad-98ea-2ee9c5a2e495">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
        <dc:identifier>ECO:0001565</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83127c03-06c1-43fa-b404-19a6e844ce96">
        <rdfs:label>brain atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
        <dc:identifier>HP:0012444</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e902d5fa-54ba-4b67-8620-f3adf3f38746">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cde916b-db3b-4e11-93bb-1b82d6ebd731"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a48e8bff-bf6c-4950-9d6c-6fc896623ee5"/>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac0fe75f-442e-4ac2-960b-b3beaa7bd4dd">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7643b357-35af-4107-b37e-307c8254a288">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4fb221bd-e81a-44cf-8efa-e44ed63882c1">
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a48e8bff-bf6c-4950-9d6c-6fc896623ee5">
        <rdfs:label>TPP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/edd5c08d-2d1a-458a-8a15-83a27be1443d">
    <rdfs:label>AMP deaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cecbab8f-665b-4fe7-8c66-f4ade3d6abf0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a08f8841-780e-4247-8487-6217ca99054f"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13d20d66-1821-4962-a2a6-3c89f6dc4ca7">
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5948958c-c2c0-48ed-a702-a536f3e243d3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
        <rdfs:label>FKRP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28cac572-29c3-46c0-a521-74553fef04f1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/accf6f60-6ea5-40d5-b543-84384d2d6d9a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>low muscle tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da8eb579-3411-478e-8d4f-5c98154dbcc8">
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32ff1606-f1b8-4c34-a4e6-648654f4b069">
        <rdfs:label>RNASEH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/adbf6f1d-c239-4976-887a-7e0201fa6eb4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc8195db-f65c-4df8-bb1b-6cebf75386f5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73909640-5a28-4933-8d89-e22541729452"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cdd6640-d2e7-409d-80f1-b9fed3de85e8">
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2e898ce0-303f-44e5-a706-8303839f6e5f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22ee4a9a-d2da-4a75-bbb0-ea352ee8a916">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6d7528b-ec70-48bd-a764-6709c949f288">
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe81493a-6a16-4b66-acce-291afff2174e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/940a376f-93eb-4431-92d4-c051440bd103">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/719dc29f-a2d6-4fe8-ae13-c054269432b9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/337460b9-11df-4a3c-9498-18e34c18a092"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7484af1d-0b15-471b-83db-64eecfcfab96"/>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c50e6994-168b-4820-a250-8d006a23c658">
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a3235dad-8013-4863-a1e9-b650e5f1f188">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
        <rdfs:label>TFR2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea717a15-2dc2-46ec-af9a-4d8eb079b1c2">
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47bcad50-c39c-478b-ace2-bde6534d0a7d">
        <rdfs:label>Metabolic stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03ab9a80-d0cb-48c4-9263-a622733931e5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86f1fda6-c9b8-4c80-b31c-0172128d5071">
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59c05b9d-6c4d-4076-b8dc-e6a7b7ce1d37">
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4970a7eb-58c6-4edb-b32f-6a636fbb02ff">
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56992ee3-4f95-4d3e-80e6-816653d10337"/>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/758ad2f6-b899-4e17-963c-21c16ed21749">
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Developmental delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/279077c9-4413-44c8-8243-04b43cf0fc31">
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b703461-caef-4c27-a50f-b5c1fd8117b8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67b6a4ac-2ca0-4410-af91-e2faab5b1403">
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89ae5356-14b7-4117-a1e5-a8b54013c458">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
        <rdfs:label>SGCG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sarcoglycan gamma</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1b78885-4b8e-4bd6-bffd-6b20f1deebf4">
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b608986-81a4-4d12-bcb0-7f5ab295eafc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
        <rdfs:label>LRPPRC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ae72835f-507c-4348-ae63-3b113abababa">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/016503f4-7cfe-43bc-8b21-1a3867b99aab">
        <rdfs:label>Megaloblastic anemia</rdfs:label>
        <dc:identifier>HP:0001889</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75023cf9-3951-4703-8c9d-b802f35429b9"/>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5863107-b6f2-4795-bb78-fe766f1e8172"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c751f12-b4f3-47ab-9ae9-5feb88f9a420">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a46c3420-ce15-4547-93dc-90f617b8c580">
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ef1637e-73da-4a7d-be39-bc341a373533">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc6b9c64-791c-4417-a549-beea70d5cbc6">
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f41f47b2-9a0e-4dc8-b22c-315449374679">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
        <rdfs:label>GLUD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dbca7401-37e4-4cd3-aa5f-280c84783b42">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/60edf3b3-cf85-44e8-b08a-4cdf4b83ee6e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucokinase-4</rdfs:label>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/96fe2648-2dbd-45e6-9b17-f9a68fff92d4">
    <rdfs:label>enolase 3</rdfs:label>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f98b35ae-3386-4684-8c7c-6e768aeb1ae3">
        <rdfs:label>ENO3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0e01055-1f07-4e91-a64a-07ff333a312f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/289f8135-6968-443f-b588-14707cf0a854">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87faf5fb-38bc-4b11-89cb-b4c781a8745f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6986064-f6a6-443a-9c62-b4db41143056"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54b0dc2b-dfd9-4555-8b2f-26895e7455e1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4391e8bb-2e9a-444b-901a-fac2730b73d5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8268073-1127-419b-891b-79e2f51810ba"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/628b31a0-0d08-4d7b-815d-072bf37e4d54"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dce6f91a-90ca-4760-8ea9-357f62caebd1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
        <dc:identifier>HP:0002072</dc:identifier>
        <rdfs:label>Chorea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/871abd42-9049-404c-8999-fbc42a848f7b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/684c6556-3432-4896-b7ee-ecd9797e1514">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002028</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c19a2373-7781-4948-a49b-e4f23434eb7c">
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <dc:identifier>HP:0025356</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1939c56f-6669-43f3-be59-fbfb2a3b9e03">
        <rdfs:label>Cognitive impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39c5d6fc-fc8c-45df-acf4-58d2b8ba1999">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9222aeb1-9a05-4949-a838-ea5f55329af0">
        <dc:identifier>HP:0000967</dc:identifier>
        <rdfs:label>Petechiae</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19062ce3-7778-43c2-ad7c-ed66b0bb8c3b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc586bcf-92be-479d-8c85-176f7412fa65">
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ef38cada-96e0-42a1-91cd-512892a093c6">
        <rdfs:label>DARS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4fd171e-bbba-4fcd-a27c-6b3b8081c996">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53873f99-e614-4a71-a17c-bb25e9d84655">
        <rdfs:label>RXYLT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f12a0912-5a62-42f2-bd9a-c3d63a50fe3a">
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f1f1b4a-2eea-4fc2-bbab-4c7e7b0f22ff">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
        <rdfs:label>ABCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c41f2d3d-bab7-4ffb-89a7-bc0406bf818e">
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e873bb6a-aaee-4a15-954e-6984c1492307">
        <rdfs:label>FUCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26496e19-24ab-42ff-bed1-cc9b6ac7bd76">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8268073-1127-419b-891b-79e2f51810ba">
        <rdfs:label>HPRT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b659f5ff-b733-4b18-8b00-db0c3e41f45a">
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc6f87fb-c8ee-4b90-a40e-eccf8b92db70">
        <rdfs:label>CASR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/71d90648-53c0-45f8-af77-83fea2d5395d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/217f8fb9-6015-46f5-917a-02b08f5edfc3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
        <rdfs:label>MVK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6fbd305a-e838-440d-8d9d-09fca8e8651b">
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84ac1d83-ea5b-4e51-b6cf-a2bde5f8ddeb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:label>Spasticity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ac26aa3-1f6e-401a-ad83-567880031774">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a438532-7c68-47cb-b201-e905f624b63f">
        <rdfs:label>Anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/087c9003-1258-4c79-bd25-7cff17a2b93d">
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3440f582-51e2-4eaf-9313-2fc1c7950f9e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ef2cb38-0ac4-40e1-bc4e-217e6100421c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f945fc7-0236-482e-a916-5d2abec5f735">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delirium</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <dc:identifier>HP:0031258</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5384b484-55bd-46b2-82ef-2894bcf96d31"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5e1bad8-2251-4b2d-8eef-8b2e2155673a">
        <rdfs:label>Haemolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4bb3204-8bdf-4dfd-aa32-85194331938f"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2631b132-0e47-4b7f-8191-61fd0cfa6031">
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2e3216ff-a9f3-482e-884a-d3c3f0fd6c59"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73973695-a66f-4fe9-8794-6047cdb8af73">
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a7ec5462-4af0-4729-9556-7449c09e884f">
        <rdfs:label>MAN2B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fda7cbd7-aef2-4407-8967-2e21ecc138ac">
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d122331b-a014-404e-8167-5c9fcc5a1101">
        <rdfs:label>CYP27A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88bbea0a-fa1b-4f42-b971-f41012206d75">
        <rdfs:label>DPM3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e01ea8ba-e51d-4a2c-a6b4-25b1089e888c">
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d9916c4-3107-4d96-9d0d-29512566a39b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/32484a72-0ad4-411f-8c41-f81b332c9889">
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c465e5d0-b9d7-45f6-b722-186d164868b7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
        <rdfs:label>PAH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7c3f605-a100-46c5-86e6-0978f8414e2c">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/155864ce-a121-4609-8a79-66d1bfd98005"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bc61e62-be09-404b-b1f7-5c36774f5cf5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a56d0e72-ccf9-4025-bf77-9195fdf36e68">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cognitive imapirment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0413914c-ba46-4bec-8f8e-65bf69cbd625">
        <rdfs:label>Memory impairment</rdfs:label>
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b60692f8-2c08-4648-bb56-0673802be396"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8bf3048-2327-414e-84ab-87b86d9e6113">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <rdfs:label>Learning impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001328</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d34e62d-3e42-4bbe-9dc2-2913ac71cac9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8c7a5dbb-6271-4ed2-b962-6d714b26b45c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0f3f3fe-d8bc-48d6-a2b6-e5854f452077">
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/092202c6-0221-44eb-bd13-eb06b50986e5"/>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1384660c-c9f0-4b11-934f-75dc15f8a694">
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cce2862b-62d2-49ab-96db-809d0890d530">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
        <rdfs:label>FA2H</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a4649bb-9246-4794-97d6-768e6b96bf02">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28c39e1b-db7c-4b81-ba91-d5feb5a87199">
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8ec5b1c-a3e1-4206-8d40-3c9bd36248b2">
        <rdfs:label>FXN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/edf43ad5-16ce-4622-9bd2-a783590dbd25">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5e89eb3-41e5-48b3-8186-5d9eaa3dbdd4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/775b445f-4f5a-451d-874b-5ac75436c808"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd0ef11d-333e-4d58-9ffe-4e49d909b3e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa74fd0f-403a-47d5-b106-bcb5b8254004"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/859a29a0-9884-4764-95bd-3b486e1c7ef3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
        <dc:identifier>HP:0000793</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31f86851-7c25-455b-ad3a-cbdce64aec83"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c5a2f7db-b1f3-473f-b6b1-14126d2bdf00">
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3dd15c67-e598-43c2-a62f-767398652d9a">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c648b3a1-aaab-4310-9cb8-1521b864f90c">
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/abe964a6-3b5a-4c11-80df-d442b3930702">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
        <rdfs:label>SERPINA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a723394c-a097-49a6-8657-45ac46664fdd">
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ed21e664-2dc2-4914-ac3c-a816840789f5">
        <rdfs:label>PRODH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/acb39840-92dc-40fc-9beb-62fba07b5437">
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <rdfs:label>kynureninase</rdfs:label>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0cfff641-6022-47dc-998c-e21967e5a65f">
        <rdfs:label>KYNU</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f0e29a96-f7f4-4508-9647-37730d145ec0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c0d67642-f433-486f-8480-747130ca3d0f">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8aaaa1ca-72fb-46f3-a096-26e82c94dece">
        <rdfs:label>CUBN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1509c050-93c5-4fac-b9f4-367072ff0790"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9374178f-77c3-4c53-ba35-191f640ff6ae">
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73a343b2-851a-44ad-abc9-f45ef66efcfb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
        <rdfs:label>DNAJC5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ad44de8-1381-4e6a-82e6-c845a50a730e">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca"/>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ab93a73-433e-44bd-8fa5-bd7b70a13041">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
        <rdfs:label>B4GAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e56bc6db-e148-4c1e-81f0-20556da40ee6">
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8cbec8c4-a3b9-4c40-b127-55658f3e8ceb">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f8f38128-3886-442f-99a6-e48269355362">
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9d16e73e-34ef-4522-a6f4-035af4b1c39b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
        <rdfs:label>D2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d5ba2fd-1ac0-4cf8-97b0-873a0b7c8866">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f32dcd47-ed17-46df-9c15-5f661a73569b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f80eec3-8423-44b8-9df1-ca27dfd7cdc1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/438e274d-63a9-422f-a179-ec65c4a77572"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/471b38de-2819-404e-bcab-36106270ecef">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b61c4a6-c34b-4f71-85f2-ca2c14b6fb2c"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/305b91a7-3fde-4dfd-b2b7-d08d636071e3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040088</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/64958d37-9834-4bff-8fdf-475dc07d42a1">
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab8f21d4-9bdc-420b-ac6b-62c444b206c3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
        <rdfs:label>TK2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e0e1d0e-97d4-4b32-8fde-ab1f8d222c0a">
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31f86851-7c25-455b-ad3a-cbdce64aec83">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
        <rdfs:label>SLC7A7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c85e8e4-9514-4ae3-955b-c36ce4120a58">
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <rdfs:label>Methionine synthase</rdfs:label>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a3d7622e-0341-4801-8dc2-f6f3045b01d4">
        <rdfs:label>MTR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9157ed5f-349a-46c9-b19b-5146fc0a83e7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a4f0687-20f5-4ac3-b475-b211368aedcc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de003c1-dc0c-4917-ad72-2831b17e2bf8"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/595bbb4b-8091-4c6f-9d9b-1cfe264042a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/124e4169-c93a-48a6-b3d4-258f61b89c5b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/345b9841-169c-4d61-985e-4856960a0d2b">
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22dc3a49-e179-4a5b-819a-f455a62075d0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eff5f835-d62f-48af-bb07-5a36a1013579">
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b3c920a0-067f-466c-9749-fbb832413ffb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
        <rdfs:label>OCRL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c2109e4c-0d39-4c5c-b836-7c6cd8aee7af">
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4e0e6147-20fb-43d9-8b57-59969590614b">
        <rdfs:label>ETHE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a1374a59-1cb5-47ee-88c4-8c700a4dec41">
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6fa34f9-9b5e-43f8-9fa2-6ea671de8c35">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0c9f85a-78de-414b-8824-c2bc7decf70b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/329be4fc-1089-42f6-a899-cb3691d84bf5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
        <rdfs:label>DPYS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51a7327d-9e97-44e4-8e01-a5b7a9ec7ce6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ea7c0ef-4f68-4e5d-9e61-eb41b2679184"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b90ad4f5-1b95-4233-88d2-49ea46f48250"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97dff530-ec43-4269-9854-cec657c9fcca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ecdaf29-0d38-4bce-87af-89f7d1621d67">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55b43847-d2e6-4d45-9259-33c6d07bd22b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa6ed2f3-18bc-440e-86e2-6efef5790f30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/60edf3b3-cf85-44e8-b08a-4cdf4b83ee6e"/>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc395368-5e4e-4f93-9594-def62c0f79e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0341ad5a-90af-4280-9976-35c5843edcb5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9a671abc-d213-4924-8c55-ae0c66ea2fd1">
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/01b04267-a542-495e-971c-24f3001caca1">
        <rdfs:label>FBP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c27f055-5ecb-4222-a6cf-5352ef8ab4b9">
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/560d8bbd-1557-4268-be67-309569a3e6bf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9c7d30e-d3e4-4414-95d3-ac3b7e1aab7a">
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/719dc29f-a2d6-4fe8-ae13-c054269432b9">
        <rdfs:label>PHKA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0320097c-516d-401c-882f-19d02041a9dc">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/88bbea0a-fa1b-4f42-b971-f41012206d75"/>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d99a9e3b-fb32-483a-b727-b8bc25be7ddf">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0f244888-d485-41dc-9ebf-d3fd39d67ec7"/>
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a9964495-bde3-4c35-ad2d-65f9600046dd">
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d2beef1f-a4c2-49a9-9a63-c7b7d4275407">
        <rdfs:label>GCH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3d87475-995b-4f5a-b508-2e9cc2c3d65b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c11a4741-c526-4f04-b586-e8ff5509121a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/178f4b6c-aba2-4956-88f6-3942018ce92b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/758ad2f6-b899-4e17-963c-21c16ed21749"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e7de8ce-ec3e-4536-a0e4-5d751dc40e2f">
        <rdfs:label>Delayed receptive language</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ddcd9e8-4d57-4322-96ee-52fa5f92b09f">
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/706a0664-cd35-43de-9812-88c76991b471">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9aba409-6f40-41fa-ac90-e717759fa3b8">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41894499-e9ce-4c3e-a2d7-ef1842b53062"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d51ab12c-9694-4736-99f0-a9a6aef43c30">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e973cd37-63f8-42e2-ba4e-cfdc5c952ab6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/706a0664-cd35-43de-9812-88c76991b471"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ab1f1e8-36b6-4ef9-9f7b-e0772c0ef003">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/725fe9a1-8890-4c79-9a61-48f4f6e11d22">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>Prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/547effb4-7c5e-4427-a9ff-e8ceba2800f3">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0da95fd8-302e-4a0d-ab0a-d6387d315ad2">
        <rdfs:label>HSD3B7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa2f3e74-43fa-4fdc-9e6b-2ad741631a0d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c220de08-6c31-4124-a016-97def314a896"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/156e9d1d-812d-4d2a-882f-793eb6de650a"/>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6f0ba48-609b-47d2-94fe-0c1bb56e7d51">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0003530</dc:identifier>
        <rdfs:label>Glutaric acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ca7538d-6a17-421d-aaf9-75a34a6b5590"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8269b17c-8f4c-4b73-850b-9f22e4797023">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77e117d7-1cc4-4b3d-a81e-7dc83d1a05dc">
        <rdfs:label>HMBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/40e3777e-c70e-4b85-9694-3f3cd97d0a0f">
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e2bd254-f928-4f9f-9360-17e17e4b35e1">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7dfbcb2b-18d6-4c8d-b18d-80b3604da25d">
        <rdfs:label>TH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d2beef1f-a4c2-49a9-9a63-c7b7d4275407"/>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ed17e6d-85f1-4cb4-9bba-6843e78402e1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/65826de0-884c-4aed-8761-a62466fd0872">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
        <rdfs:label>PIGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8e50fbbd-7458-4442-8bd3-fd140120a5e7">
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc938532-7646-4e6a-8b57-098b35546afd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
        <rdfs:label>LIPC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/33ec3b25-3c83-4d46-a4c1-0dc1555bf5f0">
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5c8caba-76f1-43cf-8187-6206818026ff">
        <rdfs:label>PFKM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b281a564-2d9e-4edb-96fb-a7de8bc5292c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3ad2fdcf-496a-4e4b-a4c1-b45e926b20d6"/>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/394505c8-cd49-4ecc-b3af-26a494474341"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14783d19-9184-4176-87be-d13a7b1b8215">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The study was terminated</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c6630a4-3cc1-4c85-b27d-87ab1112fd9c">
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1269e6d-276c-4daa-80db-d7f225dc7405">
        <rdfs:label>PRPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e8ddcb21-b496-40ea-a8e8-bd598b0088a1">
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41a49922-afaa-4d19-b7dd-9c670a3da25e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21b30ea2-fb66-43ae-99e9-0e43379b7bb9">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/489363b0-3df1-4648-831d-303b07519378">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
        <rdfs:label>ETFDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6fb3e481-0089-4bce-8bcd-b0a367ac105a">
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a6737a2-4741-4f3f-9b0a-aa451c178d43">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
        <rdfs:label>LCAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b7df0ff-43d2-49a5-905f-4a6f0e143fc5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc709272-c4ce-4226-9d14-5a1ed663af36">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/337460b9-11df-4a3c-9498-18e34c18a092"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/608515ae-6465-455a-b259-d17fa786abac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <dc:identifier>HP:0011505</dc:identifier>
        <rdfs:label>cystoid macular edema</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6c3fe2e0-0673-4810-91f3-5e3f48b0914f"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6007568f-bb92-4c7d-b768-22fc21854656">
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31b78755-12ac-422e-84d2-9e35dcd61e00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
        <rdfs:label>LIAS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/855d3ced-1b3c-45fa-99e7-6d7a17dadcd4">
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa2b9464-6b0e-45e2-81cf-a71628f71a0e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
        <rdfs:label>DBH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/745f7a86-204a-45dd-ab1f-6184d1b2c16d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/febced14-8874-421a-9d41-9e39a2738e3f">
        <rdfs:label>AASS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46d9b459-de00-4392-aef7-95438c66c269">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81129cfe-805f-4766-8ab7-4fa06f7754a6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:label>xanthomas</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6728220-8111-43bf-ab3f-e9f23bc16caa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <dc:identifier>HP:0001677</dc:identifier>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c249f4c-b87b-4402-9e73-46ae2253d989">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001681</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <rdfs:label>angina pectoris</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3bedf9e-56b4-4db5-8fb6-bcee085af451">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31c65691-345f-4d49-bfa6-aba6f69f044e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a709946-f0f8-4fb4-abea-38d5b99730ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f7c7365-c36e-4921-9581-63ba058853aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf1d2677-3735-4404-ab1c-91ea80713956">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc395368-5e4e-4f93-9594-def62c0f79e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51">
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7ca9046-e90c-4481-98c7-73727ea0b918">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12516621-b0d5-4d67-9c9c-0495a3a7f66e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f41f47b2-9a0e-4dc8-b22c-315449374679"/>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0a24898-765f-4bfe-907b-6208f7c3dfbf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a314d1f-b034-4d6c-b753-db1300fe890e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a36c6ec-2996-4ea9-9067-1c19760f9342">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65973754-8bff-487d-8ce1-7639395e2e59">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16347e82-d4d7-49d0-9ea9-d3cc8f02004f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47b0cbf0-0842-44d3-8b52-ffdc0cb170f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30472bcd-d169-42d1-a754-1fff6f29457e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b4cd0da-e8ca-4c2f-add8-0a6094e035f9"/>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a52a6a-60e3-4754-bd9a-f50d26c5afae"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fd5d5699-9e3e-4c16-b983-cf9cc8a8fb83">
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f3c37b9d-a34b-406a-8368-ea21e2adce33">
        <rdfs:label>MTRR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a3a8929b-9016-4e50-b68a-1be35a56c82c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9576ed2d-d6ea-46ca-bc4b-fbc6a175f3da">
        <rdfs:label>ABCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f98b35ae-3386-4684-8c7c-6e768aeb1ae3"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f1b08b0-a89a-47cb-a8fc-5bbd21d4538b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c7fc2b9-021f-43d4-a29c-7d67c1c6c830">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4ef7d73-fca0-4ceb-b2b7-cc868649caf9">
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6154c3f0-88db-4f74-8711-6de7d76119de">
        <rdfs:label>GLUL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa1e0cd3-0116-4328-8d06-e6d1fe4c8a8a">
        <rdfs:label>POMT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/286264cc-4624-460e-9122-c09650c2054e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e31737c2-d73a-409d-97f2-0f85ad70cfd9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/978369e9-dfa6-41ee-bf25-63a0345a8f61">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025065</dc:identifier>
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5863107-b6f2-4795-bb78-fe766f1e8172"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed36f4b9-b37e-4372-93b0-9da6f33d33e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025546</dc:identifier>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec151e15-547f-47d2-8436-7d1e8875eb0c">
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c6c8b3be-3a9a-43b7-8424-6c042d0457c6">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0f42416c-f51d-4396-95f9-9f51b7314052">
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c3fe2e0-0673-4810-91f3-5e3f48b0914f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
        <rdfs:label>OAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/718531c6-ad4b-4edb-9eb6-6c17db483d12">
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d16c891-2645-4faa-bb7e-33bf797dbae0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a94c4c8-dd91-48a2-8662-eb358be838eb">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5ae1805-09d7-457d-a426-56882ef03914"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1ae00b-14c1-4abd-9b49-4d20911cfa22"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/489363b0-3df1-4648-831d-303b07519378"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41a49922-afaa-4d19-b7dd-9c670a3da25e"/>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21b30ea2-fb66-43ae-99e9-0e43379b7bb9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffefe752-9c13-4b83-9441-ac0d59615ad2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Dysphagia</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1418db11-d26c-4ac3-89f8-07a6eed4fe53">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56476b43-8887-4cd9-ab2d-5549b5636c6a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <rdfs:label>battenin</rdfs:label>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/727986eb-a2c7-41d2-8af0-d67a4da881ad">
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9eedf5e0-552a-4b97-bf92-16b78497768c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b83bdf-8d7d-4a16-8097-876cbd7c4f4a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9dcfd31-ba5e-47d0-99b5-24b00ff4ee25"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1466137d-add9-4895-9399-e455c0691e74">
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/081fdf8c-787e-41b3-8a37-4c31421cd3a1">
        <rdfs:label>LMNA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04b09d14-406d-4a63-9834-06b22ef2439d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c27f3aca-96f5-4936-b90e-6344c359115c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f5205b7-fa05-4793-a21a-31124334ba87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af4dd7a9-9caa-4187-a2d6-a1a2f6929350">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>Lactic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3957f17a-0eab-4fae-a62c-25c94f174400">
        <rdfs:label>Encephalopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e21859ea-7a18-40d9-b447-c4ff987244e9">
        <rdfs:label>Repeated vomiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <dc:identifier>HP:0002572</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4ee4c6a-3faa-48a0-a0c6-63804d82f8b9">
    <rdfs:label>Aprataxin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32114a79-7637-44ad-8e40-61ebe404fe6b">
        <rdfs:label>APTX</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/329be4fc-1089-42f6-a899-cb3691d84bf5"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c70195fb-2997-4aff-831c-5deb260872fb">
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f51a290e-db5a-46c2-9c0b-825723a7c121">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
        <rdfs:label>AGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad5ffb11-0514-4fdc-8fbc-673f33036764">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42cad462-8af4-4a76-b96b-fdafe64ef68e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93dd31ae-aebe-435e-b71e-6946194556bb"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa1e0cd3-0116-4328-8d06-e6d1fe4c8a8a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87fbc47a-ff51-4d13-b335-816ef297d59d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/866fee48-9c94-4f74-bcb8-672db599a262">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
        <rdfs:label>POGLUT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/90431e12-602d-45fd-8e88-0d6a9fb06ade">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
        <rdfs:label>KRT5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3f003eff-3969-42c6-b546-31b26a80ea86">
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ad88108-1187-45c2-8589-0be4491f0b3c">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8e0f8da9-2288-4f9b-a820-a49aea218f26">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/221dddcd-0fe2-4de0-987a-1ee6f6b05d99">
        <rdfs:label>AP2S1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de74c7fc-bbb6-491d-911c-bc3e9902065d">
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e31737c2-d73a-409d-97f2-0f85ad70cfd9">
        <rdfs:label>DHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5857ff0b-4964-4667-aae4-85d2908099ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8bbaa33f-5c0d-4978-973e-c00a293bfa4e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bdd0bad4-a4b7-4a72-95cb-f9c98412dc92"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89ae5356-14b7-4117-a1e5-a8b54013c458"/>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/262bf27a-17c7-4ef9-8de5-1ea4aafaa0d9">
    <rdfs:label>HMG-CoA lyase</rdfs:label>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/428eabd4-ee5d-438a-933d-2a4d5f1c1966">
        <rdfs:label>HMGCL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a98feeb2-fc39-4a26-b422-9f56454e542f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ce20dd4-02a5-4d2b-bae9-1dac4be8053a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b687d885-d133-4ea0-abeb-3e512f43375e">
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4166b9ac-634c-4c60-b709-efb82c6fa854">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
        <rdfs:label>SLC17A5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a772372e-52f3-45f8-b3d3-1dd6cda58382">
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/52ae6c5d-6693-464c-83df-627af25e278a"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cb3f837-b27b-4c9a-87ac-f76d019d1341">
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f162e5f7-81a9-4a44-b3d0-6b6803fae5bd">
        <rdfs:label>SLC12A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2ef74709-67b3-4bd9-a20a-0e169647f340">
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cccd48c8-8a04-4485-9c21-616d22821a9a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
        <rdfs:label>DPM2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/743b8f79-0394-4a8e-bfbd-694e5bc5e173">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f21e3c81-d695-4882-b179-50bc71a6c9df"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb736a80-51a7-4485-80ef-2b875f870cfd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d5f9123-cf71-4b67-bd3a-2495e3f9073c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Muscle weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03ab9a80-d0cb-48c4-9263-a622733931e5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f8883d74-d58f-43ad-b6e4-38a48a18b8c2">
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/998af4ad-8265-4881-b11c-a650952fb315">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
        <rdfs:label>GLYCTK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/61ce883b-1094-4804-b51d-805614a563f4">
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a50c95d-c49f-4847-bff4-a084df788c0f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
        <rdfs:label>CRAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad7b5062-5105-4017-8b1c-f8d985e7bea6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/814fb3a8-ea11-440e-a2bd-08d324c75ddf">
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>social interaction defect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11d39531-2884-44e2-8ecf-5faf77d8d880">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c7de922-1eec-4917-abd0-47f7ed933b9b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a498622d-f42d-4c15-9a0f-cd291853535c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9aac423-cd5b-4068-b6b0-aa6238951e52">
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/229eaba7-60cc-4749-9d62-04fcadff94b7"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f00db6d-ee5b-49d2-a19b-1f4614a916a8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/109d49f5-c73a-4f1d-a58f-4eba77eb6c86">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fa1e0cd3-0116-4328-8d06-e6d1fe4c8a8a"/>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17378f47-203d-4a16-a0e1-84c93a194a0a">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/337460b9-11df-4a3c-9498-18e34c18a092"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1317dee8-5d61-489e-a321-bd1d62871335">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/87324a46-f9d1-4407-a6bd-3a1f77b0997b">
        <rdfs:label>BSND</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <rdfs:label>barttin</rdfs:label>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f761a464-22d8-4111-90e4-4b0baa24a697">
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3edb69bf-0c34-4b1b-9384-de5e4fbc326a">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/208f24bc-b524-4cb8-b18c-409832a12db8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
        <rdfs:label>LBR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ac861a6-ce66-4790-a46b-7d946babc96e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5fab3b8-33df-4f14-bca7-248b31c37985">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
        <rdfs:label>CBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0ef1ffd-df45-4a39-ad00-48faf71a92d3">
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7dfbcb2b-18d6-4c8d-b18d-80b3604da25d"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03e44932-3f0a-4e0d-ae37-c8cee68316bc">
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/22ee4a9a-d2da-4a75-bbb0-ea352ee8a916"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6a93b070-1b20-4e08-b28f-fb1b0f93d443">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ef863d37-ee8b-40b0-9464-865fc9734992">
        <rdfs:label>SAR1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Sar1b protein</rdfs:label>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3a4ac13b-62f7-45bc-b584-fc8535222502">
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1a78be1d-c3fe-47a8-a205-90e8afe85806">
        <rdfs:label>MRPL44</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccf4c27f-7f64-490f-b0e8-738cbcb1e40a"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc8ddac1-c421-4db1-9bd1-fc16e5a70034">
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <rdfs:label>fukutin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/afa7292e-9947-43be-80eb-d19dd141d919">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06e0a431-ceae-4792-a4f7-4b7489a12c41">
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c2b258d-b3c6-4368-8add-12dfdf676f88">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
        <rdfs:label>KCNJ1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c8a9c68-a03c-42be-af42-e0be683faea1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c28a179-85b2-4f5b-8efe-18ccbff1ddbb">
        <rdfs:label>CYP17A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f648a91b-39f6-4b55-803e-1d47f83bdc0c">
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ebfb4a8a-df2a-46b5-8a04-28dcf991fdfc">
        <rdfs:label>GGT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8865ce7-965d-4ed3-8d70-f7d6071e7212">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7643b357-35af-4107-b37e-307c8254a288"/>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9a7f15ae-6cd6-4772-baf1-616f85a10299">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <dc:date>4.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b94188f7-a884-4ddb-870f-0772153322d9">
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6295b1a8-209a-42e4-bc8e-a97ca1ca18af"/>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e5159501-9393-41fa-801f-ae5c9b93ccdc">
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b232d36b-a921-466e-8e4f-3846260a2e5a">
        <rdfs:label>GCDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7096867e-b411-4f3d-8766-920da41c3dfa">
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4a4649bb-9246-4794-97d6-768e6b96bf02"/>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e50809c-aab4-4a21-9bca-77c1457e6b3d">
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f32dcd47-ed17-46df-9c15-5f661a73569b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89d1f28e-4f6b-4952-8e03-6d4d47c56cfe"/>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30f08c29-bfbf-4eeb-a9f8-d449b5479fdf">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ebdad40-fc65-4cb3-a014-004217c6e59b">
        <dc:identifier>HP:0003107*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4d362b20-f5f9-4af7-a2c1-c474ea703ad0">
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0fe52612-7507-4721-b782-7d1a40b017a3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0defbdd5-874e-4636-b866-67b3691ea717">
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b4cd0da-e8ca-4c2f-add8-0a6094e035f9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
        <rdfs:label>MTTP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a0c12a6-dbc1-4a16-ac82-14d06bf24ebd">
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9d16e73e-34ef-4522-a6f4-035af4b1c39b"/>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0148f899-6c66-4746-bf1a-44a8810b7f31">
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b053012d-a273-41ff-ba99-3e7745221ef0">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b796989-4c8e-4180-b5eb-8067217d0a84">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51b88939-7787-4da1-9191-7688656bdceb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>LARGE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/690493df-88d9-41d9-9b12-0eb0a94bfa20">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90fbbf6f-ae6c-40f0-b796-7dcf80482958">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75421a1e-bff4-409a-89cd-1adc0a1ebabd">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0da95fd8-302e-4a0d-ab0a-d6387d315ad2"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b245c0b4-2e95-4c84-925a-05902a0a1ef5">
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fea8248b-43d3-4ad5-8be8-7abc309c17e4">
        <rdfs:label>NAGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b56ebfac-9824-4afa-bc54-5c25646f7106">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54b0dc2b-dfd9-4555-8b2f-26895e7455e1"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bf52c7c-5a31-4dbe-b117-bbc4a4c2f897">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6986064-f6a6-443a-9c62-b4db41143056"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2993ded-d938-4ae2-ae2e-4ab7a2aee4a2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2494a167-c888-4de8-b99d-a53584a59387">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac2a7427-a0fa-4193-a864-445f12e8e911">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e55c910-68e4-4fdc-9e39-44d502b5425f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
        <rdfs:label>PYGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d87ca177-493f-4f5d-bcee-d6be1e8bcef5">
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89d1f28e-4f6b-4952-8e03-6d4d47c56cfe">
        <rdfs:label>DHCR24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/725fe9a1-8890-4c79-9a61-48f4f6e11d22"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5dda15a6-46ba-4a8f-bfaf-f0ad1d6e6d9a">
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43472a92-8223-4feb-bd9f-be5e66e5bca7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
        <rdfs:label>PHKA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c532f79-4740-48bd-a0ae-9cbde3069513">
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6ddf9c8d-46e1-4542-a6e6-0f103db64b8b"/>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c64937ef-9e9c-4675-a7b0-7b4da8df7a8c">
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <rdfs:label>codanin 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2cf42ce7-f3a3-4890-97d9-05d651636fc5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
        <rdfs:label>CDAN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b5d4ec44-3dfb-4a63-a49a-3a585de3cd6e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
        <rdfs:label>LDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3587d632-44b9-4595-ac9a-6ffffa832cab">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ffbc7dcd-43dd-4464-80f3-6ed18bd86a13"/>
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6adb7dd7-5bcc-427c-85e4-5cb23cfc68e8">
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22315057-1117-4b0e-ad35-c03eb75fcf99">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
        <rdfs:label>COG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a755b87-a1bf-4520-8409-a7f9669cb35a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/414ab5d0-7ca2-4cf6-a686-4ff0fbf334bf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
        <rdfs:label>ACADSB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/905bb27f-c913-4a61-a6ed-310cd70ad797">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f18d873-c34f-41db-99a5-7aee7830ab4b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91644163-e98a-490f-804f-ba49fdcdf92d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c6e6b9-bde3-4b21-9ef3-b9050dfec70e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe81493a-6a16-4b66-acce-291afff2174e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b9c0e4d-5b92-438e-bc00-b2836d8aca00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d26c5b7a-40f3-4da2-8703-ce682c7d900b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31a22d07-3814-4f8a-9225-786b02e70e19">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b369209c-276f-4dc2-8cd0-e9fcfb57adfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ddd8b6f-d98b-4cc2-a966-28520f23dcff">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/963d62ed-e5f6-40ee-9343-a9d8520fcc58">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af5e09fb-68a3-4ef7-8646-cd7d0e65fc79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2505a55-7229-4230-b4b2-bfd40b160f36">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb47dce2-3343-4b67-9a72-ad68ce4533a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/be857b54-1b1d-4c4a-8203-e254bc968e79"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19f9de26-61aa-45c1-8077-597e0923419e">
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/534d190b-e0c0-421e-8c38-8337b1f0e75b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
        <rdfs:label>PNPO</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d161c17-5de0-4117-83f1-ca96abab8dd3">
        <rdfs:label>MAN1B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f0856d46-28bb-49f6-a94d-b3735e37ff98">
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f0e596dd-2846-447e-8fde-6d218f02bb93">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
        <rdfs:label>MANBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <rdfs:label>Beta-mannosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73a343b2-851a-44ad-abc9-f45ef66efcfb"/>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/509fb2a0-f7fa-404f-985d-41ac27b6b239">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7fe6ec15-a31d-465c-ae26-70f0aa0f74a4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
        <rdfs:label>APOA5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53212253-beaa-49dc-8dec-5cc9f7edfeed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
        <rdfs:label>MYH2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5809d8e6-10a6-4852-acd3-cfdd4f63ef8f">
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06b88440-c43f-4dfb-8fbc-ec937754be12">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
        <rdfs:label>AVP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2d0ca990-79dd-445b-82bd-c8c1bb226ce5">
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b5ee993-7238-48cf-96c4-fe607e0644da">
        <rdfs:label>B3GALNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22315057-1117-4b0e-ad35-c03eb75fcf99"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25b21619-f983-4c26-8a02-1cc73d062ccf">
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5cd307b0-4c12-4be1-b97e-d0b6796ae458">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8347f4f-8692-4759-8c01-9de78fba9647">
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0d161c17-5de0-4117-83f1-ca96abab8dd3"/>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dcd52175-8cde-4294-8e19-0b7a964509c3">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/32ff1606-f1b8-4c34-a4e6-648654f4b069"/>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <rdfs:label>Ribonuclease H1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7aea3c5-0943-4c35-a862-f203afe20682">
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a1bd660b-eb6c-4086-82ac-7917ab3905f7">
        <rdfs:label>HADHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42da83af-222d-4528-9d15-3c36ff588db9">
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <rdfs:label>dysferlin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f39ab1db-9088-4000-ac06-8a09c295542a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/72294a9f-855f-49f2-91c0-011298f20cb4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c92f47b-e93d-49ba-b074-e30269e268ba">
        <rdfs:label>BCKDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c62933a5-8037-4527-9d2e-0a308cb879fb">
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81814922-e5c8-4da1-9901-780c93ee314f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
        <rdfs:label>SGCA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/48842357-6905-4e9b-a957-f7a0266fdbda">
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2237bbd9-b0e8-4e9b-b2b3-4d2f5ccbf5f8">
        <rdfs:label>GAMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5edcd643-b1dd-4f9f-a045-9c0ef2e48018">
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ce85908-874c-4f1f-8ff7-a891db312707">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
        <rdfs:label>SLC2A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/49762d8d-9276-469f-9bd1-cb5c9aa98889">
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/53212253-beaa-49dc-8dec-5cc9f7edfeed"/>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/258f985b-bf70-47de-a005-e89216c77047">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a10a23e-f90d-49d0-bde8-1cdd58c929c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91dd08ba-0fc0-471b-a396-ec5eea74eb76"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a04bb14f-60cc-4340-9259-d7f059ce2d8e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c5168211-5a8d-4a25-8ab4-80d610cc7fb8">
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0255dbbc-19f7-451f-85f8-76e1498d388a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
        <rdfs:label>GLB1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01bf0db3-7af1-4131-b298-2d683039be45">
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8220c013-e884-4f9a-b810-835296506fca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
        <rdfs:label>PIGT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5da25e9c-dda5-4e79-ac4f-b0ee2d7f2414">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7fe6ec15-a31d-465c-ae26-70f0aa0f74a4"/>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>apolipoprotein A5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/07c12af3-44f9-4afc-be2f-7cee6f9bf326">
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df4df3c9-4c50-4060-8bd3-7a95b0c8a8f6">
        <rdfs:label>POMGNT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7ad09d41-6b6e-4499-b011-f512d9625eeb"/>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1cd769d7-4e4f-4cb3-8bc7-f18a74e9c529">
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
    <rdfs:label>Glycerol kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ace88581-c414-4d16-a0a9-ce87b8669c37">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <dc:date>3.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffbc7dcd-43dd-4464-80f3-6ed18bd86a13"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8f113bb-b986-4537-8f15-e07860c3fb5e"/>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a48d232-1d4e-4458-9f25-3ad73447349b">
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a849e2f4-7d17-4cdc-8d5c-0d0de5c73712">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fe81493a-6a16-4b66-acce-291afff2174e"/>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3564f2ec-e1bd-4f6a-8684-86f75842b907">
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8f1e2b0-15b6-496b-9d36-0ff64cc69e9d">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c989e37-4f20-44f5-94bc-68bfc08fca82">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41894499-e9ce-4c3e-a2d7-ef1842b53062">
        <rdfs:label>L2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f554e6ea-4814-47bb-a11d-9f279a50dd81">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bf3f7efb-d072-49b2-abf3-5e8dbe064780">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
        <rdfs:label>ABCC8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/34c1d86a-cb44-4618-8ce1-f94a3150723d">
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f2558db-0544-42ef-bc4e-6cb2a0593653">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c69048b-091e-4b79-b74b-356f0699a61a">
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea4316d1-61f1-4ac2-a681-494bbd598835">
        <rdfs:label>PGM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fd01420b-f4dc-4f85-924e-b194ba1d11a2">
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7abbaa38-8698-4e03-8565-b4ca71e70eed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
        <rdfs:label>ABHD5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/013ac84f-8115-4990-909e-411178edc256">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c8e3ec5-5e47-4bbf-81d7-639beb7371bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4feb137-00c5-45f0-8185-eaa9bcc6684b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff2d451f-ed0a-41ce-b75d-b3d7e439709f"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31f10c32-7f54-4b1c-a1d1-7eb5ae4f7e5d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34037feb-15bc-42ec-ab71-37cbb076d2a2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ceb3f16-bb55-4a22-a88c-5f8b5c71bd52"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ebc9c285-245a-4fb7-8f5d-9e94b546b540"/>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a0a6bd5-3178-4a71-8ca7-5501597c5fad">
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b032c7fa-1780-4508-8c86-601b2696a1c9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
        <rdfs:label>Dehydration</rdfs:label>
        <dc:identifier>HP:0001944</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/337460b9-11df-4a3c-9498-18e34c18a092"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed4efed5-84a3-4599-8d09-b605eabeb3ae">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dadce545-08e6-4d0a-92e9-e5344f55b6b0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/40d92f29-db6c-42df-a290-0cba1032d4ff">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04c2fff2-c78e-4264-b43a-f4ae71d8cc56">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <dc:identifier>HP:0003657</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0ed550b-09d0-42bd-ae20-b5154eb3c5fb">
        <rdfs:label>Defected alertness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004372</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d68469e6-7a03-4511-b44b-a9f57b61784a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/516289e8-eb35-41d9-9659-ac248621f72e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e881c5d1-daec-4f6f-a726-2a7dcd31e5df"/>
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bea0f444-8eb9-4d32-9f87-daf9bdc8a64f">
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6e84eba-48e7-4120-bff9-30327c6272f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>irritability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d1fd6200-671f-4885-81e4-bee01ca2349f">
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f557b977-3657-4270-8bc3-7ebf43c3c5fd">
        <rdfs:label>GLA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ab93a73-433e-44bd-8fa5-bd7b70a13041"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8ce20dd4-02a5-4d2b-bae9-1dac4be8053a"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e3d302e-5d9a-4192-aa68-7aaf85d3fae2">
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82976760-2244-4d41-b5ac-b1ce2f8fd7c4">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ef863d37-ee8b-40b0-9464-865fc9734992"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf226748-4119-4a35-be10-34a35cb2a31e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43278188-88dc-489e-b426-970cb4ec1802">
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7bd29e5-ec81-4194-ab3c-87b9fb4595db">
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5bada56-fd8f-4906-a344-7f71e5cec49e">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae364e22-28f3-4f7f-8108-fa0569d219a2">
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca4ac539-b93a-4bd2-9ff0-3c48e00b3125">
        <rdfs:label>HGD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e3b30eb-7c5e-4576-aa59-6c3043551415">
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75023cf9-3951-4703-8c9d-b802f35429b9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
        <rdfs:label>FTCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab003047-b1b3-493b-88d4-ee3a3715c12c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee16103b-a8e9-404e-865b-814451ddb001">
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5ae1805-09d7-457d-a426-56882ef03914"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f00c6032-58ee-4472-aa38-3241c1fb93a7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e39ad4c-eab5-4860-be92-fa8649e87e71">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
        <rdfs:label>TOP3A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/844c31b9-b5ec-4a9a-82dc-a736a64ba707">
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31c05392-42d0-42af-aad9-0a0c5da3dd0a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
        <rdfs:label>CTSA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0007d450-1aa5-4f93-9135-b9ee5bf3f34b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c46fe5e-689d-45c9-910f-b02f27b792ab">
        <rdfs:label>CAPN3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <rdfs:label>calpain 3</rdfs:label>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc131b4b-c272-4b77-b6b6-42c53255286e">
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/094c2de1-8d75-4b34-8990-924a8d71b9ba">
        <rdfs:label>BCKDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c86ee5ea-6560-4caf-8a08-1992aa5c01fa">
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89883534-7cd4-4e28-bbc6-81d4e64c75ac">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/841d2823-5d76-432e-83a8-47d1982e926c">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56a94c65-c0d9-4415-b664-f6320b68d1ec">
        <rdfs:label>GALT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/40badada-8f95-4a5f-bfbd-f87ece0412cf">
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/155864ce-a121-4609-8a79-66d1bfd98005">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f7e8f835-37c6-4ea5-af41-2e2320a6d473">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/97c88306-b922-4240-85ce-92972686c658">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
        <rdfs:label>GNE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04e14410-91b8-4300-b69d-125bdaddcc5d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22ee4a9a-d2da-4a75-bbb0-ea352ee8a916"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3aaeefba-003d-451c-911d-364814116137">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4add92aa-aac3-4058-8a1b-69d93bda39dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c7fc2b9-021f-43d4-a29c-7d67c1c6c830"/>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a52dc1b-35b8-4843-b5ab-ed0c2c64bdea"/>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c3a79b2-4412-4ae3-a2fd-ed3e64cb3aec">
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9c598471-68c5-4446-b146-988dd23485d5">
        <rdfs:label>DGUOK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de9dd0fb-1284-495f-94fc-3e8505551e86">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a74b31bf-994a-41fb-9957-d7d63eaf2486">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/80473d4b-3e66-47ca-8094-2b7d8e089d90">
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/111e676a-ac86-4be6-a83c-1df38693662f">
        <rdfs:label>ABAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GABA-transaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0d7a5d9-d231-46e3-8191-28b1edef299f">
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/826581c9-8d66-4427-a8ef-9be81adb900f">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c10c6df5-c366-48ea-9c6f-accaf19449e7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aee6c7a5-190c-4253-b5a6-5041bcc07ad1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
        <rdfs:label>ASL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/08795cff-c696-478d-b5a5-a304eb7c6021">
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b2924dd5-4d37-4578-9ac8-14ec0d4a403e">
        <rdfs:label>PIGN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2743ab91-92b4-44ea-897b-8d2c32033740">
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5948958c-c2c0-48ed-a702-a536f3e243d3"/>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0245dba-c1ad-4980-a6d8-97fbd6689b05">
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c510cb4-4659-48ee-9ce5-a04508a1e43b">
        <rdfs:label>GSS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glutathione synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36586a2b-b272-4cb9-b3b4-2fad7773957a">
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1a78be1d-c3fe-47a8-a205-90e8afe85806"/>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ece7837-184e-4323-be9d-6b64154602d9">
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3b703461-caef-4c27-a50f-b5c1fd8117b8"/>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7b57920c-f465-409c-931d-5e747d927f0e">
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/334b4190-8de9-4e19-a87e-a016e98bc6c7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
        <rdfs:label>BCS1L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a42072d8-ba42-4d6e-9f97-28230bea68e7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e140dc04-fe23-47c7-baf2-151a9e37483e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
        <rdfs:label>MPI</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29be23fa-fff3-4a89-bf26-021e9d024cdb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f268369b-e2a0-4dc0-99a8-86e1f4404b4a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
        <rdfs:label>CLN6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5f43a9cf-0e56-4a9a-a49b-6100ed225c1f">
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/63ba237f-31c6-48d7-943c-8404e2a9660e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fa0e8ddd-e15a-43db-8259-87c567f2cc38">
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2c751f12-b4f3-47ab-9ae9-5feb88f9a420"/>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9a2d5169-09d7-426f-896c-eb8558e18f28">
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/208f24bc-b524-4cb8-b18c-409832a12db8"/>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <rdfs:label>lamin B receptor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/891c7b72-9ac8-4707-8ec9-54258900e3ca">
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e2be668-116a-4a4e-a93f-bbdfb207ed9d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
        <rdfs:label>LDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b5d4ec44-3dfb-4a63-a49a-3a585de3cd6e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/21a340c2-e70d-4e31-a20a-34a221a0bf55">
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b6d6a804-0d4d-468d-b462-6cd64929342e">
        <rdfs:label>FOLR1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <rdfs:label>Folate receptor alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/69a056b7-0edb-469e-b237-774905adcd3e">
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e881c5d1-daec-4f6f-a726-2a7dcd31e5df">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53873f99-e614-4a71-a17c-bb25e9d84655"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef2f3ff1-9f78-455f-b8fa-52f523ff8122">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b122f7a-badb-4396-9c1e-4d1d06b73951">
        <rdfs:label>MAT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cccd48c8-8a04-4485-9c21-616d22821a9a"/>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42536b50-cabf-46f5-9bfc-b33fbbcd3259">
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e51348d-a50b-4dec-855e-488bc8a8bea3">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7c31bd70-3aa0-446e-93b0-32dfa5df601f">
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/171eb77d-af3c-4eab-8f87-5d626a33b46b">
        <rdfs:label>ADCK3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0181e05d-83fd-4205-9172-542adc8a84de">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17bda352-ff59-4c09-894e-8645ee6ee038"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5cd307b0-4c12-4be1-b97e-d0b6796ae458"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bc773dc-5ead-4bda-a49a-f01a7fe59841">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f0e596dd-2846-447e-8fde-6d218f02bb93"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e714ee2b-d4b1-4a39-b31d-d25398545df0">
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c3dacd70-b9e7-46e4-a67c-322aaaa55445">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
        <rdfs:label>IGF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2860f4a7-cb3b-4e02-94b4-89c8c5a12d5e">
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a0e90cd8-cd50-4364-81c0-2d898496e31c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e9b4a864-963d-4687-8810-b1f0fa8a2df0">
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bcfecda2-1918-4713-9949-11319fe092c1">
        <rdfs:label>NPC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bb0d5efe-f9dd-47ba-8af4-d8384a49652f">
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba34e0be-9f38-4531-a786-4a1df60575f3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
        <rdfs:label>AGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f4e2505-02b8-46b3-89c8-6748b0077aa3">
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8310da66-718a-4d41-bcf1-84c076513141">
        <rdfs:label>DNA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b88f23f4-63da-4162-baae-cfbbbd089c57">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/725fe9a1-8890-4c79-9a61-48f4f6e11d22"/>
    <rdfs:label>prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f99c4ea-37e1-4b11-b4ee-1b1d321008f4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1db1aa96-2ff0-4acd-a8f5-54d0d64d7a50">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
        <rdfs:label>NPC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9f4814f1-cf52-45e2-a6dc-cc7622f22ced">
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/63ba237f-31c6-48d7-943c-8404e2a9660e"/>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c7ad6e2-a80b-4c2c-af7e-7c1c0f61c658">
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/155864ce-a121-4609-8a79-66d1bfd98005"/>
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f3816b77-c29b-45b4-a19b-fb80fc2bea87">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffc9a7f7-ab79-4c42-a825-d786eaadb02b">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee754580-67ac-458e-b37d-9c622da2e573">
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <rdfs:label>thiamine transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/814cca25-07c1-4a8a-a7ec-9b7ac8f8737e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
        <rdfs:label>SLC19A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/103e4e21-5649-4af6-bf9b-61445a5d73da">
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c3dff729-64ae-4ed7-ba32-2052cdef1cbb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
        <rdfs:label>PYGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/866fee48-9c94-4f74-bcb8-672db599a262"/>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/65826de0-884c-4aed-8761-a62466fd0872"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28d1aa63-7e45-45ac-b631-1cecff5ce8c8">
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b069d1b-715c-48fc-a8bd-760b5a946bc7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
        <rdfs:label>CHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4831a53-0624-4034-b6ae-6de80681a4bb">
    <rdfs:label>Ferroxidase</rdfs:label>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3eaf9a95-354b-4d24-bd7c-b536e1b1b806">
        <rdfs:label>CP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/521a6b5f-992d-4a6a-8b11-7bf91801d597">
    <rdfs:label>atrophin 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77c46d75-2b43-45b1-bcca-5bdae5421f84">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
        <rdfs:label>ATN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4899eff6-e2f0-4a0c-8fb1-7f283c3d140f">
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b086efac-0dd2-4477-aeaa-c5d7d5442ed2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
        <rdfs:label>LPIN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1eb56eac-e010-4c19-8cc2-4bb5b2c4c5d4">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8310da66-718a-4d41-bcf1-84c076513141"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1ae00b-14c1-4abd-9b49-4d20911cfa22"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d44325d8-d437-447e-8454-b30bf6b8a374">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb258b32-9e0f-4b52-a526-60ef92d1f7d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84695de1-c575-452e-9309-f374f0194a87">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0c8c5806-6758-4e78-a286-18fc6ffa52b2"/>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7efb7af7-f7dc-4ec8-b43f-987a6b13b3c0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b7c5bbb-a872-4087-87f4-06b9eecf7442">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>PTPS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9fbe0b44-4b16-419b-99a0-71e9384392a1">
    <rdfs:label>glycogen synthase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1949ef1e-bc4c-44af-a1ff-e5769498b643">
        <rdfs:label>GYS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e2be668-116a-4a4e-a93f-bbdfb207ed9d"/>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2901461c-03ba-4a05-80dd-59cbac06e759">
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1525e3f-8a67-4d87-8c0f-d30d75c90081">
        <rdfs:label>ARG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b8f55b89-de76-4808-8840-ab93deadfa37">
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1ec6c6f-2481-40ec-a9ef-c38386212b20">
        <rdfs:label>RRM2B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e90b1dd-ec5e-4f01-af62-5ebba4755270">
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c25a444-4f78-4bb8-805a-a89996abd9b3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
        <rdfs:label>NSDHL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca7bbcdd-b1ef-4bd2-b1e3-3bf18a82263b">
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45d5459e-946f-4381-a9c3-a2fd936a53d7">
        <rdfs:label>SLC25A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/00698728-2bc5-447a-a41f-8b89de9901cd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3577538a-dcbf-4923-b1b8-d71698d15e78">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
        <rdfs:label>POLG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83e0d47c-f4ab-43aa-af39-f840e184e210">
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56992ee3-4f95-4d3e-80e6-816653d10337">
        <rdfs:label>IVD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ec66a69-9bda-4369-b7f2-b00ed0ae03ec">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>citrin ( protein)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cd028f94-c3c6-4f18-bc38-50e51caac95f">
        <rdfs:label>SLC25A13</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4dba2ce8-d079-4ed4-9f9e-427f2d09205c">
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/be857b54-1b1d-4c4a-8203-e254bc968e79">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
        <rdfs:label>DOLK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dolichol kinase</rdfs:label>
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/687a5627-3f5a-4808-95cd-545a6ecd44ca">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/624ad472-30d7-49fe-a309-9f323ddf4863">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
        <rdfs:label>APOE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein E</rdfs:label>
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1a5c79ef-606a-45f5-953f-8713c9adfb50">
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72153905-326d-423d-bed2-92859aea5b5b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
        <rdfs:label>SLC25A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e46a6106-c0cd-4d5e-8072-ec5f7304bcaa">
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b61c4a6-c34b-4f71-85f2-ca2c14b6fb2c">
        <rdfs:label>ATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ccc70e55-5847-42ca-87f6-102b730d29ec">
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <rdfs:label>Fukutin</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/afa7292e-9947-43be-80eb-d19dd141d919"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f974f27d-05a0-4bb0-a730-3b7f9062e8b9">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b176820-db84-4e68-ab07-33fc4086cfdd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
        <rdfs:label>CTSC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1c4e279-b3a8-413e-ba59-fa7f565d5e53">
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/084c33bb-d70a-4b03-aa41-8971b715addb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
        <rdfs:label>DNAJC19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ba91ed53-9494-43fb-b97d-c64f6e802e3f">
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/328d5184-e3f2-4a63-9aed-1f0298f85257">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
        <rdfs:label>GNA11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
  </owl:Ontology>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ddf9c8d-46e1-4542-a6e6-0f103db64b8b"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5233d2e6-4f03-4126-963b-8f3391d05e7a">
    <dc:identifier>DB01041</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4778123-955a-479e-8bfc-65655ad97b4b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03d01cb7-744f-4328-afc7-d482fe2d6241"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b29b871-62ed-40cb-adea-a9c295014bf8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ebd6877-09cd-432a-bef8-66c44ca064cc"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Thalidomide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7999f1fe-b38f-459b-8bad-b1e2403850da">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a03a88b-70e6-4edd-84c5-6bc09831cc67"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03d01cb7-744f-4328-afc7-d482fe2d6241"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53482ed6-9b99-454e-b8b9-e576a8ad1288">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c46fe5e-689d-45c9-910f-b02f27b792ab"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a147c530-24b4-4130-a66e-922d028bab6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3fd67456-2b9c-4eb2-a03e-2c9c5112e43c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/975023a0-ff45-4753-b6eb-b7f2a3ad9461">
        <rdfs:label>Low muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ae2f15b-7574-4690-b324-3c1daa42a1b0">
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002123</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa3a84c4-56ed-4b90-b543-d585123ce433">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3de10ae-03e7-44f5-ab65-d367f4c232eb">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epileptic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/391c05c1-93cd-44ba-a860-930cda8d9472">
        <dc:identifier>HP:0002453*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e309e8e-f3c3-4f36-ae12-02a364ab664c">
        <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9eedf5e0-552a-4b97-bf92-16b78497768c"/>
    <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e888b344-b549-4a68-b470-8eaecaeb1c60">
    <rdfs:label>Hyperuricemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/756866ee-1ff3-43c9-95b4-8b1c1e0f425c">
    <dc:identifier>DB00829</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
    <rdfs:label>Diazepam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ffc91906-25b7-4846-a953-214bcca2f6e3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7b2b1b1-6a6d-4701-b250-d647a2ced171"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/364e220c-531a-4bb2-b340-5da8eac6d0e3"/>
        <obo:RO_0003304>Spa</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9154d81d-582e-4b2a-9fe8-63e7031ff35e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/795ca2d9-ebe0-4148-aeb3-7e2cc3014132">
    <dc:identifier>HP:0002063</dc:identifier>
    <rdfs:label>Rigidity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04d36544-2b42-4e5f-b388-5d30bc8f3f95">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8809b39f-0c26-4c78-8871-40fa8b5469b7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdb590b0-2f13-4143-8bac-1ed7c11ad3bb">
        <rdfs:label>motor malperformance</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d841417a-e340-4277-8810-892212c9b0dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5dd4a39-fc7a-4baf-8d56-c1383f70efa9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f41f0681-5f51-4af9-a4a7-357aed573d54">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ad88108-1187-45c2-8589-0be4491f0b3c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/38e14131-0f71-43a4-8aea-0735f024070d">
    <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
    <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/758ad2f6-b899-4e17-963c-21c16ed21749"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bc773dc-5ead-4bda-a49a-f01a7fe59841"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/450378ac-f731-4b7e-83b1-df04c02e1989">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a80f87ac-703b-4f93-9225-e9053a23aa90">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7037cb2-1e44-47f6-87b1-e8a08e12efd7">
        <rdfs:label>Eliglustat</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc229304-23ea-4ac7-a59b-056afe87e3f1"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/883c2aaa-14cc-4564-a14e-fb968cd9f6a8"/>
        <dc:identifier>DB09039</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8689a14e-94f1-4cf9-a052-702a8d00737c"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c09f093-5f28-498c-9dfa-46359c69e038">
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c4d0346-0d07-4c98-895e-c7f15b35ff11">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ef38cada-96e0-42a1-91cd-512892a093c6"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91e974e3-2a7a-4c6d-9993-82f681d64464">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb5ab1cc-135d-407c-9320-5156522a1d7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f74060f9-c49e-45b9-a8b8-63096dcd2aef">
        <dc:identifier>HP:0002066*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58d71446-abaa-449f-aa6a-170c2d1f773f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/169c3186-fbc6-429c-a79d-36865fcd35d9">
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/111e676a-ac86-4be6-a83c-1df38693662f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/066df94f-19ee-4423-8975-684df8dc7c13">
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f925c241-3462-44e2-8dc9-f1d642a7d0e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7bd01dc-7a01-4f97-81d1-8988b4d8509e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2afb9adc-1b85-48ae-888b-ca885c3e863b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/855dd8f1-f66f-45da-82db-ebddd94d4e77">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78df4498-55af-45aa-aefb-1155514ff618">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0eb28d6-41ae-41db-9bd8-f7c987fde6c5">
        <rdfs:label>EEG abnormality</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d567c77d-957a-4e0f-9532-42865a512657">
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2505a55-7229-4230-b4b2-bfd40b160f36"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f149cbd9-b638-425f-82aa-eac1d5543070">
    <dc:identifier>HP:0001288</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <rdfs:label>Gait abnormality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da2d0992-ea9a-4550-b118-4bad234773b3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9756cd6-aca8-4d3a-8765-391d597fb3d0">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51386873-76b8-437c-ae83-0b32a5dfbbf0"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7c8e99c-020b-4935-b173-e5f97f99beb2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a8fb7c7-5d4e-43e1-81f3-446990435464"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17bda352-ff59-4c09-894e-8645ee6ee038"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB03085</dc:identifier>
    <rdfs:label>Glycolic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44e3b4b4-d383-4e29-b23f-88cb20b7325a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/253afa74-33a8-4b1c-8cdf-170e178f984e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6624127-39a8-4dc4-aa58-68f8a5c233c8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edf319ac-31ec-4953-9127-b48ae1235212"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b8de674-37d5-425b-a343-663d99f94b09"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <dc:identifier>CHEBI_25548</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cc51825-5d20-4b12-a6e8-e6d2006ec05f">
    <dc:identifier>HP:0007266</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brain demylination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db9c0356-cb6b-4d9c-9687-096ff54cf7b3">
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/37ae8551-3bf7-4792-936c-1d24c30d0a37">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04c4f172-bf48-4124-ae2b-2821396e0af1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e5fab3b8-33df-4f14-bca7-248b31c37985"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9475c1d-55ba-4248-bfd7-c02b996612c4">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50162574-d577-4312-9480-53ef5be4d9f7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b08597b-b3a9-4e05-9893-e867a0fdbb1f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/539a5a11-ca55-4d22-b6e4-1f01842e2e5f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f03c9cc0-8b3d-4688-8cfa-d93dfcb04cf1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94815e4b-6057-41a1-9887-3dbf4b5b4b4d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
        <dc:identifier>HP:0001129</dc:identifier>
        <rdfs:label>Large central visual field defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07bb621d-0867-4106-b47f-074851ac65a7">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d122331b-a014-404e-8167-5c9fcc5a1101"/>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbf9451c-81b5-4add-b616-7963e1582dde">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <dc:identifier>HP:0001114</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Xanthoma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfa980ba-7c55-4626-b485-3e1503538f6f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6a06e37-4d1d-4530-b35b-91ab24285ffa">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83e0127c-c701-41b3-8f8a-584c8708a452">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low plasma arginine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6b837e2-59cc-49bf-8fce-fe928001e664">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea9a79e0-4109-498a-b83e-183456899e9e">
        <dc:identifier>HP:0001946</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <rdfs:label>Ketosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55b43847-d2e6-4d45-9259-33c6d07bd22b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f2558db-0544-42ef-bc4e-6cb2a0593653"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c7f53c9-1b9a-4800-b9dd-d4afa8904dff">
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52923577-cd04-4647-8f8a-2ec11e0e88be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ba32a67-bfb5-43b7-b197-4b59967da97c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03812850-e421-4e0d-836d-e4d6acd0ed4a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Low ATP synthesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f4cb7bd-0707-47ad-a5d6-435c2481ef33">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased reactive oxygen species production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0bb34629-fc67-4db4-8376-feb075f2f6f6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3445c37-781c-4039-b0dc-225f557f0571">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100660*</dc:identifier>
        <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4aabf75-d0fd-4c9d-bf99-885bbfb93bc8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b149362-57e2-4937-8af7-4a5e27729176"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2beef1f-a4c2-49a9-9a63-c7b7d4275407"/>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e35b364-1729-4092-9fbb-9cd4b2df2316">
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21e06b10-474b-4803-a499-aa0d009d653b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa6b1d70-f3b7-4eb9-835e-b800a10fc883"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d403a27-2f8c-456a-b111-cfa1eb2a5e65"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92ad9345-c11d-42fb-ba27-c8a9c133d852"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d37d99c-0eed-406a-b730-839550a78a8f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f363bfc5-dc66-4de4-99b2-8e0be756d7bb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b087bec-7315-4cb4-91be-ea968e1eba20"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75aefac9-90ae-4bed-b64b-0d681757b613"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e04340a-9a28-4ce7-b5f2-c4cb48e6f02e"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8bdf4198-cae9-4503-a0bb-42901635a959">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e04340a-9a28-4ce7-b5f2-c4cb48e6f02e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1df87806-1baa-4d52-b2ad-a5000d8122f7"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <rdfs:label>Acitretin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1059ef75-a324-4478-810d-00996af3e58f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64252eb8-1fcf-4dc8-8c53-00e8d2725e72"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c5ec7eb-09c5-4ae2-a538-213b13e34e01"/>
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cba1d115-a5b5-411a-b37e-45753cc2878c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7192913-145d-40ee-8e3b-4e12ca0009d3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/247100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e04340a-9a28-4ce7-b5f2-c4cb48e6f02e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/924f574f-d7cf-4ecd-a05e-393f6cbcac80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09849a74-922a-461a-b264-469d7788ee51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4efe582-3209-4474-9e40-f60bfbf048ec"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1060600-ed0f-4900-b79a-2d1844a222fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c220de08-6c31-4124-a016-97def314a896"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5ae1805-09d7-457d-a426-56882ef03914"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee1287c9-5c61-4ad0-908d-b8ad1a5a9352">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <rdfs:label>Brain damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a74f5c70-cfcc-4a53-a6a3-6838601fe25b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3d73022a-405e-4fb9-974e-00ab2c8708e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efc3e282-2895-4061-9135-f6ba08759a71">
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <rdfs:label>Cerebral palsy</rdfs:label>
        <dc:identifier>HP:0100021</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02b7199d-e482-442d-bb50-af2ae2b4c813">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
        <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SALLA DISEASE; SD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4166b9ac-634c-4c60-b709-efb82c6fa854"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1b311ba-35b5-4ff8-ac98-8701849bc57e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3260af9-3b6a-4294-a8a7-e345d463dd36">
        <dc:identifier>HP:0030872</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b443115b-dcc3-4471-b39e-194c770fa3df">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
        <dc:identifier>HP:0006670*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/427418ca-17c0-41b0-b9cd-7e0af6d047e9">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be150535-3265-4c65-8361-55a9a603ac2e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21b14994-2984-4a4b-b2ff-d923db43a8f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/63ba237f-31c6-48d7-943c-8404e2a9660e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef8f40e9-9e04-4c17-b881-6a1a667d455d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <dc:identifier>HP:0001714</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ac90b03-dbbb-4c11-8940-470a76c8071f">
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb7a18ae-1e02-4d6a-a1e9-fd5ffc5c7120">
    <dc:identifier>HP:0003219</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high EMA levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c561c5ba-6e36-4452-8b7a-4dd4f08453dd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6212cbc9-48c9-4c7c-a309-3193c041187a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal renal function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d7af9d5-d753-4ddc-be35-7aa5ad2bcca5">
        <rdfs:label>Proteinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a6737a2-4741-4f3f-9b0a-aa451c178d43"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdce9d15-81e3-4ac8-92c6-7845cefab068">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74f6cf4a-4cc8-496a-8142-1e728a508552">
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010979</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/429f9201-d87d-4e05-b5b2-eaac5e3ee60d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee140925-7ae3-43ef-a9f0-186871652d5a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08b79000-e0c8-496f-a34a-0e609719427a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Dyslipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8ef1637e-73da-4a7d-be39-bc341a373533"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal liver function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/61efbf44-57df-48b1-af2d-993c6f2d3c9d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/691eda72-4ca0-42af-935d-3cda67f13c45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/832f0586-0a4e-4980-ab28-5d605f54e675">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eae7597-3a8d-4859-b30a-eee7e2bcd5cc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:label>Low dopamine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/308e0b47-5597-48f6-b9a8-c31c5e51e25a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ed38a37-93a4-4b52-94a2-f726cb1866d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b7c5bbb-a872-4087-87f4-06b9eecf7442"/>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/318018eb-90f8-4d76-ba8f-5fc9b828cdcc">
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>deambulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b321845-1d89-425d-9734-849f76d27288">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b086efac-0dd2-4477-aeaa-c5d7d5442ed2"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25065e54-ef5e-4033-9db6-5bf28cb5c65b">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High triglyceride levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2083499-cff0-4611-ae73-691d1185bbab">
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eecad72e-dc8f-46db-a9a2-22f761461aee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63c1d8ed-a7db-44e5-9fd2-da5221f70418"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84457c41-8830-478a-8ba1-1850ef068125">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c79dc56-3b33-4b45-84f0-3f68cfc0cb3c">
        <rdfs:label>Lack of emotional expressions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
        <dc:identifier>HP:0030213</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac1c8a43-8640-4013-93fa-5809a423e172">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002329</dc:identifier>
        <rdfs:label>unalertness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb164ca9-87e8-42ed-8c35-67c0b2fafeac">
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e0ba634-9a75-4b3b-9f5a-30ec684e6c88">
        <dc:identifier>HP:0030980</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c220de08-6c31-4124-a016-97def314a896"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e442f5ff-852d-4345-a2fb-ad12ed4821b3">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e650054a-96fa-4467-852c-99e2a589cd15">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <dc:identifier>HP:0030980*</dc:identifier>
        <rdfs:label>Low CSF glutamine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4c41e8a-aae1-4bb6-9471-b636f43aef38">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG results</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/701c510e-9179-4c22-87ab-d09cef52a6c2">
    <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <dc:identifier>HP:0001943</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e8df26b-594d-43f2-abb4-f9f5d0674cb0">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15fac55d-a1d7-44fa-940e-ec6cca10a71a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/40cb0550-58d5-407d-b338-55b20e1d9b26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3edb69bf-0c34-4b1b-9384-de5e4fbc326a"/>
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0336db9-ec4f-41bb-8db9-361db12a2ac7">
        <dc:identifier>HP:0001941</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/269210f2-0cb8-4fb4-95df-52ed02c49aab">
    <dc:identifier>DB02053</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e794490f-2195-4819-8bfe-72d2dc001e30">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25bff4ca-7bc6-49a3-9e85-74ac3a5bb7f3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615511"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5bc1839f-1965-47b6-ae57-ec937dafb0af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59430263-7012-4b0b-b8b5-51acf3d4a478"/>
        <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8734fe77-81df-425b-9889-d5a44ac06168"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc1a1885-4c21-48b9-bfb3-257365c8ee4d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e32bc10d-71fa-42e8-a11a-2cb63ecc686e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b608986-81a4-4d12-bcb0-7f5ab295eafc"/>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2708c829-ead9-44f4-91fa-d6472f88771a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PL-induced cytotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8499bb99-05dd-494f-a537-c64ac751bec0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1a78be1d-c3fe-47a8-a205-90e8afe85806"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bc41a42-3e4e-4abe-afe8-60744145acb3">
        <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4f1437a-1497-45fe-b1c2-bc9c308834d6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0cde9553-f808-45ea-8faa-160c2702e602">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3885644e-c230-4e2c-8073-29167dd74a50"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd0d4184-8352-4c29-b6af-61b8fb47c2fa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>hypokalemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/87324a46-f9d1-4407-a6bd-3a1f77b0997b"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2435f2ec-880b-48c2-9517-378df6636af9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51c2b035-9e11-4753-843b-ffa256b5ee9c">
        <rdfs:label>Growth Failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac6a4d47-e2cd-4ee7-9efe-f7e2ac3da6f4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003077</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:label>Hyperlipidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1582fffc-9365-4f22-a3cc-ad17088c81ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41ae6159-ea0a-492e-9b51-fac2b1d0ecd5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1da00c72-28d9-4740-96f5-11334138828e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b053012d-a273-41ff-ba99-3e7745221ef0"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec016261-7a37-4639-83a9-1ef60ce0c95c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23876f30-b11b-44c5-bd24-0f56fec7acf0">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>anaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fef6a76-dbe1-428b-af99-e301204e2ba2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025547</dc:identifier>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/330c00cd-31e7-4d80-bce8-3e8322ab2e45">
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b550372-ea28-42d8-b631-445fb2b00617">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4566d80-4c93-45d8-9cee-c64976ce2cc0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49503fe3-ab33-49a9-9719-6a0ca08cfaa8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>thrombocytopenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfc76469-64a8-48f8-af6e-abbc547d2028">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3386834d-7290-42a2-bc75-1d66ff90e7ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d2e85715-0d4a-4334-b803-3b52586e0a21"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ef8fc0a-b182-4682-b819-74b088f03955">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000855</dc:identifier>
        <rdfs:label>Insulin resistance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67004c10-7770-44fb-86a8-011701b68268">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypertension</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c28a179-85b2-4f5b-8efe-18ccbff1ddbb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5791cb81-0f54-4086-8428-2dd2b4ba5c5c">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72469bb8-ea86-4c02-94e8-ced2fda8abc7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
        <rdfs:label>Microhematuria</rdfs:label>
        <dc:identifier>HP:0002907</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02ece8c2-68e7-464e-9f4c-55e94a5c9d31">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f29f6887-7c3c-46b0-83e6-b5dc46f8da97">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
        <dc:identifier>HP:0012594</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Microalbuminura</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
        <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a3d7622e-0341-4801-8dc2-f6f3045b01d4"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fa35b04-0749-4c4c-9a1d-0a5a3a37b7ce">
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5de6ce1-d603-4c33-bc03-b110759ff733">
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64d8ab7b-ee92-4325-9fe5-a8bac0e568e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17d4f2d8-2230-4112-beed-9cd75221337e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/181894ef-99f6-466e-a8e8-275f2a3ecad2">
    <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8660bc0-7fb2-4eba-b6ef-ef3668e6b483">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b956b8e8-3c11-4861-ab14-b361cae50639">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf87e1c6-447a-4f96-b22a-c1a855dc1a51"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15eacc81-d315-4f2c-8066-f0d0ad755639">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002150</dc:identifier>
        <rdfs:label>High calcium excretion in urine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/525ae58c-fee0-4536-a496-281083b2edb7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>Hypokalemia</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/328c0738-a2a8-4680-8805-198927490a99">
        <dc:identifier>HP:0003566</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58ff0b94-a83b-45c6-9bc0-cd9addc370dd">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a59f132f-0597-4c15-a436-c4e06256f3e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f7c7365-c36e-4921-9581-63ba058853aa"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8643b01-f68d-4ff0-a2d5-59819a438cf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d43661c0-f16b-4f83-abb2-1299d1aaba13">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/301e1fe1-37af-45b6-bbba-083d2d254954">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001019</dc:identifier>
    <rdfs:label>Exfoliative erythema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ef57d53-c885-4bd1-a24b-3e837bab1eea">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c113588a-bd15-4124-9530-4eb374d0ce7a">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b1e3c20-a3a9-40cb-b26f-889b685e0c5f"/>
        <dc:identifier>DB11635</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
        <rdfs:label>Tocofersolan</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c491ef5-aa4a-427d-a9bc-6b21fd338043">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7c9f74f-faee-4879-9d06-be942700f16f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>failure-to-thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b2683c8-4b14-44ed-8fe7-b70f162547c7">
        <rdfs:label>Dental Defects</rdfs:label>
        <dc:identifier>HP:0000164</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0d856bd-1e78-413e-80f2-5584521e57e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased physical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb0d7e57-7d64-455e-8ec7-ed564efe159d">
        <rdfs:label>deteriorating pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af3edbf6-d76e-45a1-9dce-51057d2475f3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5798283-1aaf-4932-bbbc-e01dfe797ab1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a48d37c-79cd-4b74-8937-d46112d05c9b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal developmental milestones</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b703461-caef-4c27-a50f-b5c1fd8117b8"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e86fcfc3-3040-4306-9dba-0d24fcc6b73a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
    <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003495</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
    <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31b78755-12ac-422e-84d2-9e35dcd61e00"/>
    <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c05d4ec6-67c7-4359-8e60-cbc71a97d4f7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4d27429-f278-4acb-92cf-d6ed0abf1316">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfe7a0d3-96cb-4442-8ddf-044686078c81"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
        <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
        <dc:identifier>B01</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f070152-f078-4e7b-8d0a-9a46530943cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56cf4179-2c4a-4313-b1c2-e7b439eaa2ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72622cd5-5f24-4aec-9c65-10889f5c5c09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28ab33ce-1c86-4468-8847-70cb74f441bc">
        <dc:identifier>HP:0003455</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>Elevated long chain fatty acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/560d8bbd-1557-4268-be67-309569a3e6bf"/>
        <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
        <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/186c840b-b368-41a5-876b-36287d3712fa">
    <rdfs:label>Left ventricular hypertrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
    <dc:identifier>HP:0001712</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/82976760-2244-4d41-b5ac-b1ce2f8fd7c4"/>
    <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24c9bd8f-93a7-45a4-8599-95551b8940c5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c64f4f0-4173-4ca9-af97-7f8b6ed13202">
        <rdfs:label>low calcium urine excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003127</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/221dddcd-0fe2-4de0-987a-1ee6f6b05d99"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9db8d620-3354-4ef6-a737-909acf734e3c">
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3275216a-c9cd-4909-8f23-958406513664">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/251dba67-6371-4abc-8082-3f0baaafd193"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fa8c9de-1047-4454-b63d-0f000365a2b5">
        <dc:identifier>HP:0003072*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29faec18-66f5-4879-834e-67f7fedb27b8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/210500c6-7734-44dc-8e0b-ed4a23ce0644">
        <dc:identifier>HP:0001945*</dc:identifier>
        <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d287a8e5-2ff9-4595-a8a4-d207fda34221">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/446d5709-c4e1-4e68-a2a3-af24f8cd975f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/affbdae7-9f6d-416e-863e-93abdcc9cbc1">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebf2661d-287d-460b-8927-9bba3b7e9891">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2fbbb09-9416-4d51-8e31-d7132c614367"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdc2d236-dcdc-42d6-af72-6b71426952b0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:label>High ornithine plasma level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc709272-c4ce-4226-9d14-5a1ed663af36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/403dfed6-0721-4ecf-bd23-56257bba9729">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:label>Disease progresssion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e698377-6281-4578-b96c-7f232da8d880">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0aa324c9-317a-4ced-98c2-95be2779417b">
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ff81bf2-d6ef-4dce-8831-26c88cce5f4a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:label>Neurodegeneration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46f7f65b-8ae7-4a1c-9c10-f1524a4f7627">
        <dc:identifier>HP:0001392</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver injury</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff5f0c5e-6484-496f-a12a-6ff57e66b370">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/772168fd-fad4-474e-83a9-37c811c0211d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05663739-d4b4-45dd-b10e-07fd617ad7ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>Rapid progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/125c9473-ecf8-4f85-8213-07916664696e">
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1939c56f-6669-43f3-be59-fbfb2a3b9e03"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9db0a46-7325-4578-b8a3-44db4107a7ed">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Poor swallowing</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a2ee101-ba08-483e-bd28-e9fcc60ca7b5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <rdfs:label>Fine motor impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4c8a3a8-72f2-49da-9720-119ff2f5c951">
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1728417-58ac-4d13-bbbb-55334345ea9a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4375ced-8514-44dd-8bca-078faa9ca706">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a85f6e2-2ba4-4387-8b5d-d60c5ba409b9">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74f6cf4a-4cc8-496a-8142-1e728a508552"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c673a6c-1ac7-4407-a757-963d3aa1a819"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55a96ea6-2008-408c-a18f-243f30ac8e01"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>r LCAT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d0a395b-1d38-44e7-bead-ce14e6a189e5">
    <rdfs:label>neurological abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3f361a7-8022-4380-b373-f15760bb2a30">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/abbbf448-0564-451c-8e51-83923fc72490">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13f352f0-51fc-4a1e-a6af-6f3ce35ed5a1"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a64b531f-7199-41f5-be72-91ff7999f4f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0060c215-0fc3-4a03-98e5-db3f5a1d8d8e">
        <dc:identifier>HP:0025303</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/662cb3dc-81c5-4dc6-a249-b8e764becc7a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
        <rdfs:label>Refractory Arthritis</rdfs:label>
        <dc:identifier>HP:0031375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e702b168-d79a-4135-b3e6-550ee83db7f2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:label>Arthritis</rdfs:label>
        <dc:identifier>HP:0001369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f69358cf-db8f-4ff7-803b-26c899096763"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac84d4e8-10c4-4a17-8be9-95081e031906">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100769</dc:identifier>
        <rdfs:label>Synovitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07d36411-8c7e-4a9f-83c2-a6a681f27ae6">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc954b95-4728-42c8-9449-d63ecb8bfd16">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53621295-a7ce-4323-8e0d-191eb66d851e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae614995-a423-4d42-ae4c-32addb4b515f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
        <dc:identifier>HP:0004364</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/826581c9-8d66-4427-a8ef-9be81adb900f"/>
    <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
    <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6f2f4af-c77e-475e-ab9b-ab4ac4354f8f">
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a156f271-f991-4bab-ba5f-9019e91baea3">
        <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
        <dc:identifier>HP:0002071</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/019bd943-858a-4c5b-a30d-efb8e940d530">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/156e9d1d-812d-4d2a-882f-793eb6de650a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1e64f32-77a5-4a07-ae2b-931470f8511a">
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0794001-6dac-4466-afe5-e26df34ee835">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14783d19-9184-4176-87be-d13a7b1b8215"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50c9be9d-56df-4393-972f-46aa09e3e886">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbb2dce2-79c7-41fb-b013-6ddc55d35b7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/394505c8-cd49-4ecc-b3af-26a494474341"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8e5d8fa-90c6-47cd-ba2c-cdf0e4329d64">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a20dfe3c-927d-4728-b047-140aa1afc1c6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Increased ROS production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46fb6c9c-8aad-4434-8a16-03923b819839">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
        <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
        <dc:identifier>HP:0011923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/048a4786-ce60-4828-a1bb-cc6b548b5bec">
        <dc:identifier>HP:0008347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68d05e6f-36bd-45fa-ba97-61f88295d4e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39558917-1d6e-4df3-b4df-944de0e63c7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e909eea-f96d-46d6-a219-c8c2bce73a84">
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d3ec1f5-5249-4e95-ac4a-c494bc779ece">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99ea925c-260b-42ed-ab0d-b65cf7bc156a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e57bf7d-fa2f-4c88-9140-ace01fd6c284"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0da95fd8-302e-4a0d-ab0a-d6387d315ad2"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ec3f482-de06-4560-9a02-c2d89673c8ee">
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b59265d-de09-4469-87c9-0cb8bce3e8b2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e8c7abf-ff68-4dad-883e-9745bd3503ee"/>
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd478919-c30c-4407-978b-cfa776ecb181">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ea02bbb-1fa1-4f81-9cb7-f5a96a07ea1d">
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Abnormal gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66a47390-8990-4e02-bf6b-67efbe9afa50">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d3ec1f5-5249-4e95-ac4a-c494bc779ece"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9291c566-f06a-401a-abba-22f479d9264c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3b02849-1b0d-4511-a750-4b118aab0688"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a52a6a-60e3-4754-bd9a-f50d26c5afae"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc1556f1-e47a-4871-a84b-d93ddaafa82b">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02d6e12c-55aa-4c74-a36c-f2c52aba3468">
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72153905-326d-423d-bed2-92859aea5b5b"/>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/550a6ad4-d823-4827-8d89-8c52d287165b">
        <rdfs:label>Hypocitraturia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
        <dc:identifier>HP:0012405</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc609ed2-6d94-459c-a279-287868d0467a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0872abb1-1cca-4215-bd4e-00254832182e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e495d5b8-592d-457e-a6cb-01d746f3ed8c">
        <dc:identifier>HP:0040144</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7f9f1db-5d41-447e-ac7e-4544c895407d">
        <dc:identifier>HP:0012321</dc:identifier>
        <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c740ecf-9713-48b3-8461-5c6d8afcd266">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eddcb940-88f1-4eee-925c-2278487e9f74">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
        <dc:identifier>HP:0005110</dc:identifier>
        <rdfs:label>Atrial fibrillation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27806587-f009-42e4-b896-098b59f70e24"/>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/539a5a11-ca55-4d22-b6e4-1f01842e2e5f"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/18e63db3-5a15-4b1e-b35c-ad6d61832d0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c9800e7-afbb-459e-b289-89e5d38b6900"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61a82d96-c9d4-43e6-adea-99b0b6fb16c4"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef63318f-c457-4faf-973c-732dc2902899"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd2d770b-dc77-41be-a49e-339a05ea566e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/702fb3fe-28c8-4d92-9d61-b4947434bb70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/710ef60e-3009-4835-ba52-0c7d56179124">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal liver function</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7fb4cdb-bf67-423c-b8d2-fe341ba6926e">
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>hepatomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e386e293-c366-48c5-b335-f1f2cc047b80">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0c3c196-94ac-4737-ad47-5d66823545d7">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32d5386f-0635-4b1f-95ee-fef3d07c804c"/>
        <rdfs:label>Ethosuximide</rdfs:label>
        <dc:identifier>DB00593</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11b3abb4-9d96-4187-98b0-3e9b6531d537">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0704f6e-f823-45ba-a5f2-8270e1849592">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Parkinsonism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0662f242-5be5-4b81-9728-66952d6c2c16"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a5c07a2-d7dc-4528-9492-e28f0397164d">
        <rdfs:label>Limb dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f149cbd9-b638-425f-82aa-eac1d5543070"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/795ca2d9-ebe0-4148-aeb3-7e2cc3014132"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e0722f5-f2fc-42cb-bcb2-f5100bac5eb1">
        <rdfs:label>Tremor</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <dc:identifier>HP:0001337</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c25df82-1445-4cb1-995e-d2eed2688be2">
        <rdfs:label>Axial dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5243ad30-2684-4f74-8765-8651dccfa9b4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f6b53ae-0c54-4d67-84ef-651fe610fa9f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be88718d-7e6e-46b8-933d-b26065a84722"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f44f3e92-67e3-416e-9b90-8acd2e638c4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb481fa9-20ec-403c-b08a-d0701ba648c7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dd8ba25-e991-406f-a726-20ddbe73d29c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>Abormal liver size</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6ed5c4f-efee-468e-a27a-1db5caac1e67">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Developmetal delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c15dc89f-e72a-404d-827a-a644842041b2">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>Cardiomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7702c6c3-7b23-494c-ae87-b47e927be667">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012664</dc:identifier>
        <rdfs:label>Reduced ejection fraction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca9a2622-86cc-49d0-9f85-1a9a8774ed27">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d5befbb-cb48-46c6-9e2c-1d7babbdf208"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff1a2624-6ca0-4356-9e3c-2c8dea7660e8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased red blood cell production</rdfs:label>
    <dc:identifier>HP:0012133*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8cdee320-f483-45e2-91a9-b7b62015d1bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/791d1e76-e1f8-4e27-9fdc-8f4984d9a0c5">
        <dc:identifier>HP:0100529</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6794bb6-ef3e-4108-b6a4-7b0166f619a1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a6737a2-4741-4f3f-9b0a-aa451c178d43"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
    <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd0031fe-afd6-4dcd-a1e1-c26b22870eac">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d16a37e-0057-4f9e-bac0-4936f0c6dcd6">
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b2f742d-0ba5-47ef-a9a9-728292bb2258">
    <rdfs:label>Gemcabene</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b99f5ec9-5047-4445-9c39-e3ad31c75693">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6445643a-ef8f-4749-be05-b77c5f836adf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b94a4a92-d473-464c-9c63-de80ee60ee6f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <dc:identifier>DB05123</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ab79556-d8f4-4062-aa08-7d3c6cc3e8ff">
    <rdfs:label>Progesterone</rdfs:label>
    <dc:identifier>DB00396</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0b27038-2042-4fdc-9552-98c44ea75181">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2bbc06e-5730-4349-b9e6-a952fd1ede5b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fed94b22-f275-40d3-ad97-898b6ad89275"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bef5d65b-913b-4560-a16e-1374c8fe5f75">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5658a4a7-2447-4282-948f-3fc0c53d905a">
        <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
        <dc:identifier>DB09241</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e25a704-dfdf-4c65-8297-cd4b257f8492"/>
        <rdfs:label>Methylene blue</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0b21e6e-f222-4be5-a349-3e028297f828">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88d0deb9-3082-48fd-a674-9e44bc712ec1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9576ed2d-d6ea-46ca-bc4b-fbc6a175f3da"/>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f21e3c81-d695-4882-b179-50bc71a6c9df"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db845fd-c907-444e-8f5b-871a970319a9">
    <rdfs:label>Delayed Growth</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22bf67fe-676a-4663-ae9d-2b5bc2ab8d73">
    <rdfs:label>GNT0003</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/519a0a8c-5293-4e5d-8a87-746303eb2722">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c96d2a1-236c-4f8d-81a5-305e223e1e48"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46f47c8d-89ad-4351-88e6-3f7e672f54f9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a4b81e8-1c76-46a7-ab64-c699c6ab533e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b849a093-6011-4b9d-9d60-bd4fa568bc1f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
        <dc:identifier>HP:0005346</dc:identifier>
        <rdfs:label>Abnormal facial expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39c5d6fc-fc8c-45df-acf4-58d2b8ba1999"/>
    <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25b88317-bf56-4640-b769-7e7fd785ca1d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1175d81d-460a-415e-bc0f-49da3e0e3a3d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92ddf5d4-e521-48aa-af49-10216fa61cfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3007b9b2-371e-4010-9243-5b19c3840b03">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <dc:identifier>HP:0000479*</dc:identifier>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/667a36f8-81a9-4a84-b5e7-8c41393ee0cc"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c11a2d1-4c6c-4fb3-b742-27bee65c6e99"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1cda051a-b741-4af4-ac15-0947179b55a5">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52ae6c5d-6693-464c-83df-627af25e278a"/>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c96d2a1-236c-4f8d-81a5-305e223e1e48">
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dcff3c46-aa45-49ef-903d-f812924d46c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97f911c8-9791-48af-a474-3e5c334c476e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59d4f92d-43a5-444c-80da-9c59cc6ecbaa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of metabolism</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69c2f0c4-c85e-41a6-9bd5-9df33ca80c49">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58ad5d4c-ac2d-4658-a662-3a4d14d34b8a">
    <rdfs:label>Indapamide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15e0beb4-3117-46a0-8e19-57819a094e9d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6985ccef-f05f-4ce5-b064-1879cb0c551c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34310b50-5810-4cda-9362-6db385412b7f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8882d9e9-8a83-4a69-a483-28b933d36209"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/727c8155-9a21-4237-ba2c-4c4b81f354d9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00808</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a053edd3-124d-4455-88e4-bc8b85f2d05f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neurologic burden</rdfs:label>
    <dc:identifier>HP:0002344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8b0ce35-0426-47c3-a0dc-9f7cb6f442e4">
    <rdfs:label>GNeo-IDUA</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6ef1df2-d563-4b33-a05e-08dcfb75702b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d22a961-c8f8-4ebb-9967-3dde93828638"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97fc78d0-25d4-4910-bda3-b592dd8eea95"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446dcef9-3787-4ad4-9462-32753e9c0469"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
        <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1b04e96-cbfb-49d8-aa47-964fbe8ab338">
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8443e4ed-0295-4f23-bb63-09f77d599441">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42cad462-8af4-4a76-b96b-fdafe64ef68e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6501208c-2bcb-4a0f-895a-0a897df720a8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05663739-d4b4-45dd-b10e-07fd617ad7ba"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5e89eb3-41e5-48b3-8186-5d9eaa3dbdd4"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5ab4ec3-bc52-46fe-8327-83ea555cf511">
        <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040081</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5948958c-c2c0-48ed-a702-a536f3e243d3"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1ae00b-14c1-4abd-9b49-4d20911cfa22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d44bc4e5-311e-48c9-966d-9224115c043f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myositis</rdfs:label>
        <dc:identifier>HP:0100614</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e04340a-9a28-4ce7-b5f2-c4cb48e6f02e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e35b364-1729-4092-9fbb-9cd4b2df2316"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/161b48b9-885f-4372-b5f8-57869fd3c7fe">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0e61473-d52e-4cee-9161-740ed0a838d0">
        <rdfs:label>spasticity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dba1f164-7b91-43ee-8a0f-a7effe90cbf9">
        <rdfs:label>abnormal motor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bf52c7c-5a31-4dbe-b117-bbc4a4c2f897"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4ed2871-e73a-4fce-97aa-13b5af79371e">
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/18801fcb-0250-4c62-a928-ba0da4107cf4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15e22fbe-90b0-4f29-930b-795ffd0fa818"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8612652-1d68-41f4-81e7-7391cfcad695">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <dc:identifier>HP:0002149</dc:identifier>
    <rdfs:label>hyperuricemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e753fde-f9eb-45d6-98d1-c8609c0ae841">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0704f6e-f823-45ba-a5f2-8270e1849592"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ddf9c8d-46e1-4542-a6e6-0f103db64b8b"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e1824b2-5c52-498d-b50d-4aeb35880879">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:label>Decreased hemoglobin</rdfs:label>
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a932a00e-0b34-43a4-a4a0-57f5d31653fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5cfdd09a-2828-4612-a0c9-5c32e5eaa52b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c866599a-4433-49ac-9324-044025edab46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e730bef6-98c7-4c43-bac8-fb0b3f45fcff">
        <dc:identifier>HP:0011031*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d92e443-fe81-4d4e-901d-2272c1a32c3d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffe4cccd-05b9-4c79-84df-89f8e2724f88">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
        <dc:identifier>HP:0100709</dc:identifier>
        <rdfs:label>Oligodendrocyte loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76349b42-43c3-4bd2-ba97-84075b9c62c9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d068875c-1946-47ce-8469-569d46715dac">
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
        <dc:identifier>MP:0000880</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74c589de-d6f4-4d33-966c-1b1483f11755">
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3879529-e69f-414f-9b34-6ed9ea313507">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1240f303-dbda-4032-8b1a-34b2fd710767">
        <rdfs:label>Hypomyelination</rdfs:label>
        <dc:identifier>MP:0013438</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b6bb9e9-c5b8-40d1-8c82-8025e6126088">
        <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/101fbf65-d6f3-4f62-be37-ab00ebb1ad07">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10d4a674-809b-4d1b-98d4-8167ffcb41b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c8bbeee-171e-489f-b7aa-6dd27be81f6e">
        <dc:identifier>MP:0003354</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Astrocytosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4051a88e-b6e4-46e4-b7dc-3771bd7fcf03">
        <rdfs:label>Pyramidal neuron loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002062*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53986ec7-52f5-405e-99c7-babde0d19ef9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1c5a02d-4c51-409d-9e90-54661541ec07">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Microgliosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
        <dc:identifier>HP:0100708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
        <rdfs:label>FUCOSIDOSIS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e873bb6a-aaee-4a15-954e-6984c1492307"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9b52287-26bc-4edb-b24b-25e66265dd9d">
        <rdfs:label>Neuronal vacuolation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1efc7f49-496c-40ff-a05c-d71044aec20f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/548e9c2b-1453-4741-b8d1-9e92f821a356">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f712705-9d30-4e93-945c-5f1c0ecdef5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62c0165f-523a-44cf-a3d8-9aecd2dccfb2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High prolactin level</rdfs:label>
        <dc:identifier>HP:0000870</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1970286f-0482-4c41-89a8-5ccb1973b581">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Behavioural Disability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62cfdae8-d4c3-4543-bfe2-2f3db7fb5183">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81dc68ae-dfe8-4d5a-aef5-90f4c035652f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Movement Disability</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/202aaf1f-f3a2-4bb6-bd4d-1f4debc3345f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>fasting ketogenesis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
    <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af407ee7-3231-48fd-93a0-4df5dcb87970">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf9659f1-72ef-4d5a-aff3-97797e00b912">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/661e6913-4baa-4105-a371-405f6e375fea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9af47359-deb9-4843-b899-0a9d4dcbfb14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ce62f9a-c9a9-4334-ba03-97bf32321937">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84ac1d83-ea5b-4e51-b6cf-a2bde5f8ddeb"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be8f16db-ab86-4321-a6fa-76366bb97b79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f52b68e-f701-4061-8569-8412251dc48f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b157f654-8ef7-409f-be95-5f2dfe20014f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb9143c7-27fc-4472-95f6-c7cf255f3182"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bf927df-70a7-4d03-9d8a-ed9e035e7148">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9d16e73e-34ef-4522-a6f4-035af4b1c39b"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfd26ee2-278d-47dc-b061-cf6922d18afa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/034e953e-2051-4ce3-854b-6386c5593580"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d53906c5-7f8e-4fe8-a1ef-d00e5daecbfb">
    <dc:identifier>DB12374</dc:identifier>
    <rdfs:label>Velmanase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9dc5da9-df44-4c6e-b840-9b7f1ea20219">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54b59eba-42cf-4e98-a5c8-5c20088ccba1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82267104-6ffb-4328-8c25-33d4b0906a07"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82abd56e-5c46-4a1f-bcf4-d1f74690dc12"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87320aa6-142b-460d-b64a-05d110754f52"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/181894ef-99f6-466e-a8e8-275f2a3ecad2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9c16667d-007c-457a-9389-1e96eb573de2"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a26ea02-1891-492a-9e4a-e47a0bacd5e4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c6accf4-802d-4cde-9efb-707848e93488"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea44c4b1-8f9c-49fb-baec-a75f3ed18859">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0962feef-cd6c-4933-a096-e1713c567335">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>mortality</rdfs:label>
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <dc:identifier>ECO:0000305</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47a0122d-ab92-4419-a927-081c645721fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <dc:identifier>HP:0001824</dc:identifier>
        <rdfs:label>Weight loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be1090af-357a-414b-a85d-5577a3b27f32">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21859a5e-93aa-4745-b938-fae7d911393f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c296eea-ea07-4dcc-be7b-eec299d9e3fa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <rdfs:label>Daclizumab</rdfs:label>
    <dc:identifier>DB00111</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5dc59fa2-0912-470c-8b8f-7de09d03f7b5">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f57ffda4-13a0-4dc3-84d1-cea5adcf4b0a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1abd4418-e2a1-4326-b6e7-06486a4eab54"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44389b0b-5c03-49d7-b64e-6de740d87e61">
    <rdfs:label>Neurological abnormalties</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2df6c9b-26ed-49a7-a575-3afadc5ab455">
    <dc:identifier>HP:0031377</dc:identifier>
    <rdfs:label>Abnormal cellular proliferation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9413b4fb-bc48-4731-b560-ce522c70d35e">
    <dc:identifier>DB00151</dc:identifier>
    <rdfs:label>L-Cysteine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc3cfc77-b125-4920-86b2-149bfadbda2d">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1364c89c-03f2-4aa8-aebf-104a1d691083"/>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a4ef686e-0c70-4a7e-a283-91546978ba5c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd490efa-6835-48df-8c09-05ab4ec372ab">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a4f0687-20f5-4ac3-b475-b211368aedcc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702b168-d79a-4135-b3e6-550ee83db7f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01733e91-6aa1-4ebe-980c-f97ffb805985">
    <dc:identifier>HP:0002194</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lack of gross motor function</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2d0d8cb-9c7d-49f3-ac73-df355bf29383">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1221e89c-5395-42dc-b793-6e65fb93d373">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a21bcd1-9295-4d25-9d09-caeba0511f94"/>
        <rdfs:label>CoCarbs + HPro</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dabf96ad-4a69-4dac-bb29-aa893e798229">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d675ad9d-57db-402f-a736-4c3a6e6119ab">
        <dc:identifier>HP:0000718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive behavior</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44c4d71b-7552-4ebf-82fe-2b38b9059ca9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <rdfs:label>Self-injurious behaviour</rdfs:label>
        <dc:identifier>HP:0100716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8252ee73-dc34-40fe-9778-fc90afa87c3b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f78135d5-e1e7-4911-a201-5dfc283a4a5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fba10ea-badd-4b9c-9765-06c61efd8c0f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f557b977-3657-4270-8bc3-7ebf43c3c5fd"/>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77b00437-5a81-48bd-a4af-733e41b381d4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d386e362-eabb-4f1a-97bd-1bf0783d95eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c1098fa-3c99-46f0-909b-b2d6930828bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59ccdb02-261b-47df-a45a-8f5a74fc87b4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:label>lack of strenght</rdfs:label>
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4235c493-58ee-47a7-94e1-6402cf610587">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6939e441-f207-4851-9c26-b8ebfb85e6f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79f88194-700c-4ed2-90d4-a885efe5c7cd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e1824b2-5c52-498d-b50d-4aeb35880879"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30d1ed83-ea7a-4be0-a97e-f470879d347c"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb792d89-6d92-4f95-b38e-67d8a58cf842">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ferritin level</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9bd6c2f-7f01-483a-a2d3-46119951b3db">
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <dc:identifier>D07A</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a817d7d-0cf2-4d05-9737-23822dfc0e9a">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82a847e0-5684-4f75-9983-faa2c8557d35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6011f2e2-da29-4b16-ba64-9a24c8baf21c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/37a00bfd-bd96-4497-bfb1-8a622ad1149f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdbf370d-50ef-4424-a492-ba9d069f1ed0">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89781f4c-2fe7-438e-8c7a-6f386edd97cd"/>
        <dc:identifier>B02BA</dc:identifier>
        <rdfs:label>Vitamin K</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc971f12-0093-4d6f-8cb8-b66bb3ba509c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30472bcd-d169-42d1-a754-1fff6f29457e"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbe6e2f0-e70d-4d94-8fb2-c3706e39fa10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16cbcc05-f3d7-4d21-a738-ea971f16003e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a7ec5462-4af0-4729-9556-7449c09e884f"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fab8fcbd-085f-4341-aef9-8b62082340ab">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
    <rdfs:label>Benserazide</rdfs:label>
    <dc:identifier>DB12783</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41126e01-808b-475d-917c-64947b76dd2b">
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a663f416-8efc-4c15-b49a-f3174a3c96e8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7785854-5a75-4b00-a793-4579a128e4c1"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe1f24af-77db-4825-b679-c90f52517196">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
    <dc:identifier>HP:0005978*</dc:identifier>
    <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4fe87f6-4fa5-4451-9d18-4efe9c32b68f">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22afd365-4d65-4962-93f6-567b425ff9a6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:label>Myopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003198</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba195777-1765-482d-93e5-2b87217eb644">
        <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
        <dc:identifier>HP:0008972*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69a167f5-833f-4ce5-bac8-e50e7d21ce1e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/301e1fe1-37af-45b6-bbba-083d2d254954"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e79c54c0-00e6-40aa-b3a9-c630cc22839a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/101ce319-4fc0-4e9e-b6d3-53f174b6b6ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7127a84b-98da-4773-829f-83d00c624abd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003073</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
        <rdfs:label>Hypoalbuminemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffbc7dcd-43dd-4464-80f3-6ed18bd86a13"/>
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a932367c-3755-4881-8c89-73c647db5843">
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chronic diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b76bd966-70d8-41de-a16c-2dfa80315c42">
    <rdfs:label>axial hypotonia</rdfs:label>
    <dc:identifier>HP:0008936</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/06878631-6cee-4ec3-905b-ba014f8ab079">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfaf437c-4541-4644-a643-ee387bf51d04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d353687-1469-4c75-a0a4-c80231a98a27"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5442719f-6c3f-417e-ab97-6823d3cad4a9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low serum testosterone levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
        <dc:identifier>HP:004017</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3cb33523-8779-42b8-a033-f410309220ac"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4eb3d841-3975-4d4a-ae50-59b8f76f1270">
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61e910a5-4dfd-4161-9865-1abd87940e88">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cdd6640-d2e7-409d-80f1-b9fed3de85e8"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/628d782b-659c-4378-9ad6-642c40e5a0d5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cc68496-dd6e-4def-bf07-839669f27b96"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f83330c-73c8-44ac-9200-2120a1e472a4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69118432-2014-4bfc-a881-b55e1b5ff9f2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9fe91fb-9512-41ec-b2d4-fd2e41f3621c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c5b2743-08fa-4001-8793-ecaec51e262c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1149d785-e33f-4352-95dd-694891d36a6a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0704f6e-f823-45ba-a5f2-8270e1849592"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1883e1b-2863-47c5-b2d8-061b95ce82bb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/142c74aa-1414-4788-b308-c98b40987ac7">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0704f6e-f823-45ba-a5f2-8270e1849592"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11b3abb4-9d96-4187-98b0-3e9b6531d537"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dabf15dd-88f0-4dc1-be7b-6eff9ee2383b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5a6eecf-b4a4-4d34-8eda-25cc6a7dd442"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a4b81e8-1c76-46a7-ab64-c699c6ab533e"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50c2e91c-fa9c-4454-9add-92677c0eea18">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abe73f01-cd5f-4dbd-9f59-f25edf397e51">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/afcf47ed-2481-4d76-8bb9-d5f90430d26b">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a47a81f-bc70-4027-9f21-45eaa105991a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e753fde-f9eb-45d6-98d1-c8609c0ae841"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22138df4-8abd-434e-a5fb-f92b0e2d8c1d">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/467b722c-e5c0-4db5-bfa6-eaf07dc3aadb">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9e9a5b8-633f-4c61-a834-77d1bd5db386">
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b115782c-49ad-49d0-a597-8b7bdef696fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce44681c-fc7a-426f-8334-315c1c043d42"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Mannitol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <dc:identifier>DB00742</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/94bed8b6-0afc-497d-a672-e1aeb91a62c5">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49bc6df0-aa3b-4ab8-85c0-79b4b9841b2c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8868f8b-5665-4cce-8bab-de55c7a26603"/>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/afffd3d4-b94a-4b8b-8c7a-b68d652de548">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b122ae1-aadf-42cd-9b8e-f753dd5b0c58">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f2b8394-3a3e-4318-804d-471356fe4736"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ba94f54-6d92-4edb-806a-246737c34f5d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04faef2d-daaa-448b-8b58-3ffd5397b81a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a765c178-1148-4b09-868f-9cc8a515631a">
        <dc:identifier>HP:0003800</dc:identifier>
        <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a72768ab-0417-43e1-a50d-c2b7487bd134">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/513698a7-b6d3-4e48-88e1-7d70f3537552"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac803dc3-b6ef-4701-872c-f1d5783261e7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c43e6b99-355c-4392-ab43-afdc00a33037">
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/970dd136-73f1-46d9-aa0b-c9b9bda3f276">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cdf7408d-5a28-4a1a-a0d0-33df7a375bbd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d07cad0-d1df-43c6-9c32-34c33cdd55f2">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
    <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
    <dc:identifier>HP:0001877*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/06530fe8-8ba7-4f27-875c-f3f457ef6e77">
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dac3be1-737d-41d3-a10b-d4b96ea7a708">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc395368-5e4e-4f93-9594-def62c0f79e3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a8299d6-ebe9-453b-a02a-1011bae604d4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <dc:identifier>HP:0006279</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a3408eb-e9fc-4d4e-a06f-2da0f3ba6bd7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Salt wasting</rdfs:label>
    <dc:identifier>HP:0000127</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54367c30-8930-4980-ad42-07087427b6c6">
    <rdfs:label>Bone mass loss</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70265ee8-d875-4a1e-a9ca-58822f1100cd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/86ed56df-e7a7-459f-a4c6-9b90c3efd1d0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b983112-a348-4a77-ba77-03e9cf098fc7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0060c215-0fc3-4a03-98e5-db3f5a1d8d8e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB06372</dc:identifier>
    <rdfs:label>Rilonacept</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d73cf5e-966b-4dd5-a445-31d46bd1d6fa">
    <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/559bc067-5f62-48cb-b692-53841d8a9ee9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31c05392-42d0-42af-aad9-0a0c5da3dd0a"/>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e325950-ffec-4f40-9858-fcf0af9385cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1fe71bd-385f-48c4-a364-eaaf6c23f260"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9dacaa37-42da-4129-a440-95605c9c39be">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3bedf9e-56b4-4db5-8fb6-bcee085af451"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/beb5667e-2579-4c90-98cf-a587ab5069b2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79c54c0-00e6-40aa-b3a9-c630cc22839a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88d0deb9-3082-48fd-a674-9e44bc712ec1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5df8a0e2-fa8a-4bf8-a535-07f2c521ea37">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6272df9e-401d-4c96-8fb5-76c71788eec3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bbe16ac-cc49-49da-93af-90c2eef7755c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77fe6799-35d4-4d44-89d9-a477df86c5eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ee995afe-6de1-4889-b965-64ebd83ab101"/>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57f94dbd-606e-4002-a6c8-51cd0c7a0e6d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
        <dc:identifier>HP:0012187</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/101c708f-8a28-4df3-9ab0-ce66d4ab59c2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002872*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9ced8df-a731-430b-b6b8-809154f71b81">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/154acf91-91cb-4cff-9080-4b254b63c357"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50e3c8b3-a0a8-4c91-97da-61b6ab87a48a"/>
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34c58f66-6058-4da8-9075-587966a0b97f"/>
        <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad687c14-f9fa-40d4-babc-517dba08d937"/>
        <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb04e9be-627a-42c8-8319-ef01da269884">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17841dfa-5ad2-43ff-bf11-b9da2a2d4b81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27302496-6eff-41e1-ab5e-1ff0f4382f45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cf500f1-d74c-4970-b913-50e81b1dfa1e">
        <rdfs:label>Arthralgia</rdfs:label>
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702b168-d79a-4135-b3e6-550ee83db7f2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3aab6e6-cc2f-4dbb-aa04-b5a4bb726888">
    <dc:identifier>HP:0012477</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
    <rdfs:label>Voice tremor</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e596f1dc-f0dd-4750-87a6-ca99f816b7df">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60c377d5-f718-4cf6-ad48-230485266db7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10918cb8-8fff-493b-a28b-8055c56ee2f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30c57b62-ea20-4de3-96d6-8a19538bd4a9">
        <rdfs:label>Low pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2da9f180-0f05-4652-8deb-f47099a974e3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006517</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a80d124f-fdeb-4fef-add5-606158530b16">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a5aff03-9e1d-455f-a246-9ab106cc3259">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2dc9e8d1-84ac-41e9-8d46-bdee818c3c6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0eca512-cd83-4c5d-b104-80f43e6096fe">
        <rdfs:label>No result was added</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/923f8402-7e6b-41ec-901c-d6f3f9144655">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3380899-eed8-4387-a304-dc805932e99d">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ebfb4a8a-df2a-46b5-8a04-28dcf991fdfc"/>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d978a644-9da0-443f-bce6-8e00cbda5925">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010918</dc:identifier>
        <rdfs:label>low intracellular cysteine*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a386996-86c5-4208-bfc9-0eb0e555bdc4">
        <dc:identifier>HP:0003343</dc:identifier>
        <rdfs:label>GSH deficiency</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c85ad522-6602-4514-a53e-d6fa45f45d45">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1905a9b9-c3cb-4caf-a8c3-8d1a3fa6dc21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0bb799fa-df22-4913-82b7-146ee605797b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4049ab3d-cf81-442f-802e-496342c7e588">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b689587-34e8-463b-beab-019f52279e45">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a2a6a64-cfb8-4d89-bc7f-36ecdb6701cf"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cdd6640-d2e7-409d-80f1-b9fed3de85e8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5fa2dc3e-d21c-4663-ab9c-a68bf1240886">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a3b8188-5fba-42df-8e89-bc861ff67fe2"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b2c6a6b-fef3-4676-a9dc-076867127bf0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB02959</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/13c43665-131c-46b4-9afc-060c777c66ed">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ddcd9e8-4d57-4322-96ee-52fa5f92b09f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38ed262d-5230-484d-b15b-a6a6b316a50b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a17cf34b-40d0-4d0d-9d16-795b3d0dcc7d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cdd6640-d2e7-409d-80f1-b9fed3de85e8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5939e515-1dfc-4515-8b1d-9b64123cfdc0"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Oxitriptan</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6611905b-80a1-4754-a9b3-9235244f77a0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f7c7365-c36e-4921-9581-63ba058853aa">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b64f6f1-aca5-444d-90d6-87a8868366db"/>
        <dc:identifier>DB01076</dc:identifier>
        <rdfs:label>Atorvastatin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85ad617b-903f-4849-b4f4-d4386d403769"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/759ae68d-c51f-45d2-9c92-87be17ef0351"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58ff0b94-a83b-45c6-9bc0-cd9addc370dd"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c39f832-d72d-400c-9175-7cbad01fff76">
        <dc:identifier>DB01098</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f6bf2f3-3a60-468b-b03d-9f2f0b7f3316"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0424a82-8d34-48d6-92d3-2510b48cb383"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c6134f8-283f-47e7-81e8-3eb34e22e4ce"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ddbf3f9-21f9-490d-94bb-2458e8beae3f"/>
        <rdfs:label>Rosuvastatin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70fc273b-6d1e-4f42-bac9-9c71f6524441"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/759ae68d-c51f-45d2-9c92-87be17ef0351"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3d35c53c-ed9c-4638-93f2-285bebce968a">
        <dc:identifier>DB08860</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/759ae68d-c51f-45d2-9c92-87be17ef0351"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
        <rdfs:label>Pitavastatin</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27cb3241-db67-4bb1-9cd5-30454aabc8f2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af3edbf6-d76e-45a1-9dce-51057d2475f3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c870fc39-2488-41a1-863e-f5d93d106744">
        <rdfs:label>growth delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73deed94-798a-40a2-9459-8d1b9eab8e06">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>gross motor dysfunction</rdfs:label>
        <dc:identifier>HP:0007015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4a328f2-dc90-466c-93bb-5d4f6dc04542">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002093</dc:identifier>
        <rdfs:label>respiratory insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adeee1d7-07ee-46ae-bccd-898db6b9a693">
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:label>Defect of bone mineralisation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cc7bac6-7f94-4348-92ce-79ee0e8162cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f60aa287-f843-40a3-96bc-eb8c8cbd6fb2">
        <dc:identifier>HP:0000002</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:label>delayed growth(stature)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b703461-caef-4c27-a50f-b5c1fd8117b8"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07d9b9c9-afdc-4741-814c-9456bc2d677d">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95746253-7a13-4b14-97ac-e2943c114f66">
        <rdfs:label>muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f3e64b2-fbf7-4ec9-bbf2-37820b0f6b5a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:label>rickets</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f58673e6-c8d2-4e19-b6e4-2365f3d71f8f">
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fine motor dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2201990-07cf-4a75-a0bb-2f1e424428d3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:label>poor skeletal mineralization</rdfs:label>
        <dc:identifier>HP:0006462</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c028caed-1df0-4f80-833f-fd7886f6257d">
    <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011031*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21cf8820-86fa-4006-bcae-7eec17606314">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97c88306-b922-4240-85ce-92972686c658"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec87709d-c197-410c-bc79-1e3461ea85f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fe6796c-21bb-4f8a-a475-271d0a315442"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/919051f3-9c5f-4976-93ba-170d326246bc">
        <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5878e119-3f04-4364-b9bb-aca8b0377965">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d67aa4aa-15ff-4788-864e-0ae737f5949d">
        <rdfs:label>mitochondrial dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d01e2ef-7e0f-46e0-8cc8-440a6e15cf15">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/813905b5-aeb5-4ba4-b879-fa47d0e04887">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b22ca2d-7d46-4726-9213-db18f663d0bf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/727c8155-9a21-4237-ba2c-4c4b81f354d9">
        <rdfs:label>Ployuria</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/482d223c-bced-49b9-b5d7-31d983e41290"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2309889-0f30-42bb-a576-d5ee702f6edf">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001138</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
    <rdfs:label>Optic nerve damage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70fc273b-6d1e-4f42-bac9-9c71f6524441">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc938532-7646-4e6a-8b57-098b35546afd"/>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fea20399-e084-4a3a-8b3e-13733cde8d05">
        <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e63d4118-9c26-442d-9173-5eb9b6296497">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc833139-c914-4448-9090-9f5e2a019579"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43dab984-a6b7-4aab-84f0-e72237f333a6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19b10764-d13a-4f9b-8d31-fc44f394c141">
    <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7223243e-637f-4f67-b047-8a655d25e992">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d25b7f9-7375-4671-abce-02171fa621a2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0a24898-765f-4bfe-907b-6208f7c3dfbf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95d5ec22-1a34-4c5e-9d3e-6b6f22fc0897">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb68c0a1-8d35-48ba-a620-8497e3c5f765">
        <rdfs:label>Cardiac dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c085a008-8591-4ae9-ae1c-862b466a893e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8643b01-f68d-4ff0-a2d5-59819a438cf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30d5c8d4-0070-4db6-aa78-8f07f016bf6c">
        <rdfs:label>Exercise intolerance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <dc:identifier>HP:0003546</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25ad9c38-a0c2-4c0a-aa0c-84f4ffb37a95">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ef8fc0a-b182-4682-b819-74b088f03955"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57920254-25c3-4b4b-941a-5d637c3531bc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
        <dc:identifier>HP:0025521</dc:identifier>
        <rdfs:label>Abnormal Body fat composition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3665e247-90c5-46e7-81d1-038c09a005c2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low lean body mass</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <dc:identifier>HP:0045082</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c054be6-57e1-46d2-9985-54de7113c720">
        <rdfs:label>Decreased body mass index</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <dc:identifier>HP:0045082</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39ce1753-8325-40f5-ba2d-da38a2210b8c">
        <rdfs:label>Abnormal circulating GH level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0032367</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e45f5e04-d559-4084-ba7f-5d9e0c114bed">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031034</dc:identifier>
        <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e367c21-c157-4232-8fef-93c425156ec8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
        <rdfs:label>low insulin senstivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8549b6c3-f702-4397-81c8-3c2cc8f92bc6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
        <dc:identifier>HP:0040215</dc:identifier>
        <rdfs:label>Abnormal circulating insulin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab1bea66-b5a9-40fd-829c-28bf95e181f7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2b7896f-eea0-4ea5-b934-8cd936c83473">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <dc:identifier>HP:0000002</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fc9d0c1-66d3-462c-b164-18494a8e3846">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>Low height velocity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bac7ff54-34b4-4b73-a80b-ad0754ede357">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b590ae73-c95e-4dde-b091-a1930a070249">
        <dc:identifier>HP:0012100</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
        <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6449b5ce-86ec-4f84-b107-02215a38e86a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aba266f5-5df0-4fe6-8cf0-52a7671ba3ff">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0abc10d-7f04-4bb4-867e-0f56e6c79867"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
        <dc:identifier>DB11563</dc:identifier>
        <rdfs:label>Sebelipase alfa</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02e8f3a9-96b8-4ece-ae46-0eac74d07fc1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7044fb5-582b-4e4c-aba8-ba8e6860adf9">
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40b98d1d-0699-4d74-b8c0-d67368c3cc0b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da99287a-95ed-419c-9886-0aaf9771d170"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79674e00-2507-4717-841a-8bade75c65ff"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bfe59405-e9cb-41c2-ae8a-e3b7509ed2d5">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c8c5806-6758-4e78-a286-18fc6ffa52b2"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08261454-489b-48ae-9865-7dba5f624618">
        <rdfs:label>Chronic constipation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
        <dc:identifier>HP:0012450</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/510b598c-fbda-4dcc-aa58-64bceabae50a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor head control</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b0f20ad-6a9e-417e-81bf-2bee5e0e5952">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defective eye motor function</rdfs:label>
        <dc:identifier>HP:0000496</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73fcded0-1922-472d-b684-308925bd6153">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bulbar dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <dc:identifier>HP:0001283</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/441fd397-6bce-4f9e-af25-f5f56e5beb66">
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1589dca2-1f71-42ed-bbb4-f40ae0a8c566">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d51aca6-16cf-45e7-bd6b-e4f7cb0b1a40"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f78d79bf-6288-49fb-a609-fbb145863fd9">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0762e9a-dab1-4b7b-8bbf-cdf42e3aec5c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc823545-fbcf-4edf-aef1-419a91590127"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc954b95-4728-42c8-9449-d63ecb8bfd16"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc609ed2-6d94-459c-a279-287868d0467a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27c38544-9c67-4c26-8b27-53fbea8b7b4a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb619e3d-6d5b-474b-9b95-0cfe453fa8a5">
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>Recurrent infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d1fd1a7-c154-4ff5-8ef5-35ecf0451348">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/388f5e3c-b0a1-4e9b-b82f-a15815b51e1f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3204771e-9e7e-49dd-9c30-15c2c6c95f11">
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a114e330-ec9e-4682-bbb2-2641a1c1578a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03ab9a80-d0cb-48c4-9263-a622733931e5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05fbe2b2-e925-49f3-8013-66b05b0bee39">
        <rdfs:label>defected excertion of 3- MCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af12d5ea-236c-48a7-b9e7-bfb82dc38015">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c5c935c-0b7f-41a7-a799-7a930530fc39">
        <rdfs:label>epilepsy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9bfa719-33b5-4555-90fe-c43a50a6264f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41488892-adb2-44b4-b841-765b06f3dab4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2fe8d9f9-8ddc-4596-98fd-c8a97013a7a8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7062166d-ac96-40fd-9c56-853ff0de8d6f">
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:label>myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f8320fa-bc64-4b0f-b089-619590e08f01">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5cb0c2f0-265c-4bbf-ae9f-248d1efe6035">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d936780f-2675-4324-9c46-c2118a9978dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0437e56-c764-4d11-ae36-a86039d71633">
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>cardiomyopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7e7fc32-6044-463f-b109-15eafad7b2ee">
    <rdfs:label>low hemoglobin concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/536f7c14-389f-4577-8017-d7a80b475187">
    <dc:identifier>HP:0040129</dc:identifier>
    <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/394b7d88-48e6-4869-86c0-7bf8497c32c3">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bbe16ac-cc49-49da-93af-90c2eef7755c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02ece8c2-68e7-464e-9f4c-55e94a5c9d31"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39ec6656-232b-4b21-af59-09c3c1fec52b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1364a14c-9b92-4062-a242-a2079c7c492c">
        <rdfs:label>Abnormal spleen size</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/701852fc-54b1-4290-8ee7-fd59814c1b82"/>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0f607fc-3ae1-4116-9cf8-82de3aa4afa6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d08460df-85d6-4d3c-8c81-8571c925491a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd93e3db-d3ea-4128-a7f5-b492ec6e7c16">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9212c179-b79e-4c08-be39-4b5eeaef171f">
        <rdfs:label>Joint inflammation</rdfs:label>
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01ef791f-e801-4d57-abe8-6139dcd89353">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012647*</dc:identifier>
        <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0575b15f-d748-437d-8987-53281b3fa0b2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma MCP-1</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16313969-11ab-4ee6-908a-73564bc3ef8c">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
        <dc:identifier>MP:0009587</dc:identifier>
        <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/995d597d-8cf9-4e88-a16a-42ff103113cb">
        <dc:identifier>MP:0020582</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:label>High cermaide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/047e6c08-e02f-4095-9d1b-62eebda67cac">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0020582*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24d360c7-81f4-4859-bc34-70796a43b019">
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6d7e7ac-fba4-4cd8-9a15-71f6c13825be">
    <rdfs:label>Pegvaliase</rdfs:label>
    <dc:identifier>DB12839</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b4bc81f-92ef-45e0-b9a0-1ea448e7ea01">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92d06dd1-d84c-45df-8c99-93dcdcc044b5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d6ee996-0b0f-4c0b-a434-5fc4b097982e"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79123b04-92ac-4dc3-9003-e88003335677">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>abnormal muscle function</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/472c6702-b0fb-48e5-93f6-06ce5b5103e1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c5c9976-cfc5-4e52-919f-266ef9dd813b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2649d35c-e566-42db-a7ff-63931b0236f1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/841cd45a-56e0-4d2d-9541-00b652711c41"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b08877a2-18a1-467c-b1f8-98835b7b6ebc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e8a601e-0f45-4668-97eb-a4dba0c74819"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0982cc3-b466-4184-a4bb-e2564eaa006c"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
    <dc:identifier>DB09115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6e57d0c-81f4-4882-8a36-4545a87a9bf4">
    <dc:identifier>HP:0003107*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a64b531f-7199-41f5-be72-91ff7999f4f8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1a0908b-b189-4594-acda-daf166c51f1c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74bd15cb-53cc-4eb7-99e8-41414507757a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bd51933-4621-4f3c-8d83-4f57d0e2e22b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3455ac62-6e42-40f1-bb42-6e6bc8885cb2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca9acc93-b185-4345-be5c-dffc0032ff11"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Canakinumab</rdfs:label>
    <dc:identifier>DB06168</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3f361a7-8022-4380-b373-f15760bb2a30"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c557c739-50b9-4776-85be-e4a7c47196ce">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e73331c-d38e-40b8-ab70-2654718ca98a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8877aa0-fe71-45e4-8446-fcda56151aad"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28317977-7638-46d6-8316-fffac38293eb"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8b92295-ecea-4364-8faa-07cd02b00a81">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Diminished intellectual abilities</rdfs:label>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c04c6d02-2495-4f86-8374-f4c4f65fbbbb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <rdfs:label>Impaired nerve conduction</rdfs:label>
    <dc:identifier>HP:0040129</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a723de0e-bdb9-49d0-83ac-1f451ca71f17">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/814cca25-07c1-4a8a-a7ec-9b7ac8f8737e"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8317b303-3353-459e-a43a-404ec1fc9e79">
        <rdfs:label>Abnormal reflexes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <dc:identifier>HP:0001347</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67287427-1c42-4ba7-bf2d-bb3c0e824e73">
        <rdfs:label>encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea5c5b70-91ac-4ddb-88e7-eef5df08a400">
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
        <dc:identifier>HP:0030178</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c27f3aca-96f5-4936-b90e-6344c359115c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/499bdc41-4bc8-48dd-9894-d550b9da5aa2">
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Abnormal movement</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81908c52-ec82-47bc-9c75-988d25e6134d">
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
    <rdfs:label>high ornithine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dce2522f-e77d-43dd-bb7b-e220c95e8331">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88c73161-eaf6-4039-a641-a7d094aed4ea">
        <rdfs:label>high serum phenylalanine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e73f8e8b-0594-4256-a0d4-afa33ce8b28f">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/701c510e-9179-4c22-87ab-d09cef52a6c2"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f448b63-6b68-49aa-a91b-0ae88e2e2b40">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c5327a5-f2c9-4156-a393-8a7d52e686a8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57825045-9451-4e03-94b2-7804230761a9"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/584e4d57-dbed-4ec3-bd3c-61a19db125c2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/725fe9a1-8890-4c79-9a61-48f4f6e11d22"/>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a7f034f-2c3c-4e59-8ba8-9f9b7e964af6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>Short Stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d5b06d2-d314-4b11-bf11-08be0dce5cd4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
        <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2df23929-6831-40c1-85d8-0b5b449261ca"/>
        <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/664823c3-c82e-47f9-abc0-053e65a6e1e0">
        <dc:identifier>HP:0009124*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bec4f419-aeec-449e-8753-fb6f20f16cad">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased intraabdominal fat</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
        <dc:identifier>HP:0008993</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc67930e-1e66-46f4-8fad-9eabc7e4d5d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ef340b4-d008-41fa-b831-9b45f6600ef9"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab397b50-398a-4ba1-97a1-9e01080f8718">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e71413de-6300-4322-8881-f6af9e5fb6d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61caed02-d98c-4527-8ea0-7dea8369bf1e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3eaf9a95-354b-4d24-bd7c-b536e1b1b806"/>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d5e398a-db77-4435-bb76-539296b92872">
        <rdfs:label>pancreatic dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001738</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aad12751-8f7c-41db-b0ce-f06e35fe676b">
        <rdfs:label>tissue damage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea867a43-5528-4bbc-b884-25fa6abf0ee6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
        <rdfs:label>Liver dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001410</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35aec091-2291-42d2-90fe-8be496efa2da">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002311</dc:identifier>
    <rdfs:label>Incoordination</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac0b9d08-1f2f-4aed-b08a-454c501a172a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Hemoglobin concentration</rdfs:label>
    <dc:identifier>HP:0020062</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/42ac832c-244c-4b56-9c3c-ebd09215f4c1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/128dd652-a29d-4c44-a2c7-dd7ef853373a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/373d29e4-c5a1-44fa-bd24-ba7af9187735"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2f42cf9-9ce2-4517-a675-21cab64ebf19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18aecea4-67b9-44cd-8d6c-4a79a80bee0c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
        <rdfs:label>Gait instability</rdfs:label>
        <dc:identifier>HP:0002317</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76989485-d092-440c-89f2-45a1ecadb6f2">
        <dc:identifier>HP:0007340</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
        <rdfs:label>Lower extremity weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d849f48-ba1f-4474-a35f-7e62f673e376">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c72d5d87-4a60-44c3-ace0-0e7803d6b3aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1420a931-384f-4c66-84b3-5b26fadddbab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3e22cba-9396-4f3f-a0b1-8c691edd7288">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <rdfs:label>Self-injurious Behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b00f28c-d0bd-46dd-a422-6208caeaeb4e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79d45d6c-96cc-4904-aae9-a60d03ae9ad5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a2dde16-bcb9-4f50-846e-5f7c3cc9f8cd">
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <dc:identifier>HP:0003528</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b093230-6474-4ef3-903c-36cba73f8f90">
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
        <rdfs:label>Low tumor response rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed03b034-bca7-4b25-8d9c-269eed724969">
        <dc:identifier>MP:    ....</dc:identifier>
        <rdfs:label>overall survival( premature death)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9063d6ce-ce08-48f5-aa56-b8766344d6ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8944abcb-f8a1-4c4d-948f-caf306020fd8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bcb3687-f6bd-47b2-911b-0fa589d1df51">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>phospholylation of RET</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5bb41ea5-6dce-481d-b93c-74d94b04fd08">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0782c40-e4d4-4843-8714-bc1b2aba67f0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:label>Bile flow defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73c8bb08-13fd-4f8e-8351-bd778ce01c08">
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0609e386-12f2-48f0-8e16-9e891954c4db">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9393816-8a04-4a77-98be-c5bed843183c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9cea32f-ebc9-4194-a455-bc37ac91a2ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001394</dc:identifier>
        <rdfs:label>Cirrhosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c34a8cc-abb9-4c6c-8727-cac991a40088">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atypical bile acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6066656d-f024-4c38-b68b-2ae4ca25fe84">
        <dc:identifier>HP:0500014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/394505c8-cd49-4ecc-b3af-26a494474341"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66a47390-8990-4e02-bf6b-67efbe9afa50"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27f7ae0f-45c9-4a92-8e76-513b25766bbd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Defected bile flow</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c420e1e-fbf9-44dd-b493-890ae97c23ad">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aacfe052-76df-47d9-ac39-8dcbb4a5905e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c59d0f6-faa7-4be0-941e-cbcc8c24827e">
        <dc:identifier>HP:0001336*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17e95ff6-7c4d-45d2-8ff9-172a3db25f56">
        <dc:identifier>HP:0001337</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <rdfs:label>tremor</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c90ae92-33aa-4d37-be47-ead3e1730a25">
        <rdfs:label>exercise intolerance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bad775f4-2063-4282-bdd7-dd5e11fc8de1">
        <rdfs:label>Drawing inabiliity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
        <dc:identifier>MP:0004144</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f149cbd9-b638-425f-82aa-eac1d5543070"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/171eb77d-af3c-4eab-8f87-5d626a33b46b"/>
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94b5cef7-b4c2-4fe3-8a98-83440f6bb561">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ataxic gait</rdfs:label>
        <dc:identifier>HP:0002066</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94f8b96b-aa16-4d2c-8f15-a4a16cbb9b20">
        <rdfs:label>hyperlactatemia</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19ae7b48-98fa-4e37-a39b-38b1949153e3"/>
    <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fa794a9-19cc-48f4-9312-1e22f7af50f1">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c30a2da-a205-4997-bd8a-9587abc9aa87">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
        <dc:identifier>HP:0001251*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4384cc9b-2cbf-49b9-a237-216355aaefbf">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <dc:identifier>HP:0001260</dc:identifier>
        <rdfs:label>dysarthric speech</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/566fd6ea-b074-4422-8af7-bea1e374dbad">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <rdfs:label>Speech problem</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002167</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b1f2351-58fe-48d3-ad60-bbb17895a204">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>blood coagulation</rdfs:label>
    <dc:identifier>HP:0001928</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc0cbf29-e94a-44a4-bc48-15fe667605a2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e27eb666-ccc0-4752-bb68-ac55daa67043">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result was accessible</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f70a5141-5163-499e-82d8-b5192a1b6f0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85c54f35-3e96-4cdb-9850-36b9b0c96aa5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47e248aa-0ff6-45e5-83ce-8ae75f90e94c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d5298d9-61a0-4df5-8c7d-2393b01becbe">
        <dc:identifier>HP:0007359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
        <rdfs:label>Focal seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a3e92d6-2d59-4b3a-9b90-7c425954a829">
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2505a55-7229-4230-b4b2-bfd40b160f36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01eaf731-8d09-4b18-88ac-a36d05f3dfef">
    <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b61c95a1-86ca-4fd2-9056-ea8e5c651636">
    <dc:identifier>HP:0012051</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e3dc108-878c-443f-832c-1bc1f42b8cdf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35aec091-2291-42d2-90fe-8be496efa2da"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6a06e37-4d1d-4530-b35b-91ab24285ffa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32ce2419-f53d-410e-bd49-a948a1ab5c27">
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>abnormal gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbf9451c-81b5-4add-b616-7963e1582dde"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/536f7c14-389f-4577-8017-d7a80b475187"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edae834d-814f-45b0-a798-55398ec5098d">
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb3ec351-0b7c-44a7-9486-5c61ddaa44a3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
        <dc:identifier>MP:0001665</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90fbbf6f-ae6c-40f0-b796-7dcf80482958"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1939c56f-6669-43f3-be59-fbfb2a3b9e03"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbe24146-ec3e-4edc-8a89-26f6fd6cd1de">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <dc:identifier>HP:0000518</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cataracts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/628d782b-659c-4378-9ad6-642c40e5a0d5">
        <rdfs:label>Movement disorder</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a2527f8-3798-4ace-aaeb-67b35a98d9f5">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>EEG abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc1ce6c6-45cf-4a37-b141-8c105655299f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Oral ulceration</rdfs:label>
    <dc:identifier>HP:0000155</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9cf3c729-f31b-43c2-8353-cd1403b46937">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8877aa0-fe71-45e4-8446-fcda56151aad">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/782d3e4b-d6e7-4e8e-b61a-e95f72bb5752">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/88fd4c90-fa4f-499a-b40f-97719dd21f7b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25bff4ca-7bc6-49a3-9e85-74ac3a5bb7f3">
    <dc:identifier>HP:0003394</dc:identifier>
    <rdfs:label>Muscle cramps</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f07b6262-0155-4926-ab3b-4453730a7381">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77e117d7-1cc4-4b3d-a81e-7dc83d1a05dc"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6629bdf0-cea0-4792-b851-1cecbf3a33e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/972f4e8b-a929-4252-8458-327c20bdef1d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a8a325a-d62a-4aaf-822d-dea2610ef652">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9abf6938-7759-4643-b29d-137483818920">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>swollen joint</rdfs:label>
    <dc:identifier>HP:0001386</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e25a704-dfdf-4c65-8297-cd4b257f8492">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9de3a36-c287-4339-bb0d-53570e9213d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidotic crises</rdfs:label>
        <dc:identifier>HP:0001941*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/558f9708-8dee-4a98-bc7f-07ef2a32948c">
        <rdfs:label>Low COX content and activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bef5d65b-913b-4560-a16e-1374c8fe5f75"/>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ba32a67-bfb5-43b7-b197-4b59967da97c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c7f53c9-1b9a-4800-b9dd-d4afa8904dff"/>
    <rdfs:label>Elamipretide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f7c278f-6e1c-46fe-84e8-cc2a047223bd">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52923577-cd04-4647-8f8a-2ec11e0e88be"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ae41f57-2519-413b-98a7-252b025b5dbb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/169c3186-fbc6-429c-a79d-36865fcd35d9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <dc:identifier>DB11981</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d88ee5c-408e-42e3-ab0b-5cd06334a3d6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/35fb2e57-7ec5-4551-b633-56cbee7b456d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9324a25-8bcd-4438-87b3-8bcd5a3d2243"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6fdf9dc-d7d1-4e28-b4e2-a16f24c1a827">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91780ab1-4a14-4784-94bd-3a4d15afff0a">
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26f6f400-d37f-4759-9f71-8731fd39e4e0">
        <rdfs:label>Hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c68725cb-cfd9-45b4-ad4b-ed35320c7f7b">
        <dc:identifier>HP:0000952</dc:identifier>
        <rdfs:label>Jaundice</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b83ad6fc-24b7-4480-8530-4e4ab60374b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0762698f-97e0-4a3d-843e-6e626882c55e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebee42ad-501d-4e55-989d-f645e8edf50c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypersomnia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e9dbece-395e-44a7-ba77-a3f793c1cd8e">
    <dc:identifier>DB06777</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e3dc108-878c-443f-832c-1bc1f42b8cdf"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/702fb3fe-28c8-4d92-9d61-b4947434bb70"/>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/520142e3-a8b0-4cbf-8a51-0986361aa255">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ccdf1838-a28c-4ef9-ba8e-bcc82161447a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6aa07c5-6dc5-4fd3-af99-f7505bb7f456"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6ef887c-9d97-4ecc-b292-7bb0fb341b83"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e57bf7d-fa2f-4c88-9140-ace01fd6c284"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00ae68bf-dd02-4290-a824-a6c6e618e7cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d33346c-6adf-464b-99c9-8e3234af49d3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce755c5-6a17-4002-ac70-9d01e307ba3e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31bb36e8-bc76-4fa0-9fa5-244269acea06">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8cd6a7e-fce3-4d5f-aa54-3c2720f56dc1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal fat metabolism</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3dff729-64ae-4ed7-ba32-2052cdef1cbb"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/354822f9-95ef-447e-9f55-26e544d9a3f3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
        <dc:identifier>HP:0011013</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bce6b189-d6d6-405c-b640-a56c3c310bc6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c6aac1f-dc87-41df-817b-b3950d948d1a">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73caf508-4165-4727-b7ca-641fa6d83c26">
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff81bf2-d6ef-4dce-8831-26c88cce5f4a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b8bf47c-5ae9-4699-8e9f-1e83fdf786ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bebc4b53-7987-4467-ad5c-1bf801545cbd"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a932fa5f-7873-4700-8e01-e69c06c8434f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/156e9d1d-812d-4d2a-882f-793eb6de650a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/727c8155-9a21-4237-ba2c-4c4b81f354d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea585701-fc04-4bdb-987a-5d0ce6e7c494">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
        <rdfs:label>Hyposthenuria</rdfs:label>
        <dc:identifier>HP:0003158</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72dceda3-0a69-4640-b583-3108ae9e5dd4">
    <dc:identifier>DB01219</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45042f5c-e41f-4f91-ac81-a037e12ef4fc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0e61473-d52e-4cee-9161-740ed0a838d0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/975d0220-544c-4823-bf28-fa49fa69426e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Dantrolene</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c2ea3bf-3e92-4e06-b272-900051a7ea16">
    <dc:identifier>HP:0045010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
    <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/629c7f5c-be52-4fe2-bb24-462764fd108a">
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea229796-b9ad-4bc3-bb36-caf915c7a978">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b20dbc0c-a450-4950-b35e-46ae1d15e65e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6deb062e-ade4-40bf-83b8-02952d656579"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af5e09fb-68a3-4ef7-8646-cd7d0e65fc79"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6ed9c23-11b7-4d1a-9a6c-99f69f4dd0f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/209f5112-6508-498e-8351-c1cd29029df1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bfbe8f60-c245-4993-b9d8-649cb6752171">
        <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fc8812a-ed61-492d-9dc8-ced38b1e021a"/>
        <dc:identifier>DB02952</dc:identifier>
        <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ecdb07b-fe91-4d56-80a1-2c3228762531">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3f19c28-167f-4fe1-aa46-a6be185bb621">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/140a988b-3e25-4ab0-b8bc-6853c9998b0c"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d4df0a3-12e6-42af-bfb9-b01c4636f2e1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b0e59ed-f648-4f10-9f7a-877ed9226baa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00700)</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf8e4443-32c2-423d-aa5f-daf229a68e26">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77b00437-5a81-48bd-a4af-733e41b381d4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e703c12b-7ccd-4930-9d88-23dad0c5ee87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56cc0658-9645-404a-adf5-dc1a5a962b7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d386e362-eabb-4f1a-97bd-1bf0783d95eb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79578481-10c2-4ae5-aa48-13b82443fb15">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5a97bc5-6279-40a2-9011-2d3ba2984d14">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/551c54d6-6eba-42af-99ce-e2e2c874743d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/081fdf8c-787e-41b3-8a37-4c31421cd3a1"/>
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/148f06cb-1941-4b2e-848a-3107baa98ee1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high fasting triglycerides</rdfs:label>
        <dc:identifier>HP:0002155*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b08b3390-7157-40ef-870e-230141173b63">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9d92601-2294-4222-b49d-4b1e39af7aea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad56f0a2-82e1-431b-af98-6867dfb17677"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cc3ee7f-ca4a-405c-ae41-2ed45dd7612e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d13c276a-e83b-4f4c-bec8-afb2db088473"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8e3056a-088d-4d56-9ea7-c80c72f5d3b0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
        <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
        <rdfs:label>Neutropenia with IBD</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45f4c44b-590f-4161-9e2b-4212cfac8ba9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7d7142b-b5cd-4a19-895e-6929e53bf1f2"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b81fd54-c5a4-4773-a981-441ef8a1032f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2aa63c28-8d5c-49e4-8a63-f3c4a40772d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446fb2da-5eb8-4475-850e-1ad7ac5e3b92"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ab34782-2d28-44b8-a162-76a54766ae83">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69a572bd-6b90-4aa7-bf2c-1315f152f905">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee078057-d77b-41f8-88c5-6c0b1a9df6cc"/>
        <dc:identifier>(DB00440</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf85bf73-d53e-4d28-8edb-9d8b18d60f35">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd93e3db-d3ea-4128-a7f5-b492ec6e7c16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3718932e-9f5f-458f-8b2b-660a540454d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:label>Cataract</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ba32791-6c95-463b-abd1-79bbe7d1c775">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
        <dc:identifier>HP:0000144</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/569e4cf3-f2f7-4aef-9b38-3fec185f80d3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:label>High serum ferritin</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/975ba77c-e424-49d6-bd91-391c831cf278">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad8d6d7a-23e2-4906-bbcc-82ee01bf3621">
        <rdfs:label>Speech and languague delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c91ca81-301e-4bf0-987e-03cbd35e9304">
        <rdfs:label>Developmental impairment</rdfs:label>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>HP:0000750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/559166d6-3e9b-4787-880b-ac618c959771">
        <dc:identifier>HP:0001290</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Generalized muscular hypotonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8789073-c815-4ec5-9298-73f01354766f">
        <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012011</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e184552-540c-4618-966f-edb80b9c0b4d">
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/450e8ddc-fd5b-4c8b-96e0-3e28c0bdf3bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/951b50b4-4f9c-4f36-93c8-67d1616134bf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c6c8b3be-3a9a-43b7-8424-6c042d0457c6"/>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f058c09-f14e-4331-8930-ec07cf46ac95">
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <dc:identifier>HP:0012647</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5233e4d-061a-487d-a46f-d8353fc7f7e5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88ccee06-0141-4eb8-88d9-bbb6269bd9d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85fc90f5-236b-4a4d-a2d6-3603389e0fbe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cac54a1-4888-4662-97a3-7d9e16fcdaed">
        <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
        <dc:identifier>HP:0011021</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cce2862b-62d2-49ab-96db-809d0890d530"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8db5f177-2608-4e42-a56c-d55b4c2af07e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b4b0597b-3fff-4dc0-be4c-d5a84600368d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f236053-dcdd-4b24-930a-5d74f655240d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/697f4a1e-c83f-4be0-9621-e534dee61311">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
        <dc:identifier>HP:0003260*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df0707c1-84d9-4306-b67b-06f8197f3084">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001832</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cccfe60-e912-41dc-a8d1-8ac2ffec83c3">
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100036</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fa9375f-84b6-488a-a0a3-1db4e2feee6d">
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5a167fe-ee20-48cc-9123-a21a26030075">
        <dc:identifier>HP:0001376</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <rdfs:label>mobility problems</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ceb1f20-8203-4e3a-a017-81c8c118f4e2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <dc:identifier>HP:0002756*</dc:identifier>
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3adcab9-d802-48ab-b63e-d99eb3cd0324">
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
        <dc:identifier>HP:0006462</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f4f9d61-402b-4742-be16-ad59962bf620">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>Pain</rdfs:label>
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7f16c89-7aca-41d5-a91b-da597fdf1b35">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
        <dc:identifier>HP:0003239</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6567c8c3-1735-4dd1-940d-0730ce92edeb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
    <dc:identifier>HP:0000565</dc:identifier>
    <rdfs:label>esotropia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb4fddf1-d2fd-46af-9f84-3a3cb6b79df8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cardiac dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ddbf3f9-21f9-490d-94bb-2458e8beae3f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc833139-c914-4448-9090-9f5e2a019579"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9087bb3-f13b-42bb-9808-13388739858d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>High LDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7fe6ec15-a31d-465c-ae26-70f0aa0f74a4"/>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1d8b0f6-699c-4116-96c6-2926cfe63113">
    <rdfs:label>Failurre to thrive</rdfs:label>
    <dc:identifier>HP:0001508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf63f88a-3640-4158-afc9-77a796f9f38c">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f219696f-907a-4f86-aef8-22b2c2745ff5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c90ae92-33aa-4d37-be47-ead3e1730a25"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02c342f9-2040-4fcf-bf99-370bb7cc8271">
        <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dccc6f4-1f58-434a-a186-2e5c5532c023">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
    <rdfs:label>high plasma RAAS activity</rdfs:label>
    <dc:identifier>HP:0000847*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/775b445f-4f5a-451d-874b-5ac75436c808">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8443e4ed-0295-4f23-bb63-09f77d599441"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14a4e93e-ccf2-481e-a48e-55992095b86a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5e89eb3-41e5-48b3-8186-5d9eaa3dbdd4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98a0b030-9595-4125-8835-b34975f5b710"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65de41fa-2870-46ff-9d4f-7e063f5780c2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5e89eb3-41e5-48b3-8186-5d9eaa3dbdd4"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35fb2e57-7ec5-4551-b633-56cbee7b456d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/320d70c0-1729-4605-89ad-3a8b4d9809de"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d1fd1a7-c154-4ff5-8ef5-35ecf0451348"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
        <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00860</dc:identifier>
    <rdfs:label>Prednisolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3defae79-c68a-4d41-866d-03f8594d4ee1">
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c11391e-4225-4bc3-a3df-832d57427a33"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b2924dd5-4d37-4578-9ac8-14ec0d4a403e"/>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de964b1f-a53b-498c-8af7-85ceae5969be">
    <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49503fb9-fb34-47c3-b8bb-e2112bd26b4b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/628357e5-9e04-4dcf-acb4-ca1e6ba9541c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27654640-68e0-493c-8feb-6878d2940f6b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
        <rdfs:label>Levothyroxine</rdfs:label>
        <dc:identifier>DB00451</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cf070f2-cc24-4c27-8565-6149b98ebed7"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b800509b-848b-4007-8eac-57b8ad0c2f39">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d68469e6-7a03-4511-b44b-a9f57b61784a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90067478-670c-4774-b903-59db69082df4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:label>corneal crystals</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3cb33523-8779-42b8-a033-f410309220ac"/>
        <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
        <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4191d39b-93dd-4b10-99dc-481844e62ae0">
    <dc:identifier>DB00169</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e214406d-08a9-4876-a215-9237b985a0e0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77f6a055-07be-4e08-9979-847f5c70e113"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4091875b-58f6-4a7a-9e10-3f69b10df7ae"/>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2deea33c-c721-4000-a960-7cb705cec68d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cholecalciferol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f159909-1587-441c-a85f-90e0b6025c20">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0003304>p.I480M</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82f200fb-8bb0-4869-9ac3-77bb299748ae">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <rdfs:label>Increased muscle fatiguability</rdfs:label>
        <dc:identifier>HP:0003750</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/501e875d-f10f-4053-87f5-6303cab24d7b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Recurrent vomiting</rdfs:label>
        <dc:identifier>HP:0002572</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/678ecdbf-352b-4961-8c1b-b9606439c1ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
        <rdfs:label>Ptosis</rdfs:label>
        <dc:identifier>HP:0000508</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/915d2658-893c-4bd8-a596-e4c5ef426048">
    <rdfs:label>low HDL-C level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6f6ccc3-0d6f-4839-bfdd-4f9c3f3c5910">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23169d10-d78a-48e0-896c-39ae39261e09">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50e5d413-0a1f-46bb-b6b6-e29b08227cfb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5276d7d3-9bf2-47ef-a3b6-9734533211b9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:label>glomerular proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a52dbfda-827a-4b50-98ba-6c59242935f9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:label>Albuminuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012592</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4cb222b-82de-4978-9cbc-dcf5a0a4a73c">
    <rdfs:label>hypoproteinemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0005567</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0039af25-f3e1-460b-a0bb-4fa0ba05d7b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5939e515-1dfc-4515-8b1d-9b64123cfdc0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12dbf896-f3a7-4841-adc5-bc83c68359e1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8252ee73-dc34-40fe-9778-fc90afa87c3b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/746c3fcc-7200-426f-9096-5d7979191018">
        <dc:identifier>HP:0001347</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Hyperreflexia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20fb3c3c-5a2b-4eba-85c9-b9835ae0f477">
        <rdfs:label>Poor traction response</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2cfe03d-d9d4-4572-a60c-a600954649eb">
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor weight gain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c3551b3-fdd1-4c57-a244-f223ffe37bb8">
        <dc:identifier>HP:0011448</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:label>Foot clouns</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cf69b76-827d-46bb-9a43-45e4b4c55d79">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Low IQ</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1d5d9ff-3e50-40f9-ba8b-2fb0654addf1">
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b122f7a-badb-4396-9c1e-4d1d06b73951"/>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5da11566-d98d-4200-9022-14e3935c2970">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Delayed development</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43ad5a79-8e47-4002-b339-33315d2d3dac">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioural abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4977feb-78a7-4bcb-881f-0838e5636978">
        <dc:identifier>HP:0012449</dc:identifier>
        <rdfs:label>Delayed mylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aca0b251-7cfd-434c-b359-4f21a74f151f">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43f555e0-dff5-4788-a2a4-e85cff350573">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Irritability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc720795-84aa-4218-a6a1-ca9a545385b0">
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cc51825-5d20-4b12-a6e8-e6d2006ec05f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca0883c6-ce4f-4ba2-a490-4597b39e5615">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:label>Poor appetite</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d74f520-6348-41f7-842a-31f172d0c3f8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Awake EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd988b35-7dce-4c55-a795-1bd8ffe0b584">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed motor milestone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/082659a4-865f-4c6b-93e5-794452bc4ea1">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15782929-990b-46de-9304-4e1c9aeae2d8">
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d0a395b-1d38-44e7-bead-ce14e6a189e5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71b76c14-35d2-45c6-a433-821f72cad13b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6638049b-2a60-4057-a04b-1f69e94bc69b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bce6b189-d6d6-405c-b640-a56c3c310bc6">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f202f3f-9df5-4a97-90dd-0bee0245b043">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c97d0364-a5a9-4f91-9d53-2ddfbaa194eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75b19dca-d928-4240-a8ce-f23dc8ed6882"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8fc9814-3b41-4063-beac-27cc6ec2ab43">
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d2810ba-ecd5-4589-8368-997640561a32"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31bb36e8-bc76-4fa0-9fa5-244269acea06"/>
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6288728e-bcc6-4393-a386-d76e322c8349">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41526cec-41a3-42e4-8c59-ae14c64bb426"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59a04084-4144-44a1-89dd-4e8ba4b81b2a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401"/>
        <dc:provenance>PMC2676979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9388054a-4bbb-4e7a-bdda-31e734a2bf19"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <dc:identifier>DB11677</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c606e712-56cf-4da2-84ce-28f60ab384d4">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263570"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59a04084-4144-44a1-89dd-4e8ba4b81b2a"/>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/102176e4-8232-4073-9ff6-2efe3fceb7af"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ba2286b-2ac1-4c93-bff1-a616b3259ade"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d50877f6-19f0-4999-9893-dd9b3a06ca1a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e818c5d2-a832-434b-ad8c-fecd1361f6b1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/998702c7-0749-4f19-9c5c-19ee8dbb382a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f237fd0-5a96-4907-8e94-012d1c087c64"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4b1638-a828-493f-be45-cdca26ba3c7f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6503bf4-4f7c-4a20-a561-d2a0ad218c44">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0eac6477-c673-4d07-a346-0b12393229c7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0103386b-ff8e-472a-bfa3-9afe90bdb720"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2812fb8-cf82-4ff9-b3b2-b2abd5d81401"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6564e2c9-b45d-4e53-ae18-c8b8219aaac8"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d104f207-69db-4b68-aefe-42ea57d7b452">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <rdfs:label>Decreased cellular ATP level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011925*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c76b215-aeca-4aaa-866c-00ee1ef49182">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d0af979-a027-43df-9d29-92774ca36088">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Clonic contractions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>R229W</obo:RO_0003304>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/534d190b-e0c0-421e-8c38-8337b1f0e75b"/>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8caa1bf2-743a-4814-9082-095506c99be2">
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d639e1d3-c2db-4f3a-ba83-7a8f47f87422">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20a624f5-2484-49ff-8f2e-db32dac1ef3a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:label>hypomagnesemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
        <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1c2b258d-b3c6-4368-8add-12dfdf676f88"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91e974e3-2a7a-4c6d-9993-82f681d64464"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a54f58b0-4e3f-41fa-9452-7cdebb227497">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86fe4fae-2b21-4b24-8553-248de7132932">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f15c186d-cd9f-49d6-9abf-dfe26b4a0e53">
        <rdfs:label>Increased plasma triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3d5a003-b240-466a-8b9e-8370bdb15ac2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>Increased total cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3648615b-39fa-425d-9017-9364f1f52022">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>Increased LDL cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51386873-76b8-437c-ae83-0b32a5dfbbf0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
    <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
    <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1db1aa96-2ff0-4acd-a8f5-54d0d64d7a50"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5b9168f-2b1b-4376-a9c1-973a6ed01ee9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d903fe9e-82fa-43ed-8361-e99bb06f54dc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
        <dc:identifier>HP:0010876*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/691c1adf-dd52-46b6-ad5c-f3a3cad388a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70291b3d-57f9-4cb9-80d5-cca8e23a9237"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db5df1cf-4521-4620-b243-11d579c57dd3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low heamoglobin leval</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff1a2624-6ca0-4356-9e3c-2c8dea7660e8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/706aeebf-c89b-4ef7-b309-82d7723efd8a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f96fc2a6-31f8-4923-b520-299b21afb221">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/305b91a7-3fde-4dfd-b2b7-d08d636071e3"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf12df5d-5675-4125-bae0-30860b2517f7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a6f3630-eafe-4df8-a105-1e63eea86dc4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df219287-7b39-4d00-b10b-c1d2b319625f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0dc261ec-3eff-4c9d-906e-d12137819cde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb619e3d-6d5b-474b-9b95-0cfe453fa8a5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <dc:identifier>DB00061</dc:identifier>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9bed1bb-b02d-4b5e-b4d9-da5ef14642ea">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7a3ded0-291e-4725-adf3-fb75ae088621">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
        <rdfs:label>Functional loss of vision</rdfs:label>
        <dc:identifier>HP:0000572</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15e6371d-2b42-4be6-84a3-7e7b2f6213c8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002171</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
        <rdfs:label>Gliosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea2cf613-4226-4a67-8c35-c7202d5a2aee">
        <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b09fc7af-e948-43c1-a260-b95759721e2a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Retinal thickness</rdfs:label>
        <dc:identifier>HP:0000630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83157d21-5dc1-48da-bab9-6a38e4c368a0">
        <rdfs:label>Abnormal visual acuity</rdfs:label>
        <dc:identifier>HP:0030532</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eae5c136-46db-4575-a16b-fef5cb0a3ccb">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88368a55-1cb8-4c39-bc99-ed3c07b53073">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3d52798-4719-429e-8e90-154dfa5a1f91"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d0d7fec2-0b95-4530-8d60-6d5b2e2a8d5d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
    <rdfs:label>Glycocholic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a50ed58-6ad4-428e-ad2e-bb5c7a5765e4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66a47390-8990-4e02-bf6b-67efbe9afa50"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/807f60e9-8a03-4438-ab55-5942ddf78fb4"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB02691</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31bf4619-ad9c-4fc1-b7ef-8e35e3f1de50">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a22d07-3814-4f8a-9225-786b02e70e19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a8b6dc3e-d445-49a2-86ef-cc32cd9b254a"/>
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e1582c6-d567-4e94-a31d-034c62039cdc">
    <rdfs:label>Low 5‐MTHF level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e106df72-94d5-4a1d-be29-c369af008988">
    <dc:identifier>DB09269</dc:identifier>
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/94f1b356-c587-4709-91a6-a59e1867ec88">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/129bf35c-b7e7-478f-a5a4-af85b3b64564"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/827e0191-1f04-4caa-aa8d-2856819cc301">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e4f25fe-ef4d-48a1-9eb0-25d07e962a50">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:label>edematous</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bba6e695-e42f-4510-b631-49e2d5eb0e85">
        <dc:identifier>HP:0000789</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <rdfs:label>infertility</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df9ed99d-e22c-4584-bcc5-1ff3a211276a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:label>gait abnormality</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca4d9fe6-ffd4-48a0-8c3b-7d76f5b42922">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:label>incoordination</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002311</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c36122d-7ff9-403f-80ee-2501398007a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b04be452-5362-43a0-941f-167f94504958"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/251dba67-6371-4abc-8082-3f0baaafd193">
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2f82251-741c-4d3d-84be-39f6295e9f78">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9db8d620-3354-4ef6-a737-909acf734e3c"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fa8c9de-1047-4454-b63d-0f000365a2b5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145981"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3275216a-c9cd-4909-8f23-958406513664"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <rdfs:label>Cinacalcet</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7148f3c9-5c75-4681-8e32-a6200e68518a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9dd46229-94c5-4449-8c9e-af58306eb7fb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145980"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3275216a-c9cd-4909-8f23-958406513664"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac0a76e2-68b1-438d-8fd3-8b0e60caf4b2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b606247-68e8-4944-8979-5f94b0f04afb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f42af957-0ebe-46e2-a84a-4a35e00ec8b0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24c9bd8f-93a7-45a4-8599-95551b8940c5"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eeedc3c9-99bd-4425-9878-8006a3799274">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22e89710-8e12-43f6-9986-ad823d06c0a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a08fd335-8fa7-480d-a084-1eb296f160d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61a9f34a-a1a3-4760-a72f-3ec5e7c4d67e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004395</dc:identifier>
        <rdfs:label>Malnutrition</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/729d796c-ab2d-439d-840c-a37e951a87ca">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cad3fac5-a38c-4c9d-8e2b-6fa9a177012f">
        <dc:identifier>A11E</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89a95e4a-603d-43ca-9e0d-999df7dea4fe"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0855af40-00d6-4adc-8fae-798fbcebe659">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae79f443-5991-4d9b-8670-6883027665ab">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dysphagia</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a4f0687-20f5-4ac3-b475-b211368aedcc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ee1cdc7-afde-48c8-9736-d40abf158837">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000467</dc:identifier>
        <rdfs:label>neck muscle weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a07f472-1f35-4c3d-b8fb-9152ba4bebfb">
        <dc:identifier>HP:0009071</dc:identifier>
        <rdfs:label>Inflammatory myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/617d2a8e-ed46-4b74-b4f6-81f0a9164bb1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <rdfs:label>dysarthria</rdfs:label>
        <dc:identifier>HP:0001260</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab91c557-540d-462a-a327-893104369d57">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac0b9d08-1f2f-4aed-b08a-454c501a172a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/085b77dc-fbfb-447b-b31e-1d12e42bebec">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025548</dc:identifier>
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90f43f38-f704-490f-9578-579a84dae0ea">
        <dc:identifier>HP:0004312</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal reticulocyte count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/738f9ccf-cf2c-42ed-b457-ced50f0df224">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
        <dc:identifier>HP:0100502</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aebe5e41-b2b2-42ec-9761-85feba3b5347"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
    <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a849e2f4-7d17-4cdc-8d5c-0d0de5c73712"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe81493a-6a16-4b66-acce-291afff2174e"/>
    <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa23e897-9538-4cba-8d05-ee826c82e58f">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b5ee993-7238-48cf-96c4-fe607e0644da"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1c6c899-928c-4b7a-b81f-510e8cabcdfa">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cc54cf1-e391-4f89-869a-3a7871e7f829"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f802650-a5a6-48ff-ae35-3929e7d10259">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <dc:identifier>DB00035</dc:identifier>
    <rdfs:label>Desmopressin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/297d7e61-9148-457a-8548-a2536e94cf97">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55292e36-4341-4b39-af0d-f5c1dee89778"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26e3f769-48e9-4c67-8202-04ad7aeffad9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a5e1b2d-9edb-45ad-9970-44fe19dc4162"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a71906e9-324b-4dcf-afa9-37f9e4d8429d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c35e7ff-1a95-4bb5-98c1-694a9a506cbb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a5e1b2d-9edb-45ad-9970-44fe19dc4162"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26e3f769-48e9-4c67-8202-04ad7aeffad9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bff43c7c-e77d-437c-b719-9184b79c427f"/>
    <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b082a2f-8067-4e3d-9fa9-89f44591a73a">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
    <dc:identifier>HP:0012622</dc:identifier>
    <rdfs:label>renal function declines</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a2b6fcbf-b362-4d5a-aa0d-f433520b2708">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d99e4048-7f04-4b86-9ddb-be74889badee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5442267-b6e9-4339-ad25-ee78e2f92baf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a57a184d-43c5-46cc-b7c4-66c55d19aa8e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010832*</dc:identifier>
        <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2e6c2f2-24be-4732-a8f9-d38d9695417a">
    <dc:identifier>HP:0002119</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>brain ventricular dilatation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8c7a5dbb-6271-4ed2-b962-6d714b26b45c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6c5d0ec-e6a5-4fd4-bff3-cd924ecf8144">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e730bef6-98c7-4c43-bac8-fb0b3f45fcff"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d34e62d-3e42-4bbe-9dc2-2913ac71cac9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79c8d408-9b9e-4296-a1ad-47080946b369">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89b9d102-7a5b-4f8b-9973-feff0197636f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d34e62d-3e42-4bbe-9dc2-2913ac71cac9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00746</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/967d771d-8655-4f60-be15-6430211b26c0">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35d7a826-0fd5-4b46-b2a6-f9a8a32e486f"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d34e62d-3e42-4bbe-9dc2-2913ac71cac9"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bc08c6a-7b62-4a5d-a61a-fe934a03dc6a">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d34e62d-3e42-4bbe-9dc2-2913ac71cac9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e730bef6-98c7-4c43-bac8-fb0b3f45fcff"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Deferoxamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26688406-4200-456e-ba56-e6d40e269939">
    <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007166</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f128c43b-5dba-41b3-92d2-f9425234885f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiac hypertrophy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39e650cf-156e-432f-9e30-dcd5825b2484">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4ccf10b-ce05-4200-9872-020bf2b678c8">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606175"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd93e3db-d3ea-4128-a7f5-b492ec6e7c16"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb4fddf1-d2fd-46af-9f84-3a3cb6b79df8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07d9b9c9-afdc-4741-814c-9456bc2d677d"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202aaf1f-f3a2-4bb6-bd4d-1f4debc3345f"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ea1a232-75ec-4f41-a8b6-6eb82818bcef">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
        <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91780ab1-4a14-4784-94bd-3a4d15afff0a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1cced8d0-d36f-473f-865c-ee50cdd59127">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e46a3a4-d680-4a19-825a-da28fdaf717f"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d513278-10ae-4cf9-aefa-cc768da0d8d7">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53cd8de6-dc4a-47b8-8a4a-de83af7b81ef"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7d936f8-ee1c-472a-a465-f01db330b35b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb33f4b8-748e-4e63-ab41-b4c11357c038">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5fbfc08-eb30-445c-b969-53b2f2b73674"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53cd8de6-dc4a-47b8-8a4a-de83af7b81ef"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db8cd4d0-5fa6-4ed0-a5ae-144e21c80edd"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ee10f50-c32e-43bf-b40f-12691e8c017b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de45d6ff-f943-4f33-a13f-295a599046fe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61e4e954-b9ab-44ed-b1a6-71500b0e21da">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236795"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4cc3c06-3686-462d-94f2-1fb6485aec97"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec65e1ff-3d1a-407e-a702-f5b45301a750">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e1cd3d6-1688-4dbf-aa79-f351d5cc50e5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22afd365-4d65-4962-93f6-567b425ff9a6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e32bc10d-71fa-42e8-a11a-2cb63ecc686e"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45bc57b9-391c-44c6-8110-36624a471756">
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/523f67ce-3494-4874-b17a-4c28cc9cf5e0">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f04b62ff-d780-41c4-bde4-bdbdc454dced"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9939ab43-bb0e-4c48-86b8-8573dc076dd3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3d821f3-8b0f-4602-8c9a-391862fbf74a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56482c8c-d3fb-410c-914b-0c2bd11b5920">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfc5f015-85b8-42c1-9db4-1cf2fbd1cde7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e495d5b8-592d-457e-a6cb-01d746f3ed8c"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d51ab12c-9694-4736-99f0-a9a6aef43c30"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44d520fa-aa02-482f-840a-f853f2a75ed9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/706a0664-cd35-43de-9812-88c76991b471"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b9d31b0-a9a4-4cd4-a4d7-2ef04fe8c673">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee63c752-4fe3-45a7-ba29-761644bdff28"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41e70587-80d8-4717-8983-ad885e470fcf">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d07696c-d906-4e73-95c5-4f9fc3dfa298"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bac7ff54-34b4-4b73-a80b-ad0754ede357"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/990c62f2-8ffe-4dc7-8ff2-d6eea0aec6ac">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5fbfc08-eb30-445c-b969-53b2f2b73674"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58daf14f-59f2-4f34-ab0c-02aa6d9bf339"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ce31949-0260-49a5-aeb3-29fc64aa9b52">
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04d36544-2b42-4e5f-b388-5d30bc8f3f95"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5878e119-3f04-4364-b9bb-aca8b0377965"/>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d583dee6-fc80-4f11-9c22-d2cf11141fea">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600721"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fabc136-33af-4152-b8eb-57764646e623"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a691a3f-63c8-444d-a614-0c720b9d8d1e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67ac2967-ad18-4341-a21e-4f6c7f86e50a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcb02a22-2a84-4fe4-813c-eb136c282100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0d68be4-e5a4-43a8-84f3-3cfc7b4abb02">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62cd5d8c-7fed-4f90-9bda-3b26d37db395"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1bf1bfe3-a822-4f92-9cd4-6a86743f1adc"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af62ee12-866f-410d-ab12-28e07e4c407e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af66951e-9fef-43ef-a927-71726c3b59be"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32dc72d1-80be-4184-a51a-fec3c6fd92be"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ba19770-3730-450f-9f67-89ee336c98e0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01cfb604-824f-4e1a-a47c-e311d4980776"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5db845fd-c907-444e-8f5b-871a970319a9"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250950"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/158ff306-ea85-404a-90c4-1154b4a5dba1"/>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8fb04e8-eb97-48fa-9821-622d9cc3812c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2deea33c-c721-4000-a960-7cb705cec68d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89b37aee-c231-4473-8c9b-e07c598a4cf7">
        <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6eafc9e8-5c9b-401e-a362-23267473be49">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cca7b574-ed72-447a-92f3-1f622934b3f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffed9593-25cb-41cf-bdd8-bc01075dc0f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7e77910-c91c-48fe-9cca-1b62a45d77f7">
        <dc:identifier>HP:0040087</dc:identifier>
        <rdfs:label>Abnormal Folate level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37b29f0d-7f30-4158-baa2-23810cafc36b">
        <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/270886c3-911a-41a2-bb57-1177d0dfc5f6">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal fasting glucose</rdfs:label>
    <dc:identifier>MP:0013277</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5333d691-09e1-449f-9104-c5780017edac">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4fd65ef0-b3e1-462c-89fb-299de2f7765e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9ae8511-d6ee-40d1-8a16-458e3cc67570"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb736a80-51a7-4485-80ef-2b875f870cfd"/>
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3de3378a-7558-4122-b6cb-b57b878914ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c1692a5-3fc3-46c2-92e8-5ebabf3d830e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c679220-e46f-4a61-bfa1-f2752980e63f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1489da2d-c70a-497a-ad64-c699e02c7cb5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2404373f-e461-47e8-8316-549d59bbfb28">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32366052-5134-431c-b11c-ea5700c1348e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b73ec5ed-3c71-4e04-82c2-274203b2bb4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17e95ff6-7c4d-45d2-8ff9-172a3db25f56"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3417629-19ec-4851-9441-ed4e3df6f273">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c0be927-5736-4957-a518-cf78e214a210">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b83c3894-0851-43b9-98fe-bb9e9e3aa8fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/217f8fb9-6015-46f5-917a-02b08f5edfc3"/>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/320d70c0-1729-4605-89ad-3a8b4d9809de">
        <dc:identifier>HP:0001954</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>periodic fever</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a753ad1-02b0-4b88-8dbb-421ba56063ec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fab930b-3725-4c0e-b8ca-42e9b763fb1c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed130d6b-4f5b-4f40-b0fc-1256a5d1bb3d">
        <dc:identifier>HP:0010978</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>Abnormality of immune system physiology</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/589cdacc-d9e4-40ef-9373-d8eb883b82f2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34dda000-368e-4270-9897-6d9df271e925">
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8d1f69a-b983-4f1e-ae9b-501b77673dc6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c37384c-84a7-497f-b45d-572b35aefa67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d386323c-b517-4add-a421-111a35de8a3e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4f2d30c-e572-4ae8-a5b2-9761c3e88877">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3206b1dd-1764-4900-a8cb-77ef2c1cba7a">
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be620f8d-c460-47d6-a278-ff4c9297eca1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e254f61e-de7e-4ad8-9a89-aee7fd0fc3e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ae7924a-c300-42e0-b699-adcd93d1a5fd">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
    <dc:identifier>HP:0002633</dc:identifier>
    <rdfs:label>Vasculitis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41234743-0b95-4c21-93aa-5e3cc82e8c18">
    <rdfs:label>glomerular damage</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000095*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b117745f-dd89-49a1-a184-0971d86115a1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6986064-f6a6-443a-9c62-b4db41143056"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d18a342-f698-4621-9bd4-23c24917dac6">
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4481d25b-cfb2-43db-91e8-da8a5dda8343">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1949ef1e-bc4c-44af-a1ff-e5769498b643"/>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89781f4c-2fe7-438e-8c7a-6f386edd97cd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf9659f1-72ef-4d5a-aff3-97797e00b912"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37a00bfd-bd96-4497-bfb1-8a622ad1149f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/166c422f-9b57-4a67-bfe4-2d5c1e8ed91a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/417ec0c2-0759-41b8-bc5a-462d2a73e0a8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46369093-6f22-41f8-b5db-955bf73c5ee3">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/620e3367-dba3-4fac-b102-595775b08d43"/>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d2905c9-39d2-423f-8f0d-b5f66ad70004">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormalitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66">
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13053974-b419-48a1-8f4c-139bcc200d45">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
        <dc:identifier>HP:0100513*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15b2b139-c9d2-4e0d-a863-60410a4533ab">
        <dc:identifier>HP:0001251</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ataxia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6330002-9555-4871-b4e2-9cb2e0788d7f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d104f207-69db-4b68-aefe-42ea57d7b452"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf9659f1-72ef-4d5a-aff3-97797e00b912"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f357e8a9-369a-4c6c-a50d-d317eeeb38dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d56ef9cc-b433-412e-a25e-69d3da953030"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38778873-d1ef-4826-b582-ac7169e2e263">
    <dc:identifier>HP:0003146</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hypocholesterolaemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a5445cb-4348-41a9-b636-251ea615d3db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e5a30e7-0864-4333-8587-3bb905f788c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61e39991-91f7-4940-9ac5-4647eb201ccf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0437e56-c764-4d11-ae36-a86039d71633"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/060b0eee-dca4-4c2d-9a54-491fe557f2aa">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05496349-f408-49ad-96db-341f754f0c35">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cd762ee-6017-473d-8964-f780d2851648">
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2291b7ab-a634-4110-88ce-c3aa17f2dca4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9ffcc2b-bf76-4a2e-977c-76864c4d59c1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>high creatine kinase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83ee52dc-2275-48e0-bfe6-7cf1cb8d1689">
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011025*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/853f9218-4461-4924-a79a-020474db3772">
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0bff8eff-c144-4497-9e1c-e7c8990abd28">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6501208c-2bcb-4a0f-895a-0a897df720a8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253601"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b22dd0de-e018-4dd1-9e66-088823de45cb"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9a0a722-8f64-4f6e-bb8f-5ff9e65755f4">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0abc10d-7f04-4bb4-867e-0f56e6c79867">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6449b5ce-86ec-4f84-b107-02215a38e86a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96162ea5-3227-4eb5-a655-bf51f0848616">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
        <dc:identifier>HP:0003107</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08b79000-e0c8-496f-a34a-0e609719427a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26855f8e-6070-4abb-9f98-b61e0be3f98f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ce34bff-5508-4e92-a38f-13336160b1b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe8b0a09-c775-4fcd-8794-1ba1f4503695">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c12a9de4-73a6-4bea-b168-de4427a5e0df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702b168-d79a-4135-b3e6-550ee83db7f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0f5b628-2bd6-4ab0-aeb6-43505297b9e8">
    <dc:identifier>MP:0002647</dc:identifier>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7bd01dc-7a01-4f97-81d1-8988b4d8509e">
    <rdfs:label>Sirolimus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58d71446-abaa-449f-aa6a-170c2d1f773f"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e711464-0dd1-4b8e-9319-8aee3d6461ac">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f925c241-3462-44e2-8dc9-f1d642a7d0e1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50d3ea7d-f419-40bb-80b8-abdb6d0a2c7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7def8136-c1ad-44e0-8704-4bb7e5d928b1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00877</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ece3dbdd-943c-4e5a-bca6-6b1bcda9de64">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:label>Seizure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b288189-92ea-4406-9baf-325de2393560">
    <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
    <dc:identifier>HP:0012410</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfc5f015-85b8-42c1-9db4-1cf2fbd1cde7">
    <dc:identifier>HP:0002415</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Leukodystrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/383c6d9d-b88c-4c94-a672-0699c9d3c158">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/438e274d-63a9-422f-a179-ec65c4a77572"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2263bb96-660f-4126-80a7-8c5cca153704">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
        <dc:identifier>HP:0002529</dc:identifier>
        <rdfs:label>Neuronal death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35d7a826-0fd5-4b46-b2a6-f9a8a32e486f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>high plasma ferritin</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6afa57c-e0bc-45e2-9263-cf331783b170">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0cde9553-f808-45ea-8faa-160c2702e602"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cf500f1-d74c-4970-b913-50e81b1dfa1e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0060c215-0fc3-4a03-98e5-db3f5a1d8d8e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fc8812a-ed61-492d-9dc8-ced38b1e021a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc2d236-dcdc-42d6-af72-6b71426952b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/209f5112-6508-498e-8351-c1cd29029df1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2635f21-4a41-4ac9-b9cd-01fcfcdc331c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/925a9e63-2664-4dbc-aece-be054fc8e447">
    <dc:identifier>C09C</dc:identifier>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c561c5ba-6e36-4452-8b7a-4dd4f08453dd"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53e9c962-0b74-4ebc-a912-4b5b375d5311">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9f6b53ae-0c54-4d67-84ef-651fe610fa9f"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/429f9201-d87d-4e05-b5b2-eaac5e3ee60d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab2c6bb0-bfaf-4d3e-a616-7e75f05de36b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610198"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca9a2622-86cc-49d0-9f85-1a9a8774ed27"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bbbaf7a4-06a4-4f41-b4eb-a3dd96315b11">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/429f9201-d87d-4e05-b5b2-eaac5e3ee60d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/154e9fe4-e21a-4161-a24a-e56a96bb2617"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e661ead1-4c18-4239-9e4d-18086d417784">
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/790eae16-f244-42c8-816a-aa9264b8ccac">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1421f59f-ed2c-47b8-8e1f-dc5bec3577a0">
        <dc:identifier>HP:0012378*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/605dc384-6f3a-46a8-b43a-ca1eb3ad4c1f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03077a40-d317-48ac-8bcc-65ca54170b5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4fb704cd-1413-4227-9c65-9918a44dc1f5">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70d81eaa-7881-4aac-9fd0-27057c11861a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
        <rdfs:label>Growth impairment</rdfs:label>
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f211ae92-605c-432a-8a26-93ed5a5ea400">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
    <rdfs:label>DIURETICS</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/822e3bb6-c013-46af-9d9b-a839ea4db85b">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/943d2362-8715-47b3-818b-f1755e0a0fde"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82f3aef6-4844-483c-9c18-44eee769bb26"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22615c0a-94b4-4612-b885-b7a1101ad1ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613150"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57660032-c73d-4414-adda-05e6583b3d49">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/943d2362-8715-47b3-818b-f1755e0a0fde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2fb412f-236c-4c2d-8e34-ff4a4e608d70"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5270740-5979-46d0-9ddb-dfc9db1d479b">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e19b503-8c13-4ca5-ac82-5437d307f1fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2608172e-47e9-4eb5-88d4-be4aa9b3fa46"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>C03</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/110846d7-4ab4-4bb3-9b8c-2c2d27093d2c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72469bb8-ea86-4c02-94e8-ced2fda8abc7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0b71090-10a3-4512-9b7b-dd81765db2fd">
        <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/016503f4-7cfe-43bc-8b21-1a3867b99aab"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/758ad2f6-b899-4e17-963c-21c16ed21749"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b8b901c-c462-41f1-a697-3d9e0a63e219">
        <rdfs:label>Granulocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <dc:identifier>HP:0001913</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5de6ce1-d603-4c33-bc03-b110759ff733"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b27fb0b-a33f-4f4e-a91a-ae204223a4c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510b598c-fbda-4dcc-aa58-64bceabae50a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cee94af-5430-444d-bf34-ec5c0bf9fee3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <dc:identifier>HP:0010553</dc:identifier>
        <rdfs:label>Oculogyric crises</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47795f35-a794-44a1-a1fc-af9b4edada2c">
        <rdfs:label>choreoathetosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
        <dc:identifier>HP:0001266</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87f66efe-543f-4f29-b011-ab5cd2904643">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a98a2f65-824f-4f95-a6ea-12cbf5342701">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:label>hypokinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4af3edd-fc03-42bc-888c-96b587dda271">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7580b828-c90d-40f4-a52a-0e52bb7febaa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96f3255a-fb5f-4acf-9a03-98201efd1b3d">
        <dc:identifier>HP:0002459</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ab499c2-a993-437f-ac23-3883673e804a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
        <rdfs:label>limb hypertonia</rdfs:label>
        <dc:identifier>HP:0002509</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b76bd966-70d8-41de-a16c-2dfa80315c42"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85214e62-7f10-469e-8fa3-df5b3a122d59">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ddb82c59-237a-449f-a5ff-76bcb9637d5e">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/156e9d1d-812d-4d2a-882f-793eb6de650a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c96d2a1-236c-4f8d-81a5-305e223e1e48"/>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Clofibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a932fa5f-7873-4700-8e01-e69c06c8434f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/019bd943-858a-4c5b-a30d-efb8e940d530"/>
    <dc:identifier>DB00636</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b467c0bb-1a85-461e-be4c-a96797794463">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac6a4d47-e2cd-4ee7-9efe-f7e2ac3da6f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4add92aa-aac3-4058-8a1b-69d93bda39dd">
    <rdfs:label>Topiramate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5326adfc-cf6a-4ae2-8781-ccd1bf9dc0fe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3aaeefba-003d-451c-911d-364814116137"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f33cc3a-c95d-43c8-a901-e03141e664f5">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3aaeefba-003d-451c-911d-364814116137"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/554831dd-403c-473e-9f55-8390fe962eb4">
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3aaeefba-003d-451c-911d-364814116137"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00273</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6aa07c5-6dc5-4fd3-af99-f7505bb7f456">
    <rdfs:label>Pruritus</rdfs:label>
    <dc:identifier>HP:0000989</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8944abcb-f8a1-4c4d-948f-caf306020fd8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b00f28c-d0bd-46dd-a422-6208caeaeb4e"/>
    <dc:identifier>DB08875</dc:identifier>
    <rdfs:label>Cabozantinib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/406a05b2-5e5e-4c73-acaf-249dd09ae77d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bb55654-7e8f-4a06-a13e-591979089782">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/628b31a0-0d08-4d7b-815d-072bf37e4d54"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c07af5e-f0b8-4400-ab86-e1291b701e7b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>unalertencess</rdfs:label>
        <dc:identifier>HP:0002329*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e55793a7-4fad-43a7-8b68-285110b29155">
        <rdfs:label>Receptive language delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010863</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb742638-8b5d-4c4f-9c01-5b2ef6a1ee72"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13f352f0-51fc-4a1e-a6af-6f3ce35ed5a1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4210a28-fea6-455b-a003-ee1e81411543">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cf500f1-d74c-4970-b913-50e81b1dfa1e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4daa1e4f-bdd5-4a19-b2b2-6e2c4e6c5bd2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c68ddfc-40ef-4747-aac9-b3ced94199ae"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3f361a7-8022-4380-b373-f15760bb2a30"/>
    <rdfs:label>Anakinra</rdfs:label>
    <dc:identifier>DB00026</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d644c54-ea6c-43cf-86ba-271fb3d95dbb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0572c3a5-ee8d-4131-be27-453e6b3b233a">
        <dc:identifier>HP:0000742</dc:identifier>
        <rdfs:label>Self-mutilation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d9a35b41-2556-48c5-b1f4-b3995bd6f3ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4d94778-cc61-4869-b315-4dd166e2faa2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4befa089-60ab-416f-8088-b2fcdd7867d4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/087d1dfb-8fcb-4419-9c9b-eedc49d691a8">
        <dc:identifier>HP:0030953</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
        <rdfs:label>conjunctival irritation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71eca817-ca4b-4a89-a235-b9d805ad91d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
        <dc:identifier>HP:0012763</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dyspnea at rest</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3808ae65-d6e0-4686-892c-4a802c583d4d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003541</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29cede68-ab6b-4358-acdc-0a17b7bd2159">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e6c2f2-24be-4732-a8f9-d38d9695417a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f89d18a9-c529-43b3-9274-bc604f9ae62f">
        <rdfs:label>brain MRI abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cd0a90f-d36d-49c4-bf5d-71bcf5273f90">
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5dc0686-4fe1-4e92-967d-9586c838d317">
        <rdfs:label>low exercise endurance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e440a108-435c-4328-a4b8-2ecfc0d43a51">
        <rdfs:label>white matter abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002500</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4292dd4e-386c-4029-aefa-12064942043b">
        <rdfs:label>Sleep apnea</rdfs:label>
        <dc:identifier>HP:0010535</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d3e2682-9644-485d-b1cc-88998750428e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:label>photophobia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000613</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/987aa62d-e0ec-42bb-89ec-7b78c2a690f8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
        <dc:identifier>HP:0011729</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10beff29-2d64-4333-a957-1951571c129e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>low quality of sleep</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86164f1d-c32b-4927-99d5-42af714d213a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:label>pitting edema</rdfs:label>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6601f0e7-4ef9-4ec1-a34a-3d1bcc55ace9">
        <rdfs:label>pulmonary regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <dc:identifier>HP:0010444</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f00db6d-ee5b-49d2-a19b-1f4614a916a8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78f9c27f-17a8-4f01-be2a-2aa7fa1cf4a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e663c1a1-7f51-4a09-973e-c4d091b58c76"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cdb145a-6f2a-461e-9a59-a5192c9710d2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <dc:identifier>HP:0002877</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4adc9f6d-a082-4fb1-92f1-4322281f5772">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <rdfs:label>Daytime somnolence</rdfs:label>
        <dc:identifier>HP:0002189</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/638e5eb8-612a-475e-8e80-bcfa7c45eb0c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1503651-5c07-457a-a69a-a29b4aec514d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abbeb7f5-a026-4b92-b5bc-14f7f56c0c31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7fe6ec15-a31d-465c-ae26-70f0aa0f74a4"/>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c9b8f98-9989-4720-ab15-0c600cd07965">
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fe231dc-8062-4ea2-8765-906cc4738ba9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012238</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/049c0599-d72c-47ba-873a-82556f2e3868">
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6f5c775-927e-4201-aa79-64c6bda70faf">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c7cb0f1-9e8f-4839-b266-c1645b1dfd43">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
        <dc:identifier>HP:0001013*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f21e3c81-d695-4882-b179-50bc71a6c9df"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/521afbd5-fd34-466c-9de3-00e885c9feeb">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2505a55-7229-4230-b4b2-bfd40b160f36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5530865b-882b-49f5-919a-d25092222f3e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59ccdb02-261b-47df-a45a-8f5a74fc87b4"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
        <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32114a79-7637-44ad-8e40-61ebe404fe6b"/>
        <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a4bb43a-5bfc-43c1-b737-c8fde51c7363">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c90ae92-33aa-4d37-be47-ead3e1730a25"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ad150de-e88b-4bae-a66f-3d6ff52a18cd"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3885644e-c230-4e2c-8073-29167dd74a50">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6afa57c-e0bc-45e2-9263-cf331783b170"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/522dc117-21e1-4d16-8a75-aa75e5a8f2a9">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0cde9553-f808-45ea-8faa-160c2702e602"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48c1ae8e-98b2-4c8a-868e-727d9bfb3e5a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118610"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Naproxen</rdfs:label>
    <dc:identifier>DB00788</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4f1437a-1497-45fe-b1c2-bc9c308834d6"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ddfc3f5-bcb1-4db1-ad5b-c0fe2c9f5190">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06bee274-4933-4e54-9aee-915ec80cb7a9">
        <rdfs:label>High α-ketoisocaproate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b13ed6f4-0be0-4cc4-8b4c-7f7da02ac302">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce2546e6-89e4-41b1-a09b-031d69a3ca37"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3957f17a-0eab-4fae-a62c-25c94f174400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb46c7fc-bd21-48c4-8a8d-202422273bd6">
        <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <dc:identifier>HP:0008344</dc:identifier>
        <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e51348d-a50b-4dec-855e-488bc8a8bea3"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9db307e-f3ac-4ac1-9fb6-06575ff1cb10">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c11391e-4225-4bc3-a3df-832d57427a33"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5aaa8e19-8467-4df4-8f83-e1af1c262e46">
        <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
        <dc:identifier>HP:0031951</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac5fdba7-ecef-445c-8477-0df3c99cff70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8084ce3b-f0b1-406e-9c92-20f635539e79">
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11419000-0f0e-4c2b-a10e-9c32a6de8fc7">
        <rdfs:label>Atypical bile acid synthesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/394505c8-cd49-4ecc-b3af-26a494474341"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80ad9646-4bee-4bfe-b9f8-e2deb6c8cbf0">
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ba48190-5790-4590-9735-7271a869d988">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df1af070-4326-4292-b4fb-bc6ba804c9d8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/795b47e3-c151-469b-80c9-1d02abb73756">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8b560d1-b4cd-4c9d-b7d6-8a05d574be56">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7c0574c-591c-41d0-b3ab-b4037bd40c24">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>biochemical abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73c8bb08-13fd-4f8e-8351-bd778ce01c08"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0782c40-e4d4-4843-8714-bc1b2aba67f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ebb1939-0017-4001-9b14-93ddcffbf29b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71fa1b8f-3287-4c32-9b3b-e453ec19d9d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
        <dc:identifier>HP:0500014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/810a17fd-0d3c-48c6-8bfc-aa1c2db3f6a7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c87b3084-4ee2-4cc2-a1d4-814127243b69">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47e19fcb-d561-4e76-912e-db44d4ff5a77"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d37eaa4-4c3b-446f-8c90-3c55ba184a46">
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1073b13-8d6c-40b1-a09a-a61432e2ccd8">
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
        <dc:identifier>HP:0012463</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c1bab40-2343-43ad-ba60-3606c6ba1116">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c0fb81a-13cf-4821-81c7-8661b88348fb">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98ee68fb-2801-4d88-896e-39d6a53f7afe">
        <rdfs:label>Increased liver iron level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <dc:identifier>HP:0012465</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
        <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4793bb54-7d0d-420c-a195-cd45990708e7"/>
        <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06ee9bae-e66b-4d84-a7c9-435a932bbfa4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ba3a6a-125b-4ad8-935a-9b8f246f409b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:label>Increased serum iron</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a614ad2a-478c-4ebf-9c6a-1508bbfd0591">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8649ead-a27a-48e3-a7c2-a9751273e61b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba519d5d-1c6f-482b-bdae-961892d9131d">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e01fa83-1d19-4325-b542-9b1d5e3d5bed">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c51c8a9-1e1e-47b7-9b14-0198d80834a3"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/929ad6dd-a8cd-4dda-8d26-bd0380bce595"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6166da0-6ca3-42a5-90f6-ddb13f923c26"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6aeff8a-f4eb-4c23-9fff-2c1e6fa69333"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00755</dc:identifier>
    <rdfs:label>Tretinoin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f764bdb-49cd-4954-a654-2dc4f8d213d5">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e8d0bf0-28d4-4653-a9d8-7ca1f4a2f92b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/509b48ab-c5f2-4d75-aa3e-16d2abfbdb25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75536b14-c81d-4ad6-8d5e-cd395ab9aa4a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64538c6c-5aa7-494b-a690-046b07f4768e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
        <dc:identifier>HP:0012130*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78574e72-31c2-4470-bc01-5200161e2485">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a4f0687-20f5-4ac3-b475-b211368aedcc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0e623bf-7f6e-4b03-89b9-c2ed5e82ae06">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>erythroid progenitor depletion</rdfs:label>
        <dc:identifier>HP:0025034*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47d746e8-c44a-41d8-ac98-b86c8ddafcb9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low quality of ife</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a24d2bb7-2cd4-49a9-b11b-6561850e9fdc">
        <rdfs:label>Pathological apoptosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59a04084-4144-44a1-89dd-4e8ba4b81b2a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>muscle pain</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <dc:identifier>HP:0003326</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/669f4e1e-3fb0-4f0b-9df6-e4244fe85a1e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7abbaa38-8698-4e03-8565-b4ca71e70eed"/>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/391206dc-4756-4e0b-a7eb-354f0e8f46b8">
        <rdfs:label>steatohepatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a5b56b6-8a2c-4d28-afdb-c4079743dc31">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dcbc601-021d-4903-9ee2-715e0a8c7b5a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth failure</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7d7142b-b5cd-4a19-895e-6929e53bf1f2"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01de7db1-3561-473b-8ec2-6f413f4db0b2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e1c57e3-47ef-4dfb-9924-725b81481871">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ff74336c-9f00-49c7-869e-63756b6f9bd9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d9d1a5d1-d181-4f93-9873-c87fb90c4c06"/>
        <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e868283-3c5e-4f32-9d96-2c2ae8309669">
    <rdfs:label>neurological malfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e176354-3844-41a7-bee0-59efdcf984c6">
    <rdfs:label>Siagoside</rdfs:label>
    <dc:identifier>DB12351</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35e33e4d-abf4-4fad-b6b0-d742502e54d1">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69a27a3d-b2f9-4c1e-b188-65b92339998f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f501243f-1aa1-4084-8386-83da6db9ad90"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a0f47c0-f3ad-4067-bfdb-87b9b7dbdb39">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:label>Abnormal serum folate</rdfs:label>
    <dc:identifier>HP:0040087</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a854b4f2-f811-48bb-879b-68bc272f9ef9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed8f914f-724f-46fe-b498-4f61fb3f5843">
        <rdfs:label>frequent hospital admission</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8252ee73-dc34-40fe-9778-fc90afa87c3b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81b409ee-646c-40ea-9d80-5e9185ad0c32">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc67bf21-97d1-4bf2-80a5-3d841e8d7e8a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb619e3d-6d5b-474b-9b95-0cfe453fa8a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fffc8ba7-48a1-4d7a-97cf-8ab2ce35d65b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
        <rdfs:label>Noctornal difficulty breathing</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1269e6d-276c-4daa-80db-d7f225dc7405"/>
        <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
        <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e758421-342b-4cce-a249-a07a683b590f">
        <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002719</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/934b7135-3ee6-42ad-af31-edf16ea0eeac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004369</dc:identifier>
        <rdfs:label>low levels of purines</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30f0cb96-3117-4eda-ae98-c942ef8ed452">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68234b46-4679-4899-b36b-1db81c94b81a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:00011911</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51386873-76b8-437c-ae83-0b32a5dfbbf0"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17bda352-ff59-4c09-894e-8645ee6ee038"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e4b483d-1456-4cda-b4b0-7f2c147d6631"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5063b4f0-8d38-4177-9637-066119053990">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/781221e1-f527-4b1f-983e-336151b1e768">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f2d56ce-dd8a-48e1-ae24-3c74983df193"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/758ad2f6-b899-4e17-963c-21c16ed21749"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33898bde-0dcb-451d-bda9-9be660f19d28">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003713</dc:identifier>
    <rdfs:label>fiber necrosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/492bfd3e-dae0-42d7-8fe4-42ad7a690249">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5001baca-ebd0-4eb0-a91b-6a325f983081">
        <dc:identifier>HP:0000657</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oculomotor apraxia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39c5d6fc-fc8c-45df-acf4-58d2b8ba1999"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47aaaf61-7937-4b07-bf71-312bc6f41d1f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypersomnolence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afdd3a20-8c57-41c6-bf39-1d8bef570ba4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17e16652-cc8a-4fbb-820a-4233435177d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac1c8a43-8640-4013-93fa-5809a423e172"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/758ad2f6-b899-4e17-963c-21c16ed21749"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0eb28d6-41ae-41db-9bd8-f7c987fde6c5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4ca5831-c1a4-4308-ab05-7007260cd3a8">
        <rdfs:label>excessive adventitious movements</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc026105-1ca5-4c6d-86cd-c886c45741b9">
    <dc:identifier>HP:0000787</dc:identifier>
    <rdfs:label>urolithiasis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/025e301a-c0d4-4ff9-b9f0-62965bdd2ded">
    <dc:identifier>HP:0003281*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>high brain and liver iron stores</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34388610-c675-49d6-8c88-7839b6e0679d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03ccbf87-b034-418d-8114-8fc938ae6c0b">
        <rdfs:label>Retinal degeneration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
        <dc:identifier>HP:0000546</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a52a6a-60e3-4754-bd9a-f50d26c5afae"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac7a5e0c-de0d-462a-9d42-6df4cd730fef">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
    <dc:identifier>HP:0002027</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abdominal pain</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b95efe78-f8b8-4293-ac55-41613859009a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <dc:identifier>HP:0010918</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total cysteine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a9991ea-13e0-46d4-a584-54069b896830">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5580958c-17d5-4a06-aaa1-0a8639bccb94">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30c57b62-ea20-4de3-96d6-8a19538bd4a9"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40736491-e0a8-45e7-b39a-714ac6f194fd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2da9f180-0f05-4652-8deb-f47099a974e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Regramostim</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <dc:identifier>DB05386</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ce60676-5038-44ed-8636-03633491af9a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc97db4c-96df-4e08-8ffc-40a0f6c7dc13">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/948eed73-1b3f-4051-b82a-3092f786655d"/>
        <rdfs:label>enanthate</rdfs:label>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
        <dc:identifier>CHEBI_32362</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1183b60-fd49-410b-bdf0-050166ab9283">
    <rdfs:label>Glycine betaine</rdfs:label>
    <dc:identifier>DB06756</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4398927-192a-4d33-b95a-f909fa2fb1c6">
        <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed93eba0-e4e0-4865-91f7-c59b4c7b8271"/>
        <obo:RO_0003304>T122K</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc9618e1-4456-4c3d-a807-51f3e3334342"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5d77d0e-91db-4901-8703-50c05692e8aa"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20d28bf5-1d70-47b6-964f-c9b1852a6fd4"/>
        <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5435dc9f-9b76-4e85-b18d-dd681eab0672"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7fc78273-e352-43e2-b436-5eff0a5c986d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6854e3fe-e47f-40eb-8b2f-ab01e136a978"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b95efe78-f8b8-4293-ac55-41613859009a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0431b742-6d54-4e63-bec8-2f3200c03aef"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39fad675-a0f4-4adc-85f6-e62a9f100052"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3209be4d-cafc-4783-82ee-c1f52c64fff2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5d77d0e-91db-4901-8703-50c05692e8aa">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Unstable AGA enzyme</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d5311e1-dd83-4294-98cb-fa049f47fded">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00a57480-f15e-4cc0-9b1a-770334783401">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ceb75124-2239-48a4-a611-100dac6fac18"/>
        <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59df44a1-7280-41c6-b31b-807eb0459c1d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f44f3e92-67e3-416e-9b90-8acd2e638c4f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67004c10-7770-44fb-86a8-011701b68268"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18e56557-bbf0-4abf-8b08-9dce53ec3333">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b94249da-065b-428c-82e2-f55a4f3769f6">
        <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/363d9d2e-73c6-4b19-a1e3-9652f4781608">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189*</dc:identifier>
        <rdfs:label>waxy scaling plaques</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62634b24-3937-42db-b56e-5163d9e2c36a">
        <rdfs:label>skin thickening</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100725</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8d39d2c-23a1-4df8-8a57-ee241a4f5305">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
        <rdfs:label>inflammation</rdfs:label>
        <dc:identifier>MP:0001845</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35beec58-3960-4b78-9e27-10eb4f1a4c40">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
        <dc:identifier>HP:0008064</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7bdbf17-a512-438d-9d43-af7ee086c363">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f05eb646-b57a-4f01-be7f-23064db520fa"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c2ea3bf-3e92-4e06-b272-900051a7ea16"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ded2df9-ae4f-42a2-8876-8a25db5a4ac6">
        <rdfs:label>Neuropathy</rdfs:label>
        <dc:identifier>HP:0009830</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4cfe80e9-575a-4629-8bd2-12ca29001735">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/75e3932a-3f86-4c57-9b1b-53adcc29d143">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5ca8006-7e5d-47f8-8afd-d1e83f8cd583"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9945e9b7-282b-4901-bcd0-7380a763be9e">
        <rdfs:label>Generalized convulsion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e542c614-fc4f-41de-b6ca-e6cf7d5c1c91">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05b8fe72-651e-4b6c-b51d-b154d910c138"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae4e80e3-dff2-450b-a523-becefd713dd6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Complex partial seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d675ad9d-57db-402f-a736-4c3a6e6119ab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73bed7f0-4f4c-4391-a3ab-4b3cb0345087">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Agitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c587bcb-e2d3-4e84-8faf-450939d5529d">
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:label>Abnormal CSF folate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1de1a209-7b2f-4d89-8002-3ad3a86218a1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3cf96e27-53c6-425b-b045-29f0f98b2c8d">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f4ee0b5-eb14-4df3-8a08-8fa77ca99ab7"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0fed6e3-df17-4555-bd4e-2efc9b302207"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB14681</dc:identifier>
    <rdfs:label>Cortisone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/274398ed-de21-4719-b7ee-28b6bdda29d8">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b8e0165-b11e-413d-b32d-8fd4286cd2bc">
        <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
        <dc:identifier>HP:0004355</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a5f76bb-bb01-41b9-baa4-6a4aada71697">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca4ac539-b93a-4bd2-9ff0-3c48e00b3125"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f40dd33-9927-4b50-86b3-7121368eefd1">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ca7538d-6a17-421d-aaf9-75a34a6b5590"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a8299d6-ebe9-453b-a02a-1011bae604d4"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68ae9963-48e9-4378-be2d-394e4f34ba5e">
        <dc:identifier>HP:0009830*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f8736a1-c60e-4e55-ab86-0eedaabe025e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Congestive heart failure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <dc:identifier>HP:0001635</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1168346c-20e0-40f3-b2d4-0b8ee1d9b43f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:label>Stroke-like episodes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9049f57d-6bf2-4567-affd-726a17b65a38">
    <rdfs:label>low APO A level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025201*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3307302-748f-4364-bb91-f04c43197ab9">
    <dc:identifier>HP:0012379</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8eb729f-bc4e-4cae-b752-6a9f1250295b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd95e611-fb76-4ea7-9654-1f1ab4660b4e">
        <rdfs:label>low bone formation biomarkers</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
        <dc:identifier>HP:0031429</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c989f21a-b069-4dac-a691-f560db9f210b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>bone weakness</rdfs:label>
        <dc:identifier>HP:0002749</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc69052e-3aee-4641-9710-5fb2795c7190">
        <dc:identifier>HP:0004349</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone mineral density</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71200499-e66a-43be-985b-15ad797d7b89">
        <rdfs:label>bone fructure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002757</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/732cd112-90df-4cfc-a63c-91fde833ca35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4e75895-6217-40bf-adfd-900218cd0d88"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33a4b510-b4dd-4541-b7f1-cd0303ea1115">
    <rdfs:label>Sodium acetate</rdfs:label>
    <dc:identifier>DB09395</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e11f3127-eed0-4989-8101-da928d3f5f60">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af00ea8d-2c5a-4cb4-8dd8-f17cb030cf99"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/407d82e1-9771-442e-9ff3-c71396d2af51"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b656cadf-a6e1-423f-a027-0be2991704e8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f57ffda4-13a0-4dc3-84d1-cea5adcf4b0a">
        <rdfs:label>low RBC count</rdfs:label>
        <dc:identifier>HP:0001877</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d72f8fe4-1b93-41d1-a420-52f4b2d399e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01056fc6-d4be-4423-a64f-473a24ce294a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbc057b0-dba3-4e53-ac41-a9e2a69adb50">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002718</dc:identifier>
    <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e096786-a626-4d25-8132-5c2993f4af52">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030353</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
    <rdfs:label>Decreased serum IGF‐1</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/328d5184-e3f2-4a63-9aed-1f0298f85257"/>
    <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e84de51-45c3-40ee-a355-fe35bb6e61fd">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e730bef6-98c7-4c43-bac8-fb0b3f45fcff"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c427bfd-e50e-4560-b4e4-58cbe754d81d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7df4f1b-02d6-4537-8505-db45ad6c209f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d2810ba-ecd5-4589-8368-997640561a32">
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e7f1321-1a1b-4f3f-9f0a-92528a9f621b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8ae32d7-088e-4dd8-a312-d27ea8aebdce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pain in the skin</rdfs:label>
        <dc:identifier>HP:0025280*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/458a4532-b42f-40bd-9270-b29df8b1dfc4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>intolerance to sunlight</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfd66b05-8aa6-4207-b1a2-cfe5272ce4df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59693427-0657-4594-ab5d-f34b1547bfaa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7fdb75af-418a-4178-8391-e66339b77cae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f52019d-849c-4c51-9643-4822b6628c7c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004325</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:label>Low weight,growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b08877a2-18a1-467c-b1f8-98835b7b6ebc">
        <rdfs:label>Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61a9f34a-a1a3-4760-a72f-3ec5e7c4d67e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91378f66-dc08-477c-a3d4-08f82283b9a7">
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe1f24af-77db-4825-b679-c90f52517196"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
        <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
        <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d9916c4-3107-4d96-9d0d-29512566a39b"/>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d8c4348-ca6b-4118-b759-6e311b588391">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c09ae520-dbb7-4319-adcf-df872464ad27"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ba94f54-6d92-4edb-806a-246737c34f5d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afffd3d4-b94a-4b8b-8c7a-b68d652de548"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be553177-6697-4a83-b54d-5cc70bf8451e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52d3664a-3e68-4092-959f-8b33de7b6f36">
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:label>Reduced visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1bd660b-eb6c-4086-82ac-7917ab3905f7"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4fd65ef0-b3e1-462c-89fb-299de2f7765e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07d39a57-9932-4f26-ac17-a63d454df705">
        <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64252eb8-1fcf-4dc8-8c53-00e8d2725e72">
    <rdfs:label>verrucous lesions</rdfs:label>
    <dc:identifier>HP:0012500</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89c70ef7-3724-4584-bc94-e350e2126262">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d82662f0-1561-4210-a0a1-7c217c27c08c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>sensitivity to sunlight</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1df162a0-7d7d-45a6-aebb-4ceaab641f3b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>dermatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47ea3e3a-4e00-4afa-9248-ba815138aa7f">
        <rdfs:label>diarrhoea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79c54c0-00e6-40aa-b3a9-c630cc22839a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1717da19-cc06-45c2-b56f-c2ac2d998772">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:label>dementia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0cfff641-6022-47dc-998c-e21967e5a65f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e454ee5-1c42-4dfb-89b4-5b47a03d9e7e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf908cef-fd02-4e10-b7d4-188c9956c065">
        <rdfs:label>Ad-hBUGT1</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78cfa2e3-195d-4e6f-bd51-ffee7754c9c0"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86dfe81c-43b5-4195-8512-7527dfdcd8cd">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cab580d2-ee89-4a71-876b-27b68da4509a">
        <rdfs:label>N-acetylmannosamine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab85474d-44c4-40fd-bd9b-c6d4a7a15ed5"/>
        <dc:identifier>DB12536</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ee0aeec-13e6-40ff-9a8e-760c64b3a9eb">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d44325d8-d437-447e-8454-b30bf6b8a374"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c5ece96-872a-40cc-ada2-1800b56bf83a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:label>lactic acidemia</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/47a1527b-dc2c-4b06-b49d-c6c80609f6e5"/>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/951b50b4-4f9c-4f36-93c8-67d1616134bf">
    <rdfs:label>Cefoperazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e184552-540c-4618-966f-edb80b9c0b4d"/>
    <dc:identifier>DB01329</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/748b7dd8-8b54-465f-b1b8-406d9f9dbae7">
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614462"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3aaeefba-003d-451c-911d-364814116137"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d2c7a29-01b9-45fe-b2f6-d667cfb9e577">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06102afa-7f9b-4da9-aab2-f66ceee94a95"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1fed648c-d37f-4dc1-a21a-4313013de0fe">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7643b357-35af-4107-b37e-307c8254a288"/>
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b78f3acc-735a-46bb-a72f-e34b69305138">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>recurrent infection</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2497b478-2784-4826-87f8-3d05880fa42f">
        <rdfs:label>Neutropenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001875</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1414391-4ea4-4f26-b726-88323e5d5a2e">
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <dc:identifier>HP:0001263*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93341106-0639-4f60-90b2-e8da17d188ff">
        <rdfs:label>low neutrophil count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66276fcc-a57d-4f56-815e-dbb03f68af43">
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86f74cc5-db03-4e7f-993a-30522c754a75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57d2a92d-e2c8-4439-a6ea-7326bbf3e995"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0576229-19a7-48ee-bdb0-b9dbf906a688">
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ecac069-2944-46f8-8e38-44306d4ed68b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/939df02b-d6d0-4cc2-b786-1c07d6bd3c6b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
        <rdfs:label>defected phagocytic function</rdfs:label>
        <dc:identifier>HP:0010977</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed246c0f-ada3-4f78-aadb-274324545f0b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54e5c1f0-1f25-4b50-a617-372ff62cee83">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/169c3186-fbc6-429c-a79d-36865fcd35d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a8d37ef-630b-4b86-a76e-f25e9a20d815">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b5636e1-a276-48ec-a8d9-0d4b77fc569b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25fe53ea-8841-428c-9580-87d6aa53068c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/727c8155-9a21-4237-ba2c-4c4b81f354d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/522d6789-890a-4fc2-8781-6d0efd751eb8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a3408eb-e9fc-4d4e-a06f-2da0f3ba6bd7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96933263-8090-498c-8cbb-583f78bdbb58">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deleterious prognosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a22d07-3814-4f8a-9225-786b02e70e19"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b97ed77-d5d0-4452-93fb-a71237842424">
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/861118d3-adcf-4066-b6cb-b5c29ae8018e">
    <rdfs:label>Insulin Aspart</rdfs:label>
    <dc:identifier>DB01306</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8d210d1-b7ee-457f-882c-c7cbe237f4d6">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce30a751-6a0d-451b-9436-535142215b40"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/423fe478-c0e4-4dab-ab1b-85904efddfa6">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a43715a-fb37-4532-a074-a986c41750fc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed53e83f-f150-4f9e-ada1-54eb9c406700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12908f0-d59a-43ff-a23e-e5dc32d4c742"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB06667</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6eccbec7-9d7c-483b-b147-1e62234287ab">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85044e78-e08c-4382-b8a4-106ff6410a6b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12908f0-d59a-43ff-a23e-e5dc32d4c742"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7cd5b367-84ff-43b2-add1-c1056f0f100d">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f87dac1-9983-48a7-9ba0-0980a0a3f91f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
        <dc:identifier>HP:0410019</dc:identifier>
        <rdfs:label>Epigastric pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72b55451-b08a-437c-92df-aa0b427db701">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/999385fc-5020-4ac3-8151-93ff402e9e73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/909f3e21-f4ba-4c73-b9ca-22b96eceb159">
        <dc:identifier>HP:0002020</dc:identifier>
        <rdfs:label>Acid regurgitation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28bfc288-4fcf-46c2-ac1c-2ec5007905a0">
    <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0003678*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff185d1a-7460-4069-aa47-2323228efff9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1149d785-e33f-4352-95dd-694891d36a6a">
        <rdfs:label>Cerebellar dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15b2b139-c9d2-4e0d-a863-60410a4533ab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e55a7de5-074d-4e3f-b486-d4cb89c338ae">
        <dc:identifier>HP:0000570</dc:identifier>
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f10ae92-24d6-427a-b007-fd3045c1a51e">
        <rdfs:label>Nystagmus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
        <dc:identifier>HP:0000639</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/994832ff-8e9a-4696-b562-01610fef7eea">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83d11d07-5032-4788-b30c-55dda0325ce3">
        <dc:identifier>HP:0010438*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8ec5b1c-a3e1-4206-8d40-3c9bd36248b2"/>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d90c7d97-01d8-4cf3-9709-e1ea55ede57f">
        <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <dc:identifier>HP:0001712*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f200e6eb-13de-421e-a657-20e082d19c5e">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15b2b139-c9d2-4e0d-a863-60410a4533ab"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4aabf75-d0fd-4c9d-bf99-885bbfb93bc8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab309b18-8cbd-4f9f-9086-b18a6acd1223">
        <rdfs:label>involuntary movements</rdfs:label>
        <dc:identifier>HP:0004305</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5a6eecf-b4a4-4d34-8eda-25cc6a7dd442">
        <rdfs:label>parkinsonism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92ab1c9c-3e76-42e0-aac8-27e996d1131b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bb814bf-447f-4b5c-93a0-33c9a4ede2f6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/671c5a25-29ff-4069-89fe-effc2f66682f">
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cardiomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc753811-5029-40c8-873c-51f98af9a382">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:label>pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e703c12b-7ccd-4930-9d88-23dad0c5ee87"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7211dcf-f87d-427c-85c9-fe14c720eeb4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d68469e6-7a03-4511-b44b-a9f57b61784a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0f85b7f-f764-4314-8b7d-22d339547264">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63c357de-a3f5-4264-b4fc-04fea99c0186">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
        <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bf3f7efb-d072-49b2-abf3-5e8dbe064780"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc395368-5e4e-4f93-9594-def62c0f79e3"/>
    <obo:RO_0003304>E1506K</obo:RO_0003304>
    <obo:RO_0003304>R1353H</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0003304>delSer1387</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/131c46af-2c05-48fe-9807-2dd1ea9ea6c2">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d689b43-1b3a-4aea-b50a-dab39424504b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef142ea1-dd56-466f-b175-343144323ff2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13eb5d62-41dc-48d0-a5f9-d5d1bc46f863">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscular co-contraction</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e8a601e-0f45-4668-97eb-a4dba0c74819">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
    <dc:identifier>HP:0001596</dc:identifier>
    <rdfs:label>Alopecia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1cf070f2-cc24-4c27-8565-6149b98ebed7">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/141475db-0b45-49f9-ac1c-adccc7d128ca">
        <dc:identifier>HP:0000821</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>hypothyroidism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49503fb9-fb34-47c3-b8bb-e2112bd26b4b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31cc53bc-6304-4a12-b470-d78047e0c927">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7bdbf17-a512-438d-9d43-af7ee086c363"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab72c300-2222-4dfe-863c-7d5fbe4ec3d5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5cf14da-78cc-4a5f-b42b-5e50c5d9fd67"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df219287-7b39-4d00-b10b-c1d2b319625f"/>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c254cfa4-8afb-4d4e-8069-68177d44d55b">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16735507-e309-4e78-abbb-772a9b79eb1f"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/459a7162-30f3-401d-8f2a-a6a200b3d3e0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a76aa6d1-7526-4b57-9397-71bd3f737965"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e07b8b82-2213-49ba-bfea-72330cca27fb">
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d0a395b-1d38-44e7-bead-ce14e6a189e5"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/669f4e1e-3fb0-4f0b-9df6-e4244fe85a1e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46369093-6f22-41f8-b5db-955bf73c5ee3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b662731b-4aee-474c-8b45-61288175eada">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96bdf09b-a2b5-4b4c-8797-aaec7064f809"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f9d0422-1eaf-4d60-a3d7-848f2e735c65"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2497b478-2784-4826-87f8-3d05880fa42f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1bb23ada-1b03-4e0d-a2ae-6aac89d54ae1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ea61b19-f243-4e5e-b500-707866d16cb1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d07cad0-d1df-43c6-9c32-34c33cdd55f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbc057b0-dba3-4e53-ac41-a9e2a69adb50"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ffa53bc0-19c1-4c99-9159-b315bcc8b173">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e8f2064-34ca-45f9-a0d0-b2fbd0d0dcf0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03ccbf87-b034-418d-8114-8fc938ae6c0b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/161b6bec-5745-4f80-8836-97f1e01d0b13"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92054191-d875-43d6-81b4-1b0a9f68a4b4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1dcfb50c-5ad3-41b7-988e-1ec1e16b0ae9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7c8e99c-020b-4935-b173-e5f97f99beb2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da2d0992-ea9a-4550-b118-4bad234773b3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85c54f35-3e96-4cdb-9850-36b9b0c96aa5">
    <rdfs:label>Hypoxanthine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc0cbf29-e94a-44a4-bc48-15fe667605a2"/>
    <dc:identifier>DB04076</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8301d4b-0729-4c3e-a880-6ecda1a06eeb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b41c5e6-c6e1-449b-9ab1-779c4a46926a">
        <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9187d04-8cf7-47e1-b705-98d0574be559">
        <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf50fb36-61c5-405e-b3c1-39c31323d860">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20eeeed7-26ae-404c-9a68-bbfb7cc723e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ed21e664-2dc2-4914-ac3c-a816840789f5"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61e23c80-67d7-4c3a-ab9e-81740a84b111">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>impairment of reference</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79516fec-ea34-4499-ab4b-b888ad456592">
        <rdfs:label>working spatial memory impairment*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8d820b9c-aea7-426d-9915-f6ce3d9507ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a62795f7-6408-4112-a3e6-b3c3d150500c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49a012f6-0f9f-4b11-b9b2-4d82517ea073"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1525e3f-8a67-4d87-8c0f-d30d75c90081"/>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <rdfs:label>ARGININEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4455cd2d-a035-4b80-96e4-06e95de4b7fe">
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65bcfcf1-cfcd-4da1-9cc3-22cd15ac8f6e">
    <dc:identifier>DB14573</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01002695-2e97-45fc-b2ad-3955e819f1ad">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c0f5a5ea-ae7a-4c75-a6a5-e4c9e78b45c4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e37fcf4-a78b-4c36-b2ab-024d9e866a59"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57045023-378d-48b3-9104-7e1d93a87f57">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c545be8-f2be-49d2-b954-bdead8c2d979">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2309889-0f30-42bb-a576-d5ee702f6edf"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0003304>G11778A</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3c50588-d8c2-4d74-b237-21fc1d728521"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1720d64b-477b-4250-8cdb-146a7cf1ea5f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c748d11-5c72-4b64-a314-66c265c2f548">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30472bcd-d169-42d1-a754-1fff6f29457e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e5cc5ac-6a84-4843-8a7b-cd6c2f7bf714">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c87a0f8-adfc-4fae-b07b-b2a717cc245e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low level of serum B12</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
        <dc:identifier>HP:0040126</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05bf88b9-c596-434d-b0cc-b4d94cab2a67">
        <dc:identifier>HP:0001897</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Normocytic anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8aaaa1ca-72fb-46f3-a096-26e82c94dece"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c0d67642-f433-486f-8480-747130ca3d0f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79f005d1-1146-4a26-9ef9-614f8c21de2c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34f01f92-98ff-4448-9d81-4e07ba6d43d0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
        <rdfs:label>Hyperpigmentation</rdfs:label>
        <dc:identifier>HP:0000953</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1076f274-48d3-4de9-a7fc-9ea8274979cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82e267db-aad0-41fa-a23a-4963cffad1c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfaab1df-07bb-4b47-8d6d-ba39b119bb4b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Megalobalstic anaemia</rdfs:label>
        <dc:identifier>HP:0001889</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d281bd5-78be-4915-9076-3e89ffba5221">
    <dc:identifier>HP:0007346</dc:identifier>
    <rdfs:label>Subcortical calcification</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a691a3f-63c8-444d-a614-0c720b9d8d1e">
    <rdfs:label>Protein oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eaac1556-c1a9-476f-b21e-5923ac4b3019">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c035f079-d392-4325-aa5b-544672ce8a15">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f3c37b9d-a34b-406a-8368-ea21e2adce33"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
        <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/583b6366-e16c-4a21-ba51-16a545fb1bd8">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54f4b344-c018-4ced-86ca-85cd7ae4881b">
        <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
        <dc:identifier>HP:0100753</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
        <rdfs:label>schizophrenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d990c1be-6a10-4474-bcf7-e1198e62a802">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08b79000-e0c8-496f-a34a-0e609719427a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b22d0c7-fe56-44e6-82f3-17f81840cef5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e3f0f3f-17b4-4848-a277-b09d0691b805"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16cbcc05-f3d7-4d21-a738-ea971f16003e">
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc971f12-0093-4d6f-8cb8-b66bb3ba509c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ed38a37-93a4-4b52-94a2-f726cb1866d8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <rdfs:label>Isocarboxazid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/832f0586-0a4e-4980-ab28-5d605f54e675"/>
    <dc:identifier>DB01247</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9cb882db-69bc-4ad3-844d-87224b5e44dd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <dc:identifier>DB00761</dc:identifier>
    <rdfs:label>Potassium chloride</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8463008a-2f8c-424a-b22e-dc6338639a35">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd0d4184-8352-4c29-b6af-61b8fb47c2fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/140a988b-3e25-4ab0-b8bc-6853c9998b0c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b453f719-514e-41c6-a77a-166bf30edfc5">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/140a988b-3e25-4ab0-b8bc-6853c9998b0c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd0d4184-8352-4c29-b6af-61b8fb47c2fa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db35a58e-7273-46c2-9776-1500639f894a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8db5e1d5-992e-46e1-b770-8b8eb98bb852">
        <dc:identifier>DB0084</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ecbc16a-0e04-404f-9e9c-8795d6da5dda"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bbfa1806-fbd7-48da-baf1-bd66f83e9e49">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e02c9ab-806b-48fd-860f-c27f3960d2fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e36d75ce-cae6-4b0e-975f-782943689075"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2508b9e7-eb2c-458a-ac0a-0d8d5fb95d80">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de45d6ff-f943-4f33-a13f-295a599046fe">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>Decreased plasma carnitine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a5afb82-2cd2-466c-9c78-d923ab05b5d8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fatiguability</rdfs:label>
    <dc:identifier>HP:0003750</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
    <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
    <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/63ba237f-31c6-48d7-943c-8404e2a9660e"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33a3024b-8b28-45cf-ba9a-7ee8c2377802">
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6eafc9e8-5c9b-401e-a362-23267473be49"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e45161f1-49c3-4d98-a027-c5f6efdbf9db">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce360ea8-4e0b-4346-9f35-b50dfdd85aac"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67a51c08-2082-44d3-85c0-645e3604c954"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/016503f4-7cfe-43bc-8b21-1a3867b99aab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23d805fc-d50d-44f1-98a5-229bc9b7a3ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18aecea4-67b9-44cd-8d6c-4a79a80bee0c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4acfed6-df1c-47f7-ac67-b68ed8ea56af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71fd3ae3-c522-42dd-af1b-4069b2e80d49"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/110846d7-4ab4-4bb3-9b8c-2c2d27093d2c"/>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c035f079-d392-4325-aa5b-544672ce8a15"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ab073e2-0d50-4aaa-9b9e-e7826952bb86">
    <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002135</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00de5894-9306-4086-974a-75b54d764e9e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/811199cc-af2e-4781-a11c-cffe945b05ae">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9dcfd31-ba5e-47d0-99b5-24b00ff4ee25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9eb3f9a2-b7b3-49d6-8391-3bac100081cf">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18e978d1-ee85-43dc-a7bb-d5012bcf29c7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER-associated degradation of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76761396-ed02-496a-a6e9-02c869e07a3f">
        <rdfs:label>Mislocalization of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/525ae58c-fee0-4536-a496-281083b2edb7"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd088b53-e38a-44de-b4d3-b7757e2978bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b2b4f67-eb64-4a9b-9d9f-c75f61f331a5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa77d10f-42ab-4237-8582-46fb26eb1bc0">
        <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1b1734b-4adf-4c43-a41d-6839e55f9210">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <dc:identifier>HP:0000407</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4a3f3fd-a996-436c-907f-b3c3d03bd53a">
        <rdfs:label>Metabolic alkalosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <dc:identifier>HP:0200114</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af3578de-0e12-4f2c-9847-0abeed02daef">
    <dc:identifier>HP:0002540</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>loss of ambulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f2b9bb3-e7b8-4e51-a996-489164acb3c6">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/318018eb-90f8-4d76-ba8f-5fc9b828cdcc"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e1582c6-d567-4e94-a31d-034c62039cdc"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a08948b-b9fd-475d-beed-7bee086c376a">
        <rdfs:label>White matter alteration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002500</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a95bbd8-d304-47a2-8cca-585a38310dab">
    <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8efb381b-6807-4c31-8739-be1b2d0ec814">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b104a2ec-c984-45aa-b6b7-44fc355a62de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d22104f0-35dd-4c81-ae55-85f67d685de6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kidney failure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
        <dc:identifier>HP:0000083</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf249c6f-4dbd-4e32-bb9b-70afe5feb26a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000093</dc:identifier>
        <rdfs:label>proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bbcacd9-3700-43d4-9e49-edba4bbebefc">
        <rdfs:label>hypertension</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000822</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03d01cb7-744f-4328-afc7-d482fe2d6241">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5233d2e6-4f03-4126-963b-8f3391d05e7a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0dabc956-b613-446c-8c79-39e08bf9017c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d70ae49-861b-4510-be18-e6fb0c3ab6d5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601780"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/802ca466-7768-4bef-a115-61c5a5d8bf9a"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
    <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
    <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9d16e73e-34ef-4522-a6f4-035af4b1c39b"/>
    <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72f04b66-0b2e-4fe1-b0d7-459634f158a1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85324a15-7630-48ff-9199-8cfb38d53789">
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003199</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53429e2-7e0b-40c1-be5a-f3d8b22800f5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fee213c-8252-427c-b7b7-9f4293773f5e">
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2fdad45-50b0-4d45-a2e4-8b6a967a19fb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79d45d6c-96cc-4904-aae9-a60d03ae9ad5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/110abf19-937d-4b81-b13a-30faf7f095d0">
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cbb3e32-57c1-4244-9f8d-3f70654a3852">
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f4f9d61-402b-4742-be16-ad59962bf620"/>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5913daf5-6aa0-44f4-806b-d444b5a54516">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47a0122d-ab92-4419-a927-081c645721fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a2dde16-bcb9-4f50-846e-5f7c3cc9f8cd"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e2367c0-813d-4558-96c5-32b99baecc1e">
        <dc:identifier>HP:0002653</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bone pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0003304>M918T</obo:RO_0003304>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ce2fcc4-ae21-487d-93c5-50129187ebd4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/208cb443-95e3-4ed4-a82c-9a2ef6d92cbc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8252ee73-dc34-40fe-9778-fc90afa87c3b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b9c90a8-13e9-4c53-9f46-8ff52c602daf">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c04c6d02-2495-4f86-8374-f4c4f65fbbbb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/213e77c8-c4ee-4e80-9bb8-8543cf94e393">
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a4f0687-20f5-4ac3-b475-b211368aedcc"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43fd99f0-b82e-4f1c-9f43-d1af8d299181">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc4a9b4f-f03a-4ca8-b251-fba73b821969">
    <dc:identifier>HP:0001397</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:label>Liver steatosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3c5ef2a-f732-44ad-a241-d97ad27ce42d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66ba0acc-4d5e-4fc9-a3e3-06f9f340aa27">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <dc:identifier>HP:0000722</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e2bd254-f928-4f9f-9360-17e17e4b35e1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2beef1f-a4c2-49a9-9a63-c7b7d4275407"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7dfbcb2b-18d6-4c8d-b18d-80b3604da25d"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b2c6a6b-fef3-4676-a9dc-076867127bf0">
        <rdfs:label>Depression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000716</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e542c614-fc4f-41de-b6ca-e6cf7d5c1c91"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e285f366-16c6-4fc4-a8c1-6c253c441848">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad0b3ce0-df97-4d13-96d6-a061f91e0121">
        <rdfs:label>Pargyline</rdfs:label>
        <dc:identifier>DB01626</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a128f70-d4ce-4b5f-9630-ed8c79edbc17"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96ce8094-44a2-4e99-b407-e38af9d4a344">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
    <rdfs:label>protein-losing enteropathy</rdfs:label>
    <dc:identifier>HP:0002243</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6436d94-c787-4194-a526-eb546c782040">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b616ae09-e280-4fba-9c7e-c989e59c0144">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d508b6b4-20c3-4ab2-a4ba-af0bac209b0b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edf319ac-31ec-4953-9127-b48ae1235212"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0632a41-f445-4287-bf2d-4ee5801c39a0"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37ba2ab3-0110-4c76-aab2-3816fd419821"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2269c488-7a86-48bb-b06d-e55f94f3f0a3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
    <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
    <dc:identifier>CHEBI_84293</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4db02b02-f885-498e-9770-b9b6d6a614a2">
    <rdfs:label>T wave abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
    <dc:identifier>HP:0005135</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1daeb24b-a9b8-4c0c-a86b-e3159ca3e4b2">
    <dc:identifier>HP:0007663</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased visual acuity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b20dbc0c-a450-4950-b35e-46ae1d15e65e">
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e115fbd-c09b-41fd-9a91-4d24651f8c13">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c09f093-5f28-498c-9dfa-46359c69e038"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phenobarbital</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02b7199d-e482-442d-bb50-af2ae2b4c813"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa23e897-9538-4cba-8d05-ee826c82e58f"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/40a3b07f-57de-43e2-80e4-4fe7ff224174">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/629c7f5c-be52-4fe2-bb24-462764fd108a"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/beda3d79-a3d8-45fb-b206-1bf4e9593ee2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03382aad-646e-4be6-b330-76cc5a4e1365"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33ca36ba-0aec-4003-8e47-4ed95016bdb3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/923f8402-7e6b-41ec-901c-d6f3f9144655"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef6ee137-f01e-4f56-a8f6-d0810b941aea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/902c8506-8090-4aa7-90aa-fe2e13163afb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>cognitive dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d0a395b-1d38-44e7-bead-ce14e6a189e5"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1defafc1-5a89-43c6-9b56-9674ded03c84">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92196b4f-1bee-4d72-b33f-5e2f7bd60c71">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e9ef9d2-890c-4212-b969-ebdcae2aaa50"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dbbda0bc-4930-4296-b61e-973c8db7eb59">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4dd0caa-a734-4227-a851-88b16f087ad1">
        <dc:identifier>HP:0008028</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
        <rdfs:label>Macular cystoid changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a5a75fc-ae79-4988-8a0e-b06787fbc589">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94304ba3-5ae9-4a04-9b1c-df491d9f0097"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0858c89-43d0-4847-a1bd-839d91d66a1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8bbd7820-d01d-45fb-8959-431987ea4241"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37181fcf-006e-4377-b500-64ab33fb3e87">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
    <rdfs:label>Abnormal eosinophil counts</rdfs:label>
    <dc:identifier>HP:0001879</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfc3c049-5904-4afe-86d8-f036354c94ba">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/769af413-8b55-4600-98b8-031e5da7b460">
        <rdfs:label>Visual loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
        <dc:identifier>HP:0000572</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fa5687f-df39-41e1-84c9-2b6c63bd9535">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:label>Retinal ganglion loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000479</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e1c57e3-47ef-4dfb-9924-725b81481871"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83157d21-5dc1-48da-bab9-6a38e4c368a0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c85321e-15fa-450b-8f45-16e9cd347e6d">
    <dc:identifier>DB14104</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <rdfs:label>Linoleic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81f7b942-92c5-4dd3-88b5-0dbaf3d8d07a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e71413de-6300-4322-8881-f6af9e5fb6d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5839925d-2c30-49d8-af51-418d35bfab6a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5aa21c3-bdca-4965-8bde-b233036270c7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/337460b9-11df-4a3c-9498-18e34c18a092"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>Failure to thrive</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f4269751-587b-45dc-b5e1-cc7594882957">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07cf3d2d-71f5-4544-9a01-edab84429bb8">
        <rdfs:label>Propranolol</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
        <dc:identifier>DB00571</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0817e408-d725-4ac8-b966-a5dcd8397560"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a27dc96d-4f0f-4655-97f2-40937446deb1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e14f70b8-e4f3-4348-b889-ccc0a58915bb">
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42da532f-c0d5-4dd1-acbd-02ddc1f19f61"/>
        <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/afae99c6-57e9-4f76-9a8f-0db44793b3cd"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/787b3855-dafc-4962-b175-2b6214a0aea2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5704f73-5979-437d-b4bd-4d1749a7bd6a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7a0377b-5110-4008-9299-a3a12eb7a3ad">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ef00077-df6a-42ec-a638-82c260cddb08"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3f60e4e-6807-4e29-bf98-de3fcb4ecdba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7bf03c44-56a8-4b92-8ecf-9812911250b6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Urea</rdfs:label>
    <dc:identifier>DB03904</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e44f636a-94a2-4862-a38f-86dd7b5b10ae">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb736a80-51a7-4485-80ef-2b875f870cfd"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cb79704-147c-4c9c-b289-10ec8bc29e86">
    <dc:identifier>DB00129</dc:identifier>
    <rdfs:label>Ornithine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa3a84c4-56ed-4b90-b543-d585123ce433"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e576e524-18bf-40ae-bbc0-da6441945e91">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d76beca-8e9f-415e-a2c7-8a17aca1550b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioural disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa195438-a1ee-4411-96ad-5e586cc1c506">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d690b7e-f4e2-4e32-9570-31c5dc1c4561"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a8fb7c7-5d4e-43e1-81f3-446990435464">
    <dc:identifier>HP:0031517</dc:identifier>
    <rdfs:label>verruciform xanthomas</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ff81a0f-ff39-4293-9800-f20829463a3e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e80de47-630c-46db-867d-c1904a3b7d87">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Growth retardation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96933263-8090-498c-8cbb-583f78bdbb58"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a3408eb-e9fc-4d4e-a06f-2da0f3ba6bd7"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc603cc2-72b3-4d52-98b1-a85d0898771d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd93738d-9b84-42ed-91cd-473d8f7e9b36"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24893eaa-a7c1-4a6b-866b-5f6c6851f588">
        <rdfs:label>Decreased life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe9927f0-f6cd-41ba-b90b-21b41e804a69">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f32dcd47-ed17-46df-9c15-5f661a73569b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59c12bb7-d676-4d89-8054-5cc17e4fef6a">
        <rdfs:label>DNA hypermethylation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdab1f7c-ad74-4f46-a3cd-48d0454b064b">
        <dc:identifier>HP:0001395</dc:identifier>
        <rdfs:label>Liver fibrosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3d2f071-d1a5-40b6-b433-5d787238a3aa">
        <rdfs:label>Fatty liver</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc4a9b4f-f03a-4ca8-b251-fba73b821969"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffc9a7f7-ab79-4c42-a825-d786eaadb02b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/028219b7-45fd-45db-a24d-2f9b4b4339d2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/809c29f0-be46-44e6-ae3d-21453f085103">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal mental status</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55fe2333-0f27-4e7e-a974-8ec7ddae4818">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9915c189-1efb-4a4a-9b54-6113fb018c7b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ef9182e-53a7-4d00-9b0a-e8f3a2c7929a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b3b7bd1-be4c-4d3b-90cf-68d8c52c6e96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef63318f-c457-4faf-973c-732dc2902899"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f162e5f7-81a9-4a44-b3d0-6b6803fae5bd"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b9c0e4d-5b92-438e-bc00-b2836d8aca00"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d8079b3-0245-44ea-a7b0-d73032d8648e">
        <dc:identifier>HP:0003111</dc:identifier>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f18d873-c34f-41db-99a5-7aee7830ab4b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41d8ee91-fa31-4cf1-b969-1580fe503c9f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c90ae92-33aa-4d37-be47-ead3e1730a25"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f624a73-62de-4d46-baf3-4afe18ccb832">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c0216bc-b03c-4ef6-bcca-0cedd8059616"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6deb062e-ade4-40bf-83b8-02952d656579">
    <rdfs:label>Midazolam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/629c7f5c-be52-4fe2-bb24-462764fd108a"/>
    <dc:identifier>DB00683</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e33d50cb-5aad-4304-93b1-1d3069a66eee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca9acc93-b185-4345-be5c-dffc0032ff11">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>Fever</rdfs:label>
        <dc:identifier>HP:0001945</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc1ce6c6-45cf-4a37-b141-8c105655299f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f058c09-f14e-4331-8930-ec07cf46ac95"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f4f9d61-402b-4742-be16-ad59962bf620"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe8b0a09-c775-4fcd-8794-1ba1f4503695"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8fc7037-3906-4949-a417-1cd4e11f9f10"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
    <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
    <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56476b43-8887-4cd9-ab2d-5549b5636c6a"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/992404d4-9086-4831-a7c0-7970a876f87c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <dc:identifier>HP:0004359*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51551123-4f97-4766-8be6-4c7bfdf7006e">
    <rdfs:label>Oxidative Stress</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025464</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f49c125-6143-48a6-a32d-ddddec4461ab">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fb93900-a9ff-4e9a-a6a3-7d4dc36e0dc0">
        <rdfs:label>Cutaneous photosensitivity</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d37d99c-0eed-406a-b730-839550a78a8f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11d9f3ef-1e26-4d98-ae07-2925155577d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/641b086b-c502-44b2-a7c0-30fe7f20ecf8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/100404eb-2deb-4b61-881d-18934231df7b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/389a2866-caee-4134-bd72-1b9e31b4389c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e8c9fb66-0312-46c8-b657-75d1347c03bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f3b7885-4a4c-4569-a691-f4046f1a1688">
        <rdfs:label>pseudoexon activation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f42e45ec-a5f1-4f89-838f-e790a72a5f6e">
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1be2064e-95fc-496f-ad3f-24f66fe36113">
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb9a239c-d6d9-406c-b3ca-dec0c96fa06b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36b4f9d1-e42c-40a2-8c76-cccf4a5642bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/186c840b-b368-41a5-876b-36287d3712fa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19b10764-d13a-4f9b-8d31-fc44f394c141"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87320aa6-142b-460d-b64a-05d110754f52">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:label>Reduced pulmonary function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f535f082-3891-495b-9f67-bbe698ec1d1e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60696a3c-1585-41f8-af47-53ace8a1d2f5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3dee6c62-8872-4e52-8605-46a2a1dd7947"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
        <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7fe6286-f1fa-4619-a32f-49980cef33a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB14872</dc:identifier>
    <rdfs:label>Lucerastat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/051672b4-346e-4b0b-aeab-225fcadd5349">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:label>speech impairment</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73460cb6-faa0-4bfd-a0d9-310e99a302ec">
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c6e6b9-bde3-4b21-9ef3-b9050dfec70e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c165113a-a125-491c-b9ec-c8e41721c7c4">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>growth impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6089ce8b-fbaf-4285-ac3d-f60b330f63f7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003141</dc:identifier>
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28d11146-6d39-42e1-a1ae-031e2606f632">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59d5c195-ac89-46b8-8963-594f913879d8">
        <rdfs:label>Corneal Oedema</rdfs:label>
        <dc:identifier>HP:0012040</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34e5efcc-ee7d-44b3-b5b9-19137a49d3ac">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a6f3630-eafe-4df8-a105-1e63eea86dc4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>Abnormal immune function</rdfs:label>
        <dc:identifier>HP:0010978</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbf15e2b-c2ad-491c-bdaf-e4027e68cef0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <dc:identifier>HP:0001888</dc:identifier>
        <rdfs:label>lymphopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e56ec98a-c641-43df-a9d6-472bd510b6d3">
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
        <dc:identifier>HP:0002960</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a97e3657-bcde-4604-8d65-abf23ee6c681">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67662335-233f-41a5-adc1-c5da26ae8c73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12c8c60a-587e-43b9-9dc7-b51fc2c1ccb6"/>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d1c750-368e-42f0-8f52-3f2e56af7c95">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001878</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Hemolysis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a375e2c9-a90b-4dbf-83d5-3d16308dcda0">
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1df162a0-7d7d-45a6-aebb-4ceaab641f3b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37181fcf-006e-4377-b500-64ab33fb3e87"/>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/385bead7-4d3f-4522-9d7a-8de178cee4cf">
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5008f51a-5584-4d6a-945b-98fbabf4fbb9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004325</dc:identifier>
        <rdfs:label>Low weight</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc8786cd-d8b3-4355-a223-57a9a875655d">
    <rdfs:label>Abnormal neuromotor function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
    <dc:identifier>HP:0002333</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed7e340f-9b50-4db9-b55f-00d497738a33">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <dc:identifier>DB13178</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b778b8c3-13fc-4d83-b9c1-e769cfbb3c63">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d22f1fff-9768-44f6-9e47-ba0d68a9fba2"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e868283-3c5e-4f32-9d96-2c2ae8309669"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0323aa27-c7e1-439a-ab0e-2259a422e42f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Inositol</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83fa8ed6-08ec-4399-86af-d20a843cbbb1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb5ab1cc-135d-407c-9320-5156522a1d7e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19dedc80-835f-4e0a-8141-f3212238560a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4a3f3fd-a996-436c-907f-b3c3d03bd53a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91e974e3-2a7a-4c6d-9993-82f681d64464"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8559a22-b22a-48de-ae4a-8d05df8561ff"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bffe5936-2923-4116-8e11-fd883ae27ab9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/101c708f-8a28-4df3-9ab0-ce66d4ab59c2"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91e974e3-2a7a-4c6d-9993-82f681d64464"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Acetazolamide</rdfs:label>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d639e1d3-c2db-4f3a-ba83-7a8f47f87422"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c4d0346-0d07-4c98-895e-c7f15b35ff11"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dead6619-fa86-4732-8438-98a79cbab4b7">
    <rdfs:label>Abnormal brain electrical activity</rdfs:label>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a7f5a2a-a515-49e4-9549-7f48e9e4990b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c29f73f-c07e-4982-a9ca-a361614d944a">
        <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f51a290e-db5a-46c2-9c0b-825723a7c121"/>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/114b13f1-c5dd-429f-995b-134dd89ebe60">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/adff9919-6ec2-4337-88c6-7e3a2d5292e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ead69617-aa0f-45ba-bb5d-12aca409eebb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd849273-e00a-4238-b16e-51d5701504b2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/385434f4-02f0-4d0e-ac0f-abd49c702058">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain lysosomal storage disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/976ffc53-8f0b-4828-a20e-97b2eac24422">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
    <dc:identifier>MP:0012604*</dc:identifier>
    <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87fe522d-f3c5-4845-9263-413adcfc370d">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebe63efd-19bc-4edd-a65d-b8cbf71e9222">
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:label>cerebral folate depletion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1506432-deb5-4005-83b7-e274bb12015e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e80de47-630c-46db-867d-c1904a3b7d87"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcf6d079-a937-42b3-a864-9d3d8de6c812">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <dc:identifier>HP:0000105</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged kidney</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e888b344-b549-4a68-b470-8eaecaeb1c60"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55b8e257-47f7-43c1-bac8-0a859b471ca9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3ffea5f-b32e-4e88-936e-b78c9f23c59a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac6a4d47-e2cd-4ee7-9efe-f7e2ac3da6f4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/381f41f6-1fb4-4154-b2e0-6406f59dcba8">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/671ccebc-7409-45ca-909c-28c9337671d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5348744-a0c4-4764-95aa-a14eda46493f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bbcacd9-3700-43d4-9e49-edba4bbebefc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c82d091d-435d-4b9e-9127-f139378674d0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>abnormal mental status</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f0901b1-a22e-4844-8f6b-0883e701a6f8">
        <dc:identifier>HP:0011009</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <rdfs:label>Acute attack</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ae9b8b0-b190-4f54-9d12-3eb6ce6fc600">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tachycardia</rdfs:label>
        <dc:identifier>HP:0001649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc753811-5029-40c8-873c-51f98af9a382"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/797fd382-9110-49f7-8332-6b6bab37e12c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/048b8c32-370a-49a9-bc1c-104b0579156b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b259f0c-4daf-4933-aa3b-418897c1bcd1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b21efa3c-eca6-4761-8400-d3b3450a4fc4">
        <dc:identifier>HP:0040134</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated liver iron concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c7de922-1eec-4917-abd0-47f7ed933b9b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <rdfs:label>L-Citrulline</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ab48c2e-b15f-4ead-829f-648d752049ef">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11d39531-2884-44e2-8ecf-5faf77d8d880"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00155</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72915dc2-9ff7-4ab5-8723-4d319f8ad16c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/438e274d-63a9-422f-a179-ec65c4a77572"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c5ece96-872a-40cc-ada2-1800b56bf83a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/608d6de1-5b99-49d8-8af8-6e8061f97745">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pyruvic acidemia</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/266affeb-3e10-4cfc-8a6f-c8011586cb6b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510b598c-fbda-4dcc-aa58-64bceabae50a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a204bc6b-0b59-4482-934f-b856224147f8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26f6f400-d37f-4759-9f71-8731fd39e4e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb0b38f3-c5cd-4c4c-a249-1017aa1ea9c7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <dc:identifier>HP:0010553</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96f3255a-fb5f-4acf-9a03-98201efd1b3d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f785c806-2ff1-4b3f-b35b-937a80e0b946">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f195dd05-6880-4823-8387-a63f8bef80e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2872e133-5a4e-4a69-b362-4b17829ed962">
    <dc:identifier>HP:0002111</dc:identifier>
    <rdfs:label>Low Forced Vital Capacity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1559b1c-1fd4-46f1-bf40-036a77ba884a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98346444-34b4-41b3-bc1a-09220ae569e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
        <dc:identifier>HP:0010473</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0261fd1-6c2b-4a14-be86-ff95cc0e9705">
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/931f8d4b-3a47-4f9c-921d-51b99d4f333c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>skin photosensitivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb9143c7-27fc-4472-95f6-c7cf255f3182"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
        <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6fa34f9-9b5e-43f8-9fa2-6ea671de8c35"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8becce6c-0051-43a6-aa76-2413d34faae8">
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dead5e5f-e9b8-462f-8525-fac0e921da3d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92ad9345-c11d-42fb-ba27-c8a9c133d852">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b8140de-c35c-4c8f-90e4-b6f12797f3c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea79c5d3-2ffa-40c6-8b8b-39c7b50235cf">
        <rdfs:label>erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f95f9b9b-a7c0-4be6-a237-e3d20c99f55f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pruritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa6b1d70-f3b7-4eb9-835e-b800a10fc883">
        <rdfs:label>Ichthyosis</rdfs:label>
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36330a12-712a-4c58-946d-025ffcaff605">
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>scaling</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29ea734c-fc1a-4616-8d22-956f9e3cb3ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb742638-8b5d-4c4f-9c01-5b2ef6a1ee72"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91dca270-8891-4ab7-aded-955ed9cc821c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82f3af7d-7c55-4b33-b500-d1fdeab9dd5a">
        <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
        <dc:identifier>DB06742</dc:identifier>
        <rdfs:label>Ambroxol</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1910033c-d689-48a9-812e-516170003929"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0adbebed-5d12-4f37-af31-8eb30983d9b3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:label>Low IQ score</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
    <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
    <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b053012d-a273-41ff-ba99-3e7745221ef0"/>
    <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63c1d8ed-a7db-44e5-9fd2-da5221f70418">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b321845-1d89-425d-9734-849f76d27288"/>
    <dc:identifier>DB08834</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0b90730-d336-43f7-828a-db16423d7712">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1de759aa-8e83-441c-a2ef-69f6fd21a4a6">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21d7d7b0-00c2-4d89-b774-77aaf7ff31fb"/>
        <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5694e218-28fd-4f04-aac0-fb940bc5bc94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0e23fbb-be94-4c35-8fd5-a6992ce1c296">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ddca6970-ac65-43ff-9bb4-e2910757973d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18452a3b-505b-4adb-9c49-c58a3509005f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>High serum bilirubin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a314d1f-b034-4d6c-b753-db1300fe890e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f3e3faa-815c-49f4-b07a-2365eb294412">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0a24898-765f-4bfe-907b-6208f7c3dfbf"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6338901-2a38-41d4-97b2-bb55250190d5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0a24898-765f-4bfe-907b-6208f7c3dfbf"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30d5c8d4-0070-4db6-aa78-8f07f016bf6c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01914</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20eb3bf9-c07e-4732-92c2-d66fc8e99cef">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0a24898-765f-4bfe-907b-6208f7c3dfbf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51a3ddcd-5d28-4e90-89d3-347b239e3842"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe00d0b5-1a2e-4b60-8898-1317578e0d8f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d25b7f9-7375-4671-abce-02171fa621a2"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63875745-1ecc-412e-b896-600480b13130">
    <rdfs:label>Periodic fever</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <dc:identifier>HP:0001954</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc229304-23ea-4ac7-a59b-056afe87e3f1">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b053012d-a273-41ff-ba99-3e7745221ef0"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b47cbba-8a35-4bea-a2d7-506ed850e38a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004348</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec016261-7a37-4639-83a9-1ef60ce0c95c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a80f87ac-703b-4f93-9225-e9053a23aa90"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5de6ce1-d603-4c33-bc03-b110759ff733"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbb8e3c1-20cd-4920-bada-f62bc07a055c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8967e1d7-17e4-47e5-b8fe-7e7b42d6857f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>endothelial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bbcacd9-3700-43d4-9e49-edba4bbebefc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/079af6c7-0f2f-483c-a620-2cb682d05098">
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f128c43b-5dba-41b3-92d2-f9425234885f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b27f2243-d7ea-43ab-8f8f-e7e941c09580">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/382c6aee-0576-4347-83eb-fe245f87d590"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/102176e4-8232-4073-9ff6-2efe3fceb7af">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>defective heart function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d57acd3-f995-4725-a09a-1ad8bda695e2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9e643c9-1e3d-484b-9471-dc320aa13343">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27048866-0841-4a98-8137-90fc5100f8af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5a6eecf-b4a4-4d34-8eda-25cc6a7dd442"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d378b9e0-5d9a-4dd5-9b54-92ef38cb00f5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510b598c-fbda-4dcc-aa58-64bceabae50a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26f6f400-d37f-4759-9f71-8731fd39e4e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96f3255a-fb5f-4acf-9a03-98201efd1b3d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01eaf731-8d09-4b18-88ac-a36d05f3dfef"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27048866-0841-4a98-8137-90fc5100f8af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb0b38f3-c5cd-4c4c-a249-1017aa1ea9c7"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Pergolide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <dc:identifier>DB01186</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0c81832-4090-4ae5-8ee8-c96e861afea8">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/133d2175-8c40-4f7b-8784-af7c0e174e8f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941*</dc:identifier>
        <rdfs:label>high-anion gap acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0fb87be-d8f0-42c4-9978-9b67d17e9444">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ca7538d-6a17-421d-aaf9-75a34a6b5590"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3957f17a-0eab-4fae-a62c-25c94f174400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ba2286b-2ac1-4c93-bff1-a616b3259ade">
    <rdfs:label>Lack of energy</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/975d0220-544c-4823-bf28-fa49fa69426e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72dceda3-0a69-4640-b583-3108ae9e5dd4"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32a66ddb-f7f1-4b30-835d-79485874c965">
        <rdfs:label>Amphetamine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45042f5c-e41f-4f91-ac81-a037e12ef4fc"/>
        <dc:identifier>DB00182</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b73ec5ed-3c71-4e04-82c2-274203b2bb4d">
        <rdfs:label>Trihexyphenidyl</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2404373f-e461-47e8-8316-549d59bbfb28"/>
        <dc:identifier>DB00376</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45042f5c-e41f-4f91-ac81-a037e12ef4fc"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/09097f11-136b-48ed-a41b-7e1b2869e262">
        <rdfs:label>Tizanidine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45042f5c-e41f-4f91-ac81-a037e12ef4fc"/>
        <dc:identifier>DB00697</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ac96b98-e561-4da7-841e-13a5697499a6">
        <dc:identifier>DB12537</dc:identifier>
        <rdfs:label>Benzodiazepine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45042f5c-e41f-4f91-ac81-a037e12ef4fc"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3645f282-5a67-4a23-84d1-6d673e2ae73b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0003304>R125Q</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d6c4549-7f84-4cfc-9ad7-fdce16efb69b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12ba91f0-5de2-467d-8ead-b3d1feb6327c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>R266K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a79bbf97-39d5-4d24-9fa0-481f77b9556b">
        <rdfs:label>Homocystinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002156</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b157f654-8ef7-409f-be95-5f2dfe20014f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b41950d1-74b6-4133-913c-f3595d4db0ed">
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d1b9967-42bd-407a-90ef-d1b8b467e910">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613027"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/89604cf1-c268-40e6-a517-15031f83c360"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a689266-3e73-42e8-ba57-f765e70132cd">
    <dc:identifier>HP:0002621</dc:identifier>
    <rdfs:label>Atherosclerosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92ddf5d4-e521-48aa-af49-10216fa61cfc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25b88317-bf56-4640-b769-7e7fd785ca1d"/>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <dc:identifier>M02AA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74215d02-8366-44f0-b5fb-e89766a5d2a1">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0255dbbc-19f7-451f-85f8-76e1498d388a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b64a418a-5e2a-446b-8ce7-2e336c1759cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a78c9392-5679-48e5-bdd8-d527b7823c48"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff629e2d-e4b4-46d5-ac2f-9ebe45dcc71d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b606247-68e8-4944-8979-5f94b0f04afb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001959</dc:identifier>
    <rdfs:label>Polydipsia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/187bf468-bb4f-468b-8ec6-2941531d4975">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f5e3d2e-bbef-4bfb-bd1a-2b663ab9b625">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <dc:identifier>HP:0011118*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aff40f1-ca11-4211-9740-ccbdfaceb097">
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025460</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad986590-e6a3-4d41-9381-e5266ebc6841">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Inflammation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/976ffc53-8f0b-4828-a20e-97b2eac24422"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60c22acf-9ad0-456d-8942-3958c68d0ecb">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a7a711e-40fe-45ec-862a-efefcdb31367">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>primary low heamoglobin level</rdfs:label>
        <dc:identifier>HP:0001903*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f85e992-bd96-41fc-90ac-2cbf0ed78f26">
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>splenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34554537-eb1e-4f64-975b-10e3b858d812">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afa38085-6b12-412b-835a-d1029798c294"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d38cc83f-ca8c-4b2d-a583-fdb359def7f9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49503fe3-ab33-49a9-9719-6a0ca08cfaa8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/831d7980-1ffe-474f-8f1b-4ba7bc361221">
        <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
        <dc:identifier>HP:0000841</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1d89e57-e884-464f-bf7e-c58f47ea807e">
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e8e1641-73c1-43f9-8f00-5522a7444a8b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f32dcd47-ed17-46df-9c15-5f661a73569b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac46da69-6f25-446b-8b87-0d807410d836">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a8f7b17-693f-4be8-918d-7608c33a85ed">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
    <dc:identifier>HP:0030390*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/883c2aaa-14cc-4564-a14e-fb968cd9f6a8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b46e530-ccd5-47cf-9b21-2b28fc34b60a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a80f87ac-703b-4f93-9225-e9053a23aa90"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/388f12c1-2432-485f-92fa-bf759c0e60e5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c6e6b9-bde3-4b21-9ef3-b9050dfec70e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e096786-a626-4d25-8132-5c2993f4af52"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/391916c2-de2a-4f59-810e-460e8cfffd8e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c17b8a8-f29e-46f5-bd88-a15faf907bdb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9234b94-1c93-46dc-9422-b3c6a0b00f05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d08d478f-042a-4af8-898c-56118dae1151">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2697cad5-26df-4a6b-b78f-23fb4a0bf8cc">
    <rdfs:label>Heparin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf268e64-dc6a-44d5-9381-3f42ac38bf96">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5879094-f86d-4b4d-a234-ec63651b097b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f569cd9-a9db-440c-91f6-13fee00c01f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01109</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e30e521-aa01-4bac-843c-a7980ef73978">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1119238-103f-4dcc-931b-075de5abd0ab">
        <rdfs:label>Behaviour abnormalities</rdfs:label>
        <dc:identifier>HP:0100851</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/906a3fe4-e220-4909-a42f-eeaa20fba5c9">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>decrease muscle strenght</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
    <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/61586b79-ca66-467b-97ea-5b02e5dce4e8"/>
    <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de5f6e2c-249a-4f1b-994b-24f052c5a9df">
    <dc:identifier>HP:0002097</dc:identifier>
    <rdfs:label>Progressive emphysema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32ca6ca1-956c-4e48-86a1-36d48a1431b5">
    <dc:identifier>HP:0010472</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49a012f6-0f9f-4b11-b9b2-4d82517ea073">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d820b9c-aea7-426d-9915-f6ce3d9507ec"/>
    <dc:identifier>DB08909</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1910033c-d689-48a9-812e-516170003929">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02ece8c2-68e7-464e-9f4c-55e94a5c9d31"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc186409-4916-4fe6-962c-510bc223e923">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>hepatomegly</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/565b69dd-4247-48d6-8b48-d175aa3d0781">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>Thrombocytpenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5284b2d-227c-4d90-b710-b95b53f73be9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Splenomegly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34ea58f9-9f83-44fd-8085-565f2c5077df">
        <rdfs:label>High chitotriosidase level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec016261-7a37-4639-83a9-1ef60ce0c95c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91dca270-8891-4ab7-aded-955ed9cc821c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96e803d1-baf5-4709-ac3e-8c90d15a7f8e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ece75ab-c1fc-446f-9f42-80d8eef1f3e9">
        <rdfs:label>Low enzyme activity</rdfs:label>
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/781221e1-f527-4b1f-983e-336151b1e768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/01b04267-a542-495e-971c-24f3001caca1"/>
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7b2b1b1-6a6d-4701-b250-d647a2ced171">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
    <dc:identifier>HP:0003808</dc:identifier>
    <rdfs:label>Abnormal muscle tone</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/293754c8-e39e-43b1-9857-cbd4e4647528">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
    <dc:identifier>HP:0040085</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07aba146-de30-4eca-87a5-81d1e8f5250e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/254fd6a1-6bbe-415e-8f80-5563e7ccb43b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08ad472f-c681-44e3-bd6a-3d2727c3fe39"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4b414b13-a332-410a-8200-7dab780f0be2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/798ba440-c9e1-4435-a9ca-5b18abefd02b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77c46d75-2b43-45b1-bcca-5bdae5421f84"/>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31d815eb-c44f-4464-8ad3-27bcf1d279ab">
        <dc:identifier>HP:0000709</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <rdfs:label>Psychosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4efe582-3209-4474-9e40-f60bfbf048ec">
    <rdfs:label>Skin papules</rdfs:label>
    <dc:identifier>HP:0200034</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f4a1822-f89a-4c54-90c8-f428c4eab92d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ecb25207-323c-4f72-a3a3-f188aece996c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1edf1fd2-7b51-4358-9754-b2d760b48080"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f080c8f1-8dc1-450e-b1ca-36b02f461c7e">
        <dc:identifier>MP:0001426</dc:identifier>
        <rdfs:label>polydipsia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91f24860-26df-40f2-8e76-e7eb9684ba56">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:label>thirst</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2aa63c28-8d5c-49e4-8a63-f3c4a40772d0">
    <dc:identifier>DB12319</dc:identifier>
    <rdfs:label>Benzbromarone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45f4c44b-590f-4161-9e2b-4212cfac8ba9"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8f4a5aef-49fc-4bad-a5da-9d21a4b94048">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a414cb5-222a-4e38-b4bd-2ad1d483b624">
        <rdfs:label>Kidney stones</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f63d36d-bc9b-4fe4-b393-71051f3a60d8">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f8dc727-def9-4f4a-8f88-3671dd6d5ce2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hematuria</rdfs:label>
        <dc:identifier>HP:0000790</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e001d362-7d5c-47a7-bc5c-02e749317ace">
        <dc:identifier>HP:0012622</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chronic kidney disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446fb2da-5eb8-4475-850e-1ad7ac5e3b92"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff6d927a-3452-4420-a648-90386e3d35bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:label>Dysuria</rdfs:label>
        <dc:identifier>HP:0100518</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc026105-1ca5-4c6d-86cd-c886c45741b9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d09bd2ef-54fa-4c51-ab83-632b0c09d075">
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44d507a4-59ec-43d2-bcda-67fc72be666e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36826d7a-bdad-42c7-b47c-71aa45c8be99">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Arterial pluque</rdfs:label>
    <dc:identifier>HP:0002621</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b13894b3-0ce5-49f7-a6a2-d58afd6566f1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/274398ed-de21-4719-b7ee-28b6bdda29d8"/>
    <dc:identifier>DB00126</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54e5c1f0-1f25-4b50-a617-372ff62cee83"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55394b7f-63d0-42f0-9ef9-e9ea3d530c5b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfefd1fc-aa61-4402-9a45-cf28f9dd4fd5"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f87283af-3e34-43f6-b99f-de95b306b3a4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94bed8b6-0afc-497d-a672-e1aeb91a62c5"/>
    <rdfs:label>Ascorbic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0eaec586-03be-4983-97da-a55007e7d387">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be8f16db-ab86-4321-a6fa-76366bb97b79"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83189942-aeb9-4605-a729-bbfe121ea7ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ff55c63-a303-4270-9aa8-cf18f071f81e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/640650f4-2d4b-43f3-9137-dca40a6b8964">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ea46d08-c8b6-4f52-a11a-a2ead368df09"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac6bc95b-b78c-45ee-943d-61acdfdd5bdf">
    <rdfs:label>Lower limb pain</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
    <dc:identifier>HP:0012514</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9bc1570-3a35-4729-8eef-1cee891068e7">
    <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
    <dc:identifier>HP:0004387</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21c54f69-236d-418e-9aca-8ec39e102a97">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49503fe3-ab33-49a9-9719-6a0ca08cfaa8"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e1824b2-5c52-498d-b50d-4aeb35880879"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dac95e9d-9201-4688-90db-1973ed160351">
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High spleen volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f9c3ecb-48b8-490c-bc58-61ca549e8f26">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high liver volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4d0d75b-c334-44e0-8b10-85b58a6d9705">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d77e0dec-9d68-4cdf-9646-351990c8cbed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b053012d-a273-41ff-ba99-3e7745221ef0"/>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1abd4418-e2a1-4326-b6e7-06486a4eab54">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c296eea-ea07-4dcc-be7b-eec299d9e3fa"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35232a33-0faf-46b0-80f9-516903781eb2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f59f97d0-4838-492e-938d-fbfbf3169f8d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93042e15-b56c-4af2-a117-f61e48ea6174"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3793feae-3e07-44f3-b567-23291b45d11c">
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a39a196-bb48-4587-a43b-2bd7b73176db">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0fb87be-d8f0-42c4-9978-9b67d17e9444"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ea6f3dc-f937-4e2f-9573-a03841e24a63">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8efcf638-5dc8-452a-b378-3f1eab54cdbb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fd1c0ef-c8d1-4d68-a269-825fcb473f6a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ca7538d-6a17-421d-aaf9-75a34a6b5590"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e0127c-c701-41b3-8f8a-584c8708a452"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f40dd33-9927-4b50-86b3-7121368eefd1"/>
    <rdfs:label>L-Arginine</rdfs:label>
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0d68be4-e5a4-43a8-84f3-3cfc7b4abb02"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17ea3abf-ffd1-4912-9570-2da38e19e3ed">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b9419c7-e335-4315-97cf-dc7c2c5062ba">
        <rdfs:label>metabolic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/866cd54f-4677-469f-9457-9873deaac9d6">
    <rdfs:label>Copper</rdfs:label>
    <dc:identifier>DB09130</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78fcc528-ba45-4f3e-9f83-9684201af25e">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/121270"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6a6c221-f404-4466-aebd-ba24470e0eed"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edf319ac-31ec-4953-9127-b48ae1235212"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/979b0600-23f0-4d6c-ba40-7ddf45645c7e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05e8f710-51ed-46e8-aa57-2123d25b6391">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67595074-dc72-404b-9e14-45b8798e3d24"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b74f107-01e6-41ee-ac21-a27a832ad233">
        <dc:identifier>HP:0012217</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2c1d552-a649-486e-9c23-7cf9e54d84e2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510b598c-fbda-4dcc-aa58-64bceabae50a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02be67ec-3776-4c6b-bbc0-4c0fbe19aea2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01eaf731-8d09-4b18-88ac-a36d05f3dfef"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96f3255a-fb5f-4acf-9a03-98201efd1b3d"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26f6f400-d37f-4759-9f71-8731fd39e4e0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb0b38f3-c5cd-4c4c-a249-1017aa1ea9c7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/700a2be6-09d9-4b85-82da-0fe1014c5ec5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d16a37e-0057-4f9e-bac0-4936f0c6dcd6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/781221e1-f527-4b1f-983e-336151b1e768"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
    <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d39a54fb-b9b2-42e5-9f10-a488a43df2e5"/>
    <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/852a68a9-a01c-416a-b9c3-62b0553c7a9a">
    <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb47dce2-3343-4b67-9a72-ad68ce4533a0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2afb9adc-1b85-48ae-888b-ca885c3e863b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/521afbd5-fd34-466c-9de3-00e885c9feeb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/47e248aa-0ff6-45e5-83ce-8ae75f90e94c"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3a5b2c4-06c6-4a80-bf44-6b3eaf7ed117">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2505a55-7229-4230-b4b2-bfd40b160f36"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01080</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5eca70fa-ef6d-4aa2-a481-62c00b3a5ba0">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a0f47c0-f3ad-4067-bfdb-87b9b7dbdb39"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c11a4741-c526-4f04-b586-e8ff5509121a"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/494a3578-954c-4055-a174-fba9a5a8157f">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e55702af-6f0c-4210-b3b7-11104caa6fd3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/746e4d14-8514-4bb4-8f15-17452ea86294"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96bdf2fc-4870-41c7-a0cf-7a5bd8f49366">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008373</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5ae8eab-1218-4ecb-a7e1-9b581a3f56f4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e1c57e3-47ef-4dfb-9924-725b81481871"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ea34415-3a12-4bb9-8b11-e93f99a99890">
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a3b8188-5fba-42df-8e89-bc861ff67fe2">
    <rdfs:label>Serotonin deficiency</rdfs:label>
    <dc:identifier>HP:0003117*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84ebd555-397b-4270-8491-4881fa911fb2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc439f5d-5e52-4239-815e-445a6cf34fe0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2671df09-cada-45ed-a795-81ede22c3aae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/212bfe3d-a03c-4390-ab86-d9e6ad3af5c5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000287</dc:identifier>
        <rdfs:label>high facial soft tissue volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f07def1-a3c1-4a11-b4e8-52791af70b74">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <dc:identifier>HP:0040300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee65373-8865-450d-a2be-bc6a55070dda">
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
        <dc:identifier>HP:0040217</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/270886c3-911a-41a2-bb57-1177d0dfc5f6"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce2546e6-89e4-41b1-a09b-031d69a3ca37">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ddfc3f5-bcb1-4db1-ad5b-c0fe2c9f5190"/>
    <rdfs:label>Norleucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb73f9c5-b778-40d1-a8fa-a1201131c72b">
    <dc:identifier>DB04844</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b6d434c-0a67-4fa5-b7da-f9a7d8b0fa44">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dce6f91a-90ca-4760-8ea9-357f62caebd1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86d2d5ec-50f3-4fec-90c5-f1c5125e4766"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Tetrabenazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e470ada-7689-4dc8-adfa-bf36124a0b59">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebea6ee6-8e5b-4529-9c65-d49b8eb46a46">
        <dc:identifier>HP:0010885</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
        <rdfs:label>avascular osteonecrosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/385bead7-4d3f-4522-9d7a-8de178cee4cf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23876f30-b11b-44c5-bd24-0f56fec7acf0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd46efe9-2026-4257-a907-9ae8fb7ab409">
        <rdfs:label>growth faliure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49503fe3-ab33-49a9-9719-6a0ca08cfaa8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a33d4a8-5025-4f70-965f-d489de858146">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormality in bone mineral density</rdfs:label>
        <dc:identifier>HP:0004348</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a4d0d75b-c334-44e0-8b10-85b58a6d9705"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5f53fad-38be-42f3-8239-3ea1f5d89e40">
        <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
        <dc:identifier>HP:0100712</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e2367c0-813d-4558-96c5-32b99baecc1e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75bff093-a728-4aed-bb23-1f17b5e4c32b">
    <rdfs:label>Bleeding tendency</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001892</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b7fe743-2992-42c6-90ba-ab58007516b3">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c11391e-4225-4bc3-a3df-832d57427a33"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08f85898-19d8-45bd-bc94-56676e6866fd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe28c6e2-baa0-4a41-b7c7-6e2dff979cf7">
        <rdfs:label>Acidosis</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc954b95-4728-42c8-9449-d63ecb8bfd16"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ce0bed2-f45b-4986-ab3d-690b077673f6">
    <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/904ae0c9-363f-41a8-a70b-e7c5c958327c">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42ee42a2-2cf1-485c-9f1a-b4f157a447d2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0eac6477-c673-4d07-a346-0b12393229c7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6209f56e-4f06-4749-9e75-87cb8c97d0ea"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
    <dc:identifier>C09</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d4412fa-bd98-419a-94ea-b38ed7b51743">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/530819e9-430e-458f-b59a-392d98db59f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71636b55-c29a-49b8-a436-efc87bc3faf5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4db02b02-f885-498e-9770-b9b6d6a614a2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38778873-d1ef-4826-b582-ac7169e2e263"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1044478-0153-47a3-8660-ce50108fbb5a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low myocardial function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0506caba-b4d4-4792-b2e7-87050231ad83">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:label>hyperuricaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5db845fd-c907-444e-8f5b-871a970319a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2497b478-2784-4826-87f8-3d05880fa42f"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/67927463-9510-43e9-a639-02fd4f0f72b8">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf204500-9357-4369-b08a-261139ca3e06">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
        <dc:identifier>DB00112</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7f92036-3f78-42c8-9a0d-da2235fa3c3e"/>
        <rdfs:label>Bevacizumab</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cc68496-dd6e-4def-bf07-839669f27b96">
    <dc:identifier>HP:0007166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:label>Paroxysmal movements</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ccdd267a-dc93-4852-a304-5943022a408f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963d62ed-e5f6-40ee-9343-a9d8520fcc58"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdad87ae-818d-401b-94df-54e4870591d9">
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>Involuntary movement</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7e29ba2-e31e-4c82-95b8-f76c3e586969">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/947bd69a-0a1c-421f-95ed-97bd3dea6360">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2214aec9-dd77-4292-8d77-2b323ea4f840"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2139b6c-f48b-45af-beaa-54558473ecc8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdbfcbfb-b4e9-4e5e-8eb9-b296efa8a0bf"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7b83dae-30d1-4f2f-af40-1146de907d04"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
    <dc:identifier>DB01083</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4d9766e-c1b4-4d14-887f-3e18bcef1b07">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2139b6c-f48b-45af-beaa-54558473ecc8"/>
        <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdbfcbfb-b4e9-4e5e-8eb9-b296efa8a0bf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Orlistat</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8854bde-d4c4-43f6-b46a-55f331193350">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0a14996-ad52-445f-8a8d-797ca51b0c5f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f7758f6-41b9-452f-ab6c-7530afcdd71f"/>
        <rdfs:label>Gene therapy *</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83744f72-0b33-4938-85ff-69d0b5bc3aac">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22dc3a49-e179-4a5b-819a-f455a62075d0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7859676-85a1-42b1-a564-51f5dc5bf9ff">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001947</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
        <rdfs:label>Renal tubular acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2590e933-ac6a-4f62-bd34-4224f28b561d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb548131-c9e1-4ab3-beb6-2de1d79f66de">
        <rdfs:label>Metabolism abnormality</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4cb222b-82de-4978-9cbc-dcf5a0a4a73c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b9cc0a2-6df8-4b25-88f3-ac883a563075">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b7c8996-f2dc-4330-a287-354324c1d0c8">
        <rdfs:label>hypoglycaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/344c6add-19ca-4839-9a73-6315c78aae8c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5872df40-bc1c-4274-8316-81fa1516b0ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96ce8094-44a2-4e99-b407-e38af9d4a344"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b1f2351-58fe-48d3-ad60-bbb17895a204"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/695236b7-41c8-486c-afe2-20f2aedb29d5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:label>urinary tract infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e140dc04-fe23-47c7-baf2-151a9e37483e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
        <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a8e42fc-8a67-430e-b6f2-258d0b288c3b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0cdc7f8-c952-4730-b30d-0bc2afa8053e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Rapid disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8ff266d-dc3a-410d-a069-6d7ee8687dc8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <rdfs:label>Hypopigmented skin</rdfs:label>
        <dc:identifier>HP:0001010</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d17d40aa-8480-4586-853a-6ae1d87d3812">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012389</dc:identifier>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad6e19fa-a9c5-4353-8741-0b0343c107f3">
        <rdfs:label>Woolly hair</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
        <dc:identifier>HP:0002224</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5363fbc7-932f-4f21-9266-f5fff82901a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1adde62d-b0df-46ea-875c-6026263f8821"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70cd4fa8-ac6d-408c-b20a-7e676dc12d21">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025373</dc:identifier>
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/76d672d9-81d9-4701-b8c4-0f1df5f87f29"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2cfe03d-d9d4-4572-a60c-a600954649eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ff75c8-3037-4a32-a7cc-29fdeda84bdb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81b9d3bc-f5b0-4fda-90f9-ae7da37cff9c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low muscular tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a053edd3-124d-4455-88e4-bc8b85f2d05f"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dead6619-fa86-4732-8438-98a79cbab4b7"/>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1d98cc0-b3a6-4cc1-a8b8-c51bf9ac0ee4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormalities.</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/006e3cdc-2b14-46df-b755-16aee11a4129">
    <rdfs:label>Abnormal liver function test</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60c2d5fb-45c4-41b7-bb27-9e2c6f819409">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14180189-e65d-4a59-b84d-98c9d137d459">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9262993-fc73-4491-9292-7b74ab407651"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d1fd1a7-c154-4ff5-8ef5-35ecf0451348"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e661ead1-4c18-4239-9e4d-18086d417784"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0341358b-012b-4533-886b-02c0e5e012e0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/51415aaf-7d74-4bc3-a8d2-5db9a42420af">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a983b14-69a9-4ff8-8ab8-174107fadf7f"/>
        <dc:identifier>DB00143</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
        <rdfs:label>Glutathione</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dffcaf46-e421-47be-ac39-b110f4ef21ca">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c6e6b9-bde3-4b21-9ef3-b9050dfec70e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e98f425a-a4cc-4c2d-9dd9-6b2696c5571d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
    <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
    <dc:identifier>HP:0003362</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a17f866a-faec-41dd-810c-40c12ea909dd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
        <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8ce85908-874c-4f1f-8ff7-a891db312707"/>
        <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
        <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26688406-4200-456e-ba56-e6d40e269939"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d113749d-0b5e-4030-8be5-27e730742a61">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01131953-81ca-480f-89db-b47af14c6e23"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56dc3ead-0fdb-4708-80c8-ab5b0d493538">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
        <dc:identifier>HP:0031884</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b860694d-8246-4205-86f9-88804288d7d2">
        <dc:identifier>HP:0004302</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal motor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0323aa27-c7e1-439a-ab0e-2259a422e42f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed7e340f-9b50-4db9-b55f-00d497738a33"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21d7d7b0-00c2-4d89-b774-77aaf7ff31fb">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0b90730-d336-43f7-828a-db16423d7712"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/904bc1a5-a5e9-4ab3-8433-0ab342cea967">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
        <dc:identifier>HP:0040210</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/101ce319-4fc0-4e9e-b6d3-53f174b6b6ae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/beb5667e-2579-4c90-98cf-a587ab5069b2"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af2a9ff4-56ea-4845-b710-46cfa6535a3a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6f5c775-927e-4201-aa79-64c6bda70faf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abbeb7f5-a026-4b92-b5bc-14f7f56c0c31"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/476ce62d-d3f2-4aa7-99ad-c0fbd870bab5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/572f55f8-be3b-49ca-ba73-4e3a839fe731"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79c54c0-00e6-40aa-b3a9-c630cc22839a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c9b8f98-9989-4720-ab15-0c600cd07965"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/acbda79c-0da3-470c-b5a6-b259645cdd4c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79c54c0-00e6-40aa-b3a9-c630cc22839a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00627</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89c70ef7-3724-4584-bc94-e350e2126262"/>
    <rdfs:label>Niacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69a167f5-833f-4ce5-bac8-e50e7d21ce1e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f23a3d88-c689-4231-b3a3-68d188098f38">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35881fff-4058-45a0-8da2-5a86bb803772">
        <rdfs:label>Low developmental score</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cf439eb-38be-44bd-b0f9-8489cf2b33bb">
        <dc:identifier>HP:0012758</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurodevelopmental delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7248b26-e80a-49da-960b-de583bbdf8ba">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <dc:identifier>HP:0012113*</dc:identifier>
        <rdfs:label>Low cerebral creatine content</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22731fa2-83ae-4aad-ab31-4160ff06d7c5">
        <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/155ec719-c877-48e8-be3d-8ab1ef79774b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
        <rdfs:label>communicative skills abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002474*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/902c8506-8090-4aa7-90aa-fe2e13163afb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95746253-7a13-4b14-97ac-e2943c114f66"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8036ff4-05a0-4f5e-b2a6-36a0fc198713">
        <rdfs:label>psychomotor retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a95e4272-39e7-482c-9826-ef8a2ed07851">
        <rdfs:label>behavior al abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91358202-6c56-4193-8755-15fe53cbe5c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/292798b9-a42e-4db7-8882-7c84a7aa4c59"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9ceddd2-1d62-4def-8bed-74b5030677be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae6d292a-d0fa-4709-b38a-aeabaff4cc3f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>language impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
        <dc:identifier>HP:0002463</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0adbebed-5d12-4f37-af31-8eb30983d9b3"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f9cdd87-b69b-460c-881d-1fb73fc4f40c"/>
        <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb63f716-393a-469a-b54c-965a339fea8f">
    <rdfs:label>inability to walk</rdfs:label>
    <dc:identifier>HP:0002540</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6c747e2-8974-4dd4-8030-172db1061c26">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fa0d0bc-92a1-4134-8fa1-9c17e8a7c179">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low pancreatic zymogens</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/03e0dfb8-a3c8-4c9f-86b0-de0092966ee3">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446fb2da-5eb8-4475-850e-1ad7ac5e3b92"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/108eecee-0a21-4f68-8429-97dba696d0d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Mortality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7d7142b-b5cd-4a19-895e-6929e53bf1f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bbf6495-2a8e-424a-847d-8606dc09ed9a">
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04c4f172-bf48-4124-ae2b-2821396e0af1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db9c0356-cb6b-4d9c-9687-096ff54cf7b3"/>
    <dc:identifier>DB00133</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
    <rdfs:label>Serine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/595932ce-7d35-4953-a198-bdabeb55796f">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/355b6f0e-7604-4dd8-98e6-7b6e2dc9bf1f">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bc03114-f108-4648-a20c-ae13dfd356cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1e2f475-5036-456c-92e1-17eb050c29d2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3c71c93-ae10-4035-9197-41f9bc00b454"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79f2e675-18c5-43c4-9337-3dc552d205fd"/>
        <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8612652-1d68-41f4-81e7-7391cfcad695"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c5ece96-872a-40cc-ada2-1800b56bf83a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbf20eb0-8a6f-4ff6-960a-5728c7625c25">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b8bf47c-5ae9-4699-8e9f-1e83fdf786ff"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
        <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4166b9ac-634c-4c60-b709-efb82c6fa854"/>
        <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3252c321-238a-4ede-8719-2587001bf40d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93dd31ae-aebe-435e-b71e-6946194556bb"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df4df3c9-4c50-4060-8bd3-7a95b0c8a8f6"/>
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42cad462-8af4-4a76-b96b-fdafe64ef68e"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44d97479-8975-40aa-9566-081ac20e4348">
    <dc:identifier>DB00480</dc:identifier>
    <rdfs:label>Lenalidomide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5df6057e-e0f8-4a60-97c7-11b975a008e3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f57ffda4-13a0-4dc3-84d1-cea5adcf4b0a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/58ec4080-f5ed-4fff-a6f1-0e8bc117c5ba"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afe3b496-bb4f-40fc-99f2-2bb5e9521895">
    <rdfs:label>Impaired fine motor skillls</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc19d0ca-37ca-43b6-913f-353f630a30e4">
    <dc:identifier>HP:0011925</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6fc9d36-00d2-42f1-8643-935489a40d68">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9bed1bb-b02d-4b5e-b4d9-da5ef14642ea"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff185d1a-7460-4069-aa47-2323228efff9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe8d2081-aab2-470c-bac9-c11ab8e46fb4">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc19d0ca-37ca-43b6-913f-353f630a30e4"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Idebenone</rdfs:label>
    <dc:identifier>DB09081</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2814bbd-ffcc-4e31-a310-e5646741aca7">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98334183-3748-4f3a-8c28-9b9d91024163"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd289d53-9547-4919-8d6a-27c63c65c1e1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7ca9046-e90c-4481-98c7-73727ea0b918"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d9960df-1121-473f-9523-aba5999a2f2a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acute hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd66d408-2c2e-4f94-873b-16e2a1369905">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/525ae58c-fee0-4536-a496-281083b2edb7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b9c0e4d-5b92-438e-bc00-b2836d8aca00"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3af6567c-0ce7-4067-8bd5-3ebc04212e8f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/438bc8fa-9476-4610-84d5-4734e5eee9da">
        <dc:identifier>HP:0012202</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
        <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/093056a5-b72a-45ff-b6d3-25fca8ec05b6">
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:label>pruritus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cb41259-27e6-4515-bbe3-9e3fc20bd96d">
        <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29cb484e-37ea-4517-9c44-9a7cb0f47f1e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum alkaline phosphatase</rdfs:label>
        <dc:identifier>HP:0003155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85f95f0d-53dc-4288-a10a-32c42fc78b51">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperbilirunbinemia</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d3ec1f5-5249-4e95-ac4a-c494bc779ece"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
        <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
        <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f1f1b4a-2eea-4fc2-bbab-4c7e7b0f22ff"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ead9a9a9-2c11-422c-ad95-571897f1f3ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7ed2c72-b392-4a28-a8a2-db5641b93b90"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b1ff853-47b9-43f2-9099-74e5b682a38b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd70531d-ed7a-4b99-a77b-3344419d8bed">
        <rdfs:label>lack of eye contact</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e7535338-87bb-4d82-a0ca-7422fed383fb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01733e91-6aa1-4ebe-980c-f97ffb805985"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7dfbcb2b-18d6-4c8d-b18d-80b3604da25d"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1f40d29-9ad7-4816-a721-7ae1632eab24">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510b598c-fbda-4dcc-aa58-64bceabae50a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b417fe4-a05a-4f79-b672-584cd32bb52b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
        <rdfs:label>Hypokinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9fda5bc-ba0d-4afc-b092-bde74c01bf31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97e9aafe-9156-43af-913c-dd1759da727e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9780c59-adc9-4008-b457-6f3ed3f01f5b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Delayed mental development</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1b07505-f3ad-4d53-9690-44635de52240">
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5cbbbd0a-ee89-484d-bfbb-b3c538908a7e">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2cf42ce7-f3a3-4890-97d9-05d651636fc5"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/286af5cc-4bfe-4836-942b-1f136e3bd31e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/048b8c32-370a-49a9-bc1c-104b0579156b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84031e2c-fb67-44e0-ae00-fc6b993a50ad">
    <dc:identifier>HP:0000842</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hyperinsulinism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/759ae68d-c51f-45d2-9c92-87be17ef0351">
    <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6611905b-80a1-4754-a9b3-9235244f77a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0003304>TT-1131</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/572f55f8-be3b-49ca-ba73-4e3a839fe731">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3308fee1-903e-4451-9775-e876a782a1e5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/467cb302-f520-4b1c-81e8-b9b508d32155">
        <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ef24b32-7856-484a-abcf-9b940b84d1be">
    <rdfs:label>High ganglioside accumulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79f2e675-18c5-43c4-9337-3dc552d205fd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
    <rdfs:label>hyperlipidemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003077</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9bc0abb9-3826-4496-8cce-4ff1b3aa5e79">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e8d92a7-bef9-4548-a052-018ce55f9057">
        <rdfs:label>ochronosis</rdfs:label>
        <dc:identifier>HP:0030764</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87ea77e4-6224-4f10-b723-aad57b8803c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
        <dc:identifier>HP:0001367</dc:identifier>
        <rdfs:label>Joint disesae</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eaac1556-c1a9-476f-b21e-5923ac4b3019"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/605dc384-6f3a-46a8-b43a-ca1eb3ad4c1f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98694a33-1706-40ab-8242-a8f00d9b27a1">
    <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b157f654-8ef7-409f-be95-5f2dfe20014f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d21cbfd-63c0-42d1-a63d-9889c696912a">
    <rdfs:label>Carbamazepine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57747443-dae5-49ba-b846-1315eefabb6f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36b94086-c064-47cf-aaea-2106dccc8299"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
    <dc:identifier>DB00564</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/106620e6-7c57-433a-afc2-d972d58d1661">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36b94086-c064-47cf-aaea-2106dccc8299"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8cf2906c-e19a-4a87-a4f4-d8c00f00c824">
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dba910ac-3600-424b-b3a0-40596b58acfb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c28c0625-a660-4300-ac1b-22e9f39ec15d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fae6b1d1-a869-4695-b8eb-17b1d8f70d2c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
        <dc:identifier>HP:0002019</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>constipation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
        <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
        <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
        <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8f1e2b0-15b6-496b-9d36-0ff64cc69e9d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9af47359-deb9-4843-b899-0a9d4dcbfb14">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02508af2-ce93-46a0-98f6-e30ee208d430">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c4a7cef-ffbb-41ab-a083-6fdecc492d3f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/661e6913-4baa-4105-a371-405f6e375fea"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01956</dc:identifier>
    <rdfs:label>Taurine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af407ee7-3231-48fd-93a0-4df5dcb87970"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0013968-ffea-4558-97f1-84227b2678a2">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb4b5025-3a0a-4d43-af3d-0cb580cc982a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a0cedbf-fd04-477d-bda5-8164f0cfd388"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2093649c-0f9d-4940-802b-70989510b0fe">
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/befe04db-1798-4c62-a72b-c0c4128d179e">
        <rdfs:label>pathology in many somatic tissues</rdfs:label>
        <dc:identifier>HP:0000924*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f00afe35-91e3-4cb6-a9f7-2a5204b5c54f">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/807bd529-6589-453d-b323-9d226f242bda">
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8649ead-a27a-48e3-a7c2-a9751273e61b">
    <dc:identifier>DB00608</dc:identifier>
    <rdfs:label>Chloroquine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d37eaa4-4c3b-446f-8c90-3c55ba184a46"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbad9530-d953-4253-9866-06e947e768f4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5c00710-979c-4ce1-9dcc-246a8dbe2473">
        <dc:identifier>DB01025</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e77f57db-7a02-46ba-adb1-81fd60cc7a24"/>
        <rdfs:label>Amlexanox</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17e16652-cc8a-4fbb-820a-4233435177d1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/492bfd3e-dae0-42d7-8fe4-42ad7a690249"/>
    <rdfs:label>Flumazenil</rdfs:label>
    <dc:identifier>DB01205</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe4338d2-3183-4421-8f40-ea6a212edca4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
    <dc:identifier>HP:0000707*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/557c7f92-7bda-4498-b96c-9d29ca56d4a0">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/688d3362-d02d-4637-89bf-74435ba94c0f">
        <dc:identifier>HP:0004319</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b0e59ed-f648-4f10-9f7a-877ed9226baa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900*</dc:identifier>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f470df65-a24b-4b63-afe2-8c2de1693a5e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum renin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17bb6cc5-9d21-47ba-9cba-330c41d3f5ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b428821-3ca2-4082-bbb7-7744e0fbfad1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/204cb51b-93eb-42be-875e-4fa349a59681">
    <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19b409b6-70e3-4b6b-a69a-7e73bff334d2">
    <rdfs:label>High blood malonylcarnitine level</rdfs:label>
    <dc:identifier>HP:0031544</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/524783fb-6488-4c15-84ab-526dcdc64d0c">
    <dc:identifier>DB00586</dc:identifier>
    <rdfs:label>Diclofenac</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb711c45-c12a-4f25-a1fc-8dada47c32c3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29607b75-f123-4b93-bb65-aabb59641af4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07549b49-9d14-4da6-9513-3716bf04ea86"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/608515ae-6465-455a-b259-d17fa786abac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab4917fd-ca23-4a89-b491-f53ef2ba0af6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a689266-3e73-42e8-ba57-f765e70132cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf16dd61-b766-4f46-b336-1f7f621d3ccf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/333b661c-b788-4225-a104-3b292ed3b84d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b27d6d6-1f64-4d18-a239-157d94d3ca8a">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c229d5fd-7e8e-4a9e-b446-3330f59b3c61">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a8f7b17-693f-4be8-918d-7608c33a85ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af5f6a98-1ce9-40aa-949e-10888cf9f1d5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55880fda-0c72-402e-8bcf-2b0d388af5e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15d6e3eb-fa7d-465b-bd70-59ac11b28891">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8fd1863-3af5-448f-9b8d-14222fc961ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05731ba6-b8f8-48eb-9a0c-8e51cd5f19ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aea5298b-9cc7-4642-9fb0-10927745f278"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6a0bcb2-6326-4867-8281-1e16f4903c20">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca9a2622-86cc-49d0-9f85-1a9a8774ed27"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9797b8b9-e914-48e3-99e4-eed101cf263d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <dc:identifier>HP:0005180</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a663ee5-9996-4638-bcfe-252f337bd8d3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001653</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:label>Mitral incomptence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab2c6bb0-bfaf-4d3e-a616-7e75f05de36b">
        <dc:identifier>HP:0012664</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:label>Low ejection fraction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2415b33-290d-4e0f-b26b-31deda820843">
    <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1cc1095e-eb90-4e0d-9e71-fc7fd1075ef9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9363344f-73eb-440c-91c8-65ab4f3b9119">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6376d398-b0e9-4647-ab01-7249d0a1545f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a6e4359c-e46d-497b-8e20-df9406c14f30"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04cf9751-8dda-49a1-9d41-3042931d0bcd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1e64f32-77a5-4a07-ae2b-931470f8511a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b4507ed-cc01-4c32-a19e-d098651acbc1">
        <rdfs:label>High VLDL triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c56acac0-bf61-43f9-8bc1-4728e35a6f03">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/abe964a6-3b5a-4c11-80df-d442b3930702"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a87f5f67-eb38-410c-92f6-6ebe3a2930f2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1467614e-3758-4667-9b35-09c12cd0b984"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d318ddc0-cb74-4283-9893-3d41ca908fde">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased lung function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb619e3d-6d5b-474b-9b95-0cfe453fa8a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de5f6e2c-249a-4f1b-994b-24f052c5a9df"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cdf7408d-5a28-4a1a-a0d0-33df7a375bbd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac803dc3-b6ef-4701-872c-f1d5783261e7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <rdfs:label>Geneticin</rdfs:label>
    <dc:identifier>DB04263</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e89b286-862a-4cf8-83bd-b45127ba7611">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe7e123b-4909-48e1-bf8a-137b6aeb7225">
        <dc:identifier>DB09278</dc:identifier>
        <rdfs:label>Activated charcoal</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3d9ccfe-46fe-4b7a-a4f4-e5ba47ecda72"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba6e3b93-d864-4353-ac73-b679bbc868f3">
    <dc:identifier>DB11133</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd53284e-6171-4b25-aa98-9e499f702e32">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/156e9d1d-812d-4d2a-882f-793eb6de650a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb736a80-51a7-4485-80ef-2b875f870cfd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e44f636a-94a2-4862-a38f-86dd7b5b10ae"/>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75aefac9-90ae-4bed-b64b-0d681757b613">
    <dc:identifier>HP:0040189*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9e482b9-14d7-45ee-a607-4db6ba6d29a6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f38515a-d0c9-4326-b00e-30b998bba168">
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9d92601-2294-4222-b49d-4b1e39af7aea"/>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2497b478-2784-4826-87f8-3d05880fa42f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df219287-7b39-4d00-b10b-c1d2b319625f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cda51d29-744f-4883-95f8-a1690de5c6ae">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
    <rdfs:label>Cystathioninuria</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003153</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc6f87fb-c8ee-4b90-a40e-eccf8b92db70"/>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
    <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c82fc0c9-11a5-4989-8f02-618a8c61c856">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6d867ba-5e3d-4f4d-84aa-f2e4230bf620">
        <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68c0b29f-2114-4b87-9c1e-32ad5936ea56">
        <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d41b042-b674-4c43-a6fa-8cf7d111d818"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/396ffa52-4e2e-4d2c-a4d9-13183130375b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51608ef8-d1a8-4490-9ef3-2f168f096642">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d86f7548-66a3-40d6-9bdd-28c9b35dcacf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af3578de-0e12-4f2c-9847-0abeed02daef"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83127c03-06c1-43fa-b404-19a6e844ce96"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef7b708b-5b26-498d-9ef0-6f994ef6840e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5012cf8a-a0c9-4196-a437-5d37c7b08a1c">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurologic deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/902c8506-8090-4aa7-90aa-fe2e13163afb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26e3f769-48e9-4c67-8202-04ad7aeffad9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f802650-a5a6-48ff-ae35-3929e7d10259"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1975f0e3-ef86-4f6b-8327-efd976d86f2e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:label>Tiredness</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97fc78d0-25d4-4910-bda3-b592dd8eea95">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <dc:identifier>HP:0002180*</dc:identifier>
    <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/61f145ba-dcc4-48fe-baba-0e21eec03ef9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4f373fb-8fc5-40a6-b187-744c31fbd320">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/520cdd8a-9818-400b-9980-7e287edf0a19"/>
        <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47872144-7fd5-4a05-a3e6-04044fdb746e">
    <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
    <dc:identifier>HP:0003200</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d3920ca-d694-4f27-a55d-09cc2e2bc6f6">
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e53d73a4-faa8-4f8d-a284-04a4d9e86f59">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4abd300a-2c9c-496a-b033-6fe5b5a01ca3"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66d85dfe-8ec8-4470-a0b0-876e186c01f1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee63c752-4fe3-45a7-ba29-761644bdff28">
    <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003287*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5798283-1aaf-4932-bbbc-e01dfe797ab1">
    <dc:identifier>DB09105</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c491ef5-aa4a-427d-a9bc-6b21fd338043"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27cb3241-db67-4bb1-9cd5-30454aabc8f2"/>
    <rdfs:label>Asfotase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87cdd016-25e7-471e-ba7e-113e184706d2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5be146ec-b407-475d-8f4e-29f2b44f8a49">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/546270cc-4ea4-402b-9a65-9fdf010645e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36438749-6c4a-4cc5-8d52-ff3942cebb6a">
    <dc:identifier>DB01032</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <rdfs:label>Probenecid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8cdee320-f483-45e2-91a9-b7b62015d1bb"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6f0d36e-2511-401b-8a27-1ea3c84e8b47">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6794bb6-ef3e-4108-b6a4-7b0166f619a1"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7d7142b-b5cd-4a19-895e-6929e53bf1f2"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b98f070-3cfd-43a9-9a2e-9b30c335b321">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13572211-6aa3-4908-9d8e-e95137dc48bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6be88295-55dc-4b2c-8de3-b591bec7d883"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0255dbbc-19f7-451f-85f8-76e1498d388a"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c83f317b-5e4f-4b95-9f4c-3b9dfe0c859a">
        <rdfs:label>Brain pathology</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c97d0364-a5a9-4f91-9d53-2ddfbaa194eb">
    <rdfs:label>Myalgia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <dc:identifier>HP:0003326</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19c8aeab-9368-4801-8a48-1631a7fd1ddb">
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <dc:identifier>ECO:00055442</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3d81813-8ccd-4144-9350-0c074894e7c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d8e261c-2f7f-4644-ad8b-37b841565165"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae7924a-c300-42e0-b699-adcd93d1a5fd"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36826d7a-bdad-42c7-b47c-71aa45c8be99"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ce51610-51c9-4838-b876-f04d646cc8bc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1882f6e-406d-41f2-a3c3-0da76328a2c9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031799</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0707deb9-b0f5-43f2-885f-93c8449ab18e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <dc:identifier>ECO:0005242</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85bddb2a-815e-4497-9ee5-62d081837935"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6212cbc9-48c9-4c7c-a309-3193c041187a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d625eb18-ed0e-4201-a786-f7980de21234"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e67b63d-221a-4652-bf4b-e0c0a00bea10">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003676*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/512b47aa-21c7-43e3-b5ab-e9db57b52714">
    <dc:identifier>DB01026</dc:identifier>
    <rdfs:label>Ketoconazole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76d0e766-a531-48fe-ad21-b41b74aad514">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d59bfe9-f599-4337-86f8-f3e22d67c06d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68234b46-4679-4899-b36b-1db81c94b81a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85ad617b-903f-4849-b4f4-d4386d403769">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33a5a767-448d-4679-9ac6-45889c389449">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7737911a-d0c7-49c3-80cd-011c2483aaaf">
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa65014c-3cc4-422a-b0e0-2b8ae3bdbe09">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe172bde-a9f5-4a0d-bd7e-b373253674fd">
        <rdfs:label>High serum total cholesterol</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcf207f1-aa02-4e17-b9b7-d37929ff593c">
        <rdfs:label>High serum triglyceride</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1a709946-f0f8-4fb4-abea-38d5b99730ad"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec7d5f0d-38cd-4f6a-8295-0ade9c745ccf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031798</dc:identifier>
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e28d5e33-6de2-4148-a80c-467888fa7ad9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3007b9b2-371e-4010-9243-5b19c3840b03"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83157d21-5dc1-48da-bab9-6a38e4c368a0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e330f67c-09d8-4821-afd3-dc7bd83d7858">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85f16457-64cc-41f2-9660-010cd82e85ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4dd0caa-a734-4227-a851-88b16f087ad1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ae30407-2aee-48b4-b4de-0be725f6abf4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025201*</dc:identifier>
    <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67ac2967-ad18-4341-a21e-4f6c7f86e50a">
    <rdfs:label>oxidative injury*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025463</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/579c6053-aa70-45ba-a3ce-5f419eec6652">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e70fcd6-ea0c-4fab-942d-5a8c8069a25d">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8c91bdb4-874f-444b-99c5-713669fec66f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23876f30-b11b-44c5-bd24-0f56fec7acf0"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bbe16ac-cc49-49da-93af-90c2eef7755c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5863107-b6f2-4795-bb78-fe766f1e8172"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00016</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f026924a-9254-4491-91fa-8d39d1c37371">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/706a0664-cd35-43de-9812-88c76991b471"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c001f13d-a3e3-4bce-a577-7c277579c784"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc2333fc-1ac1-46bd-8482-ff616fa1b1bb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb792d89-6d92-4f95-b38e-67d8a58cf842"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d50e6e71-a680-4686-b599-1826652415ae"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8c91bdb4-874f-444b-99c5-713669fec66f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1975f0e3-ef86-4f6b-8327-efd976d86f2e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61caed02-d98c-4527-8ea0-7dea8369bf1e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb1695d5-9c32-4ed7-9350-041a84676b9d">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/385eaefc-72e0-4cc9-8910-f52da79cf43d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e71413de-6300-4322-8881-f6af9e5fb6d7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab397b50-398a-4ba1-97a1-9e01080f8718"/>
    <dc:identifier>DB01593</dc:identifier>
    <rdfs:label>Zinc</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5fe35f28-e3ff-4655-9cf5-fb0f010800cf">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6e84eba-48e7-4120-bff9-30327c6272f1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334e1108-3886-4323-b848-08c70ea85f9a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/835854c7-640a-4d82-abfe-deb42c53c2d6"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e8a601e-0f45-4668-97eb-a4dba0c74819"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e71413de-6300-4322-8881-f6af9e5fb6d7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a91371b0-9150-472e-ba71-3141c0f60790"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73bed7f0-4f4c-4391-a3ab-4b3cb0345087"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14cec9c0-1d4d-4cc5-a33e-9e1fea5dc35c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
        <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/334b4190-8de9-4e19-a87e-a016e98bc6c7"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GRACILE SYNDROME</rdfs:label>
        <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4073cc4-c458-4863-a6aa-63f63f8f9c2c">
        <rdfs:label>lactic acidosis</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15e22fbe-90b0-4f29-930b-795ffd0fa818">
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
    <dc:identifier>DB04159</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/161b48b9-885f-4372-b5f8-57869fd3c7fe"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d0768fe-894f-45af-bdbf-e186efced75a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1760710e-8952-40c6-a823-caa29d77aa91">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77b4c9d6-2f7e-4419-ada7-5e20a762b1b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/278ff4db-5354-4c52-b318-9f07c17738a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc6fdfa5-6901-4534-9f26-1aef9f59b32a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51386873-76b8-437c-ae83-0b32a5dfbbf0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c0bd579-8264-4b90-a0a5-8cb0814cc519">
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa9ded15-a76f-4eb1-9d5c-06e3c069f878">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003455</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/049bbabf-63b9-4dc5-85a1-da162de00d56">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb9a239c-d6d9-406c-b3ca-dec0c96fa06b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fea8248b-43d3-4ad5-8be8-7abc309c17e4"/>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb4f6ec7-cff4-489e-9097-8b2edf527cfa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52149bf1-0b0c-48e9-91b1-d61161cd0d7c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8b92295-ecea-4364-8faa-07cd02b00a81"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/543635cb-14fa-4272-bfa5-e481b3a04e58"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb63f716-393a-469a-b54c-965a339fea8f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76297083-3cf5-4201-b5ac-03c1b8da1b26"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB08883</dc:identifier>
    <rdfs:label>Perampanel</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59693427-0657-4594-ab5d-f34b1547bfaa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <dc:identifier>DB06755</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e7f1321-1a1b-4f3f-9f0a-92528a9f621b"/>
    <rdfs:label>Beta carotene</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02fd7a24-7f24-44e6-b807-2d83c11ea11e">
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77f6a055-07be-4e08-9979-847f5c70e113"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b3c920a0-067f-466c-9749-fbb832413ffb"/>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5b152c3-316c-4d7b-9fac-7a1a90e999ef">
        <dc:identifier>HP:0002148</dc:identifier>
        <rdfs:label>Hypophosphatasia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9bcfb8a1-aab3-44a7-9cc0-584ef10a9ee8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90e7abd5-a289-43b4-9d5e-c06e9b97661a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/164600a7-f4af-4fa4-aff0-ce84f44a6e0a">
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38e14131-0f71-43a4-8aea-0735f024070d"/>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f39e4502-cd46-4d9f-bc59-da448287b0b3">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/612e476e-4e04-4784-b8c6-9dc9ffa9991f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63875745-1ecc-412e-b896-600480b13130"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18e56557-bbf0-4abf-8b08-9dce53ec3333"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04cf9751-8dda-49a1-9d41-3042931d0bcd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b467c0bb-1a85-461e-be4c-a96797794463"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/563d9e2e-27d4-457a-9425-447c8ac15ffb">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f5376a5-9274-4340-a90c-37b63eb67f67">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
        <rdfs:label>Dorzolamide</rdfs:label>
        <dc:identifier>DB00869</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c547fc4f-3587-41b8-83f6-a4b062c0d967"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e24fc49-400b-462b-839f-f9827477c3c6">
    <rdfs:label>leucine-restricted diet</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db86ee6b-59a0-47c3-93e4-1fda3764de03">
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4721aab0-b063-42b1-8eb5-7e5a13728805"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6461887-200d-4e3e-ab47-41a08025a614"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8585bfc2-d210-4ea0-98c1-e40447033bc0">
    <dc:identifier>HP:0000491</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
    <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4a62ad4-8b96-42fc-bdb5-277c151c63b3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
    <dc:identifier>HP:0004918</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2938dfc9-4f27-466f-8816-8639f4900a84">
    <dc:identifier>DB09422</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fbe3d3f-7135-421f-822f-0c7e5c476ebd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdbcdbfb-cb4c-4c87-a0e5-58c0cc1633b4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11e8910d-97c4-4fc7-85da-e26d72bfd475"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <rdfs:label>Soybean oil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/476ce62d-d3f2-4aa7-99ad-c0fbd870bab5">
    <rdfs:label>High total plasma cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2608172e-47e9-4eb5-88d4-be4aa9b3fa46">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>Heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d5158f5-d23f-45b8-ad33-833e42de8064">
    <dc:identifier>DB01234</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d67a1ec-4de9-4342-974d-741bc006ecb2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b422bec8-bdb4-43d8-8b4b-0a9da7f2e3d3"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2df6c9b-26ed-49a7-a575-3afadc5ab455"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Dexamethasone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8866fb61-4701-494c-956c-e8a68142e8e0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/293754c8-e39e-43b1-9857-cbd4e4647528"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54367c30-8930-4980-ad42-07087427b6c6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/605ef58f-b402-49e3-8e80-ddd130564842"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67004c10-7770-44fb-86a8-011701b68268"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b422bec8-bdb4-43d8-8b4b-0a9da7f2e3d3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/525ae58c-fee0-4536-a496-281083b2edb7"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a8ad20e-e3ab-4fd2-bef2-424cded50ba9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90c6759b-d095-42d8-9280-98745eb4efb2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavioral disability</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b19bc359-2447-4c3e-81b8-cd86870bd428">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <dc:identifier>HP:0000870</dc:identifier>
        <rdfs:label>hyperprolactinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/548e9c2b-1453-4741-b8d1-9e92f821a356"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0e26890-7148-4410-aa2b-c8c54cedff40">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dopamine deficiency</rdfs:label>
        <dc:identifier>HP:0012656</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac301538-0893-49d0-ab08-d918f17314cd">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>movement disability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a797dff-460d-4947-b3df-baa853a19365">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82267104-6ffb-4328-8c25-33d4b0906a07">
        <rdfs:label>cognitive deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/71b76c14-35d2-45c6-a433-821f72cad13b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad56f0a2-82e1-431b-af98-6867dfb17677">
    <rdfs:label>Filgrastim</rdfs:label>
    <dc:identifier>DB00099</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9e482b9-14d7-45ee-a607-4db6ba6d29a6"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f1cca17-22de-4840-8c20-c244d489856b">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d03bae0f-4f3d-4dbd-b7df-549a15c8c01c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
        <dc:identifier>HP:0002155*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31de49e1-b8b9-4a16-b3c7-e7f83f959113">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fac7e8e0-22e3-4409-b510-839e9a262901"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5b95bed-34f6-4a3a-b187-c87f9945b12e">
    <dc:identifier>CHEBI_2786</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f5b62845-812c-4aa6-bf58-e40912108cf3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89b9d102-7a5b-4f8b-9973-feff0197636f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e903c9a9-76e7-4c72-a468-7ca7b6766510"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b20faa7-086b-4d0e-b5d6-764e31a4bf5f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002150</dc:identifier>
    <rdfs:label>High calcium excretion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0872abb1-1cca-4215-bd4e-00254832182e">
    <dc:identifier>DB09125</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc1556f1-e47a-4871-a84b-d93ddaafa82b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a25d141a-2309-4c48-9753-d14d0c5fe27a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc609ed2-6d94-459c-a279-287868d0467a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/525ae58c-fee0-4536-a496-281083b2edb7"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4a62ad4-8b96-42fc-bdb5-277c151c63b3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Potassium Citrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05d8091f-52f2-4a1c-acf3-3f8f99490455">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ed8d01c-6881-4195-a940-e3148fd14905">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/964ad1d0-1b03-418a-8322-8910fd71cae3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8ece3b8-0421-42c5-b61c-729a20da1c08">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ecbc16a-0e04-404f-9e9c-8795d6da5dda">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d06767dc-8043-432c-b9b5-fbccff33f364"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf420ffe-a3e0-4b77-87a6-5b16cf68ceb1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db35a58e-7273-46c2-9776-1500639f894a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2135f130-4c7f-4a75-a166-71bbc2b60a2d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a17884ec-11c2-4abf-95e5-0d282a2e0be5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00232</dc:identifier>
    <rdfs:label>Methyclothiazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a08fd335-8fa7-480d-a084-1eb296f160d2">
    <rdfs:label>VITAMINS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eeedc3c9-99bd-4425-9878-8006a3799274"/>
    <dc:identifier>A11</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84e7dc44-56e6-404e-98ff-93ce02e5baf9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ce2a04c-28e5-4d63-883c-79e76dfa19d1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002415</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <rdfs:label>progressive leukodystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60c89c1e-7edc-40bc-bd51-d5ef899277b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <rdfs:label>Impaired myocardial contractility</rdfs:label>
        <dc:identifier>HP:0006670</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5659c2e8-ac4b-4bb3-a5fd-0db790a07a0e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
        <rdfs:label>paralysis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003470</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0437e56-c764-4d11-ae36-a86039d71633"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/96bbfde2-2ca5-44ec-9ec9-d8e932a41e5d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a2be51b2-a1a3-4570-b032-3c55e48d68c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3b45dca-5bd3-4e26-b983-833d9ae27391">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/671ccebc-7409-45ca-909c-28c9337671d1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/feee6a4e-78af-4582-8972-85baa9747195">
        <dc:identifier>HP:0002574</dc:identifier>
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fa0d0bc-92a1-4134-8fa1-9c17e8a7c179"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27d27485-02ae-4e10-9ea0-37b48734b438">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a42538d5-c132-4bc9-88d6-f2e0c7723f88">
        <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
        <dc:identifier>DB11098</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de532dec-9fb2-4323-b8fe-997809afd5a2"/>
        <rdfs:label>Potassium bicarbonate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95f38ade-109a-46d2-8bfc-ab253b86a7a4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e02c9ab-806b-48fd-860f-c27f3960d2fe"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af62ee12-866f-410d-ab12-28e07e4c407e">
        <rdfs:label>hypolysinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7812242f-40ae-4cb9-9b1a-2e9dd9f26c64">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
    <dc:identifier>HP:0012335</dc:identifier>
    <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4aad6896-705a-40fd-bcc6-f4229e01b188">
    <dc:identifier>DB11735</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07a4a5b4-a116-4b05-9bea-913776106c8c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f0fe96e-d1ba-489c-bd4c-6e4e8062856f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607091"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51b9a649-f6ed-4179-aec3-a50ff79fd8e7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aabe4df8-ff14-4d70-8020-5c6ee2d78ba1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c1af6f5-5a3a-424b-9dc5-8b54610d8563"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ebd685f-fb05-4c95-8b4f-b72e12f664cf"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38abf2c6-3dca-4858-8156-bc0c5c41fc5b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9a0a722-8f64-4f6e-bb8f-5ff9e65755f4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f0fe96e-d1ba-489c-bd4c-6e4e8062856f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/568b2e5b-3126-4ed0-822b-84d55c4e7876"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64858a52-ccad-4e2b-b964-ffb15e9db6b9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83169c62-7680-45c0-ba30-66fbead38fae"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cbdc7b3-997b-40ce-94a6-b4a761d9e9fb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Galactose</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b452b835-8260-49b6-a812-d6722ea19d73">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b069d1b-715c-48fc-a8bd-760b5a946bc7"/>
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee63c752-4fe3-45a7-ba29-761644bdff28"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/06bb532a-fc17-4ad7-9771-8623713e5fc1">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6c747e2-8974-4dd4-8030-172db1061c26"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21742acb-7acf-43c4-9b76-31990897e19b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
    <dc:identifier>HP:0000934</dc:identifier>
    <rdfs:label>chondrocalcinosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97dff530-ec43-4269-9854-cec657c9fcca">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14cec9c0-1d4d-4cc5-a33e-9e1fea5dc35c"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7aef6c42-8e7c-4d1e-ad2b-4df76fdad365">
        <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5cd6bb75-e9d6-4aca-b3ff-549f5df5257b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a818af43-53fb-42b6-933e-a30d8db6e7d2"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b8199a5-7808-4dc2-9427-087d4426df81">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1508df50-4ffa-4adb-8cd0-d140bbc441f8"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83744f72-0b33-4938-85ff-69d0b5bc3aac"/>
    <dc:identifier>DB01390</dc:identifier>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17ea3abf-ffd1-4912-9570-2da38e19e3ed"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a3cc647-cf99-4588-9719-8fd2bac09394">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/229eaba7-60cc-4749-9d62-04fcadff94b7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac57bea7-7c65-4d4c-9bc1-43c01da17b18">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0e2b21c-ce57-43ed-86db-d0e05ac38ecc">
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
        <dc:identifier>HP:0004910*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16043ed9-7816-455e-8a34-e6c214a652bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/361e344b-ab3a-4178-837a-4e871e58f4ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/208f6e8f-a94b-4d9e-9615-0a326614231c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b35a8816-398e-4aee-9930-4f751730c4b6">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/367a9e8b-9b5c-456c-ba55-0fc4ccff0a82"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <dc:identifier>DB00331</dc:identifier>
    <rdfs:label>Metformin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c37384c-84a7-497f-b45d-572b35aefa67">
    <dc:identifier>DB14751</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/589cdacc-d9e4-40ef-9373-d8eb883b82f2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad0c736b-311d-4eed-a191-1ac36117c5ba">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dba910ac-3600-424b-b3a0-40596b58acfb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20a624f5-2484-49ff-8f2e-db32dac1ef3a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21742acb-7acf-43c4-9b76-31990897e19b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55292e36-4341-4b39-af0d-f5c1dee89778">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>affected functional activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cbdc7b3-997b-40ce-94a6-b4a761d9e9fb">
    <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001976</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3a3c4ae9-aafa-4020-9fab-e41a0414f38e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5f955f3-2468-475b-8c09-776870257204">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16212379-6d81-45ae-a51f-3c22f555b55e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7208d893-1dce-4cd5-8f0a-0d612f350560">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <dc:identifier>HP:0012217</dc:identifier>
        <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30c247ca-3364-49b2-a03c-2b7bb4a1f23e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9324a25-8bcd-4438-87b3-8bcd5a3d2243">
    <rdfs:label>Azathioprine</rdfs:label>
    <dc:identifier>DB00993</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65de41fa-2870-46ff-9d4f-7e063f5780c2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d88ee5c-408e-42e3-ab0b-5cd06334a3d6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ebc8345-682d-4a73-835c-c492c3adcd57">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a753ad1-02b0-4b88-8dbb-421ba56063ec"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9bc1570-3a35-4729-8eef-1cee891068e7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7dfb28a-4244-42d8-9ecf-300d0a42143d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5de6ce1-d603-4c33-bc03-b110759ff733"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de003c1-dc0c-4917-ad72-2831b17e2bf8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa77e7d6-0711-47d7-b4f8-2ada97eb91d9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10524e47-bc6a-448a-913c-be56c6a4771b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/702e5000-7835-409d-885a-1e987789cc6d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c6e6b9-bde3-4b21-9ef3-b9050dfec70e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b1e3c20-a3a9-40cb-b26f-889b685e0c5f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ef57d53-c885-4bd1-a24b-3e837bab1eea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03169be3-19cf-4952-baa4-23fc31cc23b6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No Studies were done on this drug.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e39a01d2-b369-4d2e-a3db-bb029fa1a81c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
    <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003710</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e19b503-8c13-4ca5-ac82-5437d307f1fe">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef63318f-c457-4faf-973c-732dc2902899">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5270740-5979-46d0-9ddb-dfc9db1d479b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ef9182e-53a7-4d00-9b0a-e8f3a2c7929a"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
        <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c740ecf-9713-48b3-8461-5c6d8afcd266"/>
        <dc:identifier>C09A</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f211ae92-605c-432a-8a26-93ed5a5ea400"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c9800e7-afbb-459e-b289-89e5d38b6900">
        <dc:identifier>C07</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/904ae0c9-363f-41a8-a70b-e7c5c958327c"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5270740-5979-46d0-9ddb-dfc9db1d479b"/>
        <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c740ecf-9713-48b3-8461-5c6d8afcd266"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61a82d96-c9d4-43e6-adea-99b0b6fb16c4">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c740ecf-9713-48b3-8461-5c6d8afcd266"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
        <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
        <dc:identifier>C09CA</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5270740-5979-46d0-9ddb-dfc9db1d479b"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21859a5e-93aa-4745-b938-fae7d911393f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea44c4b1-8f9c-49fb-baec-a75f3ed18859"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
    <dc:identifier>DB09144</dc:identifier>
    <rdfs:label>Uridine triacetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e247dd4-f26c-4ef0-96cd-5ab4b0bc37b0">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9dcfd31-ba5e-47d0-99b5-24b00ff4ee25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/94855abb-5470-407b-bb53-84cc86bb6de9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94b5cef7-b4c2-4fe3-8a98-83440f6bb561"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a69b3d6-714e-44d8-a0ab-e2112c0ce2bd"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ef24b32-7856-484a-abcf-9b940b84d1be"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11ab0731-d2ce-48b6-b25b-8217fecccf3b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33805570-c85f-4627-bd99-5c5b820de4be">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f6bf2f3-3a60-468b-b03d-9f2f0b7f3316">
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc833139-c914-4448-9090-9f5e2a019579"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fab219e-84ac-409d-9454-f8e785abdfb8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caff0de8-d82e-4111-ab1c-d26724a31c47">
    <dc:identifier>HP:0001324</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6455946-bc0f-459d-9411-aa2dedf58542">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73c690e6-9efa-4aa8-a0ce-bba2f691f1f4">
        <dc:identifier>HP:0012825</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
        <rdfs:label>Mild attack</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88d53415-5c30-4bde-825f-a367a7b8dc75">
        <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
        <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55b43847-d2e6-4d45-9259-33c6d07bd22b"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32ca6ca1-956c-4e48-86a1-36d48a1431b5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f7fd02c-2fea-4f04-a7e3-65463907590b">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a413a62-cd46-4d8d-abc5-56d975523a38">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cf06b25-6624-4d80-9a0a-5411c1150f9a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c60224bc-c760-4450-8c56-01620a647cbb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ceb75124-2239-48a4-a611-100dac6fac18">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/915d2658-893c-4bd8-a596-e4c5ef426048"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8509ba95-81e1-482d-9d05-62d25757ab87">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b92eb564-f3ff-48c1-8329-0e5d276d9006">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal plasma lipids levels</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b0046d3-9e6f-489f-b19a-d3a6d15f1070">
        <rdfs:label>low HDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf249c6f-4dbd-4e32-bb9b-70afe5feb26a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/525ffd5c-6dec-45ec-8763-286305b5b480">
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
        <dc:identifier>MP:0003193</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa7b86e4-1bb4-47c9-9f35-dc42ffc74d15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Apo B protein level</rdfs:label>
        <dc:identifier>HP:0025201*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd1d9592-90af-4670-a6f3-1eb88f5cb7df">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
        <dc:identifier>MP:0011598</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2676bd0-465c-495d-9eaf-106faf46ad5c">
        <rdfs:label>dyslipidemia</rdfs:label>
        <dc:identifier>MP:0003949</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d5311e1-dd83-4294-98cb-fa049f47fded"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9049f57d-6bf2-4567-affd-726a17b65a38"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1fdf1337-0313-43f6-9f87-a08671c2d6a9">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dadce545-08e6-4d0a-92e9-e5344f55b6b0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9079686-c285-426a-8109-b64e8fa6be0c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012433</dc:identifier>
        <rdfs:label>abnormal interactivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6781759-ead9-4cfd-82c1-0391b9c966ed">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:label>Poor eye contect</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2e79000-8d01-4dfb-9af8-df377978e4df">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86884af8-cbef-487e-8596-1934711f2c15">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2035f845-6af5-4d88-b8a9-f93ab999cccd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65b76c83-4d60-488a-aa4a-43f71f8bd45d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
    <rdfs:label>Diabetic polyneuropathy</rdfs:label>
    <dc:identifier>HP:0001271</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/772168fd-fad4-474e-83a9-37c811c0211d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e698377-6281-4578-b96c-7f232da8d880"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <rdfs:label>Adrabetadex</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ad4ff97-5fdf-450d-81b4-00ebcd54835d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11105495-dcd5-4b75-91ef-7724c85027ea"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1728417-58ac-4d13-bbbb-55334345ea9a"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5f0c5e-6484-496f-a12a-6ff57e66b370"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0aa324c9-317a-4ced-98c2-95be2779417b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607625"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB15146</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8962fba0-a33a-4745-a70b-9b98b2072965">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea9a79e0-4109-498a-b83e-183456899e9e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b61c95a1-86ca-4fd2-9056-ea8e5c651636"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08c9af16-04e5-452b-ac86-33defee33377">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f15c186d-cd9f-49d6-9abf-dfe26b4a0e53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c679220-e46f-4a61-bfa1-f2752980e63f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29e08cd8-a281-4ed3-84af-5985e1e3f915">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/108eecee-0a21-4f68-8429-97dba696d0d0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e86fcfc3-3040-4306-9dba-0d24fcc6b73a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a17b146d-d3d5-4928-bbe5-b471c482ec7c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
        <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
        <dc:identifier>HP:0004345</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/940ea4b4-1e9b-4a47-8800-bf05ad0db202"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd2299a8-bf97-4ab9-9c1a-cbe68e7e111c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6816f31e-c834-4ff0-94ed-316804327959">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45bfb4f3-3d18-4c9d-b86d-0cb811fa71ec"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9204db35-15ea-4ae4-bf93-273ae671ea9d"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
    <rdfs:label>Phosphorus</rdfs:label>
    <dc:identifier>DB14151</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/affc32e0-8df1-4672-af1b-db4b1ab0db4e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5ac89e-8994-416f-a9b5-2cabeddf3316">
        <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd0ef11d-333e-4d58-9ffe-4e49d909b3e8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6b21f6d-9c0e-480f-894c-8423f1047078">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d281bd5-78be-4915-9076-3e89ffba5221"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece3dbdd-943c-4e5a-bca6-6b1bcda9de64"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ab073e2-0d50-4aaa-9b9e-e7826952bb86"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c11a4741-c526-4f04-b586-e8ff5509121a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67924a06-512e-4cb6-87fb-523c17c37441">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:label>High total cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3b9c50e-4b73-463f-9c26-6ad04cc0afda">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low physical activity</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a70082c0-b34e-4cbc-bf48-efce7b311879">
    <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
    <dc:identifier>HP:0010978</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83c4e584-f116-4f32-841b-f51b58a42de0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001336</dc:identifier>
    <rdfs:label>myoclonuic Jerk</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/046ca689-abbd-4608-bcf3-f8f09c950178">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ca63ffe-40ca-43df-a598-b41d6722619d">
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9dcfd31-ba5e-47d0-99b5-24b00ff4ee25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49f8ad24-db18-4724-8837-3f52e0db0172">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <dc:identifier>HP:0008344</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c491f7c-d8b4-4b02-b5f3-7ff510411d43">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012240</dc:identifier>
    <rdfs:label>Increased muscle lipid droplets</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96bdf09b-a2b5-4b4c-8797-aaec7064f809">
    <rdfs:label>abnormal microtubule assembly</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69564c20-16eb-42a1-bfe0-f180fd4b9dcc">
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004923</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b29b871-62ed-40cb-adea-a9c295014bf8">
    <rdfs:label>NO revealed clinical benefit</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eee60b73-70f7-486b-98ea-6a2f620489e6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a689266-3e73-42e8-ba57-f765e70132cd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32f4a5bf-2b31-451a-9325-853e8cc82ce6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7aed81ab-cb0d-4577-b5f3-e6920ba7318b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad3cac85-41fb-497b-9047-c3c69686c041">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb619e3d-6d5b-474b-9b95-0cfe453fa8a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60c377d5-f718-4cf6-ad48-230485266db7"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2497b478-2784-4826-87f8-3d05880fa42f"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2cbb8e46-8e3a-466f-9542-75b7ce9d599f">
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a03a88b-70e6-4edd-84c5-6bc09831cc67">
    <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7aed81ab-cb0d-4577-b5f3-e6920ba7318b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eee60b73-70f7-486b-98ea-6a2f620489e6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
    <rdfs:label>Probucol</rdfs:label>
    <dc:identifier>DB01599</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ed0ca75-69a6-4e04-9f5c-071e7c973371">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d22a211c-4731-4c12-8a7a-ab7724c25def">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Polyurea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/482d223c-bced-49b9-b5d7-31d983e41290"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fab930b-3725-4c0e-b8ca-42e9b763fb1c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ebc8345-682d-4a73-835c-c492c3adcd57"/>
    <rdfs:label>Adalimumab</rdfs:label>
    <dc:identifier>DB00051</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f057ecb7-ee37-499f-8ba3-b9c794468b28">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e18ddde-7329-4278-953f-a362278faff2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/830ec962-39ff-4c78-b5c5-b8f3aa566774"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70d45755-4f44-48f0-b33c-00aba941f5b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2dcac369-c75e-4fb1-8cba-6e22b4b3df26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b4b4254-c932-4e85-aaed-90164d8292ca"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/290febfd-1068-4f61-ae21-63b1df25b121">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f058c09-f14e-4331-8930-ec07cf46ac95"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a641d047-e092-4b00-ac07-8371d8ed0406">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7b3d024-5745-4895-9d8b-ef50edbfa496"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60cf453c-5350-412f-aeee-d6a28fac46e2">
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b4507ed-cc01-4c32-a19e-d098651acbc1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1e64f32-77a5-4a07-ae2b-931470f8511a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f21e3c81-d695-4882-b179-50bc71a6c9df"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ea1af94-a37a-49cc-8918-c0ace7a7b4ae">
    <rdfs:label>Poor fine motor skills</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bac6c13a-705f-4f0d-9ce0-22cb53f8189c">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfa4a9c1-b80b-47a8-8d73-466e4723a5f7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/caff0de8-d82e-4111-ab1c-d26724a31c47"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8aac63a3-0475-4ce7-b9d1-14b8e1b87e6a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a84e6282-b897-410b-b84f-ca6f5a36f7e5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf9659f1-72ef-4d5a-aff3-97797e00b912"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/691eda72-4ca0-42af-935d-3cda67f13c45">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee140925-7ae3-43ef-a9f0-186871652d5a"/>
    <dc:identifier>DB00973</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <rdfs:label>Ezetimibe</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc4be3a0-60a9-4a2b-b0e6-f0eeb07c4a5f">
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a45dd4f-4753-4bb5-a24a-e9f0dd6f707c">
        <dc:identifier>HP:0000867</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0f5a5ea-ae7a-4c75-a6a5-e4c9e78b45c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65bcfcf1-cfcd-4da1-9cc3-22cd15ac8f6e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd1ca159-3ece-4b7e-98e1-965e0c6f5817">
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:label>Renal rickets</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4aaefb7-6b47-4dec-ad3d-523cdd52150d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f75c42f-39f5-4deb-9c4f-07dc30101af5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e37fcf4-a78b-4c36-b2ab-024d9e866a59">
        <dc:identifier>HP:0002148</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:label>Hypophosphatemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/292798b9-a42e-4db7-8882-7c84a7aa4c59">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8499bb99-05dd-494f-a537-c64ac751bec0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f23a3d88-c689-4231-b3a3-68d188098f38"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6f2f4af-c77e-475e-ab9b-ab4ac4354f8f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
    <rdfs:label>Creatine</rdfs:label>
    <dc:identifier>DB00148</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a4bb43a-5bfc-43c1-b737-c8fde51c7363"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/381fee6e-9168-4747-ad38-c161a27ac452">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b9419c7-e335-4315-97cf-dc7c2c5062ba"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3da7bbd-5f96-4f1b-8b16-489766a46ce9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001992*</dc:identifier>
        <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d5cfd24-c755-49e9-a9a2-5f6d1f7fec56">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:label>decreased appetite</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28e3715c-b661-435f-a515-870c6e0b7296">
        <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b78d83ee-4e24-464f-9763-fb10091c02d8">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5020f1ce-6e52-44a9-af62-4490b6c28ddc">
        <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
        <dc:identifier>HP:0011990</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52ce1e19-3920-4ee3-a31a-ab5835f8585f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a6a7cec-c77d-44dd-8ee0-3f62db56cda0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f0fe96e-d1ba-489c-bd4c-6e4e8062856f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4aad6896-705a-40fd-bcc6-f4229e01b188"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13d0e302-fbd6-4abc-bfca-352c0a9f8627">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8a08a91-42fc-4769-9cad-da43791ca567">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a9e974-392b-43c3-ab95-c00759bdc7f5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfb45fd6-ddb7-427c-871d-ffde8bd97108"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69ca58cd-afd0-48da-8448-76f1943aeaea"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
    <dc:identifier>DB01345</dc:identifier>
    <rdfs:label>Potassium cation</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c5ec7eb-09c5-4ae2-a538-213b13e34e01">
    <dc:identifier>HP:0001072</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elbow skin thickening</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bbf376a-86f4-4f7c-999a-58c314bc4084">
    <rdfs:label>disability(Functional motor problems)*</rdfs:label>
    <dc:identifier>HP:0004302*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71bc571a-dc9b-42f2-9534-0d49762baab1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c27f3aca-96f5-4936-b90e-6344c359115c"/>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0eb28d6-41ae-41db-9bd8-f7c987fde6c5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec9eb8b4-edc0-42b2-bd00-f5c51ddfbd8d">
        <rdfs:label>Hypsarrhythmia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002521</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d07696c-d906-4e73-95c5-4f9fc3dfa298">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Organic aciduria</rdfs:label>
        <dc:identifier>HP:0001992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c486945a-43ff-40cc-94fa-0fe5fadd7d6f">
    <dc:identifier>DB00119</dc:identifier>
    <rdfs:label>Pyruvic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4acd7dab-339f-4f5d-b255-c00a368000cd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60d5c2ff-febc-465b-ab87-b04a8cf27785"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a65fd80d-555c-473d-be65-687aaba7056a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60d5c2ff-febc-465b-ab87-b04a8cf27785"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d648165-ac02-42b0-8e48-79ceb878dfc7"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ebc17c9-1047-40db-b888-1aa26985eeab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b57576c-d661-446a-b746-370431a166af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/204cb51b-93eb-42be-875e-4fa349a59681"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07436fd4-26e8-48a5-a505-b0e8654f1492">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21f59a6f-ff5b-481d-afe5-e9915078af28"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60d5c2ff-febc-465b-ab87-b04a8cf27785"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d648165-ac02-42b0-8e48-79ceb878dfc7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca71cea2-e6ba-472e-8607-5c76f47cafc0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ebc17c9-1047-40db-b888-1aa26985eeab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/204cb51b-93eb-42be-875e-4fa349a59681"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09895ff3-9fc7-48f3-b5de-91f7dabcc0ca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05731ba6-b8f8-48eb-9a0c-8e51cd5f19ed"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86dfe81c-43b5-4195-8512-7527dfdcd8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/919f6437-e1bb-46b4-8b99-f20e584e83fc">
        <dc:identifier>HP:0012350</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96eff01d-dfc7-4f40-a724-3fcf5b74508a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a69b3d6-714e-44d8-a0ab-e2112c0ce2bd"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6e57d0c-81f4-4882-8a36-4545a87a9bf4"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/940ea4b4-1e9b-4a47-8800-bf05ad0db202"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41c26996-ed20-4302-8db8-4f705ed62ea5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Psychiatric disturbance</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c58cacd0-8d54-4747-a6a6-2a848390094e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75536b14-c81d-4ad6-8d5e-cd395ab9aa4a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0855af40-00d6-4adc-8fae-798fbcebe659"/>
    <dc:identifier>DB00635</dc:identifier>
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd490efa-6835-48df-8c09-05ab4ec372ab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b9c90a8-13e9-4c53-9f46-8ff52c602daf"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f69358cf-db8f-4ff7-803b-26c899096763"/>
    <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb394e16-2975-4762-9fdb-12b18eefc530">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>osteopenia</rdfs:label>
    <dc:identifier>HP:0000938</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdae96c7-9066-4168-8807-609fb873d341">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ff8b182-61e4-438b-b8c5-163beed5da91">
        <dc:identifier>DB00994</dc:identifier>
        <rdfs:label>Neomycin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39efd029-162a-4bf5-9265-5262304814ad"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/287e5226-c324-4df0-8089-9403740646e1">
    <dc:identifier>HP:0000559</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corneal scar</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c8bccf20-bd94-42ba-a379-9f125938fc81">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13ee7af5-4b4a-420e-9a4e-6fbe7c908cc7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12c57789-f62c-48ed-ab4b-a439f3c08543"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/569e4cf3-f2f7-4aef-9b38-3fec185f80d3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235200"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f7763e17-fcac-4d44-a65c-8da1c647d768">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f4ee0b5-eb14-4df3-8a08-8fa77ca99ab7">
        <dc:identifier>HP:0001252</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscular hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01f1c99-481a-4691-a735-4b10e8c9c740"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85c97678-fdcf-454d-bbac-24defa125cf4">
        <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dcbc601-021d-4903-9ee2-715e0a8c7b5a"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ddcd9e8-4d57-4322-96ee-52fa5f92b09f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2636164c-4c95-43cb-ba8c-37298b9ffcfb">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfd26ee2-278d-47dc-b061-cf6922d18afa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87c4eaba-f203-49fe-8110-59a0932cc8e5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>sleep cycle disturbance</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70291b3d-57f9-4cb9-80d5-cca8e23a9237">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <dc:identifier>DB00149</dc:identifier>
    <rdfs:label>L-Leucine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5b9168f-2b1b-4376-a9c1-973a6ed01ee9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7def8136-c1ad-44e0-8704-4bb7e5d928b1">
    <rdfs:label>liver fibrosis progression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
    <dc:identifier>HP:0001395</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1aea3e1-9719-4217-b437-d3d06039fe0c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000821</dc:identifier>
    <rdfs:label>subclinical hypothyroidism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39fad675-a0f4-4adc-85f6-e62a9f100052">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1183b60-fd49-410b-bdf0-050166ab9283"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b83e41a-e1a3-4f24-b0d9-0fca7b5f5eea">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98694a33-1706-40ab-8242-a8f00d9b27a1"/>
        <dc:identifier>DB00165</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15b751c7-dcfa-4871-b10e-79d5c0e86cfd"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd0031fe-afd6-4dcd-a1e1-c26b22870eac"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c76b215-aeca-4aaa-866c-00ee1ef49182"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf63f88a-3640-4158-afc9-77a796f9f38c"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/659363f1-a65f-41d4-a6e0-710013ce2cb1"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83fa8ed6-08ec-4399-86af-d20a843cbbb1"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06bb532a-fc17-4ad7-9771-8623713e5fc1"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4e0b094-d59b-485e-aecf-dd9216768d69"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7fc78273-e352-43e2-b436-5eff0a5c986d"/>
        <rdfs:label>Pyridoxine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b11ac804-b260-4def-a3dc-f0388fbf0ef4"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15cb2915-6b58-4b1e-bcde-326ded487aca">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f805c3-c65f-4729-97c9-5177be52b18b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d8163ba-f201-4ad1-9213-fe26b7f59653">
        <dc:identifier>HP:0001507*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a818af43-53fb-42b6-933e-a30d8db6e7d2">
    <dc:identifier>HP:0000114</dc:identifier>
    <rdfs:label>Proximal tubular dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5dd4a39-fc7a-4baf-8d56-c1383f70efa9">
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8809b39f-0c26-4c78-8871-40fa8b5469b7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/865176d3-4111-4d86-ac51-3c479f4fa345">
    <rdfs:label>hemolytic anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
    <dc:identifier>HP:0001878</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81827fff-df34-4cf9-b87d-874a215852ad">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e49de1fc-aea6-4ca6-a49d-5ea7c5bc3250">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6eed1c29-763b-45f3-9a05-452f5983ac21"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00877d14-b63e-497e-9fa5-98b27a97350b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8585bfc2-d210-4ea0-98c1-e40447033bc0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/287e5226-c324-4df0-8089-9403740646e1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1daeb24b-a9b8-4c0c-a86b-e3159ca3e4b2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04ed5f10-3ec6-4ced-bcd6-6c46bf63532f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/316dd103-f03d-4a8a-bcd0-fe7af11bb212"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28e5bd10-1fcb-4356-8ba5-c71acdbaa7c1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1d8b0f6-699c-4116-96c6-2926cfe63113"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c99c820e-b9b5-45c9-99d4-e4eb2966aed0"/>
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b22705ad-d5cc-4180-b30b-659cbcc65c2a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low endurance</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc98c87a-13bb-4601-9970-0fdc045bd147">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003679</dc:identifier>
        <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19b409b6-70e3-4b6b-a69a-7e73bff334d2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e731e8a-65fe-430b-aa51-5f8fa1f0449a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c028caed-1df0-4f80-833f-fd7886f6257d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/945460f9-da22-44dd-81a0-00ef9f32293c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2da01b85-724c-43f7-b92d-93ac1eb1fb94"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7e7fc32-6044-463f-b109-15eafad7b2ee"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ea467d2-66f0-4fd8-924e-9538512160a8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
    <rdfs:label>abnormal central vision</rdfs:label>
    <dc:identifier>HP:0000504</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a160fb7a-7ce9-415b-9f69-44de91315f0f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/169c3186-fbc6-429c-a79d-36865fcd35d9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8c8e3ec5-5e47-4bbf-81d7-639beb7371bf"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4bc1eacf-2821-4af6-969f-92900d0ec02b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b15f2330-b7da-44fe-8f33-bd92c656aac2">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4372b794-dbab-4cac-9abe-9cd78c7c9b57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2dc081e6-79f2-49d8-a9c2-e597e1e3632c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67bea59e-ef85-45c4-9a1b-d9e2c49189c2">
        <dc:identifier>HP:0012379</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91b011df-a7c3-4b4b-98ce-33e347ccb94a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Tonic-clonic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <dc:identifier>HP:0002069</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c730c88-9342-4e81-9f8e-4071bb19491b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31d815eb-c44f-4464-8ad3-27bcf1d279ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7019700f-300a-4635-b29a-3185b2391b43">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
        <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
        <dc:identifier>HP:0011999*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa195438-a1ee-4411-96ad-5e586cc1c506"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14bc6cb6-d52a-4d17-b3a9-eeea951b4621">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
        <dc:identifier>HP:0008765</dc:identifier>
        <rdfs:label>Auditory hallucinations</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
    <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0255dbbc-19f7-451f-85f8-76e1498d388a"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
    <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c12a9de4-73a6-4bea-b168-de4427a5e0df">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ce34bff-5508-4e92-a38f-13336160b1b9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <rdfs:label>Tocilizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e33d50cb-5aad-4304-93b1-1d3069a66eee"/>
    <dc:identifier>DB06273</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8efcf638-5dc8-452a-b378-3f1eab54cdbb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008281</dc:identifier>
    <rdfs:label>Acute hyperammonemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c65a8638-6b0b-49a6-8eaa-b9b76188d0d4">
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd14b746-d4a1-4b85-b066-17d2aeffd917">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cebd5565-b41f-4626-bc51-5cd8b0e4e84e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58d9dcdb-064e-4e93-8f15-531c802b0b37">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e696ef3-de73-4b8c-b312-adb02c26bc0b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3abe50a-04a8-42c6-9257-d76e2e1e522c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01323</dc:identifier>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a69decfb-983f-4ef8-b6da-3a6bb3ddeb66">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acc672ea-895a-4229-973b-722b292bd141">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90fbbf6f-ae6c-40f0-b796-7dcf80482958"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/031ac516-232e-4230-a7f1-e31f0b432524">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2ab7bb5-21f1-4650-a7e0-eb94bf3d65ca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2474e7c4-a0d0-47fa-a423-2e1fb60c364c">
        <rdfs:label>High blood ammonia levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/912d3b00-631e-4f48-b6f6-b31231bfa80c">
    <dc:identifier>CHEBI_23456</dc:identifier>
    <rdfs:label>cyclodextrins</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c82fc0c9-11a5-4989-8f02-618a8c61c856"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcc2c7a4-5547-40c3-9178-bd921d18b22a">
    <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa773322-bc14-4705-bea9-fbfcbe6512ae">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28b789ae-53f8-4bb1-bdfb-c34f81f0536f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50445b6b-5c66-498e-8351-c8c3dea4ed89"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
    <dc:identifier>DB09449</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/832c5975-b783-4c26-a5ac-b70cfd269473">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a7fc9cb-50f6-46d9-b2ff-89165c2fea00">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <dc:identifier>HP:0010472*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/671ccebc-7409-45ca-909c-28c9337671d1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48b18ae4-d7b9-43bb-a814-e9f80c90a17a">
    <rdfs:label>Deferasirox</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2276bd9-0df0-44f3-9442-1ac8bf50ce68">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cd6c08e-ee82-4578-95c7-4c67ec763f1a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf25312c-f632-441d-9b3f-560d9975d62c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/025e301a-c0d4-4ff9-b9f0-62965bdd2ded"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01609</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/161b6bec-5745-4f80-8836-97f1e01d0b13">
    <dc:identifier>HP:0002180</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d94e6eb1-7470-4434-affb-349390bb35ba">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3a0567a-9d1a-47a9-821b-0fe122b0ae44"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/628d782b-659c-4378-9ad6-642c40e5a0d5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a70446bd-ee38-4f2b-a132-c419913f9c20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:label>astatic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f34a7a5c-dff5-4d22-86ed-fb0ab1e084d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90fbbf6f-ae6c-40f0-b796-7dcf80482958"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49885e94-bca0-4390-979b-cf4d63ee99a3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>Impaired social interaction</rdfs:label>
        <dc:identifier>HP:0000735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d936780f-2675-4324-9c46-c2118a9978dd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fe8d9f9-8ddc-4596-98fd-c8a97013a7a8"/>
    <rdfs:label>high protein diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/acef3410-2422-4a8b-9784-b5bed1a86abe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a7f034f-2c3c-4e59-8ba8-9f9b7e964af6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f5866814-8cf1-4ea0-91b5-bc868d7bcae2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cdd44d0-ef9e-422e-8d24-b3b27ddc6e5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d16c891-2645-4faa-bb7e-33bf797dbae0"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/835854c7-640a-4d82-abfe-deb42c53c2d6">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:label>skin inflammation</rdfs:label>
    <dc:identifier>HP:0011123</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e30a5e4-4422-47d1-81c4-c30db3021f7a">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d361c11-7a0d-4d98-a144-93d5c562dbdf">
        <rdfs:label>Diabetes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3e9e314-0b72-4074-82b5-bc43a6c8a5e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eed0a5ed-d12e-47e4-8545-b6269ec6f94f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db8cd4d0-5fa6-4ed0-a5ae-144e21c80edd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ef340b4-d008-41fa-b831-9b45f6600ef9">
    <rdfs:label>Salbutamol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
    <dc:identifier>DB01001</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d5b06d2-d314-4b11-bf11-08be0dce5cd4"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f95daec6-8447-4153-bb12-67e4f7e2f002">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7407d2fa-50f9-43aa-a162-f4476a91a54c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>orthostatic hypotension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
        <dc:identifier>HP:0001278</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa2b9464-6b0e-45e2-81cf-a71628f71a0e"/>
        <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
        <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9abefff-9ae3-4594-b3d1-afa6c751fab8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24c8a93e-94d1-42d1-b564-894e464a3840"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29607b75-f123-4b93-bb65-aabb59641af4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/524783fb-6488-4c15-84ab-526dcdc64d0c"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07061b84-5d81-4387-be1e-9b951b66c212">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b75b02b-6958-40bb-aade-dfcc79b66362">
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
        <dc:identifier>HP:0025454*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0daa9fb0-2078-46ad-bc49-116e24ae48e4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low 5-MTHF level</rdfs:label>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/016503f4-7cfe-43bc-8b21-1a3867b99aab"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c3c9746-fa31-40ca-be3d-11ae2a32281a">
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001980</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ee1078f-89ed-49c1-8a3e-66611efb6214">
        <dc:identifier>HP:0040087</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:label>Low total RBC folate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c587bcb-e2d3-4e84-8faf-450939d5529d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe00d0b5-1a2e-4b60-8898-1317578e0d8f">
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001958</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52215489-f291-485a-9dc3-e12a1ceae63b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98e5990f-5e1b-47d0-af50-6ad46ba12dce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cbd5c74a-1fc7-4489-b2d1-8f91c5a63aa7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6aa07c5-6dc5-4fd3-af99-f7505bb7f456"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f4f9d61-402b-4742-be16-ad59962bf620"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6917c5f-2dd2-453a-80b0-6c92fa24a851">
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8612652-1d68-41f4-81e7-7391cfcad695"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8049b76e-6529-448d-8a01-939c27bb5952">
        <rdfs:label>gouty arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
        <dc:identifier>HP:0001997</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446fb2da-5eb8-4475-850e-1ad7ac5e3b92"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8aac63a3-0475-4ce7-b9d1-14b8e1b87e6a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bac6c13a-705f-4f0d-9ce0-22cb53f8189c"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48842987-df48-4529-8e9c-df1dde7e0ce5">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25e7a62c-6055-453b-b3f2-e478fdbac87c">
        <dc:identifier>HP:0003737</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4181a85a-96dc-40db-ad29-5a2a097d239e">
        <dc:identifier>HP:0003473</dc:identifier>
        <rdfs:label>Low energy level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4782b422-8964-42ab-8a49-1a064644f898">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88db5c65-2a9c-496b-90cc-ec9f226d2aa2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95746253-7a13-4b14-97ac-e2943c114f66"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08ad472f-c681-44e3-bd6a-3d2727c3fe39">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <dc:identifier>DB00502</dc:identifier>
    <rdfs:label>Haloperidol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07aba146-de30-4eca-87a5-81d1e8f5250e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcf0e02b-3551-4429-98a6-629db620d0c1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f4a5aef-49fc-4bad-a5da-9d21a4b94048"/>
    <dc:identifier>DB00437</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03e0dfb8-a3c8-4c9f-86b0-de0092966ee3"/>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6917c5f-2dd2-453a-80b0-6c92fa24a851"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f5d7e04b-f590-4d5d-ac3f-f96ee3257a88">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446fb2da-5eb8-4475-850e-1ad7ac5e3b92"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae98838b-979f-4cb9-9976-64a7ee5173b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2be51b2-a1a3-4570-b032-3c55e48d68c1">
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
    <dc:identifier>CHEBI_113373</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84e7dc44-56e6-404e-98ff-93ce02e5baf9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce360ea8-4e0b-4346-9f35-b50dfdd85aac">
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26c6502a-2c59-4b84-a0f6-425afb85e167">
    <rdfs:label>Behavioral abnormality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40c7f27f-0ebc-47b5-84b6-08dc17811563">
    <rdfs:label>hypoglycemic seizures</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002173</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/65826de0-884c-4aed-8761-a62466fd0872"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab9f11d3-6f80-4ff7-97ad-b4910c2b466f">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec41786d-48df-410d-a252-c5dc2e92d915"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6a01ca6-71af-4994-96b4-9b7f38121888">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac355a8d-517d-4010-9a01-10c5d5fed10e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/459a7162-30f3-401d-8f2a-a6a200b3d3e0">
    <rdfs:label>nervous system abnormalities</rdfs:label>
    <dc:identifier>HP:0002011</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd85097e-cce6-4f0b-8f7b-ba92d3437219">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e247dd4-f26c-4ef0-96cd-5ab4b0bc37b0"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/564027ad-7d7d-4451-ac37-c2141cea41ea">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9dcfd31-ba5e-47d0-99b5-24b00ff4ee25"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/046ca689-abbd-4608-bcf3-f8f09c950178"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/811199cc-af2e-4781-a11c-cffe945b05ae"/>
    <dc:identifier>DB06819</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cdf0b2f0-5974-4eee-8caf-61b6b3d951c6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c9fd8a3-9d2a-493d-9754-29038f193cbf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2872e133-5a4e-4a69-b362-4b17829ed962"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97757479-4e97-4aa2-9b12-070706a8e222">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <dc:identifier>HP:0010535*</dc:identifier>
        <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/335db802-e847-45aa-9227-3ce833a9e014">
        <rdfs:label>Six Minute Walk Test</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8011c79-2a6b-4a3f-89ad-ddb9fa3cd45a">
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdfaae56-56eb-4a5c-89df-63bfc3f9a5ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f9c27f-17a8-4f01-be2a-2aa7fa1cf4a9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c12faf75-cf0d-4c69-af6d-0185b5a96fa1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6c09bac-5e58-418d-a66a-91f9dabd3a43">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High blood ammonia level</rdfs:label>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d61a7c79-9e2a-49ea-b2a5-606d185dc8a9">
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:label>High plasma citrulline levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c44c4af8-c7da-4092-a2f4-797cff7af16d">
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bbcd30b-11e1-44d4-966b-a6e6697ebb57">
        <dc:identifier>HP:0001298*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91644163-e98a-490f-804f-ba49fdcdf92d">
    <dc:identifier>DB00421</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <rdfs:label>Spironolactone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ef9182e-53a7-4d00-9b0a-e8f3a2c7929a"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45d5459e-946f-4381-a9c3-a2fd936a53d7"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e663c1a1-7f51-4a09-973e-c4d091b58c76">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4befa089-60ab-416f-8088-b2fcdd7867d4"/>
    <rdfs:label>Laronidase</rdfs:label>
    <dc:identifier>DB00090</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdf0b2f0-5974-4eee-8caf-61b6b3d951c6"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8dcdacf-aaa4-4b53-8ea6-f6a9522bad6f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b20faa7-086b-4d0e-b5d6-764e31a4bf5f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a320375-b2d8-4c57-8530-277e90bd3396">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/471d5cd8-4580-4bef-8d71-c1cb99a0693d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2673a1f2-abca-40f7-b505-e4c9a9b14d6b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b9ba20e-b09f-44bb-9530-330524ef5f9d">
        <rdfs:label>Myoclonic epilepsy</rdfs:label>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/513698a7-b6d3-4e48-88e1-7d70f3537552">
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04faef2d-daaa-448b-8b58-3ffd5397b81a"/>
    <dc:identifier>DB03227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50d3ea7d-f419-40bb-80b8-abdb6d0a2c7b">
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0009051</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48724972-c899-4e6b-9009-d8c96165ab10">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9007709f-9aed-4860-94cc-ef72b4165ff8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aab3c17d-3981-4fb8-8acf-0bce9596dc4e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4f424bd-e886-4fc9-abad-544a23c52111">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
        <dc:identifier>HP:0000725</dc:identifier>
        <rdfs:label>psychotic  disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73909640-5a28-4933-8d89-e22541729452">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45581993-90bc-4711-bb6d-b85c1e28c209">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69564c20-16eb-42a1-bfe0-f180fd4b9dcc"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7277dcdb-6a1e-449a-85e2-94d35cc88186"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7763e17-fcac-4d44-a65c-8da1c647d768"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e30e521-aa01-4bac-843c-a7980ef73978"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a07a94b-3101-45ee-802d-06c0520e8da6">
        <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ddcd9e8-4d57-4322-96ee-52fa5f92b09f"/>
        <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/86456108-8cba-47e1-8527-296b62ae8aa6">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ddcd9e8-4d57-4322-96ee-52fa5f92b09f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73381535-fab1-401f-be8d-ebe8f1fbbabd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26c6502a-2c59-4b84-a0f6-425afb85e167"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/515c1833-7328-4aa8-abe7-c3eed082baf5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Sapropterin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dce2522f-e77d-43dd-bb7b-e220c95e8331"/>
    <dc:identifier>DB00360</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf12df5d-5675-4125-bae0-30860b2517f7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/706aeebf-c89b-4ef7-b309-82d7723efd8a"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8a60a37-fe40-402a-9612-337e8cafd86f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7db2fae-b55b-4367-b418-0106aae39f00">
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:label>depletion of cerebral folate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7812242f-40ae-4cb9-9b1a-2e9dd9f26c64"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c95bf6-5e75-4064-b25b-0c69bbc6a9b3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b8fc0e3-a39d-4e8f-b9f3-a1f9d7418878">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c6dbcb6-7a73-436b-88e2-178cfeb32ae6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>spastic bladder</rdfs:label>
        <dc:identifier>HP:0005340</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98e5990f-5e1b-47d0-af50-6ad46ba12dce"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/faf9b19a-8a75-4a5f-b69e-1994d408a61d">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1ac3a26-582b-4a30-a11f-8243e83d19d4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sulfide toxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52dcdb86-2743-40e7-9389-af3d9e40e314">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/afdc22e4-2e80-4319-8045-fdf35024ce07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd3121a0-4abf-4f72-93e5-b3a147a355de">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7223243e-637f-4f67-b047-8a655d25e992"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/438e274d-63a9-422f-a179-ec65c4a77572"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a2e2d4ca-fd8b-4f41-b770-623a4c296acc">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65b76c83-4d60-488a-aa4a-43f71f8bd45d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bea14ad-7758-4c5e-acce-d3e1fcb9905d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30268d44-7aad-49ba-9ab7-e8e073b6ee46">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74e7564e-1070-4f20-80cc-badfb7918231"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3d9ccfe-46fe-4b7a-a4f4-e5ba47ecda72">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f95f9b9b-a7c0-4be6-a237-e3d20c99f55f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b34c87f-3cbe-41ba-a39e-044808c339cc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d405d7a-b0bc-4a88-a647-a94225aeffcc">
        <rdfs:label>Fluid retention</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac7a5e0c-de0d-462a-9d42-6df4cd730fef"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c64b8e8-42ad-4c50-b9a8-b2b043a0e499">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Photosenstivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/006e3cdc-2b14-46df-b755-16aee11a4129"/>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e89b286-862a-4cf8-83bd-b45127ba7611"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8559a22-b22a-48de-ae4a-8d05df8561ff">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
    <dc:identifier>HP:0002900</dc:identifier>
    <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/485df016-cfdc-459f-8de6-ba1cd8c9c57c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98e5990f-5e1b-47d0-af50-6ad46ba12dce"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a70082c0-b34e-4cbc-bf48-efce7b311879"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3629549d-c964-4945-8648-acd4fc73fcf9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf9659f1-72ef-4d5a-aff3-97797e00b912"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e55702af-6f0c-4210-b3b7-11104caa6fd3"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/244889db-a747-4aad-b1c5-8abe1239536a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c544b888-9106-4b57-bcc7-87ab934691cb">
        <dc:identifier>DB00682</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
        <rdfs:label>Warfarin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/564b22f2-1ef3-46d6-acc8-fc02769265b2"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b60692f8-2c08-4648-bb56-0673802be396">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf85bf73-d53e-4d28-8edb-9d8b18d60f35"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/381fee6e-9168-4747-ad38-c161a27ac452"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <dc:identifier>DB06151</dc:identifier>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abd36f5f-2828-4e76-87aa-42c23cd34a00">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b89cb7-249e-4a31-a9f4-2b26d88b0e39"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3308fee1-903e-4451-9775-e876a782a1e5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/187bf468-bb4f-468b-8ec6-2941531d4975"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fa3ecd6-6252-4174-8b71-c921ebc454d1">
    <dc:identifier>DB00672</dc:identifier>
    <rdfs:label>Chlorpropamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ed0ca75-69a6-4e04-9f5c-071e7c973371"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c866599a-4433-49ac-9324-044025edab46">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a932a00e-0b34-43a4-a4a0-57f5d31653fd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <rdfs:label>Nifedipine</rdfs:label>
    <dc:identifier>DB01115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2dc081e6-79f2-49d8-a9c2-e597e1e3632c">
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b15f2330-b7da-44fe-8f33-bd92c656aac2"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8636d8a-ce3d-407d-9f49-8a1f641ff518">
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a59cd01-7e96-453f-9014-6bb0f98b960d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbc1ec85-50c6-4ae6-86ae-550e06d8fa69"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/998af4ad-8265-4881-b11c-a650952fb315"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f03c9cc0-8b3d-4688-8cfa-d93dfcb04cf1">
    <dc:identifier>B01A</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c740ecf-9713-48b3-8461-5c6d8afcd266"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38abf2c6-3dca-4858-8156-bc0c5c41fc5b">
    <dc:identifier>HP:0002910</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1f5a8b1b-530f-47e0-ad3f-1cc40b64106f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91b011df-a7c3-4b4b-98ce-33e347ccb94a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0103386b-ff8e-472a-bfa3-9afe90bdb720">
        <rdfs:label>Low quality of life</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19ae7b48-98fa-4e37-a39b-38b1949153e3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca0883c6-ce4f-4ba2-a490-4597b39e5615"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3de10ae-03e7-44f5-ab65-d367f4c232eb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0eb28d6-41ae-41db-9bd8-f7c987fde6c5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/516289e8-eb35-41d9-9659-ac248621f72e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7211dcf-f87d-427c-85c9-fe14c720eeb4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b800509b-848b-4007-8eac-57b8ad0c2f39"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <rdfs:label>Cysteamine</rdfs:label>
    <dc:identifier>DB00847</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d146bf68-092c-460c-8262-4da97d5c92e3">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b0a3728-f688-4ba0-8a80-9cd2be9da7b3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf61ac8e-5984-4012-b2ac-9ad487176069"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90067478-670c-4774-b903-59db69082df4"/>
        <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dcc3238-8297-45f9-9da0-9ee695579116"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41234743-0b95-4c21-93aa-5e3cc82e8c18"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28bfc288-4fcf-46c2-ac1c-2ec5007905a0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c69f7b7c-84cc-404c-bc8d-60d4e460dcb8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb91827a-377f-45c6-9cca-5a6314dd5146"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd93e3db-d3ea-4128-a7f5-b492ec6e7c16"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d15e818-c04d-4584-9f2c-391e31fc39ee"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d68469e6-7a03-4511-b44b-a9f57b61784a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b082a2f-8067-4e3d-9fa9-89f44591a73a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/141475db-0b45-49f9-ac1c-adccc7d128ca"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39655172-4381-4770-b4f4-528a5ad2f737">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d68469e6-7a03-4511-b44b-a9f57b61784a"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14359074-ca7c-4b71-8dca-dd3160901740"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bccd6b8c-e08e-43cd-84f4-b304cb3e77b2">
    <dc:identifier>DB00988</dc:identifier>
    <rdfs:label>Dopamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ecbc16a-0e04-404f-9e9c-8795d6da5dda"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bebc4b53-7987-4467-ad5c-1bf801545cbd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c6aac1f-dc87-41df-817b-b3950d948d1a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbf20eb0-8a6f-4ff6-960a-5728c7625c25"/>
    <dc:identifier>DB01151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <rdfs:label>Desipramine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69a27a3d-b2f9-4c1e-b188-65b92339998f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e176354-3844-41a7-bee0-59efdcf984c6"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36cde40c-6ef3-4513-bf24-c4ef8366b8c8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
        <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/725fe9a1-8890-4c79-9a61-48f4f6e11d22"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d307bcb-4e6b-4842-aa9b-b6e2e92867d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec7dc442-4f40-4cdd-bed4-57b0c49b6181"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66a9e4d6-4379-4919-b3ec-01fdda565834">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d689b43-1b3a-4aea-b50a-dab39424504b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6567c8c3-1735-4dd1-940d-0730ce92edeb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0944278-f447-4dd3-b5de-527b8b1d1f06">
        <dc:identifier>HP:0000486</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
        <rdfs:label>strabismus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a12cf1c-5879-4683-aea6-502456f80f4f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c679220-e46f-4a61-bfa1-f2752980e63f"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a4fd3c4-0818-429b-9bcc-8786381f1cc5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9abf6938-7759-4643-b29d-137483818920"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cf500f1-d74c-4970-b913-50e81b1dfa1e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d40a2e60-0e3b-4769-9832-84cfe8c2997a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9416568f-d6d4-488e-84c8-7a1c96b64133"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07549b49-9d14-4da6-9513-3716bf04ea86">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d004379-51f4-46ce-b689-5037c5f82c11">
        <dc:identifier>DB00311</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb711c45-c12a-4f25-a1fc-8dada47c32c3"/>
        <rdfs:label>Ethoxzolamide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72082906-ef37-4df7-9234-092f60afb7b9">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c37e93c-ce73-44db-afca-50f90675b479">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81a38f9e-fdb4-4a4e-a52a-6a53c614b5ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79123b04-92ac-4dc3-9003-e88003335677"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/37468af9-ef06-4431-9a72-c6491339a635">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cc54cf1-e391-4f89-869a-3a7871e7f829"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b288189-92ea-4406-9baf-325de2393560"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79d81cd7-1089-4714-bd99-97157ddc825c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8583517a-5581-4c10-8ae8-6720a1cc599d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76777d5b-1f5d-4b10-8260-3213f1003e7b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3f19c28-167f-4fe1-aa46-a6be185bb621"/>
    <rdfs:label>Amiloride</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <dc:identifier>DB00594</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e36d75ce-cae6-4b0e-975f-782943689075">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbfa1806-fbd7-48da-baf1-bd66f83e9e49"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0d68be4-e5a4-43a8-84f3-3cfc7b4abb02"/>
    <rdfs:label>L-Lysine</rdfs:label>
    <dc:identifier>DB00123</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95f38ade-109a-46d2-8bfc-ab253b86a7a4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aee82436-803d-4edd-8842-caec6f0d219a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c491f7c-d8b4-4b02-b5f3-7ff510411d43"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2083499-cff0-4611-ae73-691d1185bbab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c085a008-8591-4ae9-ae1c-862b466a893e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95746253-7a13-4b14-97ac-e2943c114f66"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22afd365-4d65-4962-93f6-567b425ff9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33898bde-0dcb-451d-bda9-9be660f19d28"/>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28ae6205-80ef-44bc-bad8-e8ffe225bc73">
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03ab9a80-d0cb-48c4-9263-a622733931e5"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed93eba0-e4e0-4865-91f7-c59b4c7b8271">
        <rdfs:label>Low AGA activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e2ab542-2118-46e5-b0c6-7bf035720c5d">
    <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
    <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>done</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60ec4ac2-559b-4afb-a82a-395ef099978a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec69890a-61a2-4f25-afce-077744e2c241">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/71e57775-893f-4e4c-9277-759bbdb4c855"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51551123-4f97-4766-8be6-4c7bfdf7006e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <dc:identifier>DB14307</dc:identifier>
    <rdfs:label>Green tea leaf</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1364c89c-03f2-4aa8-aebf-104a1d691083">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>photosensitivity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/546270cc-4ea4-402b-9a65-9fdf010645e8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87cdd016-25e7-471e-ba7e-113e184706d2"/>
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <dc:identifier>DB04729</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c2c6cc3-b5e1-419d-932f-d2ca69017a16">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cc54cf1-e391-4f89-869a-3a7871e7f829"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81462629-ca31-4ed5-b474-7a7332a3653d">
        <rdfs:label>Osteopenia</rdfs:label>
        <dc:identifier>HP:0000938</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6972c96b-8570-4e18-b9ef-e261632c2969">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e888b344-b549-4a68-b470-8eaecaeb1c60"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dcbc601-021d-4903-9ee2-715e0a8c7b5a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4feb137-00c5-45f0-8185-eaa9bcc6684b">
    <rdfs:label>Selenium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a160fb7a-7ce9-415b-9f69-44de91315f0f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <dc:identifier>DB11135</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3596b3bf-6a91-4bc7-b381-9f06289fa436">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22c097c4-ff21-4828-bd8c-e994819f5cd6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b733351-7fc0-44c8-98e7-412fdf6dff4c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e679232a-bb47-4c4d-9c88-a6d221a2f01b">
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum iron</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc1a1885-4c21-48b9-bfb3-257365c8ee4d">
    <rdfs:label>Limb muscle weakness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
    <dc:identifier>HP:0003690</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5693136-ce4f-4a56-95fc-e9d0113557ee">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96bdf2fc-4870-41c7-a0cf-7a5bd8f49366"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1de2543-5902-4a5f-97d5-6bad8c6f6589">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/641e4248-b2aa-41ef-b86a-2a92404b90a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57cc3ecf-32e4-4042-bf43-48809c0e3c29">
        <rdfs:label>Amenorrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2a50c95d-c49f-4847-bff4-a084df788c0f"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
    <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f36c6682-cd1f-427d-a495-129c3e9f4a30">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f35efe8b-0de6-4774-9886-55e2807ef884">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:label>Diabetes mellitus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3e9e314-0b72-4074-82b5-bc43a6c8a5e5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7548d017-0519-4ef2-be66-fc99c0068bad">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c12faf75-cf0d-4c69-af6d-0185b5a96fa1"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fb704cd-1413-4227-9c65-9918a44dc1f5"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/476094ea-f866-4edb-979a-8b1755584a77">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f326d01b-f9cb-43ac-bf3e-871e71d7127a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0cc5f94-54eb-42f4-9673-8f2cc21d95a6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c870fc39-2488-41a1-863e-f5d93d106744"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/865176d3-4111-4d86-ac51-3c479f4fa345"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78bb5fdb-63b9-4d5a-b819-1b361d407870"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ec3f482-de06-4560-9a02-c2d89673c8ee"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6972c96b-8570-4e18-b9ef-e261632c2969"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29ea734c-fc1a-4616-8d22-956f9e3cb3ab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28e5bd10-1fcb-4356-8ba5-c71acdbaa7c1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7fdb75af-418a-4178-8391-e66339b77cae"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a5b56b6-8a2c-4d28-afdb-c4079743dc31"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b83c3894-0851-43b9-98fe-bb9e9e3aa8fe">
    <dc:identifier>DB00005</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3417629-19ec-4851-9441-ed4e3df6f273"/>
    <rdfs:label>Etanercept</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43ee5b14-53d5-4b31-aff8-59ae623811cd">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/16347e82-d4d7-49d0-9ea9-d3cc8f02004f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33805570-c85f-4627-bd99-5c5b820de4be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/919f4dce-012c-464c-99b0-9e10421919b8">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f421c6c6-00c4-4eff-a5ff-5b7f030d84f2">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1e64f32-77a5-4a07-ae2b-931470f8511a"/>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51386873-76b8-437c-ae83-0b32a5dfbbf0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Lovastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc6fdfa5-6901-4534-9f26-1aef9f59b32a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a54f58b0-4e3f-41fa-9452-7cdebb227497"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b320c7c-e158-4a09-80e5-4da5556652ae">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06a9e9f2-9db4-4e8d-8c59-f56a75e970e8">
        <rdfs:label>low phosphate reabsorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
        <dc:identifier>HP:0000117</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47c83625-323b-477f-9f3c-cf99e1f8c402">
        <rdfs:label>retarded growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb923834-b921-4d6f-8ba9-46c170c1ef2e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d26c5b7a-40f3-4da2-8703-ce682c7d900b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ef9182e-53a7-4d00-9b0a-e8f3a2c7929a"/>
    <dc:identifier>DB14500</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <rdfs:label>Potassium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd66d408-2c2e-4f94-873b-16e2a1369905"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63b1382d-15da-46ce-acc0-15e82716a845">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d1fd1a7-c154-4ff5-8ef5-35ecf0451348"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb619e3d-6d5b-474b-9b95-0cfe453fa8a5"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5ca8006-7e5d-47f8-8afd-d1e83f8cd583">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4cfe80e9-575a-4629-8bd2-12ca29001735"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
    <dc:identifier>N05A</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4e0b094-d59b-485e-aecf-dd9216768d69">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc456c7e-1143-41a4-a17a-1b600897613a"/>
        <rdfs:label>CYSTATHIONINURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
        <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee59013d-42f0-44a0-955d-b865a5c148b4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High total homocysteine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e0722f5-f2fc-42cb-bcb2-f5100bac5eb1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cda51d29-744f-4883-95f8-a1690de5c6ae"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/afe3b496-bb4f-40fc-99f2-2bb5e9521895"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0eb28d6-41ae-41db-9bd8-f7c987fde6c5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b04be452-5362-43a0-941f-167f94504958">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/827e0191-1f04-4caa-aa8d-2856819cc301"/>
    <rdfs:label>rAAV-PPCR</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d508b6b4-20c3-4ab2-a4ba-af0bac209b0b">
    <dc:identifier>HP:0010836*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78a35622-f97a-444c-8486-3f2def76dd35">
    <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f2a3426-8ee4-47e2-98fc-4c1996c48b08">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c96d2a1-236c-4f8d-81a5-305e223e1e48"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1a10a23e-f90d-49d0-bde8-1cdd58c929c8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a12ef831-e7f6-4296-9409-b7c96f15fea0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <dc:identifier>DB12528</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4a1cd99-1300-4129-9ccf-aba4b80bbde0">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2aba941-eab6-4dfb-b9ea-aab24c631240"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78a35622-f97a-444c-8486-3f2def76dd35"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1b9f09d-3979-40c3-b89f-ab653a8befdd"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1b04e96-cbfb-49d8-aa47-964fbe8ab338"/>
        <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89ae5f0b-11a3-463e-b843-de2c67428de3">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f21e3c81-d695-4882-b179-50bc71a6c9df"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52ae6c5d-6693-464c-83df-627af25e278a"/>
    <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
    <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a6a7cec-c77d-44dd-8ee0-3f62db56cda0">
    <dc:identifier>DB02745</dc:identifier>
    <rdfs:label>Uridine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b78d83ee-4e24-464f-9763-fb10091c02d8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67595074-dc72-404b-9e14-45b8798e3d24">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/979b0600-23f0-4d6c-ba40-7ddf45645c7e"/>
    <rdfs:label>rhPBGD</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d821f3-8b0f-4602-8c9a-391862fbf74a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:label>High urinary malonic acid</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6e130d9-f5fb-44db-8179-a5fe3b51a3ab">
    <dc:identifier>HP:0000488</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d4df0a3-12e6-42af-bfb9-b01c4636f2e1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ecdb07b-fe91-4d56-80a1-2c3228762531"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76777d5b-1f5d-4b10-8260-3213f1003e7b"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1f30f22-7be2-4ff1-8ffb-c3102daf4098">
        <dc:identifier>(DB00328</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3f19c28-167f-4fe1-aa46-a6be185bb621"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/849de8db-702f-4b30-a4e3-e31925a0f66e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/229eaba7-60cc-4749-9d62-04fcadff94b7"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3993dd9b-f792-438e-9f08-f700f5536beb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d62427ad-9475-468a-9f2a-e48e3330e056">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7edfaff-e613-4534-95bd-33fa73a37670">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
        <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
        <dc:identifier>S01BC</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f284be3c-5c6c-4425-a941-50b4a2743489"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d353687-1469-4c75-a0a4-c80231a98a27">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06878631-6cee-4ec3-905b-ba014f8ab079"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f3ffff3-c11f-488e-8e4d-8f873ee1b61e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfaf437c-4541-4644-a643-ee387bf51d04"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96bdf2fc-4870-41c7-a0cf-7a5bd8f49366"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00624</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ef716f2-afce-4c29-aafd-2851cf40db1c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ad0e8a1-22fb-4f6f-b1b6-c86dbc5771bc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfaf437c-4541-4644-a643-ee387bf51d04"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3b9c50e-4b73-463f-9c26-6ad04cc0afda"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/906a3fe4-e220-4909-a42f-eeaa20fba5c9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <rdfs:label>Testosterone</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a96cfd45-3af9-45d1-b0d0-0ea9b1b1c373">
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f34a7a5c-dff5-4d22-86ed-fb0ab1e084d5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/757a242a-aa8b-48bd-a693-5218d4156767">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4c0f73a-a137-4880-8016-4e5afdee44c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3f0df50-93ee-4fb2-bc2b-c759c87f070e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22fdcade-45f5-464b-95a4-4eda1fb24f10">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f58276c7-5d32-45b4-aae6-3cbb736e74b2"/>
        <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f75c42f-39f5-4deb-9c4f-07dc30101af5">
    <dc:identifier>DB00136</dc:identifier>
    <rdfs:label>Calcitriol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc4be3a0-60a9-4a2b-b0e6-f0eeb07c4a5f"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df3adb71-c14f-4244-900d-1b52118b4477">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9dc81179-9cd5-4d4d-b027-ddcc7963e128">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0776697a-0eef-4f85-b9c9-2ef28f0d1ae7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/696f6b33-e684-4aac-8297-fd7139e14b72">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscle strenght</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91f29959-ff80-46a1-86e6-1c9c4d28aa49">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
        <rdfs:label>Muscle atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003797</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f2de4ff-1462-4964-9da8-34c6b10fb3a5">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e2ab542-2118-46e5-b0c6-7bf035720c5d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/94ebb6ad-f1cf-4879-aa1f-96b0aceb4e2b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5db76761-44af-457f-9a15-5ec9629aba5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/81814922-e5c8-4da1-9901-780c93ee314f"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6796b752-c08e-4f42-8f2e-27378cda9cf6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96eff01d-dfc7-4f40-a724-3fcf5b74508a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29e08cd8-a281-4ed3-84af-5985e1e3f915"/>
    <rdfs:label>Brexanolone</rdfs:label>
    <dc:identifier>DB11859</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c547fc4f-3587-41b8-83f6-a4b062c0d967">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/563d9e2e-27d4-457a-9425-447c8ac15ffb"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/608515ae-6465-455a-b259-d17fa786abac"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91e974e3-2a7a-4c6d-9993-82f681d64464"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2dcac369-c75e-4fb1-8cba-6e22b4b3df26">
    <rdfs:label>Entacapone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f057ecb7-ee37-499f-8ba3-b9c794468b28"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
    <dc:identifier>DB00494</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22ee4a9a-d2da-4a75-bbb0-ea352ee8a916"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ddca6970-ac65-43ff-9bb4-e2910757973d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5694e218-28fd-4f04-aac0-fb940bc5bc94"/>
    <rdfs:label>Protoporphyrin</rdfs:label>
    <dc:identifier>DB02285</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d214d99-663d-42d3-b363-34e19140e508">
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f284be3c-5c6c-4425-a941-50b4a2743489">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac6bc95b-b78c-45ee-943d-61acdfdd5bdf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87faf5fb-38bc-4b11-89cb-b4c781a8745f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e652346-c718-48aa-82d0-5ac086af3190">
        <rdfs:label>Abnormal walking distance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d62427ad-9475-468a-9f2a-e48e3330e056"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb78ddb1-fac7-41ce-9392-7bc7c79a2ae7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011023</dc:identifier>
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34318e85-0397-42c7-964a-41654e1fdc7d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c679220-e46f-4a61-bfa1-f2752980e63f"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40b0c2c6-fda6-46d4-bb39-dd78d2c9c227">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88fd4c90-fa4f-499a-b40f-97719dd21f7b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cf3c729-f31b-43c2-8353-cd1403b46937"/>
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca71cea2-e6ba-472e-8607-5c76f47cafc0">
    <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <dc:identifier>HP:0200125</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb0d1b66-bfa1-42da-9d2a-b22cfec06a77">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/810431b5-2f15-44ea-872c-f25be32fa1e8">
        <rdfs:label>Muscle necrosis</rdfs:label>
        <dc:identifier>HP:0003713</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb89dbee-d2d8-435a-9882-b5b82f948f92"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/afa7292e-9947-43be-80eb-d19dd141d919"/>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98e5990f-5e1b-47d0-af50-6ad46ba12dce"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cdd01e3-272a-4ab6-98cb-eb9bcbb48a42">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <dc:identifier>HP:0100614</dc:identifier>
        <rdfs:label>Muscle inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66d85dfe-8ec8-4470-a0b0-876e186c01f1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Imapired muscle function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b11ac804-b260-4def-a3dc-f0388fbf0ef4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ece3dbdd-943c-4e5a-bca6-6b1bcda9de64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89883534-7cd4-4e28-bbc6-81d4e64c75ac"/>
    <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
    <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02ac6878-dced-4b0f-a1aa-4f6378d5efca">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8acde2fe-beb7-45ca-91f5-e11ca7cec248">
        <dc:identifier>CHEBI_32030</dc:identifier>
        <rdfs:label>Kaliumbromid</rdfs:label>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5010515-eea0-4fda-b103-2ba310d8ebb7"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f712705-9d30-4e93-945c-5f1c0ecdef5e">
    <dc:identifier>DB00413</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a8ad20e-e3ab-4fd2-bef2-424cded50ba9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1efc7f49-496c-40ff-a05c-d71044aec20f"/>
    <rdfs:label>Pramipexole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98a0b030-9595-4125-8835-b34975f5b710">
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
    <dc:identifier>HP:0004295</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6487db69-a078-4455-bcad-8a016919c7cc">
    <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
    <dc:identifier>HP:0012187</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed6d9788-f97d-448f-9b32-c0462eb38f16">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <dc:identifier>DB00252</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/737dd209-5c73-4c71-acd1-bd1aa119c561">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70a8c7cc-4b34-4fe4-89bc-50629ad68845"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phenytoin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3bab7b9-f06d-455d-8fc9-57ef54606539">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70a8c7cc-4b34-4fe4-89bc-50629ad68845"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
        <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89a95e4a-603d-43ca-9e0d-999df7dea4fe">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/729d796c-ab2d-439d-840c-a37e951a87ca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1b02160-d119-4d15-9b0d-83f52d29458e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of the nervous system</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89b9d102-7a5b-4f8b-9973-feff0197636f">
    <rdfs:label>hypochromic anemia</rdfs:label>
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfefd1fc-aa61-4402-9a45-cf28f9dd4fd5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
    <dc:identifier>HP:0003688</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/252e27c3-7644-4833-aefc-76d9505d3486">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcbd88c2-a21e-4a81-9a82-6ad2032e37b6">
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05e552fa-79f2-417b-ab66-401895a8b8f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23556c2f-f976-4924-9383-1b2aa133c1d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/643a5b13-f865-434a-b4b1-d465d4b6a706">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cf500f1-d74c-4970-b913-50e81b1dfa1e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9abf6938-7759-4643-b29d-137483818920"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f34c565d-f034-476e-b6b6-be543dced40e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4332b57-13d1-4014-af1b-79235d5bb83a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fca0c36d-e1b9-4938-8b18-209041e31d20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003040</dc:identifier>
        <rdfs:label>Arthropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de532dec-9fb2-4323-b8fe-997809afd5a2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27d27485-02ae-4e10-9ea0-37b48734b438"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/525ae58c-fee0-4536-a496-281083b2edb7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/817595f0-394f-4769-99d7-4161bf755b76">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fa98d9f-b7f4-4c25-8a79-151db8597610">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
        <dc:identifier>HP:0000114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a5e1b2d-9edb-45ad-9970-44fe19dc4162">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74305dba-8ef3-448b-80f7-394767873e3b">
        <dc:identifier>HP:0004324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
        <rdfs:label>weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a22d07-3814-4f8a-9225-786b02e70e19"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/587aa14b-15ab-47a0-9245-4357251acc95">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:label>renal salt wasting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e129103b-42c2-4bfc-80de-9bf9f84aaace">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963d62ed-e5f6-40ee-9343-a9d8520fcc58"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33ca36ba-0aec-4003-8e47-4ed95016bdb3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
        <dc:identifier>HP:0011167*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8220c013-e884-4f9a-b810-835296506fca"/>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47e19fcb-d561-4e76-912e-db44d4ff5a77">
    <rdfs:label>Fish oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <dc:identifier>DB13961</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/810a17fd-0d3c-48c6-8bfc-aa1c2db3f6a7"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8845bbd3-15f8-4af8-9d76-8b237b71f1bc">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1ae00b-14c1-4abd-9b49-4d20911cfa22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78bb5fdb-63b9-4d5a-b819-1b361d407870">
    <rdfs:label>failure to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001508</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23556c2f-f976-4924-9383-1b2aa133c1d1">
    <rdfs:label>Isoniazid</rdfs:label>
    <dc:identifier>DB00951</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/252e27c3-7644-4833-aefc-76d9505d3486"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/535fc557-62fa-48ae-a245-218ba6034ce8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85dc6e8b-2e12-4894-ad2d-e27f51172444">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8754bb1-e850-4b15-9c2f-c53c8b078820">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33789e57-6a4b-46a8-9fd7-05d415691f26">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c700b5d-9160-4030-b4a8-a53f1e6690c8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ebb51be-dddf-455d-83ad-6759567bd4e0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
        <dc:identifier>HP:0011018</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>extended G1 interval</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8cff36a-c2af-49c5-afae-3db9b0903a47">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low cell autofluorescence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c8f680e7-7482-41ad-a3b4-053bb298f6dc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84ac1d83-ea5b-4e51-b6cf-a2bde5f8ddeb"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
        <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff18f1ad-4184-42e0-9c49-5de01d733984"/>
        <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
        <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c33ac87-341c-4f11-a0f1-79b8f4731bce"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be8f16db-ab86-4321-a6fa-76366bb97b79"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb1f92f0-92cd-4422-bb13-c2dc6d1c290d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3e9e314-0b72-4074-82b5-bc43a6c8a5e5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f35efe8b-0de6-4774-9886-55e2807ef884"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4c0f73a-a137-4880-8016-4e5afdee44c5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <dc:identifier>DB09210</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a96cfd45-3af9-45d1-b0d0-0ea9b1b1c373"/>
    <rdfs:label>Piracetam</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14298360-4eb9-4f9f-91c2-eb428733b1ec">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67924a06-512e-4cb6-87fb-523c17c37441"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d04bcfa1-c42b-449c-8355-aef6758027cc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL-cholesterol</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3bedf9e-56b4-4db5-8fb6-bcee085af451"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/572f55f8-be3b-49ca-ba73-4e3a839fe731"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e98f425a-a4cc-4c2d-9dd9-6b2696c5571d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e5332c1-017c-4ee4-a080-c7032bc0ca6d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83c4e584-f116-4f32-841b-f51b58a42de0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/746a8912-abbe-4cd2-9186-c7474b42340f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor intelligibility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3aab6e6-cc2f-4dbb-aa04-b5a4bb726888"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ea1af94-a37a-49cc-8918-c0ace7a7b4ae"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963d62ed-e5f6-40ee-9343-a9d8520fcc58"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0431b742-6d54-4e63-bec8-2f3200c03aef">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69ca58cd-afd0-48da-8448-76f1943aeaea">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13d0e302-fbd6-4abc-bfca-352c0a9f8627"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85044e78-e08c-4382-b8a4-106ff6410a6b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No result is  added</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7595b81-abe0-46a3-9fc7-c0d00fbf8c94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de003c1-dc0c-4917-ad72-2831b17e2bf8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/595bbb4b-8091-4c6f-9d9b-1cfe264042a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e9e26ad-aa85-4fc1-9576-7556fcac8adb">
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced hematocrit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0763a5ab-a040-4a36-be9b-1bb02058e767">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/628b31a0-0d08-4d7b-815d-072bf37e4d54"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cdd6640-d2e7-409d-80f1-b9fed3de85e8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbb2dce2-79c7-41fb-b013-6ddc55d35b7e">
    <dc:identifier>DB14555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0794001-6dac-4466-afe5-e26df34ee835"/>
    <rdfs:label>Ursadiol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5348744-a0c4-4764-95aa-a14eda46493f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <dc:identifier>DB03404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/381f41f6-1fb4-4154-b2e0-6406f59dcba8"/>
    <rdfs:label>Hemin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/832c5975-b783-4c26-a5ac-b70cfd269473"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3b45dca-5bd3-4e26-b983-833d9ae27391"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dd46229-94c5-4449-8c9e-af58306eb7fb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
    <dc:identifier>HP:0004732</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/40526a3b-94a0-49db-9c0a-57416e307c11">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1239d67d-e016-483b-b9a7-eb8bfb4c608e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa84b5b4-4327-4a06-9988-03ae76e33ddf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71e31ea2-3f79-44c6-9476-b47487969413">
        <dc:identifier>HP:0003077*</dc:identifier>
        <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b94a4a92-d473-464c-9c63-de80ee60ee6f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:label>Hepatic steatosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/572e1000-245f-4376-b38e-4b9012c04ec6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac989579-38b7-42ea-97b7-6acb049b67bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53621295-a7ce-4323-8e0d-191eb66d851e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08f85898-19d8-45bd-bc94-56676e6866fd"/>
    <rdfs:label>Sodium citrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07d36411-8c7e-4a9f-83c2-a6a681f27ae6"/>
    <dc:identifier>DB09154</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
    <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c81aa8b1-02d0-4beb-8677-0dfbafdc2563"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97f911c8-9791-48af-a474-3e5c334c476e">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1cda051a-b741-4af4-ac15-0947179b55a5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f2d56ce-dd8a-48e1-ae24-3c74983df193">
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <dc:identifier>DB00114</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96e803d1-baf5-4709-ac3e-8c90d15a7f8e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5063b4f0-8d38-4177-9637-066119053990"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/700a2be6-09d9-4b85-82da-0fe1014c5ec5"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29f690af-2e73-400e-a8c2-470ddacbcf81">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b2c6a6b-fef3-4676-a9dc-076867127bf0"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1991164-1fee-43ab-a728-a8fd1c4b2251">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ccac15f4-cf53-40da-ac54-40d7d80eff2c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0341ad5a-90af-4280-9976-35c5843edcb5">
    <rdfs:label>Diazoxide</rdfs:label>
    <dc:identifier>DB01119</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ad7cfa8-9c51-479b-9168-c062bd8b46c5">
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84031e2c-fb67-44e0-ae00-fc6b993a50ad"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b8407b1-a1a2-479e-9ec0-8f5f20c0dcae"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc395368-5e4e-4f93-9594-def62c0f79e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e10c444-e4c1-4b44-b924-9560cfc3aa51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06530fe8-8ba7-4f27-875c-f3f457ef6e77"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63c357de-a3f5-4264-b4fc-04fea99c0186"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6985ccef-f05f-4ce5-b064-1879cb0c551c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum osmolality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75b19dca-d928-4240-a8ce-f23dc8ed6882">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal cardiac function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b27e927e-9940-4ebb-a7ce-65614c80eab1">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb394e16-2975-4762-9fdb-12b18eefc530"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2635f21-4a41-4ac9-b9cd-01fcfcdc331c"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12c57789-f62c-48ed-ab4b-a439f3c08543">
    <rdfs:label>Pantoprazole</rdfs:label>
    <dc:identifier>DB00213</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8bccf20-bd94-42ba-a379-9f125938fc81"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ce16f25-88b0-415d-b642-ba3fcac85b86">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a79bbf97-39d5-4d24-9fa0-481f77b9556b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/470c7aa9-ccb0-456f-85a0-6c2d98564075">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a20a05b6-8dc9-4775-a6b1-8b89706a1bc2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a667c4b0-419f-4d23-9501-1609e4201a7b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <dc:identifier>HP:0010919*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10524e47-bc6a-448a-913c-be56c6a4771b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
    <dc:identifier>DB06210</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7dfb28a-4244-42d8-9ecf-300d0a42143d"/>
    <rdfs:label>Eltrombopag</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e3f0f3f-17b4-4848-a277-b09d0691b805">
    <rdfs:label>Cholestyramine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d990c1be-6a10-4474-bcf7-e1198e62a802"/>
    <dc:identifier>DB01432</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/620407ea-deb3-43d5-8b80-d02bbfb87b10">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6487db69-a078-4455-bcad-8a016919c7cc"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b22d0c7-fe56-44e6-82f3-17f81840cef5"/>
        <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3954c143-6144-459b-a7fb-5b4c8468ff97">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68c23363-94dd-4e41-8ac3-efdb1dcb87f3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>short stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cde57f45-21dc-4c32-abf3-f8f25bf1b2cd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <dc:identifier>HP:0011015</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc4da495-6a4b-4a3b-af02-d8aa8111bdc9">
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d3b0d95-85ad-4258-9968-613be1320241"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7092a982-37b2-42bb-bf72-92662f7f44e0"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f084e2d-806e-463e-811e-6e59a91eabdf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011042</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b22ca2d-7d46-4726-9213-db18f663d0bf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
    <dc:identifier>DB00999</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6d01e2ef-7e0f-46e0-8cc8-440a6e15cf15"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a76aa6d1-7526-4b57-9397-71bd3f737965">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>neurologic dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27654640-68e0-493c-8feb-6878d2940f6b">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1aea3e1-9719-4217-b437-d3d06039fe0c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49503fb9-fb34-47c3-b8bb-e2112bd26b4b"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/198172ee-f0b7-457f-91ab-877316d8c758">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72f04b66-0b2e-4fe1-b0d7-459634f158a1"/>
    <rdfs:label>Vandetanib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <dc:identifier>DB05294</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e818c5d2-a832-434b-ad8c-fecd1361f6b1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14359074-ca7c-4b71-8dca-dd3160901740">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <dc:identifier>HP:0002344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e3b7e1d-da77-4786-994d-9be9d243ee8a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75bff093-a728-4aed-bb23-1f17b5e4c32b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9291c566-f06a-401a-abba-22f479d9264c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/751c26c1-27da-49ae-ad11-d4efc30c692b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Vitamin K insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/963ad641-44e4-46fe-b787-87548762867c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/527b7405-1097-44bb-9e6a-7701141f032b">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
        <dc:identifier>DB00321</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89261823-f74e-4856-a263-5c0d4e73ecb5"/>
        <rdfs:label>Amitriptyline</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8882d9e9-8a83-4a69-a483-28b933d36209">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8b20ae8-5288-4ecf-9866-657a9e23f5a4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
    <rdfs:label>abnormal glucocerebroside level</rdfs:label>
    <dc:identifier>HP:0003656</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71636b55-c29a-49b8-a436-efc87bc3faf5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d4412fa-bd98-419a-94ea-b38ed7b51743"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
    <dc:identifier>DB01783</dc:identifier>
    <rdfs:label>Pantothenic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/119ab3d5-5f70-49ca-a5ca-7ebbeb533fb9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e495d5b8-592d-457e-a6cb-01d746f3ed8c"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a166db79-d48a-45d2-9445-0264bf6b4dc8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:label>Poor motor coordination</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1939c56f-6669-43f3-be59-fbfb2a3b9e03"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bf4c43b-5353-4832-8b27-eb4bb257372b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee63c752-4fe3-45a7-ba29-761644bdff28"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a83d8c32-15a4-40a2-8d89-b92bf883012b">
    <rdfs:label>choroidal neovascularization</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011506</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6edc686-ef49-4363-823c-ccb55b313ae7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64d8ab7b-ee92-4325-9fe5-a8bac0e568e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd5ed5ed-4d51-42a8-b164-57e26f26cffc">
        <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004818</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/921a66c6-df9f-4440-85bd-0617f3c5317f">
    <rdfs:label>L-Glutamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1060600-ed0f-4900-b79a-2d1844a222fe"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84457c41-8830-478a-8ba1-1850ef068125"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da99287a-95ed-419c-9886-0aaf9771d170">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02e8f3a9-96b8-4ece-ae46-0eac74d07fc1"/>
    <dc:identifier>DB00472</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <rdfs:label>Fluoxetine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b983112-a348-4a77-ba77-03e9cf098fc7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70265ee8-d875-4a1e-a9ca-58822f1100cd"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6aeff8a-f4eb-4c23-9fff-2c1e6fa69333">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
    <dc:identifier>HP:0006530</dc:identifier>
    <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9ceddd2-1d62-4def-8bed-74b5030677be">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f23a3d88-c689-4231-b3a3-68d188098f38"/>
    <dc:identifier>DB13191</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce6d8250-ef76-4aaf-bd7c-3860c821b4f9">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f101d893-fa35-4af3-8880-70599660a7c0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8066ecbc-0fd7-44c0-8bcb-6637c51e64e2"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
    <rdfs:label>Phosphocreatine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbc1ec85-50c6-4ae6-86ae-550e06d8fa69">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8636d8a-ce3d-407d-9f49-8a1f641ff518"/>
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <dc:identifier>DB02209</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b64f6f1-aca5-444d-90d6-87a8868366db">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/936274f5-97d0-4b69-b651-856374d35648">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c9b68a7-c24b-4d98-87de-1f7bc10ff00d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/852a68a9-a01c-416a-b9c3-62b0553c7a9a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1a709946-f0f8-4fb4-abea-38d5b99730ad"/>
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57d2a92d-e2c8-4439-a6ea-7326bbf3e995">
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <dc:identifier>DB03485</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1fed648c-d37f-4dc1-a21a-4313013de0fe"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f237fd0-5a96-4907-8e94-012d1c087c64">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
    <rdfs:label>Dyskinesia</rdfs:label>
    <dc:identifier>HP:0100660</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d22f1fff-9768-44f6-9e47-ba0d68a9fba2">
    <dc:identifier>HP:0002715</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>immune dysfunctions</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7b3d024-5745-4895-9d8b-ef50edbfa496">
    <rdfs:label>Tazobactam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <dc:identifier>DB01606</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/290febfd-1068-4f61-ae21-63b1df25b121"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b5ce10b-e687-48c8-a06c-920b67d05b94">
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d3ec1f5-5249-4e95-ac4a-c494bc779ece"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/391206dc-4756-4e0b-a7eb-354f0e8f46b8"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/afa38085-6b12-412b-835a-d1029798c294">
    <dc:identifier>DB00053</dc:identifier>
    <rdfs:label>Imiglucerase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60c22acf-9ad0-456d-8942-3958c68d0ecb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfe7a0d3-96cb-4442-8ddf-044686078c81">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/092202c6-0221-44eb-bd13-eb06b50986e5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e945af03-0b00-4f03-910e-d3e3d057452a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001977</dc:identifier>
        <rdfs:label>Thrombosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c05d4ec6-67c7-4359-8e60-cbc71a97d4f7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/564b22f2-1ef3-46d6-acc8-fc02769265b2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/244889db-a747-4aad-b1c5-8abe1239536a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/694fed8e-3643-4e07-ae11-d38b5b0a2546">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deep venous thrombosis</rdfs:label>
        <dc:identifier>HP:0002625</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af66951e-9fef-43ef-a927-71726c3b59be">
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <rdfs:label>intracellular defect of arginine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f5205b7-fa05-4793-a21a-31124334ba87">
    <rdfs:label>Biotin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0194b09-cb70-4dc1-823e-94f0d756587f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90fbbf6f-ae6c-40f0-b796-7dcf80482958"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c27f3aca-96f5-4936-b90e-6344c359115c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <dc:identifier>DB00121</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71bc571a-dc9b-42f2-9534-0d49762baab1"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11e8910d-97c4-4fc7-85da-e26d72bfd475">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2938dfc9-4f27-466f-8816-8639f4900a84"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7dc98c48-4151-4dab-ae81-dcdd6d03a24b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1caf739-0e2b-4a36-a156-0ec2742bc1a5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5a34cc0-d4d4-4ef7-8ba3-749a0a05eae3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d1a0f2d-97ab-43a0-88ff-80dd240a53a6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231690"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71179da5-514e-46b9-af6a-b2641aa7ef11"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bf4c43b-5353-4832-8b27-eb4bb257372b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/faf0560b-fc85-4aeb-89f5-532d82560d3a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af4dd7a9-9caa-4187-a2d6-a1a2f6929350"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ea8d84c-af1b-4558-be74-642fafd05b16"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a5afb82-2cd2-466c-9c78-d923ab05b5d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22afd365-4d65-4962-93f6-567b425ff9a6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30d5c8d4-0070-4db6-aa78-8f07f016bf6c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47872144-7fd5-4a05-a3e6-04044fdb746e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Riboflavin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/119ab3d5-5f70-49ca-a5ca-7ebbeb533fb9"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/659363f1-a65f-41d4-a6e0-710013ce2cb1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
        <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/092202c6-0221-44eb-bd13-eb06b50986e5"/>
        <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e444cc6-86ee-428e-8a22-f3a1343d3a60">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>somnolence</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfc2f13b-a35b-4291-bc95-9886334aa85e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/730c7d32-a3e5-4fb3-a46f-fd2490ac9fed">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8d762fb-4f37-4002-a9c6-87e95cb2bfdc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82ec4879-f987-402a-b9a2-dc286b90b2e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68c23363-94dd-4e41-8ac3-efdb1dcb87f3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cfb74776-ae3a-4858-8463-b164e6bebabf">
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1503651-5c07-457a-a69a-a29b4aec514d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60cf453c-5350-412f-aeee-d6a28fac46e2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0b21e6e-f222-4be5-a349-3e028297f828"/>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89ae5f0b-11a3-463e-b843-de2c67428de3"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d1e9a63-9929-4034-a198-1f67f4a63c73">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/051672b4-346e-4b0b-aeab-225fcadd5349"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a69b3d6-714e-44d8-a0ab-e2112c0ce2bd"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ec4e303-a23b-4a1c-892e-f20047b012a4">
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <dc:identifier>HP:0002069</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba016cb8-0e24-4787-852a-08826e80046c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <dc:identifier>HP:0009830</dc:identifier>
        <rdfs:label>neuropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34554537-eb1e-4f64-975b-10e3b858d812"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/278ff4db-5354-4c52-b318-9f07c17738a4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d0768fe-894f-45af-bdbf-e186efced75a"/>
    <dc:identifier>DB04815</dc:identifier>
    <rdfs:label>Clioquinol</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60f1e8eb-0ab1-42c3-83d3-584d4924ca92">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d0dc1775-bb90-4125-acdf-712a4af01557">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82308a1a-be01-461a-83ab-a7f84ea06e80"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe1754d9-7665-42d1-b81f-ff28d88e962d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f7fd02c-2fea-4f04-a7e3-65463907590b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9c5a796-acf6-408c-9901-9c82880ef9bd"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f5a8b1b-530f-47e0-ad3f-1cc40b64106f"/>
        <rdfs:label>Levetiracetam</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
        <dc:identifier>DB01202</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d214d99-663d-42d3-b363-34e19140e508"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af5e09fb-68a3-4ef7-8646-cd7d0e65fc79">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5d5ff59-8dc5-4863-a05d-3d2c7878c84d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe1754d9-7665-42d1-b81f-ff28d88e962d"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
        <rdfs:label>Clonazepam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccdd267a-dc93-4852-a304-5943022a408f"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/629c7f5c-be52-4fe2-bb24-462764fd108a"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e5332c1-017c-4ee4-a080-c7032bc0ca6d"/>
        <dc:identifier>DB01068</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e129103b-42c2-4bfc-80de-9bf9f84aaace"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/034e953e-2051-4ce3-854b-6386c5593580">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe1754d9-7665-42d1-b81f-ff28d88e962d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7bf927df-70a7-4d03-9d8a-ed9e035e7148"/>
        <rdfs:label>Zonisamide</rdfs:label>
        <dc:identifier>DB00909</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2636164c-4c95-43cb-ba8c-37298b9ffcfb"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3131f60-8862-431b-a87a-a8917f487de8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1410a590-7d7f-4c96-bf18-b30bb45258c0">
        <rdfs:label>Status epilepticus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
        <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ddf9c8d-46e1-4542-a6e6-0f103db64b8b"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dba910ac-3600-424b-b3a0-40596b58acfb"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24c8a93e-94d1-42d1-b564-894e464a3840">
    <rdfs:label>Droxidopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f95daec6-8447-4153-bb12-67e4f7e2f002"/>
    <dc:identifier>DB06262</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a475504-d393-442b-a09b-bfe3141e3a80">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0003304>R219K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfa980ba-7c55-4626-b485-3e1503538f6f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5df8a0e2-fa8a-4bf8-a535-07f2c521ea37"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88d0deb9-3082-48fd-a674-9e44bc712ec1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6089ce8b-fbaf-4285-ac3d-f60b330f63f7"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb828af4-3940-47b3-a02c-bafe967e26da">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49f8ad24-db18-4724-8837-3f52e0db0172"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b37518d-2479-4da7-8801-55f230b61ec7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b8de674-37d5-425b-a343-663d99f94b09">
    <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a78c9392-5679-48e5-bdd8-d527b7823c48">
    <rdfs:label>AAV-treated βgal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74215d02-8366-44f0-b5fb-e89766a5d2a1"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/948eed73-1b3f-4051-b82a-3092f786655d">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ce60676-5038-44ed-8636-03633491af9a"/>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfa584ce-0b49-40b8-ba4f-cc6db044fc5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>Elevation of creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e39a01d2-b369-4d2e-a3db-bb029fa1a81c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdbcdbfb-cb4c-4c87-a0e5-58c0cc1633b4">
    <rdfs:label>Fat malabsorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <dc:identifier>HP:0001324</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d733489-0bd4-4fb0-acbc-e7a0e9c18dc0">
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e902d5fa-54ba-4b67-8620-f3adf3f38746"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83127c03-06c1-43fa-b404-19a6e844ce96"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d59bfe9-f599-4337-86f8-f3e22d67c06d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/512b47aa-21c7-43e3-b5ab-e9db57b52714"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a5cf598-8ec7-4b90-b8d7-f8aa180af206">
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <dc:identifier>CHEBI_15724</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f43a7949-5041-4a12-84c2-832d1c99f700">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8412727b-a690-4904-8302-b645928c5334"/>
        <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/126069ac-b98e-4740-a525-1beb8f4d677d"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/178f4b6c-aba2-4956-88f6-3942018ce92b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5eca70fa-ef6d-4aa2-a481-62c00b3a5ba0"/>
    <dc:identifier>DB03256</dc:identifier>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6b21f6d-9c0e-480f-894c-8423f1047078"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01cfb604-824f-4e1a-a47c-e311d4980776">
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Metabolic Decompensation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21b14994-2984-4a4b-b2ff-d923db43a8f3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1b311ba-35b5-4ff8-ac98-8701849bc57e"/>
    <rdfs:label>Gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b087bec-7315-4cb4-91be-ea968e1eba20">
    <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
    <dc:identifier>HP:0007479*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9416568f-d6d4-488e-84c8-7a1c96b64133">
    <dc:identifier>DB00563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <rdfs:label>Methotrexate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a4fd3c4-0818-429b-9bcc-8786381f1cc5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5879094-f86d-4b4d-a234-ec63651b097b">
    <rdfs:label>Acute pancreatitis</rdfs:label>
    <dc:identifier>HP:0001735</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0becf02-4fe4-4f88-93bd-c69e961e06f4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f448b63-6b68-49aa-a91b-0ae88e2e2b40"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d3b0d95-85ad-4258-9968-613be1320241"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1ecb7cb-0b0f-44e8-b21e-c4c5229cde15">
        <rdfs:label>Hepatomeglay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6517c9f-07fb-4bb1-948c-7a42c6354ecd">
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/39efd029-162a-4bf5-9265-5262304814ad">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fdae96c7-9066-4168-8807-609fb873d341"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32d4e731-87cf-4020-a76b-f6995b29d7d4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
        <dc:identifier>HP:0011943</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/385eaefc-72e0-4cc9-8910-f52da79cf43d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Increased ROS formation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f363bfc5-dc66-4de4-99b2-8e0be756d7bb">
    <dc:identifier>HP:0001019</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <rdfs:label>Erythroderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bb1b8a4-0916-495c-93c1-c3c912f18da6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35eb65ba-c485-4c33-bb2b-de2b62a4fd9f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9f25039-e42f-4ee1-90ad-f7c504a6f2a1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3a983b14-69a9-4ff8-8ab8-174107fadf7f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0341358b-012b-4533-886b-02c0e5e012e0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f5239ae-c7ff-4013-b3b4-44ba0a79c5cc"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d403a27-2f8c-456a-b111-cfa1eb2a5e65">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:label>Scaling</rdfs:label>
    <dc:identifier>HP:0040189</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06102afa-7f9b-4da9-aab2-f66ceee94a95">
    <rdfs:label>Lamotrigine</rdfs:label>
    <dc:identifier>DB00555</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/748b7dd8-8b54-465f-b1b8-406d9f9dbae7"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/acab85af-1c20-4249-97aa-5ecbdafa3523">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bbaa33f-5c0d-4978-973e-c00a293bfa4e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e4d5f23-3874-467a-b457-bba5de1e229e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased muscle mass</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c55a9f3-1941-44bf-a838-89092a067375">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f32dcd47-ed17-46df-9c15-5f661a73569b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e442f5ff-852d-4345-a2fb-ad12ed4821b3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab85474d-44c4-40fd-bd9b-c6d4a7a15ed5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/919f6437-e1bb-46b4-8b99-f20e584e83fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba5225d5-8408-4238-a9d7-f1c18884c482">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012363</dc:identifier>
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86a98d30-b95a-4b35-8596-8613021b8dfb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
        <rdfs:label>Rimmed vacuoles</rdfs:label>
        <dc:identifier>HP:0003805</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/412bf6e0-b107-4cee-b207-9f20fa985df2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Amyloid deposition</rdfs:label>
        <dc:identifier>HP:0003216*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86dfe81c-43b5-4195-8512-7527dfdcd8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82308a1a-be01-461a-83ab-a7f84ea06e80">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da0af330-495f-47e4-af5e-2a67ba0ff04d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2035f845-6af5-4d88-b8a9-f93ab999cccd">
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2e79000-8d01-4dfb-9af8-df377978e4df"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93042e15-b56c-4af2-a117-f61e48ea6174">
    <dc:identifier>DB03766</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35232a33-0faf-46b0-80f9-516903781eb2"/>
    <rdfs:label>Propanoic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31c65691-345f-4d49-bfa6-aba6f69f044e">
    <rdfs:label>Fenofibric acid</rdfs:label>
    <dc:identifier>DB13873</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14298360-4eb9-4f9f-91c2-eb428733b1ec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dacaa37-42da-4129-a440-95605c9c39be"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
    <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/428eabd4-ee5d-438a-933d-2a4d5f1c1966"/>
    <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4d94778-cc61-4869-b315-4dd166e2faa2">
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3f01a1c-c54a-42e7-a8d7-ac427ccc6d31">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9a35b41-2556-48c5-b1f4-b3995bd6f3ba"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41c26996-ed20-4302-8db8-4f705ed62ea5"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Risperidone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d644c54-ea6c-43cf-86ba-271fb3d95dbb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5010515-eea0-4fda-b103-2ba310d8ebb7">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33ca36ba-0aec-4003-8e47-4ed95016bdb3"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02ac6878-dced-4b0f-a1aa-4f6378d5efca"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83169c62-7680-45c0-ba30-66fbead38fae">
    <rdfs:label>abnormal nucleotide sugars</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/543635cb-14fa-4272-bfa5-e481b3a04e58">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb4f6ec7-cff4-489e-9097-8b2edf527cfa"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03077a40-d317-48ac-8bcc-65ca54170b5e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9bc0abb9-3826-4496-8cce-4ff1b3aa5e79"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/790eae16-f244-42c8-816a-aa9264b8ccac"/>
    <rdfs:label>Nitisinone</rdfs:label>
    <dc:identifier>DB00348</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5fc338f-03a4-4e68-a66b-c898dcb2772a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d386323c-b517-4add-a421-111a35de8a3e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/71b76c14-35d2-45c6-a433-821f72cad13b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82267104-6ffb-4328-8c25-33d4b0906a07"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31fc7cfc-b88e-4c25-afcf-5a8968ac86a8">
        <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b422bec8-bdb4-43d8-8b4b-0a9da7f2e3d3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d5158f5-d23f-45b8-ad33-833e42de8064"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/afdc22e4-2e80-4319-8045-fdf35024ce07">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/faf9b19a-8a75-4a5f-b69e-1994d408a61d"/>
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <dc:identifier>DB08830</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac0a76e2-68b1-438d-8fd3-8b0e60caf4b2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypercalcemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
    <dc:identifier>HP:0003072</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ad0e8a1-22fb-4f6f-b1b6-c86dbc5771bc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
    <rdfs:label>decreased male libido</rdfs:label>
    <dc:identifier>HP:0040306</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f58276c7-5d32-45b4-aae6-3cbb736e74b2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fc79d46-a7cf-4c55-a737-2b1549172d15">
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fab219e-84ac-409d-9454-f8e785abdfb8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee41058c-6584-423d-9df3-5a895d4e5863">
        <dc:identifier>HP:0001507</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:label>Abnormal growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26c6502a-2c59-4b84-a0f6-425afb85e167"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c8bff36-8d64-4109-98e5-4b3cf2deedf8">
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f0df50-93ee-4fb2-bc2b-c759c87f070e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44389b0b-5c03-49d7-b64e-6de740d87e61"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82a847e0-5684-4f75-9983-faa2c8557d35">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9bd6c2f-7f01-483a-a2d3-46119951b3db"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/576590c0-590a-4f25-8b37-9b6928a86953">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24f218ba-44a6-401f-83f5-25faea4d2508">
        <rdfs:label>β-galactosidase:RTB lectin fusion</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12be6564-9de8-478e-bdc9-c0e053ea70ab"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef142ea1-dd56-466f-b175-343144323ff2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/131c46af-2c05-48fe-9807-2dd1ea9ea6c2"/>
    <dc:identifier>DB00083</dc:identifier>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1265b52e-8e68-4ae2-b725-86b5993a3e90">
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d689b43-1b3a-4aea-b50a-dab39424504b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d512c70-d0e2-46bd-927a-896d9512ee5f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66a9e4d6-4379-4919-b3ec-01fdda565834"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3f25f5a-7a1a-49f3-8c51-1812ae503daa">
    <rdfs:label>Enlarged size of the liver</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eac6477-c673-4d07-a346-0b12393229c7">
    <rdfs:label>Cardiomyopathy</rdfs:label>
    <dc:identifier>HP:0001638</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffd000e4-811d-4448-bc96-00166c626fe3">
    <dc:identifier>DB00188</dc:identifier>
    <rdfs:label>Bortezomib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f52b68e-f701-4061-8569-8412251dc48f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1559b1c-1fd4-46f1-bf40-036a77ba884a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4566d80-4c93-45d8-9cee-c64976ce2cc0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1da00c72-28d9-4740-96f5-11334138828e"/>
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <dc:identifier>DB08876</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0fed6e3-df17-4555-bd4e-2efc9b302207">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1de1a209-7b2f-4d89-8002-3ad3a86218a1"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/414e49a5-e158-4c27-b8c4-cb0e4d183a28">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/229eaba7-60cc-4749-9d62-04fcadff94b7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58afb3a5-722f-4aab-a8c7-15a4947d334d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low physical capacity</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a21bcd1-9295-4d25-9d09-caeba0511f94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2d0d8cb-9c7d-49f3-ac73-df355bf29383"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad97180a-e795-46a4-9aab-b72e9e213531"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/417ec0c2-0759-41b8-bc5a-462d2a73e0a8">
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <dc:identifier>A11EB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89781f4c-2fe7-438e-8c7a-6f386edd97cd"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8583517a-5581-4c10-8ae8-6720a1cc599d">
    <dc:identifier>DB00098</dc:identifier>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37468af9-ef06-4431-9a72-c6491339a635"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ea46d08-c8b6-4f52-a11a-a2ead368df09">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0eaec586-03be-4983-97da-a55007e7d387"/>
    <dc:identifier>DB00679</dc:identifier>
    <rdfs:label>Thioridazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b104a2ec-c984-45aa-b6b7-44fc355a62de">
    <rdfs:label>Benazepril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a95bbd8-d304-47a2-8cca-585a38310dab"/>
    <dc:identifier>DB00542</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aabe4df8-ff14-4d70-8020-5c6ee2d78ba1">
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal aPTT level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b1c2965-717e-4f9c-a3ab-033fbf7b960b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1bbf376a-86f4-4f7c-999a-58c314bc4084"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c586f9e-b9bd-496e-8a87-910547fc1d44">
        <rdfs:label>Abnormal exercise physiology</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <dc:identifier>HP:0009020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38a1ded9-0b9d-4fb4-b1ae-b04c2a44e58d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eba8884e-ec93-44f2-b575-9062b101c40c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3d52798-4719-429e-8e90-154dfa5a1f91">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eae5c136-46db-4575-a16b-fef5cb0a3ccb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71179da5-514e-46b9-af6a-b2641aa7ef11">
    <rdfs:label>Bacterial glutric acid production</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d512c70-d0e2-46bd-927a-896d9512ee5f">
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:label>Delayed motor development</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90049ccd-afe4-4c72-b041-f4b9d220c347">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c611116-f7da-48a1-ab0b-513ac0934b3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c28ee287-2208-47a2-b74b-46177fb1328d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dee65373-8865-450d-a2be-bc6a55070dda"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/270886c3-911a-41a2-bb57-1177d0dfc5f6"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91cbc48a-0450-441c-99dd-bcd5a30156da">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/394b7d88-48e6-4869-86c0-7bf8497c32c3"/>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab91c557-540d-462a-a327-893104369d57"/>
    <dc:identifier>DB00115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20df4e14-0cf9-4255-be35-5d7c785013aa">
    <rdfs:label>Febuxostat</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4a577d7-ec2a-45af-be5e-f79a758676af">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d09bd2ef-54fa-4c51-ab83-632b0c09d075"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5eaec50-5c11-452e-91fe-9a9a9235d37a"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff6d927a-3452-4420-a648-90386e3d35bd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f8dc727-def9-4f4a-8f88-3671dd6d5ce2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc026105-1ca5-4c6d-86cd-c886c45741b9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f63d36d-bc9b-4fe4-b393-71051f3a60d8"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e001d362-7d5c-47a7-bc5c-02e749317ace"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44d507a4-59ec-43d2-bcda-67fc72be666e"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB04854</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cba1d115-a5b5-411a-b37e-45753cc2878c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
    <rdfs:label>Skin lesion</rdfs:label>
    <dc:identifier>HP:0011122</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d76adc04-ec11-409a-804c-b57ddf26a365">
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/628b31a0-0d08-4d7b-815d-072bf37e4d54"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17e95ff6-7c4d-45d2-8ff9-172a3db25f56"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60bb0071-fc17-4e26-a7e7-6376b8c66932">
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20c06b13-d332-4176-9650-e3dfa039f75e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21ab9bba-7f9e-4774-82c9-494bff0aa877"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7a0025c-e5a4-4045-b465-fdf32e786603">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdd004ee-dbbf-4c2d-b998-1285be781e57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/260587ed-d566-402b-96f5-9ace59e5164b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83157d21-5dc1-48da-bab9-6a38e4c368a0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12be6564-9de8-478e-bdc9-c0e053ea70ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84ef3553-2981-4e0b-8c3e-4d44818841dd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <dc:identifier>HP:0008166</dc:identifier>
        <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/576590c0-590a-4f25-8b37-9b6928a86953"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4fc115f8-0fb9-4cf9-af24-5032de3e286a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bfa980ba-7c55-4626-b485-3e1503538f6f"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0f5b628-2bd6-4ab0-aeb6-43505297b9e8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2214aec9-dd77-4292-8d77-2b323ea4f840">
    <rdfs:label>increased fecal fat excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
    <dc:identifier>HP:0002570</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/183e801c-99fc-4f3d-8c63-0aa71593f6b6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000867</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d28ae8e1-4cc6-47bf-ab8b-3473e68ddf6c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b26f228a-a113-4bd0-815a-d9cc8cae6925">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b0403d8-e40b-4be4-8e4f-4396eeadeb23"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c55b304-466e-4330-90d6-237bbd6385bf">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e99af308-c8d6-45f6-ae4f-121041d9d29b">
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low life span (Mortality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54077733-8097-4dcb-8afb-dfebc1258b44">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c91849f-1e4a-4dbd-a064-7f0d2bbd6bfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a26ea02-1891-492a-9e4a-e47a0bacd5e4">
    <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d164290f-f871-491e-8000-5c2debd93d93">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b1a6edb9-d6bb-416e-830e-f14f76e57085">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06595b29-259a-4c2f-862e-bf5ae129402b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
        <dc:identifier>DB00741</dc:identifier>
        <rdfs:label>Hydrocortisone</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eed0a5ed-d12e-47e4-8545-b6269ec6f94f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e30a5e4-4422-47d1-81c4-c30db3021f7a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb1f92f0-92cd-4422-bb13-c2dc6d1c290d"/>
    <rdfs:label>Insulin Human</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f36c6682-cd1f-427d-a495-129c3e9f4a30"/>
    <dc:identifier>DB00030</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53cd8de6-dc4a-47b8-8a4a-de83af7b81ef">
    <rdfs:label>secondary carnitine deficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76297083-3cf5-4201-b5ac-03c1b8da1b26">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:label>myoclonic seizures</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf420ffe-a3e0-4b77-87a6-5b16cf68ceb1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a01afa24-7495-4cef-a82e-047a8f4fe670">
        <dc:identifier>DB00235</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ecbc16a-0e04-404f-9e9c-8795d6da5dda"/>
        <rdfs:label>Milrinone</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a2a6a64-cfb8-4d89-bc7f-36ecdb6701cf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
    <dc:identifier>HP:0003117</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1489da2d-c70a-497a-ad64-c699e02c7cb5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34318e85-0397-42c7-964a-41654e1fdc7d"/>
    <rdfs:label>Fenofibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08c9af16-04e5-452b-ac86-33defee33377"/>
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a12cf1c-5879-4683-aea6-502456f80f4f"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e970158b-731d-417e-930c-1abf5c0815e1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3978f15e-d00d-420a-8c6c-bbb6303c727f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/140f1b62-6d86-4def-bcf9-9d3b581ea5b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc8786cd-d8b3-4355-a223-57a9a875655d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4782b422-8964-42ab-8a49-1a064644f898"/>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9915c189-1efb-4a4a-9b54-6113fb018c7b">
    <dc:identifier>DB00186</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/028219b7-45fd-45db-a24d-2f9b4b4339d2"/>
    <rdfs:label>Lorazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eba8884e-ec93-44f2-b575-9062b101c40c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b1c2965-717e-4f9c-a3ab-033fbf7b960b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
    <rdfs:label>Ramipril</rdfs:label>
    <dc:identifier>DB00178</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e8c9fb66-0312-46c8-b657-75d1347c03bd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/100404eb-2deb-4b61-881d-18934231df7b"/>
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b22dd0de-e018-4dd1-9e66-088823de45cb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/853f9218-4461-4924-a79a-020474db3772"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb481fa9-20ec-403c-b08a-d0701ba648c7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5243ad30-2684-4f74-8765-8651dccfa9b4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59df44a1-7280-41c6-b31b-807eb0459c1d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <rdfs:label>Captopril</rdfs:label>
    <dc:identifier>DB01197</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9262993-fc73-4491-9292-7b74ab407651">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60c2d5fb-45c4-41b7-bb27-9e2c6f819409"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <dc:identifier>DB14644</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4e75895-6217-40bf-adfd-900218cd0d88">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8eb729f-bc4e-4cae-b752-6a9f1250295b"/>
    <rdfs:label>Setrusumab</rdfs:label>
    <dc:identifier>DB14778</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c5327a5-f2c9-4156-a393-8a7d52e686a8">
    <rdfs:label>Dextrothyroxine</rdfs:label>
    <dc:identifier>DB00509</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0becf02-4fe4-4f88-93bd-c69e961e06f4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e73f8e8b-0594-4256-a0d4-afa33ce8b28f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a91371b0-9150-472e-ba71-3141c0f60790">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>diarrhea</rdfs:label>
    <dc:identifier>HP:0002014</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd31aaab-744a-469b-bc7a-0cc29a2aaa5b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3f25f5a-7a1a-49f3-8c51-1812ae503daa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40c7f27f-0ebc-47b5-84b6-08dc17811563"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3f8324f-f0fe-428a-a5ed-c46446120c43">
        <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
        <dc:identifier>HP:0000002*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15b751c7-dcfa-4871-b10e-79d5c0e86cfd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81908c52-ec82-47bc-9c75-988d25e6134d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44d520fa-aa02-482f-840a-f853f2a75ed9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f42af957-0ebe-46e2-a84a-4a35e00ec8b0">
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e1cd3d6-1688-4dbf-aa79-f351d5cc50e5">
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <dc:identifier>HP:0200125</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/158ff306-ea85-404a-90c4-1154b4a5dba1">
    <rdfs:label>Abnormality of movement</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c9b68a7-c24b-4d98-87de-1f7bc10ff00d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b64f6f1-aca5-444d-90d6-87a8868366db"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
    <dc:identifier>DB06281</dc:identifier>
    <rdfs:label>Torcetrapib</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/807f60e9-8a03-4438-ab55-5942ddf78fb4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d0d7fec2-0b95-4530-8d60-6d5b2e2a8d5d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ffd20b7-b6ee-481d-bfdf-6acdbe114351">
    <rdfs:label>Mecasermin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25ad9c38-a0c2-4c0a-aa0c-84f4ffb37a95"/>
    <dc:identifier>DB01277</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12516621-b0d5-4d67-9c9c-0495a3a7f66e">
    <rdfs:label>Carglumic acid</rdfs:label>
    <dc:identifier>DB06775</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd289d53-9547-4919-8d6a-27c63c65c1e1"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8e36bbe-c35f-4e28-812e-c95867409308">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9237864c-7917-4e97-9b05-5c486c3d63e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7ca9046-e90c-4481-98c7-73727ea0b918"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ab46386-dbb2-4358-9dff-eb45429b7e46">
    <dc:identifier>DB11599</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3954c143-6144-459b-a7fb-5b4c8468ff97"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8962fba0-a33a-4745-a70b-9b98b2072965"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd31aaab-744a-469b-bc7a-0cc29a2aaa5b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15cb2915-6b58-4b1e-bcde-326ded487aca"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/240ccd52-d28b-4de2-adc0-6f5c098b0c04">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a26438a-4247-400c-b06c-cba40eae5aeb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9b7e710-9fc5-4f41-91ff-73ad5795f9b4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16212379-6d81-45ae-a51f-3c22f555b55e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a3c4ae9-aafa-4020-9fab-e41a0414f38e"/>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5c8caba-76f1-43cf-8187-6206818026ff"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1720d64b-477b-4250-8cdb-146a7cf1ea5f">
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/998702c7-0749-4f19-9c5c-19ee8dbb382a">
    <rdfs:label>EEG with focal spike waves</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
    <dc:identifier>HP:0011197</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f7758f6-41b9-452f-ab6c-7530afcdd71f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8854bde-d4c4-43f6-b46a-55f331193350"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3307302-748f-4364-bb91-f04c43197ab9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6461887-200d-4e3e-ab47-41a08025a614">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>White matter changes</rdfs:label>
    <dc:identifier>HP:0007103</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa6ed2f3-18bc-440e-86e2-6efef5790f30">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <dc:identifier>DB09341</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6b837e2-59cc-49bf-8fce-fe928001e664"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6455946-bc0f-459d-9411-aa2dedf58542"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0dc261ec-3eff-4c9d-906e-d12137819cde">
    <dc:identifier>HP:0010975</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
    <rdfs:label>Abnormal number of b cells</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d2e85715-0d4a-4334-b803-3b52586e0a21">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfc76469-64a8-48f8-af6e-abbc547d2028"/>
    <rdfs:label>Pioglitazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <dc:identifier>DB01132</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ea4316d1-61f1-4ac2-a681-494bbd598835"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/594ade33-96c6-4e28-8857-8fe760648d60">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:label>Renal salt wasting</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be88718d-7e6e-46b8-933d-b26065a84722">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <rdfs:label>Furosemide</rdfs:label>
    <dc:identifier>DB00695</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5243ad30-2684-4f74-8765-8651dccfa9b4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f80eec3-8423-44b8-9df1-ca27dfd7cdc1">
    <rdfs:label>Nicotinamide</rdfs:label>
    <dc:identifier>DB02701</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e8e1641-73c1-43f9-8f00-5522a7444a8b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c55a9f3-1941-44bf-a838-89092a067375"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe9927f0-f6cd-41ba-b90b-21b41e804a69"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6be88295-55dc-4b2c-8de3-b591bec7d883">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b98f070-3cfd-43a9-9a2e-9b30c335b321"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32d5386f-0635-4b1f-95ee-fef3d07c804c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e386e293-c366-48c5-b335-f1f2cc047b80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e77f57db-7a02-46ba-adb1-81fd60cc7a24">
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed93eba0-e4e0-4865-91f7-c59b4c7b8271"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbad9530-d953-4253-9866-06e947e768f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d86f7548-66a3-40d6-9bdd-28c9b35dcacf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/396ffa52-4e2e-4d2c-a4d9-13183130375b"/>
    <dc:identifier>DB13173</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <rdfs:label>Cerliponase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed53e83f-f150-4f9e-ada1-54eb9c406700">
    <rdfs:label>Trial is no longer available</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53762b75-11f1-47d3-be54-c0ef7172200d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <dc:identifier>DB13245</dc:identifier>
    <rdfs:label>Thiram</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b616ae09-e280-4fba-9c7e-c989e59c0144"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f501243f-1aa1-4084-8386-83da6db9ad90">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Delayed Develoment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <dc:identifier>HP:0001263</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99ea925c-260b-42ed-ab0d-b65cf7bc156a">
    <dc:identifier>DB01586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b5ce10b-e687-48c8-a06c-920b67d05b94"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e909eea-f96d-46d6-a219-c8c2bce73a84"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22615c0a-94b4-4612-b885-b7a1101ad1ee">
    <dc:identifier>HP:0002789</dc:identifier>
    <rdfs:label>tachypnea</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92d06dd1-d84c-45df-8c99-93dcdcc044b5">
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c6134f8-283f-47e7-81e8-3eb34e22e4ce">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9087bb3-f13b-42bb-9808-13388739858d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc833139-c914-4448-9090-9f5e2a019579"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/572f55f8-be3b-49ca-ba73-4e3a839fe731"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67924a06-512e-4cb6-87fb-523c17c37441"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ae30407-2aee-48b4-b4de-0be725f6abf4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bc1839f-1965-47b6-ae57-ec937dafb0af">
    <dc:identifier>HP:0009020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c69f7b7c-84cc-404c-bc8d-60d4e460dcb8">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
    <dc:identifier>HP:0003358</dc:identifier>
    <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da97151b-a6c9-44e2-9d55-b05999442bb2">
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/408b241e-d334-4bb2-bb34-0a4f6dc3c3ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100512*</dc:identifier>
        <rdfs:label>concommitant low vit D level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/06595b29-259a-4c2f-862e-bf5ae129402b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d164290f-f871-491e-8000-5c2debd93d93"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/293754c8-e39e-43b1-9857-cbd4e4647528"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/605ef58f-b402-49e3-8e80-ddd130564842">
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:label>Abnormal circulating renin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67004c10-7770-44fb-86a8-011701b68268"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f084e2d-806e-463e-811e-6e59a91eabdf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb258b32-9e0f-4b52-a526-60ef92d1f7d3">
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ee0aeec-13e6-40ff-9a8e-760c64b3a9eb"/>
    <dc:identifier>DB08809</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b259f0c-4daf-4933-aa3b-418897c1bcd1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/797fd382-9110-49f7-8332-6b6bab37e12c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5cbbbd0a-ee89-484d-bfbb-b3c538908a7e"/>
    <rdfs:label>Deferiprone</rdfs:label>
    <dc:identifier>DB08826</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a98819bd-548b-41d7-8afb-63026382aadb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11ab0731-d2ce-48b6-b25b-8217fecccf3b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/583b6366-e16c-4a21-ba51-16a545fb1bd8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b27e927e-9940-4ebb-a7ce-65614c80eab1"/>
    <dc:identifier>DB11094</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3a67107e-2658-4979-b33c-3a59beab8ea0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00e76aff-b1dd-4f13-ad58-037ed0a77b53"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/183e801c-99fc-4f3d-8c63-0aa71593f6b6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dffcaf46-e421-47be-ac39-b110f4ef21ca"/>
    <rdfs:label>Vitamin D</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da97151b-a6c9-44e2-9d55-b05999442bb2"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfb45fd6-ddb7-427c-871d-ffde8bd97108">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acidosis</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b428821-3ca2-4082-bbb7-7744e0fbfad1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
    <dc:identifier>DB00533</dc:identifier>
    <rdfs:label>Rofecoxib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/557c7f92-7bda-4498-b96c-9d29ca56d4a0"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4b177964-a993-454f-a9aa-fe7561bd860f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ce398c9-37ba-4da0-a118-5a0cb217ec21">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
        <rdfs:label>Gabapentin</rdfs:label>
        <dc:identifier>DB00996</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b246ff1-6f0f-4a8f-8a71-83cc3d2e4f3b"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1a74438-b213-4141-bd0f-bc357a382a0f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34037feb-15bc-42ec-ab71-37cbb076d2a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c90ae92-33aa-4d37-be47-ead3e1730a25"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5d5ff59-8dc5-4863-a05d-3d2c7878c84d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963d62ed-e5f6-40ee-9343-a9d8520fcc58"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2415b33-290d-4e0f-b26b-31deda820843"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/140f1b62-6d86-4def-bcf9-9d3b581ea5b5">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e970158b-731d-417e-930c-1abf5c0815e1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bdd0bad4-a4b7-4a72-95cb-f9c98412dc92">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acab85af-1c20-4249-97aa-5ecbdafa3523"/>
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad4b5a4f-f14a-4797-81b1-8918f1f4dbfa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0763a5ab-a040-4a36-be9b-1bb02058e767"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d76adc04-ec11-409a-804c-b57ddf26a365"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
    <dc:identifier>DB00190</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/406a05b2-5e5e-4c73-acaf-249dd09ae77d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c5b2743-08fa-4001-8793-ecaec51e262c"/>
    <rdfs:label>Carbidopa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2ab7bb5-21f1-4650-a7e0-eb94bf3d65ca">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a69decfb-983f-4ef8-b6da-3a6bb3ddeb66"/>
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91dd08ba-0fc0-471b-a396-ec5eea74eb76">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f2a3426-8ee4-47e2-98fc-4c1996c48b08"/>
    <rdfs:label>AT342</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ff55c63-a303-4270-9aa8-cf18f071f81e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0eaec586-03be-4983-97da-a55007e7d387"/>
    <dc:identifier>DB01563</dc:identifier>
    <rdfs:label>Chloral hydrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cd6c08e-ee82-4578-95c7-4c67ec763f1a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high serum ferritin concentration</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0d971cd-fd58-4553-a520-cf7bbddb5fab">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3252c321-238a-4ede-8719-2587001bf40d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4acfed6-df1c-47f7-ac67-b68ed8ea56af">
    <dc:identifier>HP:0002196</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myelopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b0a3728-f688-4ba0-8a80-9cd2be9da7b3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1a0f2d-97ab-43a0-88ff-80dd240a53a6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002013</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
    <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eecd0f7d-5e8c-417d-89d0-7c1e973e6b04">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7f34f10-916d-4e59-9842-d5e284a30c04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6913161f-121d-4f5c-9579-8aeb70d9b325">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Developmental abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57d2e529-b8a1-4785-a722-f47f56ba74a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebcf4e3c-a480-4879-b37c-0367263ebfee"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7386cd13-7178-415f-a1be-2d9100047f79">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec06f773-4481-400e-90fc-634e2044e511">
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07f01b91-5bd3-4ff6-b889-febf5b86160b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04eb1963-dd24-474c-9ea9-ad22af63bb98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc9618e1-4456-4c3d-a807-51f3e3334342">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Misfolded AGA</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb1a0ace-b695-44f1-8f23-40eb86e0073a">
    <rdfs:label>Neurologic abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2da01b85-724c-43f7-b92d-93ac1eb1fb94">
    <dc:identifier>DB00034</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e731e8a-65fe-430b-aa51-5f8fa1f0449a"/>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c51c8a9-1e1e-47b7-9b14-0198d80834a3">
    <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
    <dc:identifier>HP:0002086</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc9f4f86-8d47-4198-ba4d-de418dce9c89">
    <dc:identifier>DB01373</dc:identifier>
    <rdfs:label>Calcium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8fb04e8-eb97-48fa-9821-622d9cc3812c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/333b661c-b788-4225-a104-3b292ed3b84d">
    <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab4917fd-ca23-4a89-b491-f53ef2ba0af6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5442267-b6e9-4339-ad25-ee78e2f92baf">
    <rdfs:label>Pregabalin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
    <dc:identifier>DB00230</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2b6fcbf-b362-4d5a-aa0d-f433520b2708"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/313e49f3-8426-4df6-ba7e-80bf69cd1819">
    <dc:identifier>HP:0000982</dc:identifier>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45bfb4f3-3d18-4c9d-b86d-0cb811fa71ec">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd2299a8-bf97-4ab9-9c1a-cbe68e7e111c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fabc136-33af-4152-b8eb-57764646e623">
    <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <dc:identifier>HP:0003254*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0982cc3-b466-4184-a4bb-e2564eaa006c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
    <dc:identifier>HP:0011123</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b115782c-49ad-49d0-a597-8b7bdef696fe">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/467b722c-e5c0-4db5-bfa6-eaf07dc3aadb"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41488892-adb2-44b4-b841-765b06f3dab4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <rdfs:label>Pyridoxal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af12d5ea-236c-48a7-b9e7-bfb82dc38015"/>
    <dc:identifier>DB00147</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bd51933-4621-4f3c-8d83-4f57d0e2e22b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum amyloid A protein</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c70a40d3-fc25-4974-acc7-9f675ef4844d">
    <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
    <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
    <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c085a008-8591-4ae9-ae1c-862b466a893e"/>
    <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
    <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a18d29f9-8d37-4210-a040-1e06e20b1cff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/992404d4-9086-4831-a7c0-7970a876f87c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c728e15c-f22d-48a0-b9d1-cde59f6b5443">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3204771e-9e7e-49dd-9c30-15c2c6c95f11"/>
    <dc:identifier>DB00145</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28ae6205-80ef-44bc-bad8-e8ffe225bc73"/>
    <rdfs:label>Glycine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89261823-f74e-4856-a263-5c0d4e73ecb5">
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963ad641-44e4-46fe-b787-87548762867c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de964b1f-a53b-498c-8af7-85ceae5969be"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf0dae62-4a83-428b-a93a-d8ce9f51525f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
    <dc:identifier>DB00158</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e70fcd6-ea0c-4fab-942d-5a8c8069a25d"/>
    <rdfs:label>Folic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f44f6232-09b1-4ba3-a6cf-e805174fa469">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f88ca05a-d67b-4c11-bd6b-45762552bb7f">
        <rdfs:label>Decreased niacinamide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4dbf2357-7b40-4663-b906-fa7e3d3d209a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42bfbbc8-3f8c-488f-83d7-1dea8f8e54d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fd1c0ef-c8d1-4d68-a269-825fcb473f6a">
    <rdfs:label>abnormal hepatic function tests</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0776697a-0eef-4f85-b9c9-2ef28f0d1ae7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df3adb71-c14f-4244-900d-1b52118b4477"/>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c8c5806-6758-4e78-a286-18fc6ffa52b2"/>
    <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f242ef35-7397-4db8-87fd-726c7d6109ae">
    <rdfs:label>hepcidin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9ced8df-a731-430b-b6b8-809154f71b81"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e9ef9d2-890c-4212-b969-ebdcae2aaa50">
    <rdfs:label>AAV-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef6ee137-f01e-4f56-a8f6-d0810b941aea"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c510a66-33eb-408b-be4e-1ddbe343e5d4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc1799e4-b4dd-4c48-974f-5a37a0c36676">
        <rdfs:label>Keratoderma</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000982</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6328b1a7-0be0-41cc-bfbf-f5d52d19eeec">
        <dc:identifier>HP:0000166</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f577bb6d-ebf7-4ee9-9e1f-5ed94c641b33">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/842e8640-6777-442b-9d3c-95d42645ba26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
        <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b176820-db84-4e68-ab07-33fc4086cfdd"/>
        <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
        <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c6accf4-802d-4cde-9efb-707848e93488">
    <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0817e408-d725-4ac8-b966-a5dcd8397560">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5f0424b-3991-489f-917f-3dc769a4dfc5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f4269751-587b-45dc-b5e1-cc7594882957"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58afb3a5-722f-4aab-a8c7-15a4947d334d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8762937e-3cd7-42be-a595-477eb3155b91">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d94e6eb1-7470-4434-affb-349390bb35ba"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87fe522d-f3c5-4845-9263-413adcfc370d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f2b9bb3-e7b8-4e51-a996-489164acb3c6"/>
    <dc:identifier>DB00650</dc:identifier>
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8a60a37-fe40-402a-9612-337e8cafd86f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07061b84-5d81-4387-be1e-9b951b66c212"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a128f70-d4ce-4b5f-9630-ed8c79edbc17">
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26f6f400-d37f-4759-9f71-8731fd39e4e0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e285f366-16c6-4fc4-a8c1-6c253c441848"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee1fefc8-9b3e-4214-94bf-5dcf1a0eae3d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b452b835-8260-49b6-a812-d6722ea19d73"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a723de0e-bdb9-49d0-83ac-1f451ca71f17"/>
    <rdfs:label>Thiamine</rdfs:label>
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb828af4-3940-47b3-a02c-bafe967e26da"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f159909-1587-441c-a85f-90e0b6025c20"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25fe53ea-8841-428c-9580-87d6aa53068c">
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a8d37ef-630b-4b86-a76e-f25e9a20d815"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe1754d9-7665-42d1-b81f-ff28d88e962d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60f1e8eb-0ab1-42c3-83d3-584d4924ca92"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ae2f15b-7574-4690-b324-3c1daa42a1b0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aab3c17d-3981-4fb8-8acf-0bce9596dc4e">
    <rdfs:label>Lithium citrate</rdfs:label>
    <dc:identifier>DB14507</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48724972-c899-4e6b-9009-d8c96165ab10"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b08597b-b3a9-4e05-9893-e867a0fdbb1f">
    <dc:identifier>H02</dc:identifier>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9475c1d-55ba-4248-bfd7-c02b996612c4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffed9593-25cb-41cf-bdd8-bc01075dc0f9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <dc:identifier>DB04789</dc:identifier>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6eafc9e8-5c9b-401e-a362-23267473be49"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a0cedbf-fd04-477d-bda5-8164f0cfd388">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0013968-ffea-4558-97f1-84227b2678a2"/>
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42ee42a2-2cf1-485c-9f1a-b4f157a447d2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ce0bed2-f45b-4986-ab3d-690b077673f6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd93738d-9b84-42ed-91cd-473d8f7e9b36">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
    <dc:identifier>C03D</dc:identifier>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ff81a0f-ff39-4293-9800-f20829463a3e"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd2399c4-a402-43a2-a175-4a14fa1b30a0">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d7a0eef-a9dc-4e96-a810-287eb10c5c60">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oedema</rdfs:label>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/16043ed9-7816-455e-8a34-e6c214a652bd"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa74fd0f-403a-47d5-b106-bcb5b8254004">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <dc:identifier>DB00688</dc:identifier>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/affc32e0-8df1-4672-af1b-db4b1ab0db4e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94304ba3-5ae9-4a04-9b1c-df491d9f0097">
    <dc:identifier>S01EC</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dbbda0bc-4930-4296-b61e-973c8db7eb59"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1467614e-3758-4667-9b35-09c12cd0b984">
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c56acac0-bf61-43f9-8bc1-4728e35a6f03"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <dc:identifier>DB05481</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf87e1c6-447a-4f96-b22a-c1a855dc1a51">
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
    <dc:identifier>M01AX</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8660bc0-7fb2-4eba-b6ef-ef3668e6b483"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b57576c-d661-446a-b746-370431a166af">
    <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0bb799fa-df22-4913-82b7-146ee605797b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3380899-eed8-4387-a304-dc805932e99d"/>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/520cdd8a-9818-400b-9980-7e287edf0a19">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03812850-e421-4e0d-836d-e4d6acd0ed4a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15fb8402-6f6b-4233-a16d-ee4110789c5e">
        <rdfs:label>Optic atrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
        <dc:identifier>HP:0000648</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83157d21-5dc1-48da-bab9-6a38e4c368a0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/61f145ba-dcc4-48fe-baba-0e21eec03ef9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9c598471-68c5-4446-b146-988dd23485d5"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55880fda-0c72-402e-8bcf-2b0d388af5e5">
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b27d6d6-1f64-4d18-a239-157d94d3ca8a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <dc:identifier>DB14002</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6ed9c23-11b7-4d1a-9a6c-99f69f4dd0f8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15d6e3eb-fa7d-465b-bd70-59ac11b28891"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40526a3b-94a0-49db-9c0a-57416e307c11"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2673a1f2-abca-40f7-b505-e4c9a9b14d6b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/975ba77c-e424-49d6-bd91-391c831cf278"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8845bbd3-15f8-4af8-9d76-8b237b71f1bc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00de5894-9306-4086-974a-75b54d764e9e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/629c7f5c-be52-4fe2-bb24-462764fd108a"/>
    <dc:identifier>DB00313</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
    <rdfs:label>Valproic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cbb8e46-8e3a-466f-9542-75b7ce9d599f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8066ecbc-0fd7-44c0-8bcb-6637c51e64e2">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7971d15b-9fa9-4d18-8a79-3d6d446701ae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0707deb9-b0f5-43f2-885f-93c8449ab18e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <rdfs:label>Tempol</rdfs:label>
    <dc:identifier>DB12449</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77fe6799-35d4-4d44-89d9-a477df86c5eb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6272df9e-401d-4c96-8fb5-76c71788eec3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/394b7d88-48e6-4869-86c0-7bf8497c32c3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <dc:identifier>DB01592</dc:identifier>
    <rdfs:label>Iron</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a20a05b6-8dc9-4775-a6b1-8b89706a1bc2">
    <rdfs:label>Oprozomib</rdfs:label>
    <dc:identifier>DB11991</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ce16f25-88b0-415d-b642-ba3fcac85b86"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c68ddfc-40ef-4747-aac9-b3ced94199ae">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13f352f0-51fc-4a1e-a6af-6f3ce35ed5a1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56cc0658-9645-404a-adf5-dc1a5a962b7a">
    <dc:identifier>DB00103</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf8e4443-32c2-423d-aa5f-daf229a68e26"/>
    <rdfs:label>Agalsidase beta</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92ab1c9c-3e76-42e0-aac8-27e996d1131b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2fb412f-236c-4c2d-8e34-ff4a4e608d70">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Fukutin function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2269c488-7a86-48bb-b06d-e55f94f3f0a3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c09ae520-dbb7-4319-adcf-df872464ad27">
    <dc:identifier>DB01124</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91378f66-dc08-477c-a3d4-08f82283b9a7"/>
    <rdfs:label>Tolbutamide</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3c50588-d8c2-4d74-b237-21fc1d728521">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57045023-378d-48b3-9104-7e1d93a87f57"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c367f08f-35eb-4348-89db-f3bb3ef12277">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ea34415-3a12-4bb9-8b11-e93f99a99890"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74a8514e-16f0-43ab-a766-bdaac167d637">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a52a6a-60e3-4754-bd9a-f50d26c5afae"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6e130d9-f5fb-44db-8179-a5fe3b51a3ab"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2139b6c-f48b-45af-beaa-54558473ecc8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7e29ba2-e31e-4c82-95b8-f76c3e586969"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bc03114-f108-4648-a20c-ae13dfd356cc">
    <rdfs:label>obesity</rdfs:label>
    <dc:identifier>HP:0001513</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ceb3f16-bb55-4a22-a88c-5f8b5c71bd52">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1a74438-b213-4141-bd0f-bc357a382a0f"/>
    <rdfs:label>Fructose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <dc:identifier>DB04173</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7d936f8-ee1c-472a-a465-f01db330b35b">
    <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed7c6a5d-67d7-43da-be7b-579341095136">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c2c6cc3-b5e1-419d-932f-d2ca69017a16"/>
    <rdfs:label>Ciclosporin</rdfs:label>
    <dc:identifier>DB00091</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1c6c899-928c-4b7a-b81f-510e8cabcdfa"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37468af9-ef06-4431-9a72-c6491339a635"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cbda4d7f-9be7-426d-ad0d-d3e18f49c670">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/317578b2-9801-4c83-835a-fc714390a56b">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70f7e49a-76b6-48be-bbad-b44a3b9b109a"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a91371b0-9150-472e-ba71-3141c0f60790"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26f6f400-d37f-4759-9f71-8731fd39e4e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d5007d7e-c78b-457a-9690-7041691be841"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb7a18ae-1e02-4d6a-a1e9-fd5ffc5c7120"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <dc:identifier>DB00916</dc:identifier>
    <rdfs:label>Metronidazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d13c276a-e83b-4f4c-bec8-afb2db088473">
    <rdfs:label>Mesalazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <dc:identifier>DB00244</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b08b3390-7157-40ef-870e-230141173b63"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/787b3855-dafc-4962-b175-2b6214a0aea2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a27dc96d-4f0f-4655-97f2-40937446deb1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01131953-81ca-480f-89db-b47af14c6e23">
    <rdfs:label>AAV-GLUT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a17f866a-faec-41dd-810c-40c12ea909dd"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c1af6f5-5a3a-424b-9dc5-8b54610d8563">
    <dc:identifier>HP:0001976</dc:identifier>
    <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e254f61e-de7e-4ad8-9a89-aee7fd0fc3e5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4f2d30c-e572-4ae8-a5b2-9761c3e88877"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <rdfs:label>Niflumic acid</rdfs:label>
    <dc:identifier>DB04552</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7bf03c44-56a8-4b92-8ecf-9812911250b6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5704f73-5979-437d-b4bd-4d1749a7bd6a"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a04133d0-a5e5-4be0-b24c-3cc66c508749">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/688d3362-d02d-4637-89bf-74435ba94c0f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f470df65-a24b-4b63-afe2-8c2de1693a5e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dccc6f4-1f58-434a-a186-2e5c5532c023"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb742638-8b5d-4c4f-9c01-5b2ef6a1ee72"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31a22d07-3814-4f8a-9225-786b02e70e19"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4721aab0-b063-42b1-8eb5-7e5a13728805">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e24fc49-400b-462b-839f-f9827477c3c6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/40cb0550-58d5-407d-b338-55b20e1d9b26">
    <dc:identifier>DB04075</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e8df26b-594d-43f2-abb4-f9f5d0674cb0"/>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43472a92-8223-4feb-bd9f-be5e66e5bca7"/>
    <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
    <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d51aca6-16cf-45e7-bd6b-e4f7cb0b1a40">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfe59405-e9cb-41c2-ae8a-e3b7509ed2d5"/>
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c28c0625-a660-4300-ac1b-22e9f39ec15d">
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3131f60-8862-431b-a87a-a8917f487de8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8cf2906c-e19a-4a87-a4f4-d8c00f00c824"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d3bb9db-b7f5-4d40-98d8-5b32ec0b0528">
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dba910ac-3600-424b-b3a0-40596b58acfb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/760cfd7f-aec9-423a-998c-05590b4a7ee3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad0c736b-311d-4eed-a191-1ac36117c5ba"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <dc:identifier>DB14513</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af00ea8d-2c5a-4cb4-8dd8-f17cb030cf99">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
    <dc:identifier>HP:0002902</dc:identifier>
    <rdfs:label>Hyponatremia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e24fef9-b1d5-4d44-9f56-94d4bb7123cb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d1e9a63-9929-4034-a198-1f67f4a63c73"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94855abb-5470-407b-bb53-84cc86bb6de9"/>
    <rdfs:label>Miglustat</rdfs:label>
    <dc:identifier>DB00419</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42bfbbc8-3f8c-488f-83d7-1dea8f8e54d4">
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f44f6232-09b1-4ba3-a6cf-e805174fa469"/>
    <dc:identifier>DB14933</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e85a63a2-d460-4306-b6b4-a69c29703eb9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54a5704c-c163-4f0f-9313-476ff5c54a2a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17bda352-ff59-4c09-894e-8645ee6ee038"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30f08c29-bfbf-4eeb-a9f8-d449b5479fdf"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <rdfs:label>Cholesterol</rdfs:label>
    <dc:identifier>DB04540</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30f0cb96-3117-4eda-ae98-c942ef8ed452"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8643b01-f68d-4ff0-a2d5-59819a438cf4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c70a40d3-fc25-4974-acc7-9f675ef4844d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aee82436-803d-4edd-8842-caec6f0d219a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58ff0b94-a83b-45c6-9bc0-cd9addc370dd"/>
    <rdfs:label>Bezafibrate</rdfs:label>
    <dc:identifier>DB01393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95d5ec22-1a34-4c5e-9d3e-6b6f22fc0897"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b63dbae-b9cc-4060-97cb-a255110247f5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/388f12c1-2432-485f-92fa-bf759c0e60e5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/584e4d57-dbed-4ec3-bd3c-61a19db125c2"/>
    <rdfs:label>Somatotropin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/702e5000-7835-409d-885a-1e987789cc6d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/73460cb6-faa0-4bfd-a0d9-310e99a302ec"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b320c7c-e158-4a09-80e5-4da5556652ae"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b246ff1-6f0f-4a8f-8a71-83cc3d2e4f3b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4b177964-a993-454f-a9aa-fe7561bd860f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/641e4248-b2aa-41ef-b86a-2a92404b90a9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5693136-ce4f-4a56-95fc-e9d0113557ee"/>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <dc:identifier>DB00603</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6209f56e-4f06-4749-9e75-87cb8c97d0ea">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c9800e7-afbb-459e-b289-89e5d38b6900"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/802ca466-7768-4bef-a115-61c5a5d8bf9a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0dabc956-b613-446c-8c79-39e08bf9017c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8c53661-72b2-4617-8ac8-a41a24b1af51">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9db307e-f3ac-4ac1-9fb6-06575ff1cb10"/>
    <dc:identifier>DB00776</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3defae79-c68a-4d41-866d-03f8594d4ee1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b7fe743-2992-42c6-90ba-ab58007516b3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce44681c-fc7a-426f-8334-315c1c043d42">
    <rdfs:label>Brain oedema</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
    <dc:identifier>HP:0002181</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4332b57-13d1-4014-af1b-79235d5bb83a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/643a5b13-f865-434a-b4b1-d465d4b6a706"/>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <dc:identifier>DB01611</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a6e4359c-e46d-497b-8e20-df9406c14f30">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1cc1095e-eb90-4e0d-9e71-fc7fd1075ef9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f78135d5-e1e7-4911-a201-5dfc283a4a5e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dabf96ad-4a69-4dac-bb29-aa893e798229"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0039af25-f3e1-460b-a0bb-4fa0ba05d7b1"/>
    <rdfs:label>Ademetionine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a854b4f2-f811-48bb-879b-68bc272f9ef9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ce2fcc4-ae21-487d-93c5-50129187ebd4"/>
    <dc:identifier>DB00118</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7580b828-c90d-40f4-a52a-0e52bb7febaa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <rdfs:label>Bromocriptine</rdfs:label>
    <dc:identifier>DB01200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b27fb0b-a33f-4f4e-a91a-ae204223a4c0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b369209c-276f-4dc2-8cd0-e9fcfb57adfe">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31bf4619-ad9c-4fc1-b7ef-8e35e3f1de50"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a04133d0-a5e5-4be0-b24c-3cc66c508749"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/522d6789-890a-4fc2-8781-6d0efd751eb8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/817595f0-394f-4769-99d7-4161bf755b76"/>
    <dc:identifier>DB00328</dc:identifier>
    <rdfs:label>Indometacin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9465bf0b-37c3-4386-9bcf-90c57981837d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88db5c65-2a9c-496b-90cc-ec9f226d2aa2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48842987-df48-4529-8e9c-df1dde7e0ce5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5530865b-882b-49f5-919a-d25092222f3e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1fdf1337-0313-43f6-9f87-a08671c2d6a9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bb1b8a4-0916-495c-93c1-c3c912f18da6"/>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4fe87f6-4fa5-4451-9d18-4efe9c32b68f"/>
    <dc:identifier>DB09270</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28d11146-6d39-42e1-a1ae-031e2606f632"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aacfe052-76df-47d9-ac39-8dcbb4a5905e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4bc1eacf-2821-4af6-969f-92900d0ec02b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0c81832-4090-4ae5-8ee8-c96e861afea8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8689a14e-94f1-4cf9-a052-702a8d00737c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f00db6d-ee5b-49d2-a19b-1f4614a916a8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8b20ae8-5288-4ecf-9866-657a9e23f5a4"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fef6a76-dbe1-428b-af99-e301204e2ba2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a80f87ac-703b-4f93-9225-e9053a23aa90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49503fe3-ab33-49a9-9719-6a0ca08cfaa8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/890ec28d-3757-4444-b250-5b17d99275bc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
    <dc:identifier>DB14502</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa773322-bc14-4705-bea9-fbfcbe6512ae"/>
    <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d690b7e-f4e2-4e32-9570-31c5dc1c4561">
    <dc:identifier>DB00334</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e576e524-18bf-40ae-bbc0-da6441945e91"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c730c88-9342-4e81-9f8e-4071bb19491b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <rdfs:label>Olanzapine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/55b41b08-14ef-4b64-b120-29405222fddf"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
    <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb91827a-377f-45c6-9cca-5a6314dd5146">
    <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/798ba440-c9e1-4435-a9ca-5b18abefd02b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07aba146-de30-4eca-87a5-81d1e8f5250e"/>
    <dc:identifier>DB01403</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <rdfs:label>Methotrimeprazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5db76761-44af-457f-9a15-5ec9629aba5e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f2de4ff-1462-4964-9da8-34c6b10fb3a5"/>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b2b4f67-eb64-4a9b-9d9f-c75f61f331a5">
    <rdfs:label>Tanespimycin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9eb3f9a2-b7b3-49d6-8391-3bac100081cf"/>
    <dc:identifier>DB05134</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce46decd-e7fa-4987-b938-1db7f4edb199">
    <rdfs:label>electrolytes</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <dc:identifier>B05BB01</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69d25b06-a237-4c0a-a466-1108073f084b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/71049e83-1a1f-4e80-a486-bab2ab523075"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/594ade33-96c6-4e28-8857-8fe760648d60"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16735507-e309-4e78-abbb-772a9b79eb1f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <rdfs:label>Retinopathy</rdfs:label>
    <dc:identifier>HP:0000488</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc18e774-1a01-48f6-adfa-f7b3505c3031">
    <dc:identifier>DB00060</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4778123-955a-479e-8bfc-65655ad97b4b"/>
    <rdfs:label>Interferon beta-1a</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82e267db-aad0-41fa-a23a-4963cffad1c4">
    <dc:identifier>DB03614</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <rdfs:label>Methylcobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c748d11-5c72-4b64-a314-66c265c2f548"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c35e7ff-1a95-4bb5-98c1-694a9a506cbb">
    <dc:identifier>HP:0000103</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased urine output</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/446d5709-c4e1-4e68-a2a3-af24f8cd975f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29faec18-66f5-4879-834e-67f7fedb27b8"/>
    <dc:identifier>DB00477</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
    <rdfs:label>Chlorpromazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc4b1638-a828-493f-be45-cdca26ba3c7f">
    <rdfs:label>movement disorders</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89604cf1-c268-40e6-a517-15031f83c360">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b41950d1-74b6-4133-913c-f3595d4db0ed"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9154d81d-582e-4b2a-9fe8-63e7031ff35e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
    <rdfs:label>anxiety</rdfs:label>
    <dc:identifier>HP:0000739</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b8407b1-a1a2-479e-9ec0-8f5f20c0dcae">
    <rdfs:label>epileptic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20eeeed7-26ae-404c-9a68-bbfb7cc723e2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8301d4b-0729-4c3e-a880-6ecda1a06eeb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
    <dc:identifier>DB14476</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ff74336c-9f00-49c7-869e-63756b6f9bd9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfc3c049-5904-4afe-86d8-f036354c94ba"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01de7db1-3561-473b-8ec2-6f413f4db0b2"/>
    <rdfs:label>Vatiquinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5ae8eab-1218-4ecb-a7e1-9b581a3f56f4"/>
    <dc:identifier>DB11917</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9c5a796-acf6-408c-9901-9c82880ef9bd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b054169-b169-4ff6-a9a4-53f2a1da1e3f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58489ea1-449d-4cee-98eb-80875335f08b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47b0cbf0-0842-44d3-8b52-ffdc0cb170f0">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <rdfs:label>vitamine K</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43ee5b14-53d5-4b31-aff8-59ae623811cd"/>
    <dc:identifier>CHEBI_28384</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/929ad6dd-a8cd-4dda-8d26-bd0380bce595">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba519d5d-1c6f-482b-bdae-961892d9131d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20d28bf5-1d70-47b6-964f-c9b1852a6fd4">
    <rdfs:label>Abnormal AGA processing</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78cfa2e3-195d-4e6f-bd51-ffee7754c9c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8877aa0-fe71-45e4-8446-fcda56151aad"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e454ee5-1c42-4dfb-89b4-5b47a03d9e7e"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6a6c221-f404-4466-aebd-ba24470e0eed">
    <dc:identifier>HP:0010836</dc:identifier>
    <rdfs:label>hypocupraemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8ec361d-634e-4178-864c-e0814826dd5e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <dc:identifier>DB00936</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7a0377b-5110-4008-9299-a3a12eb7a3ad"/>
    <rdfs:label>Salicylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c700b5d-9160-4030-b4a8-a53f1e6690c8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/535fc557-62fa-48ae-a245-218ba6034ce8"/>
    <dc:identifier>DB02329</dc:identifier>
    <rdfs:label>Carbenoxolone</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d1138b2-7c18-492d-9b28-b0bf926364f0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf055573-1fca-4520-bf0a-c447e73549ef">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a40a97dc-e32b-4ecf-a45d-22428bab144b"/>
        <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/471d5cd8-4580-4bef-8d71-c1cb99a0693d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8dcdacf-aaa4-4b53-8ea6-f6a9522bad6f"/>
    <rdfs:label>Quinethazone</rdfs:label>
    <dc:identifier>DB01325</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58daf14f-59f2-4f34-ab0c-02aa6d9bf339">
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27302496-6eff-41e1-ab5e-1ff0f4382f45">
    <rdfs:label>Colchicine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb04e9be-627a-42c8-8319-ef01da269884"/>
    <dc:identifier>DB01394</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54b59eba-42cf-4e98-a5c8-5c20088ccba1">
    <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41526cec-41a3-42e4-8c59-ae14c64bb426">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64858a52-ccad-4e2b-b964-ffb15e9db6b9">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/367a9e8b-9b5c-456c-ba55-0fc4ccff0a82">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/208f6e8f-a94b-4d9e-9615-0a326614231c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3b02849-1b0d-4511-a750-4b118aab0688">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e3b7e1d-da77-4786-994d-9be9d243ee8a"/>
    <dc:identifier>DB01022</dc:identifier>
    <rdfs:label>Phylloquinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd478919-c30c-4407-978b-cfa776ecb181"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6ef887c-9d97-4ecc-b292-7bb0fb341b83">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
    <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012029</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/77671da6-dd9c-4b2d-aac6-2d6e0b396340">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe4338d2-3183-4421-8f40-ea6a212edca4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6173515b-5ba3-4a3f-8b4e-8b51ca925588">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0aaa997c-a15d-41c3-85a1-01c387123946"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc200816-3396-4637-8b2f-ad3d8cf82a66"/>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26e680be-c3bf-49f3-9c8c-b14fd2124c7c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010909*</dc:identifier>
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a40a97dc-e32b-4ecf-a45d-22428bab144b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb1a0ace-b695-44f1-8f23-40eb86e0073a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d1138b2-7c18-492d-9b28-b0bf926364f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7f92036-3f78-42c8-9a0d-da2235fa3c3e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a83d8c32-15a4-40a2-8d89-b92bf883012b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24904bba-e32a-44c7-9b10-87074ebcb91e">
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>decreased visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67927463-9510-43e9-a639-02fd4f0f72b8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ea467d2-66f0-4fd8-924e-9538512160a8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dcc3238-8297-45f9-9da0-9ee695579116">
    <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010918*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1edf1fd2-7b51-4358-9754-b2d760b48080">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f4a1822-f89a-4c54-90c8-f428c4eab92d"/>
    <rdfs:label>Vasopressin</rdfs:label>
    <dc:identifier>DB00067</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc2333fc-1ac1-46bd-8482-ff616fa1b1bb">
    <rdfs:label>Low Frataxin expression level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11105495-dcd5-4b75-91ef-7724c85027ea">
    <dc:identifier>HP:0003107*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2dc9e8d1-84ac-41e9-8d46-bdee818c3c6f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a80d124f-fdeb-4fef-add5-606158530b16"/>
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52ae6c5d-6693-464c-83df-627af25e278a"/>
    <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6638049b-2a60-4057-a04b-1f69e94bc69b">
    <dc:identifier>DB11251</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/082659a4-865f-4c6b-93e5-794452bc4ea1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a797dff-460d-4947-b3df-baa853a19365"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5fc338f-03a4-4e68-a66b-c898dcb2772a"/>
    <rdfs:label>Tocopherol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc823545-fbcf-4edf-aef1-419a91590127">
    <dc:identifier>DB04272</dc:identifier>
    <rdfs:label>Citric acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f78d79bf-6288-49fb-a609-fbb145863fd9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afae99c6-57e9-4f76-9a8f-0db44793b3cd">
    <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
    <dc:identifier>HP:0030098</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac989579-38b7-42ea-97b7-6acb049b67bd">
    <dc:identifier>DB05990</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
    <rdfs:label>Obeticholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa84b5b4-4327-4a06-9988-03ae76e33ddf"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d648165-ac02-42b0-8e48-79ceb878dfc7">
    <rdfs:label>Elevated serum lactate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
    <dc:identifier>HP:0002151</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/515c1833-7328-4aa8-abe7-c3eed082baf5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Personality disorder</rdfs:label>
    <dc:identifier>HP:0012075</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdbfcbfb-b4e9-4e5e-8eb9-b296efa8a0bf">
    <dc:identifier>HP:0008282</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0762698f-97e0-4a3d-843e-6e626882c55e">
    <dc:identifier>DB14098</dc:identifier>
    <rdfs:label>Cobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6fdf9dc-d7d1-4e28-b4e2-a16f24c1a827"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d77e0dec-9d68-4cdf-9646-351990c8cbed">
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <dc:identifier>DB06720</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e470ada-7689-4dc8-adfa-bf36124a0b59"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21c54f69-236d-418e-9aca-8ec39e102a97"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1ec6c6f-2481-40ec-a9ef-c38386212b20"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5872df40-bc1c-4274-8316-81fa1516b0ad">
    <dc:identifier>DB12907</dc:identifier>
    <rdfs:label>Mannose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2590e933-ac6a-4f62-bd34-4224f28b561d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1adde62d-b0df-46ea-875c-6026263f8821">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a8e42fc-8a67-430e-b6f2-258d0b288c3b"/>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74bd15cb-53cc-4eb7-99e8-41414507757a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
    <dc:identifier>HP:0011227</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated C-reactive protein</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd2d770b-dc77-41be-a49e-339a05ea566e">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c740ecf-9713-48b3-8461-5c6d8afcd266"/>
    <dc:identifier>C04</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90e7abd5-a289-43b4-9d5e-c06e9b97661a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
    <rdfs:label>Pamidronic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02fd7a24-7f24-44e6-b807-2d83c11ea11e"/>
    <dc:identifier>DB00282</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2bbc06e-5730-4349-b9e6-a952fd1ede5b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ab79556-d8f4-4062-aa08-7d3c6cc3e8ff"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23d805fc-d50d-44f1-98a5-229bc9b7a3ee">
    <rdfs:label>Elevated blood homocystine</rdfs:label>
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cbd5c74a-1fc7-4489-b2d1-8f91c5a63aa7">
    <rdfs:label>Amcinonide</rdfs:label>
    <dc:identifier>DB00288</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b8fc0e3-a39d-4e8f-b9f3-a1f9d7418878"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/485df016-cfdc-459f-8de6-ba1cd8c9c57c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb0d1b66-bfa1-42da-9d2a-b22cfec06a77"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52215489-f291-485a-9dc3-e12a1ceae63b"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee078057-d77b-41f8-88c5-6c0b1a9df6cc">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1df87806-1baa-4d52-b2ad-a5000d8122f7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
        <dc:identifier>HP:0000704</dc:identifier>
        <rdfs:label>Periodontitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38e17a53-452f-4808-aa34-7dfedf71aea3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2de7a9b-c6e3-44ff-be1b-d4297c0bdd4f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ab34782-2d28-44b8-a162-76a54766ae83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e04340a-9a28-4ce7-b5f2-c4cb48e6f02e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/313e49f3-8426-4df6-ba7e-80bf69cd1819"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ea61b19-f243-4e5e-b500-707866d16cb1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>retinal dystrophy</rdfs:label>
    <dc:identifier>HP:0000556</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85f16457-64cc-41f2-9660-010cd82e85ef">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e28d5e33-6de2-4148-a80c-467888fa7ad9"/>
    <rdfs:label>Triamcinolone</rdfs:label>
    <dc:identifier>DB00620</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7ed2c72-b392-4a28-a8a2-db5641b93b90">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3af6567c-0ce7-4067-8bd5-3ebc04212e8f"/>
    <rdfs:label>Rifampicin</rdfs:label>
    <dc:identifier>DB01045</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0424a82-8d34-48d6-92d3-2510b48cb383">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3d992d6-466c-4999-b87d-6bca1bfad519"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc833139-c914-4448-9090-9f5e2a019579"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6166da0-6ca3-42a5-90f6-ddb13f923c26">
    <rdfs:label>Difficulty breathing</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002098</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71e57775-893f-4e4c-9277-759bbdb4c855">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60ec4ac2-559b-4afb-a82a-395ef099978a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55a96ea6-2008-408c-a18f-243f30ac8e01">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4375ced-8514-44dd-8bca-078faa9ca706"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/746e4d14-8514-4bb4-8f15-17452ea86294">
    <rdfs:label>Estradiol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/494a3578-954c-4055-a174-fba9a5a8157f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <dc:identifier>DB00783</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3629549d-c964-4945-8648-acd4fc73fcf9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f195dd05-6880-4823-8387-a63f8bef80e0">
    <dc:identifier>DB12890</dc:identifier>
    <rdfs:label>Dihydrexidine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/266affeb-3e10-4cfc-8a6f-c8011586cb6b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7b83dae-30d1-4f2f-af40-1146de907d04">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008282*</dc:identifier>
    <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3455ac62-6e42-40f1-bb42-6e6bc8885cb2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a64b531f-7199-41f5-be72-91ff7999f4f8"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/364e220c-531a-4bb2-b340-5da8eac6d0e3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/756866ee-1ff3-43c9-95b4-8b1c1e0f425c"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97aa692f-bb48-4693-a089-4c26a7face74">
        <dc:identifier>DB00404</dc:identifier>
        <rdfs:label>Alprazolam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ffc91906-25b7-4846-a953-214bcca2f6e3"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4cc3c06-3686-462d-94f2-1fb6485aec97">
    <rdfs:label>acidemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2135f130-4c7f-4a75-a166-71bbc2b60a2d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8ece3b8-0421-42c5-b61c-729a20da1c08"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/334e1108-3886-4323-b848-08c70ea85f9a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
    <rdfs:label>emotional disturbances</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000712</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92054191-d875-43d6-81b4-1b0a9f68a4b4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007009</dc:identifier>
    <rdfs:label>Central nervous degeneration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/509b48ab-c5f2-4d75-aa3e-16d2abfbdb25">
    <dc:identifier>DB11672</dc:identifier>
    <rdfs:label>Curcumin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f764bdb-49cd-4954-a654-2dc4f8d213d5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ccac15f4-cf53-40da-ac54-40d7d80eff2c">
    <dc:identifier>DB00476</dc:identifier>
    <rdfs:label>Duloxetine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29f690af-2e73-400e-a8c2-470ddacbcf81"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3dee6c62-8872-4e52-8605-46a2a1dd7947">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f535f082-3891-495b-9f67-bbe698ec1d1e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98867ddb-85b8-4648-89cd-f2d96e1f1b3e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72915dc2-9ff7-4ab5-8723-4d319f8ad16c"/>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd3121a0-4abf-4f72-93e5-b3a147a355de"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/383c6d9d-b88c-4c94-a672-0699c9d3c158"/>
    <dc:identifier>DB00166</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17d4f2d8-2230-4112-beed-9cd75221337e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6edc686-ef49-4363-823c-ccb55b313ae7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5791cb81-0f54-4086-8428-2dd2b4ba5c5c"/>
    <rdfs:label>Eculizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <dc:identifier>DB01257</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3fd67456-2b9c-4eb2-a03e-2c9c5112e43c">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53482ed6-9b99-454e-b8b9-e576a8ad1288"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/316dd103-f03d-4a8a-bcd0-fe7af11bb212">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00877d14-b63e-497e-9fa5-98b27a97350b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <rdfs:label>Infliximab</rdfs:label>
    <dc:identifier>DB00065</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35b89cb7-249e-4a31-a9f4-2b26d88b0e39">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003648</dc:identifier>
    <rdfs:label>high Lactic acid</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ec45e91-d32d-454e-92f7-76c69af32e11">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a475504-d393-442b-a09b-bfe3141e3a80"/>
    <dc:identifier>DB00175</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <rdfs:label>Pravastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fc115f8-0fb9-4cf9-af24-5032de3e286a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07bb621d-0867-4106-b47f-074851ac65a7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7192913-145d-40ee-8e3b-4e12ca0009d3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
    <rdfs:label>Hoarseness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001609</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9388054a-4bbb-4e7a-bdda-31e734a2bf19">
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <rdfs:label>rhabdomyolysis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ead69617-aa0f-45ba-bb5d-12aca409eebb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a7f5a2a-a515-49e4-9549-7f48e9e4990b"/>
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6376d398-b0e9-4647-ab01-7249d0a1545f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low PBGD expression in liver</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a84e6282-b897-410b-b84f-ca6f5a36f7e5">
    <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f39ab1db-9088-4000-ac06-8a09c295542a"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2649d35c-e566-42db-a7ff-63931b0236f1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/472c6702-b0fb-48e5-93f6-06ce5b5103e1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fed94b22-f275-40d3-ad97-898b6ad89275">
    <dc:identifier>HP:0008222</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
    <rdfs:label>Female infertility</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/084c33bb-d70a-4b03-aa41-8971b715addb"/>
    <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f9d0422-1eaf-4d60-a3d7-848f2e735c65">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001874</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
    <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b733351-7fc0-44c8-98e7-412fdf6dff4c">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3596b3bf-6a91-4bc7-b381-9f06289fa436"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/924f574f-d7cf-4ecd-a05e-393f6cbcac80">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
    <rdfs:label>hyperkeratosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000962</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7785854-5a75-4b00-a793-4579a128e4c1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
    <dc:identifier>HP:0012048</dc:identifier>
    <rdfs:label>oromandibular dystonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c28ee287-2208-47a2-b74b-46177fb1328d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90049ccd-afe4-4c72-b041-f4b9d220c347"/>
    <dc:identifier>DB09043</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <rdfs:label>Albiglutide</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28b789ae-53f8-4bb1-bdfb-c34f81f0536f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/890ec28d-3757-4444-b250-5b17d99275bc"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcc2c7a4-5547-40c3-9178-bd921d18b22a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/388f5e3c-b0a1-4e9b-b82f-a15815b51e1f">
    <dc:identifier>DB00028</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63b1382d-15da-46ce-acc0-15e82716a845"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27c38544-9c67-4c26-8b27-53fbea8b7b4a"/>
    <rdfs:label>Immune Globulin Human</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27048866-0841-4a98-8137-90fc5100f8af">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d57acd3-f995-4725-a09a-1ad8bda695e2"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f03a8c5-b4f9-4f35-a1bf-2162e67b547b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/849de8db-702f-4b30-a4e3-e31925a0f66e"/>
    <dc:identifier>DB03793</dc:identifier>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a3cc647-cf99-4588-9719-8fd2bac09394"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/414e49a5-e158-4c27-b8c4-cb0e4d183a28"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ebd685f-fb05-4c95-8b4f-b72e12f664cf">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c1692a5-3fc3-46c2-92e8-5ebabf3d830e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5333d691-09e1-449f-9104-c5780017edac"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
    <rdfs:label>Icosapent</rdfs:label>
    <dc:identifier>DB00159</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
    <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
    <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
    <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c465e5d0-b9d7-45f6-b722-186d164868b7"/>
  </ddiem:Disease>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
    <dc:identifier>EC:0007121</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
  </ddiem:Evidence>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/414ab5d0-7ca2-4cf6-a686-4ff0fbf334bf"/>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bf1bfe3-a822-4f92-9cd4-6a86743f1adc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0003218</dc:identifier>
    <rdfs:label>orotic aciduria</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40736491-e0a8-45e7-b39a-714ac6f194fd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a9991ea-13e0-46d4-a584-54069b896830"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3f60e4e-6807-4e29-bf98-de3fcb4ecdba">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8ec361d-634e-4178-864c-e0814826dd5e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2671df09-cada-45ed-a795-81ede22c3aae">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <dc:identifier>DB09046</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84ebd555-397b-4270-8491-4881fa911fb2"/>
    <rdfs:label>Metreleptin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1fe71bd-385f-48c4-a364-eaaf6c23f260">
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d73cf5e-966b-4dd5-a445-31d46bd1d6fa"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d08460df-85d6-4d3c-8c81-8571c925491a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39ec6656-232b-4b21-af59-09c3c1fec52b"/>
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f04b62ff-d780-41c4-bde4-bdbdc454dced">
    <rdfs:label>Abnormal muscle physiology</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d33346c-6adf-464b-99c9-8e3234af49d3">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e39ad4c-eab5-4860-be92-fa8649e87e71"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
    <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f268369b-e2a0-4dc0-99a8-86e1f4404b4a"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7fe6286-f1fa-4619-a32f-49980cef33a2">
    <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74e7564e-1070-4f20-80cc-badfb7918231">
    <rdfs:label>Imipramine</rdfs:label>
    <dc:identifier>DB00458</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2e2d4ca-fd8b-4f41-b770-623a4c296acc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59430263-7012-4b0b-b8b5-51acf3d4a478">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003738</dc:identifier>
    <rdfs:label>Exercise-induced myalgia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01056fc6-d4be-4423-a64f-473a24ce294a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <rdfs:label>Rituximab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b656cadf-a6e1-423f-a027-0be2991704e8"/>
    <dc:identifier>DB00073</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf61ac8e-5984-4012-b2ac-9ad487176069">
    <rdfs:label>Photophobia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000613</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fe6796c-21bb-4f8a-a475-271d0a315442">
    <rdfs:label>GNE gene lipoplex</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21cf8820-86fa-4006-bcae-7eec17606314"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/760cfd7f-aec9-423a-998c-05590b4a7ee3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypomagnesemia</rdfs:label>
    <dc:identifier>HP:0002917</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fac7e8e0-22e3-4409-b510-839e9a262901">
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f1cca17-22de-4840-8c20-c244d489856b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f2b8394-3a3e-4318-804d-471356fe4736">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10918cb8-8fff-493b-a28b-8055c56ee2f8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad3cac85-41fb-497b-9047-c3c69686c041"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e596f1dc-f0dd-4750-87a6-ca99f816b7df"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <dc:identifier>DB00020</dc:identifier>
    <rdfs:label>Sargramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/568b2e5b-3126-4ed0-822b-84d55c4e7876">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
    <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dcfb50c-5ad3-41b7-988e-1ec1e16b0ae9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <dc:identifier>HP:0003434</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
    <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cecbab8f-665b-4fe7-8c66-f4ade3d6abf0"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81a38f9e-fdb4-4a4e-a52a-6a53c614b5ae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72082906-ef37-4df7-9234-092f60afb7b9"/>
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79f88194-700c-4ed2-90d4-a885efe5c7cd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4235c493-58ee-47a7-94e1-6402cf610587"/>
    <dc:identifier>DB13257</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d8e261c-2f7f-4644-ad8b-37b841565165">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19c8aeab-9368-4801-8a48-1631a7fd1ddb"/>
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6fd8515-d9af-4627-8742-3996305b94a2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34388610-c675-49d6-8c88-7839b6e0679d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c367f08f-35eb-4348-89db-f3bb3ef12277"/>
    <rdfs:label>Vitamin A</rdfs:label>
    <dc:identifier>DB00162</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c001f13d-a3e3-4bce-a577-7c277579c784">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
    <dc:identifier>HP:0003254</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4daa1e4f-bdd5-4a19-b2b2-6e2c4e6c5bd2">
    <rdfs:label>joint swelling</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001386</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c4a7cef-ffbb-41ab-a083-6fdecc492d3f">
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d666a57-0f7a-4a04-a773-ede5340e42f3">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b117745f-dd89-49a1-a184-0971d86115a1"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b8140de-c35c-4c8f-90e4-b6f12797f3c4">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <rdfs:label> Softeners, emollients</rdfs:label>
    <dc:identifier>A06AA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dead5e5f-e9b8-462f-8525-fac0e921da3d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21e06b10-474b-4803-a499-aa0d009d653b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3d73022a-405e-4fb9-974e-00ab2c8708e1">
    <dc:identifier>DB09393</dc:identifier>
    <rdfs:label>Amino acids</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1060600-ed0f-4900-b79a-2d1844a222fe"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04eb1963-dd24-474c-9ea9-ad22af63bb98">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7386cd13-7178-415f-a1be-2d9100047f79"/>
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48c1ae8e-98b2-4c8a-868e-727d9bfb3e5a">
    <rdfs:label>acute arthritis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001369</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c0216bc-b03c-4ef6-bcca-0cedd8059616">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41d8ee91-fa31-4cf1-b969-1580fe503c9f"/>
    <dc:identifier>DB02772</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
    <rdfs:label>Sucrose</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0632a41-f445-4287-bf2d-4ee5801c39a0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6436d94-c787-4194-a526-eb546c782040"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6445643a-ef8f-4749-be05-b77c5f836adf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b2f742d-0ba5-47ef-a9a9-728292bb2258"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3c71c93-ae10-4035-9197-41f9bc00b454">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
    <dc:identifier>HP:0000855*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6011f2e2-da29-4b16-ba64-9a24c8baf21c">
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
    <dc:identifier>HP:0000964*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7df4f1b-02d6-4537-8505-db45ad6c209f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e84de51-45c3-40ee-a355-fe35bb6e61fd"/>
    <rdfs:label>flavanols</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/37ba2ab3-0110-4c76-aab2-3816fd419821">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53762b75-11f1-47d3-be54-c0ef7172200d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/551c54d6-6eba-42af-99ce-e2e2c874743d">
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79578481-10c2-4ae5-aa48-13b82443fb15"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8734fe77-81df-425b-9889-d5a44ac06168">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/269210f2-0cb8-4fb4-95df-52ed02c49aab"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
    <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8881984d-4f87-4869-887e-8effc49f9e7d"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/361e344b-ab3a-4178-837a-4e871e58f4ad">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd2399c4-a402-43a2-a175-4a14fa1b30a0"/>
    <dc:identifier>DB01324</dc:identifier>
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac57bea7-7c65-4d4c-9bc1-43c01da17b18"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/972f4e8b-a929-4252-8458-327c20bdef1d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f07b6262-0155-4926-ab3b-4453730a7381"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <dc:identifier>DB15066</dc:identifier>
    <rdfs:label>Givosiran</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f236053-dcdd-4b24-930a-5d74f655240d">
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <dc:identifier>DB06285</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8db5f177-2608-4e42-a56c-d55b4c2af07e"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab8f21d4-9bdc-420b-ac6b-62c444b206c3"/>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85fc90f5-236b-4a4d-a2d6-3603389e0fbe">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5233e4d-061a-487d-a46f-d8353fc7f7e5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <dc:identifier>DB00393</dc:identifier>
    <rdfs:label>Nimodipine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9ae8511-d6ee-40d1-8a16-458e3cc67570">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
    <rdfs:label>Doconexent</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be553177-6697-4a83-b54d-5cc70bf8451e"/>
    <dc:identifier>DB03756</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33ff6f47-82be-4ce7-94f4-e4cc121de3a6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac5fdba7-ecef-445c-8477-0df3c99cff70"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bb41ea5-6dce-481d-b93c-74d94b04fd08"/>
    <dc:identifier>DB02659</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <rdfs:label>Cholic Acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9dffca04-b813-418b-a4e5-c867980db299">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b1ff853-47b9-43f2-9099-74e5b682a38b"/>
    <dc:identifier>DB01037</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <rdfs:label>Selegiline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf2dd1ed-fb52-448e-8617-bf202e6ca761">
    <rdfs:label>Rotigotine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2c1d552-a649-486e-9c23-7cf9e54d84e2"/>
    <dc:identifier>DB05271</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3ffea5f-b32e-4e88-936e-b78c9f23c59a">
    <rdfs:label>Ad-mG6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1506432-deb5-4005-83b7-e274bb12015e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d50e6e71-a680-4686-b599-1826652415ae">
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3209be4d-cafc-4783-82ee-c1f52c64fff2">
    <dc:identifier>HP:0002160</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total homocysteine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c1098fa-3c99-46f0-909b-b2d6930828bd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf8e4443-32c2-423d-aa5f-daf229a68e26"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fba10ea-badd-4b9c-9765-06c61efd8c0f"/>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <dc:identifier>DB14992</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebcf4e3c-a480-4879-b37c-0367263ebfee">
    <dc:identifier>DB6756</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eecd0f7d-5e8c-417d-89d0-7c1e973e6b04"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec7dc442-4f40-4cdd-bed4-57b0c49b6181">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36cde40c-6ef3-4513-bf24-c4ef8366b8c8"/>
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5fbfc08-eb30-445c-b969-53b2f2b73674">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09849a74-922a-461a-b264-469d7788ee51">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mucosal lesions</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6624127-39a8-4dc4-aa58-68f8a5c233c8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44e3b4b4-d383-4e29-b23f-88cb20b7325a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d5befbb-cb48-46c6-9e2c-1d7babbdf208">
    <rdfs:label>Digoxin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <dc:identifier>DB00390</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6a0bcb2-6326-4867-8281-1e16f4903c20"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bb23ada-1b03-4e0d-a2ae-6aac89d54ae1">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007367</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
    <rdfs:label>CNS damage progression</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf25312c-f632-441d-9b3f-560d9975d62c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48b18ae4-d7b9-43bb-a814-e9f80c90a17a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32dc72d1-80be-4184-a51a-fec3c6fd92be">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a39a196-bb48-4587-a43b-2bd7b73176db"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39e650cf-156e-432f-9e30-dcd5825b2484"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e36d75ce-cae6-4b0e-975f-782943689075"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/260587ed-d566-402b-96f5-9ace59e5164b">
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7a0025c-e5a4-4045-b465-fdf32e786603"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cebd5565-b41f-4626-bc51-5cd8b0e4e84e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c65a8638-6b0b-49a6-8eaa-b9b76188d0d4"/>
    <rdfs:label>ARC-AAT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/373d29e4-c5a1-44fa-bd24-ba7af9187735">
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/42ac832c-244c-4b56-9c3c-ebd09215f4c1"/>
    <dc:identifier>A11EA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50e5d413-0a1f-46bb-b6b6-e29b08227cfb">
    <rdfs:label>Spirapril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6f6ccc3-0d6f-4839-bfdd-4f9c3f3c5910"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <dc:identifier>DB01348</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38ed262d-5230-484d-b15b-a6a6b316a50b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Intellectual disability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/124e4169-c93a-48a6-b3d4-258f61b89c5b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7595b81-abe0-46a3-9fc7-c0d00fbf8c94"/>
    <rdfs:label>Metoclopramide</rdfs:label>
    <dc:identifier>DB01233</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41ae6159-ea0a-492e-9b51-fac2b1d0ecd5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2435f2ec-880b-48c2-9517-378df6636af9"/>
    <rdfs:label>AAV-cG6PGH</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1e2f475-5036-456c-92e1-17eb050c29d2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/595932ce-7d35-4953-a198-bdabeb55796f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9234b94-1c93-46dc-9422-b3c6a0b00f05">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/391916c2-de2a-4f59-810e-460e8cfffd8e"/>
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae98838b-979f-4cb9-9976-64a7ee5173b9">
    <rdfs:label>High plasma uric acid levels</rdfs:label>
    <dc:identifier>HP:0002149</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/641b086b-c502-44b2-a7c0-30fe7f20ecf8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f49c125-6143-48a6-a32d-ddddec4461ab"/>
    <dc:identifier>DB04931</dc:identifier>
    <rdfs:label>Afamelanotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6eed1c29-763b-45f3-9a05-452f5983ac21">
    <dc:identifier>DB09539</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81827fff-df34-4cf9-b87d-874a215852ad"/>
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a663f416-8efc-4c15-b49a-f3174a3c96e8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fab8fcbd-085f-4341-aef9-8b62082340ab"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e973cd37-63f8-42e2-ba4e-cfdc5c952ab6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56482c8c-d3fb-410c-914b-0c2bd11b5920"/>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <dc:identifier>DB03147</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c91bdb4-874f-444b-99c5-713669fec66f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/579c6053-aa70-45ba-a3ce-5f419eec6652"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c91849f-1e4a-4dbd-a064-7f0d2bbd6bfc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c55b304-466e-4330-90d6-237bbd6385bf"/>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4ef686e-0c70-4a7e-a283-91546978ba5c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9413b4fb-bc48-4731-b560-ce522c70d35e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6564e2c9-b45d-4e53-ae18-c8b8219aaac8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rhabdomyolysis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82f3aef6-4844-483c-9c18-44eee769bb26">
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>congestive cardiac failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82ec4879-f987-402a-b9a2-dc286b90b2e5">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/730c7d32-a3e5-4fb3-a46f-fd2490ac9fed"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72622cd5-5f24-4aec-9c65-10889f5c5c09">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f070152-f078-4e7b-8d0a-9a46530943cf"/>
    <dc:identifier>DB07425</dc:identifier>
    <rdfs:label>Sobetirome</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82abd56e-5c46-4a1f-bcf4-d1f74690dc12">
    <dc:identifier>HP:0030878*</dc:identifier>
    <rdfs:label>Low FVC%</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50445b6b-5c66-498e-8351-c8c3dea4ed89">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100529</dc:identifier>
    <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9204db35-15ea-4ae4-bf93-273ae671ea9d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:label>Rickets</rdfs:label>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edf319ac-31ec-4953-9127-b48ae1235212">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/866cd54f-4677-469f-9457-9873deaac9d6"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9c16667d-007c-457a-9389-1e96eb573de2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d53906c5-7f8e-4fe8-a1ef-d00e5daecbfb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/126069ac-b98e-4740-a525-1beb8f4d677d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21f59a6f-ff5b-481d-afe5-e9915078af28">
    <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1420a931-384f-4c66-84b3-5b26fadddbab">
    <dc:identifier>DB12273</dc:identifier>
    <rdfs:label>Ecopipam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d849f48-ba1f-4474-a35f-7e62f673e376"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d22a961-c8f8-4ebb-9967-3dde93828638">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
    <dc:identifier>HP:0004371</dc:identifier>
    <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00ae68bf-dd02-4290-a824-a6c6e618e7cd">
    <rdfs:label>Abnormal urinary steroid level</rdfs:label>
    <dc:identifier>HP:0012030</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/154e9fe4-e21a-4161-a24a-e56a96bb2617">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
    <dc:identifier>HP:0012212</dc:identifier>
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcb02a22-2a84-4fe4-813c-eb136c282100">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lipid peroxidation</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58ec4080-f5ed-4fff-a6f1-0e8bc117c5ba">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44d97479-8975-40aa-9566-081ac20e4348"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ae41f57-2519-413b-98a7-252b025b5dbb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
    <dc:identifier>HP:0003287</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/964ad1d0-1b03-418a-8322-8910fd71cae3">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05d8091f-52f2-4a1c-acf3-3f8f99490455"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62cd5d8c-7fed-4f90-9bda-3b26d37db395">
    <dc:identifier>HP:0002152</dc:identifier>
    <rdfs:label>hyperproteinemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac355a8d-517d-4010-9a01-10c5d5fed10e">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
    <rdfs:label>retinoid</rdfs:label>
    <dc:identifier>CHEBI_26537</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab9f11d3-6f80-4ff7-97ad-b4910c2b466f"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f101d893-fa35-4af3-8880-70599660a7c0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9ceddd2-1d62-4def-8bed-74b5030677be"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/842e8640-6777-442b-9d3c-95d42645ba26">
    <rdfs:label>Etretinate</rdfs:label>
    <dc:identifier>DB00926</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c510a66-33eb-408b-be4e-1ddbe343e5d4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61e39991-91f7-4940-9ac5-4647eb201ccf">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a5445cb-4348-41a9-b636-251ea615d3db"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aea5298b-9cc7-4642-9fb0-10927745f278">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8fd1863-3af5-448f-9b8d-14222fc961ff"/>
    <rdfs:label>NeuAc</rdfs:label>
    <dc:identifier>CHEBI_17012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09895ff3-9fc7-48f3-b5de-91f7dabcc0ca"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a17884ec-11c2-4abf-95e5-0d282a2e0be5">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cdd44d0-ef9e-422e-8d24-b3b27ddc6e5e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acef3410-2422-4a8b-9784-b5bed1a86abe"/>
    <rdfs:label>Complex Carbohydrates</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3125b5c-5deb-424c-a605-6cebb16cc9e6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5aa21c3-bdca-4965-8bde-b233036270c7"/>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12ba91f0-5de2-467d-8ead-b3d1feb6327c">
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3645f282-5a67-4a23-84d1-6d673e2ae73b"/>
    <dc:identifier>DB00855</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ef00077-df6a-42ec-a638-82c260cddb08">
    <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
    <dc:identifier>HP:0000972</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1883e1b-2863-47c5-b2d8-061b95ce82bb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4eb3d841-3975-4d4a-ae50-59b8f76f1270"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad4b5a4f-f14a-4797-81b1-8918f1f4dbfa"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d15e818-c04d-4584-9f2c-391e31fc39ee">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>shorter life expectancy</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e903c9a9-76e7-4c72-a468-7ca7b6766510">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5b95bed-34f6-4a3a-b187-c87f9945b12e"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/407d82e1-9771-442e-9ff3-c71396d2af51">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33a4b510-b4dd-4541-b7f1-cd0303ea1115"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51a3ddcd-5d28-4e90-89d3-347b239e3842">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acute decompensation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6df6dec2-4887-47c5-a2d2-e226ce2219d2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <dc:identifier>DB00181</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8f680e7-7482-41ad-a3b4-053bb298f6dc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ce62f9a-c9a9-4334-ba03-97bf32321937"/>
    <rdfs:label>Baclofen</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/129bf35c-b7e7-478f-a5a4-af85b3b64564">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e106df72-94d5-4a1d-be29-c369af008988"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05b8fe72-651e-4b6c-b51d-b154d910c138">
    <dc:identifier>N06AB</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3c5ef2a-f732-44ad-a241-d97ad27ce42d"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b149362-57e2-4937-8af7-4a5e27729176">
    <rdfs:label>Amantadine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bb34629-fc67-4db4-8376-feb075f2f6f6"/>
    <dc:identifier>DB00915</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f200e6eb-13de-421e-a657-20e082d19c5e"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ebd6877-09cd-432a-bef8-66c44ca064cc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc18e774-1a01-48f6-adfa-f7b3505c3031"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/382c6aee-0576-4347-83eb-fe245f87d590">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <rdfs:label>Nitric Oxide</rdfs:label>
    <dc:identifier>DB00435</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbb8e3c1-20cd-4920-bada-f62bc07a055c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a17cf34b-40d0-4d0d-9d16-795b3d0dcc7d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
    <rdfs:label>Delayed CNS mylinaton</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002188</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3abe50a-04a8-42c6-9257-d76e2e1e522c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58d9dcdb-064e-4e93-8f15-531c802b0b37"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cde916b-db3b-4e11-93bb-1b82d6ebd731">
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d733489-0bd4-4fb0-acbc-e7a0e9c18dc0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6854e3fe-e47f-40eb-8b2f-ab01e136a978">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
    <dc:identifier>HP:0012279</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low plasma serine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8bbd7820-d01d-45fb-8959-431987ea4241">
    <dc:identifier>L04</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dbbda0bc-4930-4296-b61e-973c8db7eb59"/>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c673a6c-1ac7-4407-a757-963d3aa1a819">
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:label>Low HDL-C  level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2fbbb09-9416-4d51-8e31-d7132c614367">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/affbdae7-9f6d-416e-863e-93abdcc9cbc1"/>
    <rdfs:label>Arginine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34310b50-5810-4cda-9362-6db385412b7f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58ad5d4c-ac2d-4658-a662-3a4d14d34b8a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28317977-7638-46d6-8316-fffac38293eb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c557c739-50b9-4776-85be-e4a7c47196ce"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42da532f-c0d5-4dd1-acbd-02ddc1f19f61">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pathogenic exon trapping</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ebc17c9-1047-40db-b888-1aa26985eeab">
    <rdfs:label>High serum GDF15 level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67662335-233f-41a5-adc1-c5da26ae8c73">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34e5efcc-ee7d-44b3-b5b9-19137a49d3ac"/>
    <rdfs:label>Elapegademase</rdfs:label>
    <dc:identifier>DB14712</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/841cd45a-56e0-4d2d-9541-00b652711c41">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
    <rdfs:label>Perioral dermatitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040181</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d06767dc-8043-432c-b9b5-fbccff33f364">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bccd6b8c-e08e-43cd-84f4-b304cb3e77b2"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2de7a9b-c6e3-44ff-be1b-d4297c0bdd4f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee078057-d77b-41f8-88c5-6c0b1a9df6cc"/>
    <dc:identifier>DB01015)</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36b4f9d1-e42c-40a2-8c76-cccf4a5642bc">
    <dc:identifier>DB05018</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f42e45ec-a5f1-4f89-838f-e790a72a5f6e"/>
    <rdfs:label>Migalastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/049bbabf-63b9-4dc5-85a1-da162de00d56"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56a94c65-c0d9-4415-b664-f6320b68d1ec"/>
    <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/446dcef9-3787-4ad4-9462-32753e9c0469">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8b0ce35-0426-47c3-a0dc-9f7cb6f442e4"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/140a988b-3e25-4ab0-b8bc-6853c9998b0c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9cb882db-69bc-4ad3-844d-87224b5e44dd"/>
  </rdf:Alt>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
    <dc:identifier>EC0:0007121</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
  </ddiem:Evidence>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/943d2362-8715-47b3-818b-f1755e0a0fde">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f211ae92-605c-432a-8a26-93ed5a5ea400"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c60224bc-c760-4450-8c56-01620a647cbb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a413a62-cd46-4d8d-abc5-56d975523a38"/>
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4091875b-58f6-4a7a-9e10-3f69b10df7ae">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4191d39b-93dd-4b10-99dc-481844e62ae0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10d4a674-809b-4d1b-98d4-8167ffcb41b9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d92e443-fe81-4d4e-901d-2272c1a32c3d"/>
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5eaec50-5c11-452e-91fe-9a9a9235d37a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20df4e14-0cf9-4255-be35-5d7c785013aa"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8412727b-a690-4904-8302-b645928c5334">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a5cf598-8ec7-4b90-b8d7-f8aa180af206"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86d2d5ec-50f3-4fec-90c5-f1c5125e4766">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb73f9c5-b778-40d1-a8fa-a1201131c72b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0aaa997c-a15d-41c3-85a1-01c387123946">
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/77671da6-dd9c-4b2d-aac6-2d6e0b396340"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f569cd9-a9db-440c-91f6-13fee00c01f2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2697cad5-26df-4a6b-b78f-23fb4a0bf8cc"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e12908f0-d59a-43ff-a23e-e5dc32d4c742">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/423fe478-c0e4-4dab-ab1b-85904efddfa6"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4abd300a-2c9c-496a-b033-6fe5b5a01ca3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d3920ca-d694-4f27-a55d-09cc2e2bc6f6"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5839925d-2c30-49d8-af51-418d35bfab6a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c85321e-15fa-450b-8f45-16e9cd347e6d"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71049e83-1a1f-4e80-a486-bab2ab523075">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce46decd-e7fa-4987-b938-1db7f4edb199"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b0403d8-e40b-4be4-8e4f-4396eeadeb23">
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d28ae8e1-4cc6-47bf-ab8b-3473e68ddf6c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d56ef9cc-b433-412e-a25e-69d3da953030">
    <rdfs:label>mitochonic acid 5</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6330002-9555-4871-b4e2-9cb2e0788d7f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5cf14da-78cc-4a5f-b42b-5e50c5d9fd67">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001875</dc:identifier>
    <rdfs:label>neutropenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39558917-1d6e-4df3-b4df-944de0e63c7e">
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8e5d8fa-90c6-47cd-ba2c-cdf0e4329d64"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/999385fc-5020-4ac3-8151-93ff402e9e73">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cd5b367-84ff-43b2-add1-c1056f0f100d"/>
    <rdfs:label>Prokinetic agents</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d6ee996-0b0f-4c0b-a434-5fc4b097982e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6d7e7ac-fba4-4cd8-9a15-71f6c13825be"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1b9f09d-3979-40c3-b89f-ab653a8befdd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a12ef831-e7f6-4296-9409-b7c96f15fea0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21ab9bba-7f9e-4774-82c9-494bff0aa877">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60bb0071-fc17-4e26-a7e7-6376b8c66932"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0cc5f94-54eb-42f4-9673-8f2cc21d95a6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
  </ddiem:Phenotype>
</rdf:RDF>
